{"39d151187f99948f24c3f0d3c59cfba72fe9bc10": [["IntroductionSmall reversible posttranslational modifications of proteins provide a widespread mechanism for regulating a broad range of cellular processes, enabling cells to respond rapidly to changes in their environment.", [["cellular", "ANATOMY", 136, 144], ["cells", "ANATOMY", 165, 170], ["cellular", "CELL", 136, 144], ["cells", "CELL", 165, 170], ["Small reversible posttranslational modifications of proteins", "PROBLEM", 12, 72], ["Small", "OBSERVATION_MODIFIER", 12, 17], ["reversible", "OBSERVATION_MODIFIER", 18, 28], ["posttranslational modifications", "OBSERVATION", 29, 60], ["cellular processes", "OBSERVATION", 136, 154]]], ["Such modifications include phosphorylation, acetylation, and among eukaryotes, ubiquitination and ubiquitin-like modifications such as sumoylation and neddylation.IntroductionUbiquitin (Ub) is a small protein of 76 amino acids (Goldstein et al., 1975) .", [["amino acids", "CHEMICAL", 215, 226], ["amino acids", "CHEMICAL", 215, 226], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 98, 107], ["IntroductionUbiquitin", "GENE_OR_GENE_PRODUCT", 163, 184], ["Ub", "GENE_OR_GENE_PRODUCT", 186, 188], ["amino acids", "AMINO_ACID", 215, 226], ["ubiquitin", "PROTEIN", 98, 107], ["Ub", "PROTEIN", 186, 188], ["phosphorylation", "TREATMENT", 27, 42], ["acetylation", "TREATMENT", 44, 55], ["ubiquitination", "TREATMENT", 79, 93], ["ubiquitin", "TREATMENT", 98, 107], ["sumoylation and neddylation", "TREATMENT", 135, 162]]], ["It is present in all eukaryotes and is highly conserved, with only three amino acid differences between the yeast and human proteins.", [["amino acid", "CHEMICAL", 73, 83], ["amino acid", "CHEMICAL", 73, 83], ["amino acid", "AMINO_ACID", 73, 83], ["human", "ORGANISM", 118, 123], ["yeast and human proteins", "PROTEIN", 108, 132], ["yeast", "SPECIES", 108, 113], ["human", "SPECIES", 118, 123], ["yeast", "SPECIES", 108, 113], ["human", "SPECIES", 118, 123], ["three amino acid differences", "PROBLEM", 67, 95], ["all eukaryotes", "OBSERVATION_MODIFIER", 17, 31]]], ["Ubiquitination involves covalent addition of Ub monomers to lysine residues of target proteins or of Ub itself (to form poly-Ub chains), via the involvement of at least three enzymes: a Ub-activating enzyme (E1), a Ub-conjugating enzyme (E2), and a Ub ligase (E3) (Figure 1 ).", [["lysine", "CHEMICAL", 60, 66], ["E2", "CHEMICAL", 238, 240], ["lysine", "CHEMICAL", 60, 66], ["Ub", "GENE_OR_GENE_PRODUCT", 45, 47], ["lysine", "AMINO_ACID", 60, 66], ["Ub", "GENE_OR_GENE_PRODUCT", 101, 103], ["Ub", "GENE_OR_GENE_PRODUCT", 186, 188], ["E1", "GENE_OR_GENE_PRODUCT", 208, 210], ["Ub", "GENE_OR_GENE_PRODUCT", 215, 217], ["E2", "SIMPLE_CHEMICAL", 238, 240], ["Ub", "GENE_OR_GENE_PRODUCT", 249, 251], ["E3", "GENE_OR_GENE_PRODUCT", 260, 262], ["Ub monomers", "PROTEIN", 45, 56], ["target proteins", "PROTEIN", 79, 94], ["Ub", "PROTEIN", 101, 103], ["poly-Ub chains", "PROTEIN", 120, 134], ["enzymes", "PROTEIN", 175, 182], ["Ub", "PROTEIN", 186, 188], ["activating enzyme", "PROTEIN", 189, 206], ["E1", "PROTEIN", 208, 210], ["Ub", "PROTEIN", 215, 217], ["conjugating enzyme", "PROTEIN", 218, 236], ["E2", "PROTEIN", 238, 240], ["Ub ligase", "PROTEIN", 249, 258], ["E3", "PROTEIN", 260, 262], ["Figure 1", "PROTEIN", 265, 273], ["Ub monomers", "TREATMENT", 45, 56], ["target proteins", "PROBLEM", 79, 94], ["a Ub", "TEST", 184, 188], ["a Ub-conjugating enzyme", "TEST", 213, 236], ["a Ub ligase", "TEST", 247, 258], ["lysine residues", "OBSERVATION", 60, 75], ["ligase", "OBSERVATION_MODIFIER", 252, 258]]], ["E1 enzymes are responsible for the ATP-dependent activation of the C terminus of Ub, which is then directed to the active site of an E2 enzyme.", [["ATP", "CHEMICAL", 35, 38], ["E2", "CHEMICAL", 133, 135], ["ATP", "CHEMICAL", 35, 38], ["C", "CHEMICAL", 67, 68], ["E1", "GENE_OR_GENE_PRODUCT", 0, 2], ["ATP", "SIMPLE_CHEMICAL", 35, 38], ["Ub", "GENE_OR_GENE_PRODUCT", 81, 83], ["E2", "GENE_OR_GENE_PRODUCT", 133, 135], ["E1 enzymes", "PROTEIN", 0, 10], ["C terminus", "PROTEIN", 67, 77], ["Ub", "PROTEIN", 81, 83], ["E2 enzyme", "PROTEIN", 133, 142], ["E1 enzymes", "TEST", 0, 10], ["the ATP", "PROBLEM", 31, 38], ["the C terminus of Ub", "PROBLEM", 63, 83], ["an E2 enzyme", "TEST", 130, 142], ["dependent", "OBSERVATION_MODIFIER", 39, 48], ["activation", "OBSERVATION", 49, 59]]], ["E3 ligases (of which there are over 1000 encoded by human genome) are a large and diverse group of proteins that have been subclassified by the presence of different motifs, including HECT, RING, and U box domains.", [["E3", "GENE_OR_GENE_PRODUCT", 0, 2], ["human", "ORGANISM", 52, 57], ["HECT", "GENE_OR_GENE_PRODUCT", 184, 188], ["RING", "GENE_OR_GENE_PRODUCT", 190, 194], ["U box domains", "GENE_OR_GENE_PRODUCT", 200, 213], ["E3 ligases", "PROTEIN", 0, 10], ["human genome", "DNA", 52, 64], ["HECT", "PROTEIN", 184, 188], ["RING", "PROTEIN", 190, 194], ["U box domains", "PROTEIN", 200, 213], ["human", "SPECIES", 52, 57], ["human", "SPECIES", 52, 57], ["E3 ligases", "TEST", 0, 10], ["a large and diverse group of proteins", "PROBLEM", 70, 107], ["HECT, RING, and U box domains", "TREATMENT", 184, 213], ["ligases", "OBSERVATION", 3, 10], ["large", "OBSERVATION_MODIFIER", 72, 77], ["diverse", "OBSERVATION_MODIFIER", 82, 89], ["RING", "OBSERVATION_MODIFIER", 190, 194]]], ["HECT E3s transfer Ub from the E2 to a thioester linkage on the E3, and then to the substrate, while RING and U box E3s enable protein ubiquitination by acting as adaptors that bind to E2 proteins and substrates separately and facilitate direct transfer of Ub from the E2 protein to the substrate.", [["E2", "CHEMICAL", 30, 32], ["E2", "CHEMICAL", 184, 186], ["E2", "CHEMICAL", 268, 270], ["thioester", "CHEMICAL", 38, 47], ["HECT", "GENE_OR_GENE_PRODUCT", 0, 4], ["Ub", "GENE_OR_GENE_PRODUCT", 18, 20], ["E2", "GENE_OR_GENE_PRODUCT", 30, 32], ["E3", "GENE_OR_GENE_PRODUCT", 63, 65], ["RING", "GENE_OR_GENE_PRODUCT", 100, 104], ["U box E3s", "GENE_OR_GENE_PRODUCT", 109, 118], ["E2", "GENE_OR_GENE_PRODUCT", 184, 186], ["Ub", "GENE_OR_GENE_PRODUCT", 256, 258], ["E2", "GENE_OR_GENE_PRODUCT", 268, 270], ["HECT E3s", "PROTEIN", 0, 8], ["Ub", "PROTEIN", 18, 20], ["E3", "PROTEIN", 63, 65], ["RING", "PROTEIN", 100, 104], ["U box E3s", "PROTEIN", 109, 118], ["E2 proteins", "PROTEIN", 184, 195], ["Ub", "PROTEIN", 256, 258], ["E2 protein", "PROTEIN", 268, 278], ["RING and U box E3s", "TREATMENT", 100, 118], ["protein ubiquitination", "TREATMENT", 126, 148], ["E2 proteins", "TEST", 184, 195]]], ["A fourth group of E3 ligases, called the modulator of immune recognition (MIR) family, comprises membrane-bound proteins containing a specialized form of the RING finger, plant homeodomain (PHD) (Coscoy and Ganem, 2003; Ohmura-Hoshino et al., 2006) .IntroductionSeveral RING E3s appear to act independently, but others are components of larger multiprotein complexes.", [["membrane", "ANATOMY", 97, 105], ["E3", "GENE_OR_GENE_PRODUCT", 18, 20], ["membrane", "CELLULAR_COMPONENT", 97, 105], ["PHD", "GENE_OR_GENE_PRODUCT", 190, 193], ["E3s", "GENE_OR_GENE_PRODUCT", 275, 278], ["E3 ligases", "PROTEIN", 18, 28], ["modulator of immune recognition (MIR) family", "PROTEIN", 41, 85], ["membrane-bound proteins", "PROTEIN", 97, 120], ["RING finger", "PROTEIN", 158, 169], ["plant homeodomain", "PROTEIN", 171, 188], ["PHD", "PROTEIN", 190, 193], ["RING E3s", "PROTEIN", 270, 278], ["multiprotein complexes", "PROTEIN", 344, 366], ["bound proteins", "PROBLEM", 106, 120], ["Several RING E3s", "TREATMENT", 262, 278], ["larger multiprotein complexes", "PROBLEM", 337, 366], ["RING finger", "ANATOMY", 158, 169], ["RING E3s", "OBSERVATION", 270, 278], ["larger", "OBSERVATION_MODIFIER", 337, 343], ["multiprotein complexes", "OBSERVATION", 344, 366]]], ["A good example of the latter are the cullin RING Ub ligases.", [["cullin", "GENE_OR_GENE_PRODUCT", 37, 43], ["Ub", "GENE_OR_GENE_PRODUCT", 49, 51], ["cullin RING Ub ligases", "PROTEIN", 37, 59], ["the cullin RING Ub ligases", "TREATMENT", 33, 59], ["good", "OBSERVATION_MODIFIER", 2, 6], ["cullin RING", "OBSERVATION", 37, 48], ["Ub ligases", "OBSERVATION", 49, 59]]], ["The C-terminal regions of cullin proteins interact with the E2-interacting RING protein ROC-1.", [["E2", "CHEMICAL", 60, 62], ["cullin", "GENE_OR_GENE_PRODUCT", 26, 32], ["E2", "GENE_OR_GENE_PRODUCT", 60, 62], ["ROC-1", "GENE_OR_GENE_PRODUCT", 88, 93], ["C-terminal regions", "PROTEIN", 4, 22], ["cullin proteins", "PROTEIN", 26, 41], ["E2-interacting RING protein ROC-1", "PROTEIN", 60, 93], ["The C-terminal regions of cullin proteins", "PROBLEM", 0, 41], ["RING protein ROC", "TEST", 75, 91], ["cullin proteins", "OBSERVATION", 26, 41]]], ["The N-termi-nal region of cullins interact with linker or adaptor proteins such as SCF (Skp-1, Cul-1, F box), which in turn bind to the substrate.", [["cullins", "GENE_OR_GENE_PRODUCT", 26, 33], ["SCF", "GENE_OR_GENE_PRODUCT", 83, 86], ["Skp-1", "GENE_OR_GENE_PRODUCT", 88, 93], ["Cul-1", "GENE_OR_GENE_PRODUCT", 95, 100], ["F box", "GENE_OR_GENE_PRODUCT", 102, 107], ["N-termi-nal region", "PROTEIN", 4, 22], ["cullins", "PROTEIN", 26, 33], ["linker or adaptor proteins", "PROTEIN", 48, 74], ["SCF", "PROTEIN", 83, 86], ["Skp", "PROTEIN", 88, 91], ["Cul", "PROTEIN", 95, 98], ["1", "PROTEIN", 99, 100], ["F box", "PROTEIN", 102, 107], ["adaptor proteins", "TEST", 58, 74], ["SCF", "TEST", 83, 86], ["Skp", "TEST", 88, 91], ["Cul", "TEST", 95, 98]]], ["Cullins are themselves positively regulated by the binding of the small Ub-like protein (Ubl) neural precursor cell-expressed developmentally downregulated 8 (NEDD8) (RUB1 in S. cerevisiae).IntroductionIn addition to NEDD8, other small proteins with various degrees of sequence similarity to Ub have been identified that link to proteins in an analogous manner to ubiquitination.", [["neural precursor cell", "ANATOMY", 94, 115], ["Cullins", "GENE_OR_GENE_PRODUCT", 0, 7], ["Ub", "GENE_OR_GENE_PRODUCT", 72, 74], ["Ubl", "GENE_OR_GENE_PRODUCT", 89, 92], ["8", "GENE_OR_GENE_PRODUCT", 156, 157], ["NEDD8", "GENE_OR_GENE_PRODUCT", 159, 164], ["RUB1", "GENE_OR_GENE_PRODUCT", 167, 171], ["S. cerevisiae", "ORGANISM", 175, 188], ["NEDD8", "GENE_OR_GENE_PRODUCT", 217, 222], ["Ub", "GENE_OR_GENE_PRODUCT", 292, 294], ["Cullins", "PROTEIN", 0, 7], ["small Ub-like protein", "PROTEIN", 66, 87], ["Ubl", "PROTEIN", 89, 92], ["neural precursor cell", "CELL_TYPE", 94, 115], ["developmentally downregulated 8", "PROTEIN", 126, 157], ["NEDD8", "PROTEIN", 159, 164], ["RUB1", "PROTEIN", 167, 171], ["NEDD8", "PROTEIN", 217, 222], ["small proteins", "PROTEIN", 230, 244], ["Ub", "PROTEIN", 292, 294], ["S. cerevisiae", "SPECIES", 175, 188], ["S. cerevisiae", "SPECIES", 175, 188], ["the small Ub-like protein (Ubl) neural precursor cell", "PROBLEM", 62, 115], ["NEDD8", "TREATMENT", 217, 222], ["other small proteins", "PROBLEM", 224, 244], ["small", "OBSERVATION_MODIFIER", 66, 71], ["precursor cell", "OBSERVATION", 101, 115], ["small", "OBSERVATION_MODIFIER", 230, 235], ["proteins", "OBSERVATION", 236, 244]]], ["These include small ubiquitin-like modifier 1 (SUMO-1) also known as Ubl1, Sentrin, or PIC-1 (Jentsch and Pyrowolakis, 2000; Yeh et al., 2000) .", [["small ubiquitin-like modifier 1", "GENE_OR_GENE_PRODUCT", 14, 45], ["SUMO-1", "GENE_OR_GENE_PRODUCT", 47, 53], ["Ubl1", "GENE_OR_GENE_PRODUCT", 69, 73], ["Sentrin", "GENE_OR_GENE_PRODUCT", 75, 82], ["PIC-1", "GENE_OR_GENE_PRODUCT", 87, 92], ["small ubiquitin-like modifier 1", "PROTEIN", 14, 45], ["SUMO", "PROTEIN", 47, 51], ["Ubl1", "PROTEIN", 69, 73], ["Sentrin", "PROTEIN", 75, 82], ["PIC", "PROTEIN", 87, 90], ["small ubiquitin-like modifier", "TREATMENT", 14, 43], ["Sentrin", "TREATMENT", 75, 82], ["PIC", "TEST", 87, 90], ["small", "OBSERVATION_MODIFIER", 14, 19], ["ubiquitin", "OBSERVATION", 20, 29]]], ["Sumoylation occurs on a wide range of substrates including signaling molecules and several transcriptional regulators (Muller et al., 2001; Sapetschnig et al., 2002; Seeler and Dejean, 2001) .", [["signaling molecules", "PROTEIN", 59, 78], ["transcriptional regulators", "PROTEIN", 91, 117], ["signaling molecules", "PROBLEM", 59, 78]]], ["SUMO can also act by blocking Ub attachment sites (Hoege et al., 2002) .", [["SUMO", "GENE_OR_GENE_PRODUCT", 0, 4], ["Ub", "GENE_OR_GENE_PRODUCT", 30, 32], ["SUMO", "PROTEIN", 0, 4], ["Ub", "PROTEIN", 30, 32]]], ["A key distinction between SUMO and Ub is the inability of SUMO to conjugate to itself (Pickart, 1997) .", [["SUMO", "GENE_OR_GENE_PRODUCT", 26, 30], ["Ub", "GENE_OR_GENE_PRODUCT", 35, 37], ["SUMO", "GENE_OR_GENE_PRODUCT", 58, 62], ["SUMO", "PROTEIN", 26, 30], ["Ub", "PROTEIN", 35, 37], ["SUMO", "PROTEIN", 58, 62], ["SUMO", "OBSERVATION", 26, 30]]], ["The ability of Ub to interact with a wide range of proteins, including itself, and to form a variety of different length and linkages of chains, increases its capacity to manipulate a larger array of signals compared to Ubls.", [["Ub", "GENE_OR_GENE_PRODUCT", 15, 17], ["Ubls", "GENE_OR_GENE_PRODUCT", 220, 224], ["Ub", "PROTEIN", 15, 17], ["Ubls", "PROTEIN", 220, 224], ["its capacity", "PROBLEM", 155, 167]]], ["For a comprehensive review of Ub and Ub-like protein modifications, the reader is referred to a recent review (Kerscher et al., 2006) .IntroductionThe fate of ubiquitinated proteins depends on the combination of interacting E2 and E3 enzymes and the length and linkage of the Ub chains.", [["E2", "CHEMICAL", 224, 226], ["Ub", "GENE_OR_GENE_PRODUCT", 30, 32], ["Ub", "GENE_OR_GENE_PRODUCT", 37, 39], ["E2", "GENE_OR_GENE_PRODUCT", 224, 226], ["E3", "GENE_OR_GENE_PRODUCT", 231, 233], ["Ub", "GENE_OR_GENE_PRODUCT", 276, 278], ["Ub", "PROTEIN", 30, 32], ["Ub", "PROTEIN", 37, 39], ["ubiquitinated proteins", "PROTEIN", 159, 181], ["interacting E2 and E3 enzymes", "PROTEIN", 212, 241], ["Ub chains", "PROTEIN", 276, 285], ["Ub", "TEST", 30, 32], ["ubiquitinated proteins", "PROBLEM", 159, 181], ["interacting E2 and E3 enzymes", "TREATMENT", 212, 241], ["ubiquitinated proteins", "OBSERVATION", 159, 181], ["Ub", "ANATOMY_MODIFIER", 276, 278], ["chains", "ANATOMY_MODIFIER", 279, 285]]], ["Chains of four or more Ub molecules linked through lysine 48 (K48) of Ub target the modified protein for proteasomal degradation (Thrower et al., 2000) .", [["proteasomal", "ANATOMY", 105, 116], ["lysine", "CHEMICAL", 51, 57], ["lysine", "CHEMICAL", 51, 57], ["Ub", "GENE_OR_GENE_PRODUCT", 23, 25], ["lysine 48", "SIMPLE_CHEMICAL", 51, 60], ["Ub", "GENE_OR_GENE_PRODUCT", 70, 72], ["Ub molecules", "PROTEIN", 23, 35], ["Ub", "PROTEIN", 70, 72], ["modified protein", "PROTEIN", 84, 100], ["proteasomal degradation", "PROBLEM", 105, 128]]], ["K63-linked polyubiquitin chains regulate a wide range of important cellular processes such as DNA repair, signaling, endocytosis, vesicular trafficking, and cell-cycle progression (Haglund and Dikic, 2005; Hicke and Dunn, 2003; Huang and D'Andrea, 2006) .", [["cellular", "ANATOMY", 67, 75], ["vesicular", "ANATOMY", 130, 139], ["cell", "ANATOMY", 157, 161], ["K63", "SIMPLE_CHEMICAL", 0, 3], ["polyubiquitin chains", "GENE_OR_GENE_PRODUCT", 11, 31], ["cellular", "CELL", 67, 75], ["DNA", "CELLULAR_COMPONENT", 94, 97], ["vesicular", "MULTI-TISSUE_STRUCTURE", 130, 139], ["cell", "CELL", 157, 161], ["K63", "PROTEIN", 0, 3], ["polyubiquitin chains", "PROTEIN", 11, 31], ["K63-linked polyubiquitin chains", "TREATMENT", 0, 31], ["important cellular processes", "TREATMENT", 57, 85], ["DNA repair", "TREATMENT", 94, 104], ["vesicular trafficking", "PROBLEM", 130, 151], ["polyubiquitin chains", "OBSERVATION", 11, 31], ["wide range", "OBSERVATION_MODIFIER", 43, 53], ["cellular processes", "OBSERVATION", 67, 85], ["vesicular trafficking", "OBSERVATION", 130, 151]]], ["Monoubiquitination (modification with one ubiquitin molecule) controls subcellular protein localization, endocytosis, and recruitment of Ub-binding proteins (Haglund and Dikic, 2005) .Deubiquitinating EnzymesProtein ubiquitination is a reversible process, and Ub deconjugation, catalyzed by deubiquitinating enzymes (DUBs), plays an important role in processing Ub precursors, proofreading Ub protein conjugates, and removing Ub from target proteins ( Figure 1 ).", [["subcellular", "ANATOMY", 71, 82], ["Ub-binding proteins", "GENE_OR_GENE_PRODUCT", 137, 156], ["EnzymesProtein", "GENE_OR_GENE_PRODUCT", 201, 215], ["Ub", "GENE_OR_GENE_PRODUCT", 260, 262], ["deubiquitinating enzymes", "GENE_OR_GENE_PRODUCT", 291, 315], ["DUBs", "GENE_OR_GENE_PRODUCT", 317, 321], ["Ub", "GENE_OR_GENE_PRODUCT", 362, 364], ["Ub", "GENE_OR_GENE_PRODUCT", 390, 392], ["Ub", "GENE_OR_GENE_PRODUCT", 426, 428], ["ubiquitin molecule", "PROTEIN", 42, 60], ["Ub", "PROTEIN", 137, 139], ["binding proteins", "PROTEIN", 140, 156], ["EnzymesProtein", "PROTEIN", 201, 215], ["Ub", "PROTEIN", 260, 262], ["deubiquitinating enzymes", "PROTEIN", 291, 315], ["DUBs", "PROTEIN", 317, 321], ["Ub precursors", "PROTEIN", 362, 375], ["Ub protein conjugates", "PROTEIN", 390, 411], ["Ub", "PROTEIN", 426, 428], ["target proteins", "PROTEIN", 434, 449], ["Monoubiquitination (modification", "TREATMENT", 0, 32], ["one ubiquitin molecule", "TREATMENT", 38, 60], ["subcellular protein localization", "TEST", 71, 103], ["endocytosis", "PROBLEM", 105, 116], ["a reversible process", "PROBLEM", 234, 254], ["Ub deconjugation", "TEST", 260, 276], ["proofreading Ub protein conjugates", "TEST", 377, 411], ["EnzymesProtein ubiquitination", "OBSERVATION", 201, 230], ["reversible", "OBSERVATION_MODIFIER", 236, 246], ["process", "OBSERVATION", 247, 254]]], ["Major progress has been made in understanding pathways of ubiquitination, but our understanding of the functions of DUBs is much less advanced.", [["DUBs", "GENE_OR_GENE_PRODUCT", 116, 120], ["DUBs", "PROTEIN", 116, 120]]], ["DUBs are present in all eukaryotic cells, and approximately 100 are predicted to be encoded by the human genome.", [["cells", "ANATOMY", 35, 40], ["DUBs", "GENE_OR_GENE_PRODUCT", 0, 4], ["cells", "CELL", 35, 40], ["human", "ORGANISM", 99, 104], ["DUBs", "PROTEIN", 0, 4], ["eukaryotic cells", "CELL_TYPE", 24, 40], ["human genome", "DNA", 99, 111], ["human", "SPECIES", 99, 104], ["human", "SPECIES", 99, 104], ["all", "ANATOMY_MODIFIER", 20, 23], ["eukaryotic cells", "OBSERVATION", 24, 40], ["human genome", "OBSERVATION", 99, 111]]], ["They include both metalloproteases (JAMM/MPN+) and cysteine proteases, with the majority being of the latter type.", [["cysteine", "CHEMICAL", 51, 59], ["JAMM", "GENE_OR_GENE_PRODUCT", 36, 40], ["cysteine", "AMINO_ACID", 51, 59], ["metalloproteases", "PROTEIN", 18, 34], ["JAMM", "PROTEIN", 36, 40], ["MPN", "PROTEIN", 41, 44], ["cysteine proteases", "PROTEIN", 51, 69], ["both metalloproteases (JAMM/MPN", "TREATMENT", 13, 44], ["cysteine proteases", "TREATMENT", 51, 69]]], ["The cysteine protease DUBs have been grouped into four different classes based on their sequence and predicted activity: Ub-specific proteases (USPs, also referred to as Ub processing proteases, UBPs), Ub C-terminal hydrolases (UCHs), ovarian tumorrelated proteases/Cezanne (OTUs), and Josephin domain proteases (JD) (Amerik and Hochstrasser, 2004; Nijman et al., 2005; Sulea et al., 2006) .", [["cysteine", "CHEMICAL", 4, 12], ["cysteine", "CHEMICAL", 4, 12], ["cysteine protease DUBs", "GENE_OR_GENE_PRODUCT", 4, 26], ["Ub", "GENE_OR_GENE_PRODUCT", 121, 123], ["USPs", "GENE_OR_GENE_PRODUCT", 144, 148], ["Ub", "GENE_OR_GENE_PRODUCT", 170, 172], ["UBPs", "GENE_OR_GENE_PRODUCT", 195, 199], ["Ub C-terminal hydrolases", "GENE_OR_GENE_PRODUCT", 202, 226], ["UCHs", "GENE_OR_GENE_PRODUCT", 228, 232], ["ovarian tumorrelated proteases", "GENE_OR_GENE_PRODUCT", 235, 265], ["Cezanne", "GENE_OR_GENE_PRODUCT", 266, 273], ["Josephin domain proteases", "GENE_OR_GENE_PRODUCT", 286, 311], ["cysteine protease DUBs", "PROTEIN", 4, 26], ["Ub", "PROTEIN", 121, 123], ["specific proteases", "PROTEIN", 124, 142], ["USPs", "PROTEIN", 144, 148], ["Ub processing proteases", "PROTEIN", 170, 193], ["UBPs", "PROTEIN", 195, 199], ["Ub C-terminal hydrolases", "PROTEIN", 202, 226], ["UCHs", "PROTEIN", 228, 232], ["ovarian tumorrelated proteases", "PROTEIN", 235, 265], ["Cezanne", "PROTEIN", 266, 273], ["OTUs", "PROTEIN", 275, 279], ["Josephin domain proteases", "PROTEIN", 286, 311], ["JD", "PROTEIN", 313, 315], ["The cysteine protease DUBs", "TREATMENT", 0, 26], ["their sequence", "TEST", 82, 96], ["proteases", "TEST", 184, 193], ["UBPs", "TEST", 195, 199], ["Ub C-terminal hydrolases (UCHs)", "PROBLEM", 202, 233], ["ovarian tumorrelated proteases", "TREATMENT", 235, 265], ["Cezanne (OTUs", "TREATMENT", 266, 279], ["ovarian", "ANATOMY", 235, 242]]], ["USPs represent the most diverse class, comprising proteases with two short conserved motifs, the Cys and His boxes, flanked by N-and C-terminal regions of differing length and sequence.", [["Cys", "CHEMICAL", 97, 100], ["His", "CHEMICAL", 105, 108], ["N", "CHEMICAL", 127, 128], ["C", "CHEMICAL", 133, 134], ["USPs", "GENE_OR_GENE_PRODUCT", 0, 4], ["USPs", "PROTEIN", 0, 4], ["proteases", "PROTEIN", 50, 59], ["Cys and His boxes", "DNA", 97, 114], ["N-and C-terminal regions", "DNA", 127, 151], ["the Cys", "TEST", 93, 100], ["His boxes", "TEST", 105, 114]]], ["The UCH class contains small proteins originally identified by their ability to hydrolyze small amides and esters at the C terminus of Ub.", [["amides", "CHEMICAL", 96, 102], ["esters", "CHEMICAL", 107, 113], ["UCH class", "GENE_OR_GENE_PRODUCT", 4, 13], ["small amides", "SIMPLE_CHEMICAL", 90, 102], ["esters", "SIMPLE_CHEMICAL", 107, 113], ["UCH class", "PROTEIN", 4, 13], ["C terminus", "PROTEIN", 121, 131], ["small proteins", "PROBLEM", 23, 37], ["small", "OBSERVATION_MODIFIER", 23, 28], ["proteins", "OBSERVATION", 29, 37]]], ["Proteases have also been divided into families and clans according to a hierarchical classification on the basis of degree of similarity in amino acid sequence.", [["amino acid", "CHEMICAL", 140, 150], ["amino acid", "CHEMICAL", 140, 150], ["amino acid", "AMINO_ACID", 140, 150], ["Proteases", "PROTEIN", 0, 9], ["amino acid sequence", "PROTEIN", 140, 159], ["Proteases", "TREATMENT", 0, 9], ["similarity in amino acid sequence", "PROBLEM", 126, 159]]], ["Families of proteases that are homologous are grouped together in a clan.", [["proteases", "PROTEIN", 12, 21]]], ["According to this system, cysteine proteases have been divided into 9 clans and 47 families (http://merops. sanger.ac.uk/index.htm).", [["cysteine", "CHEMICAL", 26, 34], ["cysteine", "AMINO_ACID", 26, 34], ["cysteine proteases", "PROTEIN", 26, 44], ["http://merops", "PROTEIN", 93, 106], ["index.htm", "PROTEIN", 121, 130], ["cysteine proteases", "TREATMENT", 26, 44]]], ["Several cysteine proteases that are DUBs or Ub-like protein-specific proteases (ULPs) have been classified into the clans CA and CE.", [["cysteine", "CHEMICAL", 8, 16], ["cysteine", "AMINO_ACID", 8, 16], ["DUBs", "GENE_OR_GENE_PRODUCT", 36, 40], ["Ub", "GENE_OR_GENE_PRODUCT", 44, 46], ["ULPs", "GENE_OR_GENE_PRODUCT", 80, 84], ["CA", "GENE_OR_GENE_PRODUCT", 122, 124], ["cysteine proteases", "PROTEIN", 8, 26], ["DUBs", "PROTEIN", 36, 40], ["Ub", "PROTEIN", 44, 46], ["protein-specific proteases", "PROTEIN", 52, 78], ["ULPs", "PROTEIN", 80, 84], ["CA", "PROTEIN", 122, 124], ["Several cysteine proteases", "PROBLEM", 0, 26], ["DUBs", "TEST", 36, 40], ["Ub", "TEST", 44, 46], ["cysteine proteases", "OBSERVATION", 8, 26]]], ["In clan CA, the Cys motif is N proximal to the His box, whereas the reverse is the case in clan CE.Deubiquitinating EnzymesIn contrast to many other proteases, which are translated as inactive precursors, DUBs are generally produced as active enzymes, and structural analysis has revealed that the catalytic triad only assumes the active conformation upon binding of Ub, thereby preventing nonspecific protease activity (Nijman et al., 2005) .", [["Cys", "CHEMICAL", 16, 19], ["N", "CHEMICAL", 29, 30], ["His", "CHEMICAL", 47, 50], ["clan CA", "GENE_OR_GENE_PRODUCT", 3, 10], ["DUBs", "GENE_OR_GENE_PRODUCT", 205, 209], ["Ub", "GENE_OR_GENE_PRODUCT", 367, 369], ["clan CA", "PROTEIN", 3, 10], ["Cys motif", "PROTEIN", 16, 25], ["His box", "DNA", 47, 54], ["EnzymesIn", "PROTEIN", 116, 125], ["proteases", "PROTEIN", 149, 158], ["DUBs", "PROTEIN", 205, 209], ["enzymes", "PROTEIN", 243, 250], ["catalytic triad", "PROTEIN", 298, 313], ["Ub", "PROTEIN", 367, 369], ["protease", "PROTEIN", 402, 410], ["the Cys motif", "TREATMENT", 12, 25], ["many other proteases", "PROBLEM", 138, 158], ["DUBs", "TEST", 205, 209], ["active enzymes", "TEST", 236, 250], ["structural analysis", "TEST", 256, 275], ["the catalytic triad", "PROBLEM", 294, 313], ["nonspecific protease activity", "PROBLEM", 390, 419], ["active conformation", "OBSERVATION", 331, 350], ["nonspecific", "OBSERVATION_MODIFIER", 390, 401]]], ["Specificity of DUBs is also likely to be determined by regions outside the catalytic core of the enzyme, and both the target and the attached Ub monomer or polymer are likely to be important for recognition by the DUB.Bacterial InterventionStudies on the interactions between bacteria and host cells over the last decade have revealed a remarkable diversity of cellular processes that are modulated by Gram-positive and Gram-negative pathogens.", [["cells", "ANATOMY", 294, 299], ["cellular", "ANATOMY", 361, 369], ["DUBs", "GENE_OR_GENE_PRODUCT", 15, 19], ["Ub", "GENE_OR_GENE_PRODUCT", 142, 144], ["DUB", "GENE_OR_GENE_PRODUCT", 214, 217], ["host cells", "CELL", 289, 299], ["cellular", "CELL", 361, 369], ["Gram-", "GENE_OR_GENE_PRODUCT", 402, 407], ["Gram", "GENE_OR_GENE_PRODUCT", 420, 424], ["DUBs", "PROTEIN", 15, 19], ["catalytic core", "PROTEIN", 75, 89], ["enzyme", "PROTEIN", 97, 103], ["Ub monomer", "PROTEIN", 142, 152], ["DUB", "PROTEIN", 214, 217], ["host cells", "CELL_TYPE", 289, 299], ["DUBs", "PROBLEM", 15, 19], ["Bacterial InterventionStudies", "PROBLEM", 218, 247], ["bacteria", "PROBLEM", 276, 284], ["host cells", "PROBLEM", 289, 299], ["cellular processes", "PROBLEM", 361, 379], ["Gram-positive and Gram-negative pathogens", "PROBLEM", 402, 443], ["DUBs", "OBSERVATION", 15, 19], ["DUB", "OBSERVATION", 214, 217], ["host cells", "OBSERVATION", 289, 299], ["remarkable", "OBSERVATION_MODIFIER", 337, 347], ["diversity", "OBSERVATION", 348, 357], ["cellular processes", "OBSERVATION", 361, 379], ["negative pathogens", "OBSERVATION", 425, 443]]], ["Several Gram-negative bacterial pathogens use type three secretion (T3S) systems to deliver effector proteins into host cells.", [["cells", "ANATOMY", 120, 125], ["host cells", "CELL", 115, 125], ["effector proteins", "PROTEIN", 92, 109], ["host cells", "CELL_TYPE", 115, 125], ["Several Gram-negative bacterial pathogens", "PROBLEM", 0, 41], ["negative bacterial pathogens", "OBSERVATION", 13, 41], ["host cells", "OBSERVATION", 115, 125]]], ["Components of the T3S apparatus (which resembles a needle-like structure in both form and function; Galan and Wolf-Watz, 2006) are conserved in different pathogens; however, each pathogen is endowed with a unique repertoire of effectors that contribute to the disease processes caused by that pathogen.", [["T3S", "GENE_OR_GENE_PRODUCT", 18, 21], ["the T3S apparatus", "PROBLEM", 14, 31], ["a needle-like structure", "PROBLEM", 49, 72], ["different pathogens", "PROBLEM", 144, 163], ["each pathogen", "PROBLEM", 174, 187], ["the disease processes", "PROBLEM", 256, 277], ["pathogen", "PROBLEM", 293, 301], ["different", "OBSERVATION_MODIFIER", 144, 153], ["pathogens", "OBSERVATION", 154, 163], ["disease", "OBSERVATION", 260, 267]]], ["These effectors interfere with the actin, microtubule, and intermediate filament cytoskeletons; microtubule motors; specific stages of the endocytic and secretory pathways; and a host of signaling pathways, affecting, for example, transcription, translation, cell division, cell migration, and immune responses.", [["microtubule", "ANATOMY", 42, 53], ["cytoskeletons", "ANATOMY", 81, 94], ["microtubule", "ANATOMY", 96, 107], ["cell", "ANATOMY", 259, 263], ["cell", "ANATOMY", 274, 278], ["actin", "GENE_OR_GENE_PRODUCT", 35, 40], ["microtubule", "CELLULAR_COMPONENT", 42, 53], ["intermediate filament cytoskeletons", "CELLULAR_COMPONENT", 59, 94], ["microtubule", "CELLULAR_COMPONENT", 96, 107], ["cell", "CELL", 259, 263], ["cell", "CELL", 274, 278], ["actin", "PROTEIN", 35, 40], ["microtubule", "PROTEIN", 42, 53], ["microtubule motors", "PROTEIN", 96, 114], ["intermediate filament cytoskeletons", "OBSERVATION", 59, 94], ["cell migration", "OBSERVATION", 274, 288]]], ["Given the importance of ubiquitination and deubiquitination in the regulation of many cellular processes, it is not surprising that pathogenic bacteria have developed the means to interfere extensively with different stages of Ub pathways.", [["cellular", "ANATOMY", 86, 94], ["cellular", "CELL", 86, 94], ["Ub", "GENE_OR_GENE_PRODUCT", 227, 229], ["Ub", "PROTEIN", 227, 229], ["ubiquitination", "PROBLEM", 24, 38], ["deubiquitination", "TREATMENT", 43, 59], ["many cellular processes", "PROBLEM", 81, 104], ["pathogenic bacteria", "PROBLEM", 132, 151], ["ubiquitination", "OBSERVATION", 24, 38], ["many", "OBSERVATION_MODIFIER", 81, 85], ["cellular processes", "OBSERVATION", 86, 104], ["not surprising", "UNCERTAINTY", 112, 126]]], ["In this review we focus on the bacterial virulence proteins that mediate these effects (summarized in Table 1 ), and what is known of the mechanisms by which they interfere with Ub pathways.Bacterial InterventionYersinia YopJ/P The first bacterial protein shown to have DUB activity was the Yersinia T3S effector YopJ/P (referred to as YopJ in Yersinia pseudotuberculosis and YopP in Yersinia enterocolitica) (Figure 2 ).", [["Yersinia pseudotuberculosis", "DISEASE", 344, 371], ["Yersinia enterocolitica", "DISEASE", 384, 407], ["Ub", "GENE_OR_GENE_PRODUCT", 178, 180], ["DUB", "GENE_OR_GENE_PRODUCT", 270, 273], ["YopJ", "GENE_OR_GENE_PRODUCT", 313, 317], ["YopJ", "GENE_OR_GENE_PRODUCT", 336, 340], ["Yersinia pseudotuberculosis", "ORGANISM", 344, 371], ["YopP", "GENE_OR_GENE_PRODUCT", 376, 380], ["Yersinia enterocolitica", "ORGANISM", 384, 407], ["bacterial virulence proteins", "PROTEIN", 31, 59], ["Ub", "PROTEIN", 178, 180], ["DUB", "PROTEIN", 270, 273], ["Yersinia T3S effector", "PROTEIN", 291, 312], ["YopJ", "PROTEIN", 313, 317], ["P", "PROTEIN", 318, 319], ["YopJ", "PROTEIN", 336, 340], ["Yersinia pseudotuberculosis", "SPECIES", 344, 371], ["Yersinia enterocolitica", "SPECIES", 384, 407], ["Yersinia pseudotuberculosis", "SPECIES", 344, 371], ["Yersinia enterocolitica", "SPECIES", 384, 407], ["the bacterial virulence proteins", "PROBLEM", 27, 59], ["The first bacterial protein", "TEST", 228, 255], ["DUB activity", "PROBLEM", 270, 282], ["Yersinia pseudotuberculosis", "PROBLEM", 344, 371], ["Yersinia enterocolitica", "PROBLEM", 384, 407]]], ["YopJ is present in all three Yersinia spp. pathogenic for humans; these bacteria are mainly extracellular pathogens causing both enteric diseases (Y. pseudotuberculosis and Y. enterocolitica) and plague (Y. pestis).", [["extracellular", "ANATOMY", 92, 105], ["YopJ", "CHEMICAL", 0, 4], ["enteric diseases", "DISEASE", 129, 145], ["Y. pseudotuberculosis", "DISEASE", 147, 168], ["Y. enterocolitica", "DISEASE", 173, 190], ["Y. pestis", "DISEASE", 204, 213], ["YopJ", "GENE_OR_GENE_PRODUCT", 0, 4], ["Yersinia spp", "ORGANISM", 29, 41], ["humans", "ORGANISM", 58, 64], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 92, 105], ["Y. pseudotuberculosis", "ORGANISM", 147, 168], ["Y. enterocolitica", "ORGANISM", 173, 190], ["Y. pestis", "ORGANISM", 204, 213], ["YopJ", "PROTEIN", 0, 4], ["humans", "SPECIES", 58, 64], ["Y. pseudotuberculosis", "SPECIES", 147, 168], ["Y. enterocolitica", "SPECIES", 173, 190], ["Y. pestis", "SPECIES", 204, 213], ["humans", "SPECIES", 58, 64], ["Y. pseudotuberculosis", "SPECIES", 147, 168], ["Y. enterocolitica", "SPECIES", 173, 190], ["Y. pestis", "SPECIES", 204, 213], ["pathogenic", "PROBLEM", 43, 53], ["these bacteria", "PROBLEM", 66, 80], ["extracellular pathogens", "PROBLEM", 92, 115], ["both enteric diseases", "PROBLEM", 124, 145], ["all three", "OBSERVATION_MODIFIER", 19, 28], ["Yersinia spp", "OBSERVATION", 29, 41], ["enteric diseases", "OBSERVATION", 129, 145], ["pseudotuberculosis", "OBSERVATION_MODIFIER", 150, 168]]], ["YopJ plays an important role in inhibiting the inflammatory response and inducing apoptosis in E1 enzymes activate the C terminus of ubiquitin in an ATP-dependent manner, which directs ubiquitin to an E2 enzyme.", [["YopJ", "CHEMICAL", 0, 4], ["ATP", "CHEMICAL", 149, 152], ["E2", "CHEMICAL", 201, 203], ["ATP", "CHEMICAL", 149, 152], ["YopJ", "GENE_OR_GENE_PRODUCT", 0, 4], ["E1 enzymes", "GENE_OR_GENE_PRODUCT", 95, 105], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 133, 142], ["ATP", "SIMPLE_CHEMICAL", 149, 152], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 185, 194], ["E2", "GENE_OR_GENE_PRODUCT", 201, 203], ["YopJ", "PROTEIN", 0, 4], ["E1 enzymes", "PROTEIN", 95, 105], ["C terminus", "PROTEIN", 119, 129], ["ubiquitin", "PROTEIN", 133, 142], ["E2 enzyme", "PROTEIN", 201, 210], ["the inflammatory response", "PROBLEM", 43, 68], ["inducing apoptosis in E1 enzymes", "PROBLEM", 73, 105], ["the C terminus of ubiquitin", "PROBLEM", 115, 142], ["an E2 enzyme", "TEST", 198, 210], ["inflammatory", "OBSERVATION", 47, 59]]], ["E3 ligases transfer ubiquitin either from the E2 to a thioester linkage on the E3, and then to the substrate, or by acting as adaptors that bind to E2 proteins and substrates separately, and facilitate direct transfer of Ub from the E2 protein to the substrate.", [["E2", "CHEMICAL", 46, 48], ["E2", "CHEMICAL", 148, 150], ["E2", "CHEMICAL", 233, 235], ["thioester", "CHEMICAL", 54, 63], ["E3", "GENE_OR_GENE_PRODUCT", 0, 2], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 20, 29], ["E2", "GENE_OR_GENE_PRODUCT", 46, 48], ["E3", "GENE_OR_GENE_PRODUCT", 79, 81], ["E2", "GENE_OR_GENE_PRODUCT", 148, 150], ["Ub", "GENE_OR_GENE_PRODUCT", 221, 223], ["E2", "GENE_OR_GENE_PRODUCT", 233, 235], ["E3 ligases", "PROTEIN", 0, 10], ["ubiquitin", "PROTEIN", 20, 29], ["E3", "PROTEIN", 79, 81], ["adaptors", "PROTEIN", 126, 134], ["E2 proteins", "PROTEIN", 148, 159], ["Ub", "PROTEIN", 221, 223], ["E2 protein", "PROTEIN", 233, 243]]], ["Chains of four or more Ub molecules linked through lysine 48 (K48) of ubiquitin target the modified protein for proteasomal degradation, whereas K63-linked polyubiquitin chains regulate several cellular processes, such as DNA repair, signaling, endocytosis, vesicular trafficking, and cell-cycle progression.", [["proteasomal", "ANATOMY", 112, 123], ["cellular", "ANATOMY", 194, 202], ["vesicular", "ANATOMY", 258, 267], ["cell", "ANATOMY", 285, 289], ["lysine", "CHEMICAL", 51, 57], ["lysine", "CHEMICAL", 51, 57], ["Ub", "GENE_OR_GENE_PRODUCT", 23, 25], ["lysine 48", "SIMPLE_CHEMICAL", 51, 60], ["K48", "AMINO_ACID", 62, 65], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 70, 79], ["K63-linked polyubiquitin chains", "GENE_OR_GENE_PRODUCT", 145, 176], ["cellular", "CELL", 194, 202], ["DNA", "CELLULAR_COMPONENT", 222, 225], ["vesicular", "MULTI-TISSUE_STRUCTURE", 258, 267], ["cell", "CELL", 285, 289], ["Ub molecules", "PROTEIN", 23, 35], ["ubiquitin", "PROTEIN", 70, 79], ["modified protein", "PROTEIN", 91, 107], ["K63", "PROTEIN", 145, 148], ["polyubiquitin chains", "PROTEIN", 156, 176], ["ubiquitin", "TREATMENT", 70, 79], ["proteasomal degradation", "PROBLEM", 112, 135], ["K63", "TEST", 145, 148], ["polyubiquitin chains", "PROBLEM", 156, 176], ["several cellular processes", "PROBLEM", 186, 212], ["DNA repair", "TREATMENT", 222, 232], ["vesicular trafficking", "PROBLEM", 258, 279], ["polyubiquitin chains", "OBSERVATION", 156, 176], ["several", "OBSERVATION_MODIFIER", 186, 193], ["cellular processes", "OBSERVATION", 194, 212], ["vesicular trafficking", "OBSERVATION", 258, 279]]], ["Ubiquitin deconjugation is a reversible process catalyzed by deubiquitinating enzymes (DUBs).", [["Ubiquitin", "GENE_OR_GENE_PRODUCT", 0, 9], ["deubiquitinating enzymes", "GENE_OR_GENE_PRODUCT", 61, 85], ["DUBs", "GENE_OR_GENE_PRODUCT", 87, 91], ["deubiquitinating enzymes", "PROTEIN", 61, 85], ["DUBs", "PROTEIN", 87, 91], ["Ubiquitin deconjugation", "PROBLEM", 0, 23], ["a reversible process", "PROBLEM", 27, 47], ["deconjugation", "OBSERVATION", 10, 23], ["reversible", "OBSERVATION_MODIFIER", 29, 39], ["process", "OBSERVATION", 40, 47]]], ["These play an important role in processing Ub precursors, proofreading Ub protein conjugates, and removing Ub from substrate proteins. macrophages.", [["macrophages", "ANATOMY", 135, 146], ["Ub", "GENE_OR_GENE_PRODUCT", 43, 45], ["Ub", "GENE_OR_GENE_PRODUCT", 71, 73], ["Ub", "GENE_OR_GENE_PRODUCT", 107, 109], ["macrophages", "CELL", 135, 146], ["Ub precursors", "PROTEIN", 43, 56], ["Ub protein conjugates", "PROTEIN", 71, 92], ["Ub", "PROTEIN", 107, 109], ["substrate proteins", "PROTEIN", 115, 133], ["macrophages", "CELL_TYPE", 135, 146], ["proofreading Ub protein conjugates", "TEST", 58, 92], ["macrophages", "PROBLEM", 135, 146]]], ["By interfering with the NF-kB pathway through inhibition of MAPK (mitogen-activated protein kinase) kinases and IKKb, YopJ suppresses proinflammatory signaling via TNF and IL-8 production, as well as inducing apoptosis (Boland and Cornelis, 1998; Mills et al., 1997; Monack et al., 1997; Orth et al., 1999; Palmer et al., 1998; Yoon et al., 2003; Zhou et al., 2004) .", [["NF-kB", "GENE_OR_GENE_PRODUCT", 24, 29], ["MAPK (mitogen-activated protein kinase) kinases", "GENE_OR_GENE_PRODUCT", 60, 107], ["IKKb", "GENE_OR_GENE_PRODUCT", 112, 116], ["YopJ", "GENE_OR_GENE_PRODUCT", 118, 122], ["TNF", "GENE_OR_GENE_PRODUCT", 164, 167], ["IL-8", "GENE_OR_GENE_PRODUCT", 172, 176], ["NF-kB", "PROTEIN", 24, 29], ["MAPK (mitogen-activated protein kinase) kinases", "PROTEIN", 60, 107], ["IKKb", "PROTEIN", 112, 116], ["YopJ", "PROTEIN", 118, 122], ["TNF", "PROTEIN", 164, 167], ["MAPK", "TEST", 60, 64], ["mitogen-activated protein kinase", "TREATMENT", 66, 98], ["kinases", "TEST", 100, 107], ["IKKb", "TEST", 112, 116], ["TNF", "TEST", 164, 167], ["IL", "TEST", 172, 174]]], ["YopJ is a member of clan CE, family 55, and its substrate was originally thought to be SUMO-1, since expression of YopJ in mammalian cells decreased the cellular concentration of SUMO-1-conjugated proteins (Orth et al., 2000) .", [["mammalian cells", "ANATOMY", 123, 138], ["cellular", "ANATOMY", 153, 161], ["YopJ", "CHEMICAL", 0, 4], ["YopJ", "GENE_OR_GENE_PRODUCT", 0, 4], ["SUMO-1", "GENE_OR_GENE_PRODUCT", 87, 93], ["YopJ", "GENE_OR_GENE_PRODUCT", 115, 119], ["mammalian cells", "CELL", 123, 138], ["cellular", "CELL", 153, 161], ["SUMO-1", "GENE_OR_GENE_PRODUCT", 179, 185], ["YopJ", "PROTEIN", 0, 4], ["clan CE, family 55", "PROTEIN", 20, 38], ["SUMO-1", "PROTEIN", 87, 93], ["YopJ", "PROTEIN", 115, 119], ["mammalian cells", "CELL_TYPE", 123, 138], ["SUMO-1-conjugated proteins", "PROTEIN", 179, 205], ["YopJ in mammalian cells", "PROBLEM", 115, 138]]], ["However, a subsequent study showed that purified YopJ cleaves Ub-amino methyl coumarin (Ub-AMC) (a fluorogenic Ub conjugate) but not SUMO-1-AMC in vitro .", [["YopJ", "CHEMICAL", 49, 53], ["Ub-amino methyl coumarin", "CHEMICAL", 62, 86], ["Ub-AMC", "CHEMICAL", 88, 94], ["Ub-amino methyl coumarin", "CHEMICAL", 62, 86], ["Ub-AMC", "CHEMICAL", 88, 94], ["YopJ", "SIMPLE_CHEMICAL", 49, 53], ["Ub-amino methyl coumarin", "SIMPLE_CHEMICAL", 62, 86], ["Ub-AMC", "SIMPLE_CHEMICAL", 88, 94], ["Ub", "GENE_OR_GENE_PRODUCT", 111, 113], ["SUMO-1-AMC", "SIMPLE_CHEMICAL", 133, 143], ["Ub", "PROTEIN", 62, 64], ["Ub", "PROTEIN", 88, 90], ["fluorogenic Ub conjugate", "PROTEIN", 99, 123], ["SUMO", "PROTEIN", 133, 137], ["AMC", "PROTEIN", 140, 143], ["a subsequent study", "TEST", 9, 27], ["amino methyl coumarin", "TREATMENT", 65, 86], ["a fluorogenic Ub conjugate", "TREATMENT", 97, 123]]], ["Furthermore, infection of macrophages with a Y. pseudotuberculosis strain expressing a mutant version of YopJ in which the catalytic cysteine was replaced by alanine resulted in the accumulation of ubiquitinated IkBa in the macrophage cytosol .", [["macrophages", "ANATOMY", 26, 37], ["macrophage cytosol", "ANATOMY", 224, 242], ["infection", "DISEASE", 13, 22], ["Y. pseudotuberculosis", "DISEASE", 45, 66], ["cysteine", "CHEMICAL", 133, 141], ["alanine", "CHEMICAL", 158, 165], ["cysteine", "CHEMICAL", 133, 141], ["alanine", "CHEMICAL", 158, 165], ["Ba", "CHEMICAL", 214, 216], ["macrophages", "CELL", 26, 37], ["Y. pseudotuberculosis strain", "ORGANISM", 45, 73], ["YopJ", "GENE_OR_GENE_PRODUCT", 105, 109], ["cysteine", "AMINO_ACID", 133, 141], ["alanine", "AMINO_ACID", 158, 165], ["IkBa", "GENE_OR_GENE_PRODUCT", 212, 216], ["macrophage cytosol", "CELLULAR_COMPONENT", 224, 242], ["macrophages", "CELL_TYPE", 26, 37], ["YopJ", "PROTEIN", 105, 109], ["IkBa", "PROTEIN", 212, 216], ["Y. pseudotuberculosis", "SPECIES", 45, 66], ["Y. pseudotuberculosis", "SPECIES", 45, 66], ["infection of macrophages", "PROBLEM", 13, 37], ["a Y. pseudotuberculosis strain", "PROBLEM", 43, 73], ["YopJ", "TREATMENT", 105, 109], ["the catalytic cysteine", "TREATMENT", 119, 141], ["alanine", "TREATMENT", 158, 165], ["infection", "OBSERVATION", 13, 22], ["macrophages", "OBSERVATION", 26, 37], ["pseudotuberculosis", "OBSERVATION", 48, 66], ["ubiquitinated IkBa", "OBSERVATION", 198, 216], ["macrophage cytosol", "OBSERVATION", 224, 242]]], ["Normally, activation of the NF-kB pathway leads to phosphorylation, ubiquitination, and proteasomal degradation of IkBa, which allows the translocation of NF-kB to the nucleus, where it regulates transcription of genes involved in proinflammatory signaling.", [["proteasomal", "ANATOMY", 88, 99], ["nucleus", "ANATOMY", 168, 175], ["NF-kB", "GENE_OR_GENE_PRODUCT", 28, 33], ["IkBa", "GENE_OR_GENE_PRODUCT", 115, 119], ["NF-kB", "GENE_OR_GENE_PRODUCT", 155, 160], ["nucleus", "CELLULAR_COMPONENT", 168, 175], ["NF-kB", "PROTEIN", 28, 33], ["IkBa", "PROTEIN", 115, 119], ["NF-kB", "PROTEIN", 155, 160], ["proteasomal degradation of IkBa", "PROBLEM", 88, 119], ["proteasomal degradation", "OBSERVATION", 88, 111], ["nucleus", "ANATOMY", 168, 175], ["proinflammatory signaling", "OBSERVATION", 231, 256]]], ["Translocated YopJ was therefore proposed to act as a DUB for ubiquitinated IkBa, thereby preventing its degradation.", [["YopJ", "GENE_OR_GENE_PRODUCT", 13, 17], ["DUB", "GENE_OR_GENE_PRODUCT", 53, 56], ["IkBa", "GENE_OR_GENE_PRODUCT", 75, 79], ["YopJ", "PROTEIN", 13, 17], ["DUB", "PROTEIN", 53, 56], ["ubiquitinated IkBa", "PROTEIN", 61, 79], ["ubiquitinated IkBa", "TREATMENT", 61, 79], ["its degradation", "PROBLEM", 100, 115]]], ["However, YopJ is evidently not able to hydrolyze ubiquitinated IkBa in vitro (Collier-Hyams et al., 2002) .", [["YopJ", "GENE_OR_GENE_PRODUCT", 9, 13], ["IkBa", "GENE_OR_GENE_PRODUCT", 63, 67], ["YopJ", "PROTEIN", 9, 13], ["ubiquitinated IkBa", "PROTEIN", 49, 67]]], ["Furthermore, it has been shown recently by two groups that YopJ can function as an acetyltransferase in vitro by transferring acetyl groups to serine and threonine residues in the activation loop of MAPKK6, effectively preventing their phosphorylation and hence kinase activation (Bliska, 2006; Mittal et al., 2006; Mukherjee et al., 2006) .", [["YopJ", "CHEMICAL", 59, 63], ["acetyl", "CHEMICAL", 126, 132], ["threonine", "CHEMICAL", 154, 163], ["acetyl", "CHEMICAL", 126, 132], ["serine", "CHEMICAL", 143, 149], ["threonine", "CHEMICAL", 154, 163], ["YopJ", "SIMPLE_CHEMICAL", 59, 63], ["serine", "AMINO_ACID", 143, 149], ["threonine residues", "AMINO_ACID", 154, 172], ["MAPKK6", "GENE_OR_GENE_PRODUCT", 199, 205], ["YopJ", "PROTEIN", 59, 63], ["acetyltransferase", "PROTEIN", 83, 100], ["MAPKK6", "PROTEIN", 199, 205], ["an acetyltransferase in vitro", "TREATMENT", 80, 109], ["acetyl groups", "TREATMENT", 126, 139], ["threonine residues", "TREATMENT", 154, 172]]], ["It is important to know if YopJ can cause similar modifications in vivo, since it is not immediately obvious how a loss of acetyltransferase activity on MAPKK6 would result in an accumulation of ubiquitinated IkBa in infected cells .", [["cells", "ANATOMY", 226, 231], ["YopJ", "CHEMICAL", 27, 31], ["Ba", "CHEMICAL", 211, 213], ["YopJ", "SIMPLE_CHEMICAL", 27, 31], ["acetyltransferase", "GENE_OR_GENE_PRODUCT", 123, 140], ["MAPKK6", "GENE_OR_GENE_PRODUCT", 153, 159], ["IkBa", "GENE_OR_GENE_PRODUCT", 209, 213], ["cells", "CELL", 226, 231], ["acetyltransferase", "PROTEIN", 123, 140], ["MAPKK6", "PROTEIN", 153, 159], ["IkBa", "PROTEIN", 209, 213], ["infected cells", "CELL_TYPE", 217, 231], ["a loss of acetyltransferase activity", "PROBLEM", 113, 149], ["MAPKK6", "TREATMENT", 153, 159], ["ubiquitinated IkBa in infected cells", "PROBLEM", 195, 231], ["ubiquitinated IkBa", "OBSERVATION", 195, 213], ["infected cells", "OBSERVATION", 217, 231]]], ["However, these studies raise the possibility that YopJ is a bifunctional enzyme that acetylates one or more substrate and deubiquitinates another.", [["YopJ", "CHEMICAL", 50, 54], ["YopJ", "GENE_OR_GENE_PRODUCT", 50, 54], ["YopJ", "PROTEIN", 50, 54], ["bifunctional enzyme", "PROTEIN", 60, 79], ["these studies", "TEST", 9, 22], ["a bifunctional enzyme", "TREATMENT", 58, 79], ["raise the possibility", "UNCERTAINTY", 23, 44]]], ["Such relaxed substrate specificity of a bacterial enzyme would not be unprecedented: E. coli TAP is a multifunctional enzyme that has both protease and deacetylating activities (Lee et al., 2006) .SalmonellaSalmonella enterica serovar Typhimurium is an invasive pathogen that colonizes the small intestine, and in the murine model of typhoid it penetrates the epithelium and transits from Peyer's patches and mesenteric lymph nodes to the spleen and liver, where it replicates in macrophages.", [["small intestine", "ANATOMY", 290, 305], ["epithelium", "ANATOMY", 360, 370], ["Peyer's patches", "ANATOMY", 389, 404], ["mesenteric lymph nodes", "ANATOMY", 409, 431], ["spleen", "ANATOMY", 439, 445], ["liver", "ANATOMY", 450, 455], ["macrophages", "ANATOMY", 480, 491], ["typhoid", "DISEASE", 334, 341], ["E. coli", "ORGANISM", 85, 92], ["TAP", "GENE_OR_GENE_PRODUCT", 93, 96], ["Salmonella", "ORGANISM", 197, 207], ["Salmonella enterica serovar Typhimurium", "ORGANISM", 207, 246], ["small intestine", "ORGAN", 290, 305], ["murine", "ORGANISM", 318, 324], ["epithelium", "TISSUE", 360, 370], ["Peyer's patches", "TISSUE", 389, 404], ["mesenteric lymph nodes", "MULTI-TISSUE_STRUCTURE", 409, 431], ["spleen", "ORGAN", 439, 445], ["liver", "ORGAN", 450, 455], ["macrophages", "CELL", 480, 491], ["bacterial enzyme", "PROTEIN", 40, 56], ["TAP", "PROTEIN", 93, 96], ["multifunctional enzyme", "PROTEIN", 102, 124], ["protease", "PROTEIN", 139, 147], ["macrophages", "CELL_TYPE", 480, 491], ["E. coli", "SPECIES", 85, 92], ["Salmonella", "SPECIES", 197, 207], ["Salmonella", "SPECIES", 207, 217], ["enterica serovar Typhimurium", "SPECIES", 218, 246], ["murine", "SPECIES", 318, 324], ["E. coli", "SPECIES", 85, 92], ["Salmonella enterica serovar Typhimurium", "SPECIES", 207, 246], ["a bacterial enzyme", "TEST", 38, 56], ["E. coli TAP", "PROBLEM", 85, 96], ["a multifunctional enzyme", "TEST", 100, 124], ["both protease", "TREATMENT", 134, 147], ["SalmonellaSalmonella enterica serovar Typhimurium", "TREATMENT", 197, 246], ["an invasive pathogen", "PROBLEM", 250, 270], ["typhoid", "PROBLEM", 334, 341], ["serovar Typhimurium", "OBSERVATION", 227, 246], ["invasive", "OBSERVATION_MODIFIER", 253, 261], ["pathogen", "OBSERVATION", 262, 270], ["small intestine", "ANATOMY", 290, 305], ["typhoid", "OBSERVATION", 334, 341], ["epithelium", "ANATOMY_MODIFIER", 360, 370], ["mesenteric", "ANATOMY", 409, 419], ["lymph nodes", "OBSERVATION", 420, 431], ["spleen", "ANATOMY", 439, 445], ["liver", "ANATOMY", 450, 455], ["macrophages", "OBSERVATION", 480, 491]]], ["Following invasion or phagocytosis by macrophages, the vast majority of intracellular S. enterica remain in a membrane-bound compartment, the Salmonellacontaining vacuole (SCV), which the bacteria modify to provide an environment favorable for replication.", [["macrophages", "ANATOMY", 38, 49], ["intracellular", "ANATOMY", 72, 85], ["membrane", "ANATOMY", 110, 118], ["compartment", "ANATOMY", 125, 136], ["vacuole", "ANATOMY", 163, 170], ["SCV", "ANATOMY", 172, 175], ["macrophages", "CELL", 38, 49], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 72, 85], ["S. enterica", "ORGANISM", 86, 97], ["membrane", "CELLULAR_COMPONENT", 110, 118], ["Salmonellacontaining vacuole", "CELLULAR_COMPONENT", 142, 170], ["macrophages", "CELL_TYPE", 38, 49], ["S. enterica", "SPECIES", 86, 97], ["S. enterica", "SPECIES", 86, 97], ["invasion", "PROBLEM", 10, 18], ["phagocytosis", "PROBLEM", 22, 34], ["intracellular S. enterica", "PROBLEM", 72, 97], ["the Salmonellacontaining vacuole (SCV)", "TREATMENT", 138, 176], ["the bacteria", "PROBLEM", 184, 196], ["invasion", "OBSERVATION", 10, 18], ["phagocytosis", "OBSERVATION_MODIFIER", 22, 34], ["macrophages", "OBSERVATION_MODIFIER", 38, 49], ["vast", "OBSERVATION_MODIFIER", 55, 59], ["majority", "OBSERVATION_MODIFIER", 60, 68], ["intracellular S. enterica", "OBSERVATION", 72, 97], ["SCV", "ANATOMY", 172, 175]]], ["To invade host cells, Salmonella uses a T3S system encoded by the Salmonella pathogenicity island 1 (SPI-1).", [["cells", "ANATOMY", 15, 20], ["host cells", "CELL", 10, 20], ["Salmonella pathogenicity island 1", "GENE_OR_GENE_PRODUCT", 66, 99], ["SPI-1", "GENE_OR_GENE_PRODUCT", 101, 106], ["host cells", "CELL_TYPE", 10, 20], ["Salmonella pathogenicity island 1", "DNA", 66, 99], ["SPI-1", "DNA", 101, 106], ["Salmonella", "PROBLEM", 22, 32], ["host cells", "OBSERVATION", 10, 20]]], ["This system translocates several effector proteins across the hostcell plasma membrane.", [["hostcell plasma membrane", "ANATOMY", 62, 86], ["hostcell", "CELLULAR_COMPONENT", 62, 70], ["plasma membrane", "CELLULAR_COMPONENT", 71, 86], ["effector proteins", "PROTEIN", 33, 50], ["several", "OBSERVATION_MODIFIER", 25, 32], ["effector proteins", "OBSERVATION", 33, 50], ["hostcell plasma membrane", "OBSERVATION", 62, 86]]], ["Some of these remodel the actin cytoskeleton to cause localized membrane ruffling and bacterial uptake.", [["cytoskeleton", "ANATOMY", 32, 44], ["membrane", "ANATOMY", 64, 72], ["actin", "GENE_OR_GENE_PRODUCT", 26, 31], ["cytoskeleton", "CELLULAR_COMPONENT", 32, 44], ["membrane", "CELLULAR_COMPONENT", 64, 72], ["actin", "PROTEIN", 26, 31], ["localized membrane ruffling", "PROBLEM", 54, 81], ["bacterial uptake", "PROBLEM", 86, 102], ["actin cytoskeleton", "OBSERVATION", 26, 44], ["localized", "OBSERVATION_MODIFIER", 54, 63], ["membrane ruffling", "OBSERVATION", 64, 81], ["bacterial uptake", "OBSERVATION", 86, 102]]], ["Thereafter, another set of effectors is translocated across the vacuolar membrane.", [["vacuolar membrane", "ANATOMY", 64, 81], ["vacuolar membrane", "CELLULAR_COMPONENT", 64, 81], ["effectors", "OBSERVATION", 27, 36], ["vacuolar membrane", "OBSERVATION", 64, 81]]], ["This is accomplished by the T3S system encoded by SPI-2, which translocates over 20 effectors, detectable approximately 4 hr following entry of bacteria.", [["SPI-2", "GENE_OR_GENE_PRODUCT", 50, 55], ["T3S", "PROTEIN", 28, 31], ["SPI", "PROTEIN", 50, 53], ["bacteria", "PROBLEM", 144, 152], ["bacteria", "OBSERVATION", 144, 152]]], ["Together, these effector proteins enable bacterial replication in a variety of Review host-cell types and also induce a delayed cytotoxicity in macrophages (Kuhle and Hensel, 2004; Waterman and Holden, 2003) .", [["cell", "ANATOMY", 91, 95], ["macrophages", "ANATOMY", 144, 155], ["host-cell", "CELL", 86, 95], ["macrophages", "CELL", 144, 155], ["effector proteins", "PROTEIN", 16, 33], ["macrophages", "CELL_TYPE", 144, 155], ["bacterial replication", "PROBLEM", 41, 62], ["a delayed cytotoxicity in macrophages", "PROBLEM", 118, 155], ["bacterial replication", "OBSERVATION", 41, 62], ["delayed", "OBSERVATION_MODIFIER", 120, 127], ["cytotoxicity", "OBSERVATION", 128, 140]]], ["Salmonellae that are both pathogenic and nonpathogenic for humans interfere with ubiquitination pathways.", [["Salmonellae", "ORGANISM", 0, 11], ["humans", "ORGANISM", 59, 65], ["humans", "SPECIES", 59, 65], ["humans", "SPECIES", 59, 65], ["Salmonellae", "PROBLEM", 0, 11]]], ["Whereas pathogenic Salmonella elicits an NF-kB-dependent proinflammatory response upon colonization of human intestinal epithelial cells in vitro, nonpathogenic strains are capable of suppressing this response.", [["intestinal epithelial cells", "ANATOMY", 109, 136], ["NF-kB", "GENE_OR_GENE_PRODUCT", 41, 46], ["human", "ORGANISM", 103, 108], ["intestinal epithelial cells", "CELL", 109, 136], ["NF-kB", "PROTEIN", 41, 46], ["human intestinal epithelial cells", "CELL_TYPE", 103, 136], ["human", "SPECIES", 103, 108], ["Salmonella", "SPECIES", 19, 29], ["human", "SPECIES", 103, 108], ["pathogenic Salmonella elicits", "PROBLEM", 8, 37], ["an NF", "TEST", 38, 43], ["dependent proinflammatory response", "PROBLEM", 47, 81], ["human intestinal epithelial cells", "PROBLEM", 103, 136], ["nonpathogenic strains", "PROBLEM", 147, 168], ["kB-dependent", "OBSERVATION_MODIFIER", 44, 56], ["proinflammatory response", "OBSERVATION", 57, 81], ["intestinal epithelial cells", "OBSERVATION", 109, 136], ["nonpathogenic strains", "OBSERVATION", 147, 168]]], ["The inhibition does not affect the phosphorylation of IkBa but somehow affects its subsequent ubiquitination, and thereby prevents its degradation (Neish et al., 2000) .", [["IkBa", "GENE_OR_GENE_PRODUCT", 54, 58], ["IkBa", "PROTEIN", 54, 58]]], ["The inhibition appears to be specific to the E3-SCF b-TrCP substrates IkBa and b-catenin and caused by a rapid loss of neddylated Cullin-1, which is a subunit of the E3-SCF complex necessary for ubiquitination of IkBa and subsequent activation of NF-kB (Collier-Hyams et al., 2005) .", [["IkBa", "CHEMICAL", 70, 74], ["E3", "GENE_OR_GENE_PRODUCT", 45, 47], ["IkBa", "GENE_OR_GENE_PRODUCT", 70, 74], ["b-catenin", "GENE_OR_GENE_PRODUCT", 79, 88], ["Cullin-1", "GENE_OR_GENE_PRODUCT", 130, 138], ["E3", "GENE_OR_GENE_PRODUCT", 166, 168], ["SCF", "GENE_OR_GENE_PRODUCT", 169, 172], ["IkBa", "GENE_OR_GENE_PRODUCT", 213, 217], ["NF-kB", "GENE_OR_GENE_PRODUCT", 247, 252], ["E3", "PROTEIN", 45, 47], ["SCF", "PROTEIN", 48, 51], ["TrCP substrates", "PROTEIN", 54, 69], ["IkBa", "PROTEIN", 70, 74], ["b-catenin", "PROTEIN", 79, 88], ["neddylated Cullin-1", "PROTEIN", 119, 138], ["E3", "PROTEIN", 166, 168], ["SCF complex", "PROTEIN", 169, 180], ["IkBa", "PROTEIN", 213, 217], ["NF-kB", "PROTEIN", 247, 252], ["a rapid loss of neddylated Cullin", "PROBLEM", 103, 136], ["ubiquitination of IkBa", "TREATMENT", 195, 217], ["rapid", "OBSERVATION_MODIFIER", 105, 110]]], ["The Salmonella molecule(s) responsible and the mechanisms involved in this interesting activity are not yet known.SalmonellaAvrA is predicted to be a clan CE protein translocated by the SPI-1 T3S system in a subset of strains of S. enterica (Hardt and Galan, 1997) .", [["SalmonellaAvrA", "CHEMICAL", 114, 128], ["Salmonella molecule", "GENE_OR_GENE_PRODUCT", 4, 23], ["SalmonellaAvrA", "GENE_OR_GENE_PRODUCT", 114, 128], ["SPI-1", "GENE_OR_GENE_PRODUCT", 186, 191], ["S. enterica", "ORGANISM", 229, 240], ["Salmonella molecule", "PROTEIN", 4, 23], ["SalmonellaAvrA", "PROTEIN", 114, 128], ["clan CE protein", "PROTEIN", 150, 165], ["SPI", "PROTEIN", 186, 189], ["T3S", "PROTEIN", 192, 195], ["S. enterica", "SPECIES", 229, 240], ["S. enterica", "SPECIES", 229, 240], ["The Salmonella molecule", "PROBLEM", 0, 23], ["SalmonellaAvrA", "TREATMENT", 114, 128], ["a clan CE protein", "TEST", 148, 165], ["the SPI", "TEST", 182, 189], ["Salmonella molecule", "OBSERVATION", 4, 23]]], ["AvrA has 56% identity to YopJ and also inhibits the NF-kB pathway.", [["AvrA", "CHEMICAL", 0, 4], ["YopJ", "CHEMICAL", 25, 29], ["AvrA", "GENE_OR_GENE_PRODUCT", 0, 4], ["YopJ", "GENE_OR_GENE_PRODUCT", 25, 29], ["NF-kB", "GENE_OR_GENE_PRODUCT", 52, 57], ["AvrA", "PROTEIN", 0, 4], ["NF-kB", "PROTEIN", 52, 57]]], ["However, this seems to occur at a different stage than YopJ, because in transfected cells YopJ had little effect on NF-kB-dependent reporter gene activity when cells were stimulated with IKK-b, whereas AvrA effectively inhibited reporter gene activity (Collier-Hyams et al., 2002) .", [["cells", "ANATOMY", 84, 89], ["cells", "ANATOMY", 160, 165], ["YopJ", "CHEMICAL", 90, 94], ["YopJ", "SIMPLE_CHEMICAL", 55, 59], ["cells", "CELL", 84, 89], ["NF-kB", "GENE_OR_GENE_PRODUCT", 116, 121], ["cells", "CELL", 160, 165], ["IKK-b", "GENE_OR_GENE_PRODUCT", 187, 192], ["AvrA", "GENE_OR_GENE_PRODUCT", 202, 206], ["transfected cells", "CELL_LINE", 72, 89], ["NF-kB", "PROTEIN", 116, 121], ["reporter gene", "DNA", 132, 145], ["IKK", "PROTEIN", 187, 190], ["AvrA", "PROTEIN", 202, 206], ["reporter gene", "DNA", 229, 242], ["IKK", "TEST", 187, 190]]], ["However, like YopJ, AvrA contributes to apoptosis of host cells (Collier-Hyams et al., 2002) .", [["cells", "ANATOMY", 58, 63], ["AvrA", "CHEMICAL", 20, 24], ["YopJ", "GENE_OR_GENE_PRODUCT", 14, 18], ["AvrA", "GENE_OR_GENE_PRODUCT", 20, 24], ["host cells", "CELL", 53, 63], ["YopJ", "PROTEIN", 14, 18], ["AvrA", "PROTEIN", 20, 24], ["host cells", "CELL_TYPE", 53, 63], ["apoptosis of host cells", "PROBLEM", 40, 63], ["host cells", "OBSERVATION", 53, 63]]], ["While the inhibitory activity of AvrA on the NF-kB pathway was shown to be dependent on a putative catalytic cysteine, it has yet to be established if AvrA is a DUB.SalmonellaSeveral other effectors involved in Salmonella invasion are either ubiquitinated or modulate ubiquitination following their translocation to the host cells.", [["cells", "ANATOMY", 325, 330], ["AvrA", "CHEMICAL", 33, 37], ["cysteine", "CHEMICAL", 109, 117], ["AvrA", "SIMPLE_CHEMICAL", 33, 37], ["NF-kB", "GENE_OR_GENE_PRODUCT", 45, 50], ["cysteine", "AMINO_ACID", 109, 117], ["AvrA", "SIMPLE_CHEMICAL", 151, 155], ["DUB", "GENE_OR_GENE_PRODUCT", 161, 164], ["cells", "CELL", 325, 330], ["AvrA", "PROTEIN", 33, 37], ["NF-kB", "PROTEIN", 45, 50], ["AvrA", "PROTEIN", 151, 155], ["DUB", "PROTEIN", 161, 164], ["host cells", "CELL_TYPE", 320, 330], ["Salmonella", "SPECIES", 211, 221], ["a putative catalytic cysteine", "TREATMENT", 88, 117], ["SalmonellaSeveral other effectors", "TREATMENT", 165, 198], ["Salmonella invasion", "PROBLEM", 211, 230], ["modulate ubiquitination", "PROBLEM", 259, 282], ["DUB", "OBSERVATION", 161, 164], ["Salmonella invasion", "OBSERVATION", 211, 230], ["modulate", "OBSERVATION_MODIFIER", 259, 267], ["ubiquitination", "OBSERVATION_MODIFIER", 268, 282], ["host cells", "OBSERVATION", 320, 330]]], ["SopE is a guanine nucleotide exchange factor for Rac1 that stimulates the actin polymerization required for membrane ruffling and bacterial uptake (Patel and Galan, 2006) .", [["membrane", "ANATOMY", 108, 116], ["SopE", "CHEMICAL", 0, 4], ["guanine nucleotide", "CHEMICAL", 10, 28], ["guanine nucleotide", "CHEMICAL", 10, 28], ["SopE", "GENE_OR_GENE_PRODUCT", 0, 4], ["Rac1", "GENE_OR_GENE_PRODUCT", 49, 53], ["actin", "GENE_OR_GENE_PRODUCT", 74, 79], ["membrane", "CELLULAR_COMPONENT", 108, 116], ["SopE", "PROTEIN", 0, 4], ["guanine nucleotide exchange factor", "PROTEIN", 10, 44], ["Rac1", "PROTEIN", 49, 53], ["actin", "PROTEIN", 74, 79], ["a guanine nucleotide exchange factor", "TREATMENT", 8, 44], ["Rac1", "TREATMENT", 49, 53], ["the actin polymerization", "TREATMENT", 70, 94], ["membrane ruffling", "PROBLEM", 108, 125], ["bacterial uptake", "PROBLEM", 130, 146], ["actin polymerization", "OBSERVATION", 74, 94], ["bacterial uptake", "OBSERVATION", 130, 146]]], ["SptP, which is codelivered into host cells in similar quantities to SopE, acts as a GTPase-activating protein and counteracts the activity of SopE (Fu and Galan, 1999) .", [["cells", "ANATOMY", 37, 42], ["SptP", "CHEMICAL", 0, 4], ["SptP", "GENE_OR_GENE_PRODUCT", 0, 4], ["host cells", "CELL", 32, 42], ["SopE", "GENE_OR_GENE_PRODUCT", 68, 72], ["SopE", "GENE_OR_GENE_PRODUCT", 142, 146], ["SptP", "PROTEIN", 0, 4], ["host cells", "CELL_TYPE", 32, 42], ["SopE", "PROTEIN", 68, 72], ["GTPase-activating protein", "PROTEIN", 84, 109], ["SopE", "PROTEIN", 142, 146], ["host cells", "OBSERVATION", 32, 42]]], ["SopE is rapidly ubiquitinated and degraded, while the half-life of SptP is much longer.", [["SopE", "CHEMICAL", 0, 4], ["SopE", "GENE_OR_GENE_PRODUCT", 0, 4], ["SptP", "SIMPLE_CHEMICAL", 67, 71], ["SopE", "PROTEIN", 0, 4], ["SptP", "PROTEIN", 67, 71], ["SptP", "TREATMENT", 67, 71], ["rapidly", "OBSERVATION_MODIFIER", 8, 15], ["ubiquitinated", "OBSERVATION_MODIFIER", 16, 29]]], ["Domain-swapping experiments revealed that differential degradation kinetics is controlled by information in the N-terminal secretion and translocation domains of these proteins.", [["N", "CHEMICAL", 112, 113], ["N-terminal secretion and translocation domains", "PROTEIN", 112, 158], ["Domain-swapping experiments", "TEST", 0, 27], ["differential degradation kinetics", "PROBLEM", 42, 75], ["these proteins", "PROBLEM", 162, 176], ["differential", "OBSERVATION_MODIFIER", 42, 54], ["degradation kinetics", "OBSERVATION", 55, 75]]], ["The differential half-life of these proteins therefore accounts for the transient nature of the ruffling response induced by Salmonella (Kubori and Galan, 2003) .Figure 2.", [["Salmonella", "SPECIES", 125, 135], ["these proteins", "PROBLEM", 30, 44], ["the ruffling response", "PROBLEM", 92, 113], ["Salmonella", "PROBLEM", 125, 135], ["differential", "OBSERVATION_MODIFIER", 4, 16], ["half-life", "OBSERVATION_MODIFIER", 17, 26], ["ruffling response", "OBSERVATION", 96, 113]]], ["Examples of Interference of Mammalian Ub Pathways by Bacterial PathogensYopJ/P, a Yersinia T3S effector protein with DUB and acetyltransferase activity, is translocated into host cells, where it interferes with the NF-kB pathway through inhibition of MKKs (mitogen-activated protein kinase kinases) and IKKb and possibly by deubiquitinating ubiquitinated IkB-a.", [["cells", "ANATOMY", 179, 184], ["Ub", "GENE_OR_GENE_PRODUCT", 38, 40], ["DUB", "GENE_OR_GENE_PRODUCT", 117, 120], ["acetyltransferase", "GENE_OR_GENE_PRODUCT", 125, 142], ["cells", "CELL", 179, 184], ["NF-kB", "GENE_OR_GENE_PRODUCT", 215, 220], ["MKKs", "GENE_OR_GENE_PRODUCT", 251, 255], ["mitogen-activated protein kinase kinases", "GENE_OR_GENE_PRODUCT", 257, 297], ["IKKb", "GENE_OR_GENE_PRODUCT", 303, 307], ["IkB", "GENE_OR_GENE_PRODUCT", 355, 358], ["Bacterial PathogensYopJ/P", "PROTEIN", 53, 78], ["Yersinia T3S effector protein", "PROTEIN", 82, 111], ["DUB", "PROTEIN", 117, 120], ["acetyltransferase", "PROTEIN", 125, 142], ["host cells", "CELL_TYPE", 174, 184], ["NF-kB", "PROTEIN", 215, 220], ["MKKs", "PROTEIN", 251, 255], ["mitogen-activated protein kinase kinases", "PROTEIN", 257, 297], ["IKKb", "PROTEIN", 303, 307], ["IkB", "PROTEIN", 355, 358], ["Mammalian Ub Pathways", "PROBLEM", 28, 49], ["Bacterial Pathogens", "PROBLEM", 53, 72], ["a Yersinia T3S effector protein", "TEST", 80, 111], ["DUB and acetyltransferase activity", "TREATMENT", 117, 151], ["MKKs", "TEST", 251, 255], ["mitogen-activated protein kinase kinases", "TREATMENT", 257, 297], ["IKKb", "TREATMENT", 303, 307], ["acetyltransferase activity", "OBSERVATION", 125, 151]]], ["YopJ plays an important role in inhibiting the inflammatory response and induces apoptosis in macrophages.", [["macrophages", "ANATOMY", 94, 105], ["YopJ", "CHEMICAL", 0, 4], ["YopJ", "GENE_OR_GENE_PRODUCT", 0, 4], ["macrophages", "CELL", 94, 105], ["YopJ", "PROTEIN", 0, 4], ["macrophages", "CELL_TYPE", 94, 105], ["the inflammatory response", "PROBLEM", 43, 68], ["apoptosis in macrophages", "PROBLEM", 81, 105], ["inflammatory", "OBSERVATION", 47, 59]]], ["Shigella also inhibits host immune responses.", [["Shigella", "ORGANISM", 0, 8], ["Shigella", "PROBLEM", 0, 8], ["host immune", "OBSERVATION", 23, 34]]], ["Following translocation into host cells, OspG acts as a kinase and blocks TNF-induced IkBa degradation, conceivably by phosphorylating a component of SCF b-TrCP complex.", [["cells", "ANATOMY", 34, 39], ["host cells", "CELL", 29, 39], ["OspG", "GENE_OR_GENE_PRODUCT", 41, 45], ["TNF", "GENE_OR_GENE_PRODUCT", 74, 77], ["IkBa", "GENE_OR_GENE_PRODUCT", 86, 90], ["SCF", "GENE_OR_GENE_PRODUCT", 150, 153], ["TrCP", "GENE_OR_GENE_PRODUCT", 156, 160], ["host cells", "CELL_TYPE", 29, 39], ["OspG", "PROTEIN", 41, 45], ["TNF", "PROTEIN", 74, 77], ["IkBa", "PROTEIN", 86, 90], ["SCF", "PROTEIN", 150, 153], ["TrCP complex", "PROTEIN", 156, 168], ["a kinase and blocks TNF", "TREATMENT", 54, 77], ["IkBa degradation", "PROBLEM", 86, 102], ["SCF b-TrCP complex", "PROBLEM", 150, 168], ["host cells", "OBSERVATION", 29, 39], ["SCF b-", "OBSERVATION", 150, 156]]], ["IpaH9.8, another Shigella effector, functions as an E3 Ub ligase that interferes with the pheromone response signaling pathway in yeast by ubiquitinating the MAPKK Ste7.", [["IpaH9.8", "GENE_OR_GENE_PRODUCT", 0, 7], ["E3", "GENE_OR_GENE_PRODUCT", 52, 54], ["MAPKK Ste7", "GENE_OR_GENE_PRODUCT", 158, 168], ["IpaH9.8", "PROTEIN", 0, 7], ["Shigella effector", "PROTEIN", 17, 34], ["E3 Ub ligase", "PROTEIN", 52, 64], ["MAPKK Ste7", "PROTEIN", 158, 168], ["yeast", "SPECIES", 130, 135], ["yeast", "SPECIES", 130, 135], ["another Shigella effector", "PROBLEM", 9, 34], ["an E3 Ub ligase", "TEST", 49, 64]]], ["To facilitate invasion and intracellular survival, Salmonella translocates two sets of effector proteins into the host cells.", [["intracellular", "ANATOMY", 27, 40], ["cells", "ANATOMY", 119, 124], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 27, 40], ["host cells", "CELL", 114, 124], ["effector proteins", "PROTEIN", 87, 104], ["host cells", "CELL_TYPE", 114, 124], ["Salmonella", "SPECIES", 51, 61], ["invasion and intracellular survival", "TREATMENT", 14, 49], ["Salmonella", "PROBLEM", 51, 61], ["invasion", "OBSERVATION", 14, 22], ["host cells", "OBSERVATION", 114, 124]]], ["The Salmonella pathogenicity island 1 (SPI-1) T3S system translocates effector proteins across the host-cell plasma membrane.", [["cell plasma membrane", "ANATOMY", 104, 124], ["Salmonella pathogenicity island 1", "GENE_OR_GENE_PRODUCT", 4, 37], ["SPI-1", "GENE_OR_GENE_PRODUCT", 39, 44], ["T3S", "GENE_OR_GENE_PRODUCT", 46, 49], ["cell", "CELLULAR_COMPONENT", 104, 108], ["plasma membrane", "CELLULAR_COMPONENT", 109, 124], ["effector proteins", "PROTEIN", 70, 87], ["The Salmonella pathogenicity island", "TEST", 0, 35], ["SPI", "TEST", 39, 42], ["Salmonella pathogenicity", "OBSERVATION", 4, 28], ["host", "ANATOMY", 99, 103], ["cell plasma membrane", "OBSERVATION", 104, 124]]], ["Several of these effectors are ubiquitinated following translocation, but one, SopA, functions as a HECT-like E3 Ub ligase that preferentially uses the inflammation-associated E2s UbcH5a, UbcH5c, and UbcH7 for ubiquitination in vitro.", [["inflammation", "DISEASE", 152, 164], ["SopA", "GENE_OR_GENE_PRODUCT", 79, 83], ["HECT", "GENE_OR_GENE_PRODUCT", 100, 104], ["E3", "GENE_OR_GENE_PRODUCT", 110, 112], ["E2s", "GENE_OR_GENE_PRODUCT", 176, 179], ["UbcH5a", "GENE_OR_GENE_PRODUCT", 180, 186], ["UbcH5c", "GENE_OR_GENE_PRODUCT", 188, 194], ["UbcH7", "GENE_OR_GENE_PRODUCT", 200, 205], ["SopA", "PROTEIN", 79, 83], ["HECT", "PROTEIN", 100, 104], ["E3 Ub ligase", "PROTEIN", 110, 122], ["E2s", "PROTEIN", 176, 179], ["UbcH5a", "PROTEIN", 180, 186], ["UbcH5c", "PROTEIN", 188, 194], ["UbcH7", "PROTEIN", 200, 205], ["a HECT", "TEST", 98, 104], ["the inflammation", "PROBLEM", 148, 164], ["UbcH5c", "TEST", 188, 194], ["ubiquitination in vitro", "PROBLEM", 210, 233], ["effectors", "OBSERVATION", 17, 26], ["ubiquitinated", "OBSERVATION_MODIFIER", 31, 44], ["ligase", "OBSERVATION", 116, 122], ["inflammation", "OBSERVATION", 152, 164]]], ["SopA induces a host inflammatory response by promoting polymorphonuclear leukocyte transepithelial migration.", [["polymorphonuclear leukocyte", "ANATOMY", 55, 82], ["SopA", "CHEMICAL", 0, 4], ["SopA", "SIMPLE_CHEMICAL", 0, 4], ["polymorphonuclear leukocyte", "CELL", 55, 82], ["SopA", "PROTEIN", 0, 4], ["a host inflammatory response", "PROBLEM", 13, 41], ["polymorphonuclear leukocyte transepithelial migration", "PROBLEM", 55, 108], ["host", "OBSERVATION_MODIFIER", 15, 19], ["inflammatory", "OBSERVATION_MODIFIER", 20, 32], ["polymorphonuclear leukocyte transepithelial migration", "OBSERVATION", 55, 108]]], ["Following uptake, Salmonella translocates another set of effectors across the Salmonellacontaining vacuole via the SPI-2 T3S system.", [["vacuole", "ANATOMY", 99, 106], ["Salmonellacontaining vacuole", "CELLULAR_COMPONENT", 78, 106], ["SPI-2", "GENE_OR_GENE_PRODUCT", 115, 120], ["SPI", "PROTEIN", 115, 118], ["T3S", "PROTEIN", 121, 124], ["Salmonella", "SPECIES", 18, 28], ["Salmonella", "PROBLEM", 18, 28]]], ["SseL is translocated approximately 6 hr postuptake and acts as a DUB in vivo to trigger a delayed cytotoxic effect in macrophages.ReviewSopA is another SPI-1 effector that has an important role in the induction of host inflammatory responses by promoting polymorphonuclear (PMN) leukocyte transepithelial migration (Wood et al., 2000) (Figure 2 ).", [["macrophages", "ANATOMY", 118, 129], ["polymorphonuclear", "ANATOMY", 255, 272], ["PMN", "ANATOMY", 274, 277], ["leukocyte", "ANATOMY", 279, 288], ["SseL", "GENE_OR_GENE_PRODUCT", 0, 4], ["DUB", "GENE_OR_GENE_PRODUCT", 65, 68], ["macrophages", "CELL", 118, 129], ["ReviewSopA", "GENE_OR_GENE_PRODUCT", 130, 140], ["SPI-1", "GENE_OR_GENE_PRODUCT", 152, 157], ["polymorphonuclear (PMN) leukocyte", "CELL", 255, 288], ["SseL", "PROTEIN", 0, 4], ["DUB", "PROTEIN", 65, 68], ["macrophages", "CELL_TYPE", 118, 129], ["ReviewSopA", "PROTEIN", 130, 140], ["SPI-1 effector", "PROTEIN", 152, 166], ["PMN", "CELL_TYPE", 274, 277], ["a delayed cytotoxic effect in macrophages", "PROBLEM", 88, 129], ["host inflammatory responses", "PROBLEM", 214, 241], ["polymorphonuclear (PMN) leukocyte transepithelial migration", "PROBLEM", 255, 314], ["macrophages", "OBSERVATION", 118, 129], ["leukocyte transepithelial migration", "OBSERVATION", 279, 314]]], ["In epithelial cells, translocated SopA is ubiquitinated by an E3 ligase, HsRMA1, and subsequently degraded.", [["epithelial cells", "ANATOMY", 3, 19], ["epithelial cells", "CELL", 3, 19], ["SopA", "GENE_OR_GENE_PRODUCT", 34, 38], ["E3", "GENE_OR_GENE_PRODUCT", 62, 64], ["HsRMA1", "GENE_OR_GENE_PRODUCT", 73, 79], ["epithelial cells", "CELL_TYPE", 3, 19], ["SopA", "PROTEIN", 34, 38], ["E3 ligase", "PROTEIN", 62, 71], ["HsRMA1", "PROTEIN", 73, 79], ["an E3 ligase", "TEST", 59, 71], ["HsRMA1", "TEST", 73, 79], ["epithelial cells", "OBSERVATION", 3, 19]]], ["While the majority of S. enterica serovar Typhimurium (S. Typhimurium) bacteria remain within membrane-bound vacuoles, a small proportion escape into the epithelial cell cytosol, where they replicate.", [["membrane", "ANATOMY", 94, 102], ["vacuoles", "ANATOMY", 109, 117], ["epithelial cell cytosol", "ANATOMY", 154, 177], ["S. enterica serovar Typhimurium", "ORGANISM", 22, 53], ["S. Typhimurium", "ORGANISM", 55, 69], ["membrane", "CELLULAR_COMPONENT", 94, 102], ["vacuoles", "CELLULAR_COMPONENT", 109, 117], ["epithelial cell cytosol", "CELLULAR_COMPONENT", 154, 177], ["epithelial cell cytosol", "CELL_TYPE", 154, 177], ["S.", "SPECIES", 22, 24], ["enterica serovar Typhimurium", "SPECIES", 25, 53], ["S. Typhimurium", "SPECIES", 55, 69], ["S. enterica serovar Typhimurium", "SPECIES", 22, 53], ["S. Typhimurium", "SPECIES", 55, 69], ["S. enterica serovar Typhimurium (S. Typhimurium", "TEST", 22, 69], ["bacteria", "PROBLEM", 71, 79], ["bound vacuoles", "OBSERVATION", 103, 117], ["small", "OBSERVATION_MODIFIER", 121, 126], ["proportion escape", "OBSERVATION", 127, 144], ["epithelial cell cytosol", "OBSERVATION", 154, 177]]], ["Ubiquitinated SopA appears to have a minor role in promoting vacuolar escape, since mutation of sopA or RNAi of HsRMA1 reduced the numbers of bacteria that escaped their vacuoles (Zhang et al., 2005) .", [["vacuolar", "ANATOMY", 61, 69], ["vacuoles", "ANATOMY", 170, 178], ["SopA", "GENE_OR_GENE_PRODUCT", 14, 18], ["vacuolar", "CELLULAR_COMPONENT", 61, 69], ["sopA", "GENE_OR_GENE_PRODUCT", 96, 100], ["HsRMA1", "GENE_OR_GENE_PRODUCT", 112, 118], ["vacuoles", "CELLULAR_COMPONENT", 170, 178], ["SopA", "PROTEIN", 14, 18], ["sopA", "PROTEIN", 96, 100], ["HsRMA1", "PROTEIN", 112, 118], ["mutation of sopA", "PROBLEM", 84, 100], ["bacteria", "PROBLEM", 142, 150], ["vacuolar escape", "OBSERVATION", 61, 76]]], ["In macrophages, cytosolic bacteria fail to replicate (Beuzon et al., 2002) and become surrounded by polyubiquitinated proteins and proteasomes, which might contribute to bacterial growth suppression (Perrin et al., 2004) .", [["macrophages", "ANATOMY", 3, 14], ["cytosolic bacteria", "ANATOMY", 16, 34], ["macrophages", "CELL", 3, 14], ["macrophages", "CELL_TYPE", 3, 14], ["polyubiquitinated proteins", "PROTEIN", 100, 126], ["proteasomes", "PROTEIN", 131, 142], ["cytosolic bacteria", "PROBLEM", 16, 34], ["polyubiquitinated proteins and proteasomes", "PROBLEM", 100, 142], ["bacterial growth suppression", "PROBLEM", 170, 198], ["macrophages", "OBSERVATION", 3, 14], ["cytosolic bacteria", "OBSERVATION", 16, 34], ["polyubiquitinated proteins", "OBSERVATION", 100, 126]]], ["Remarkably, recent work has shown that SopA is itself a HECTlike E3 Ub ligase .", [["SopA", "CHEMICAL", 39, 43], ["SopA", "GENE_OR_GENE_PRODUCT", 39, 43], ["Ub", "GENE_OR_GENE_PRODUCT", 68, 70], ["SopA", "PROTEIN", 39, 43], ["HECTlike E3 Ub ligase", "PROTEIN", 56, 77]]], ["Consistent with a regulatory role in inflammation, SopA preferentially used the inflammation-associated E2s UbcH5a, UbcH5c, and UbcH7 for ubiquitination in vitro, and a Salmonella strain expressing an E3 ligase-dead point mutant version of SopA induced less PMN transepithelial migration in vitro .", [["PMN", "ANATOMY", 258, 261], ["inflammation", "DISEASE", 37, 49], ["inflammation", "DISEASE", 80, 92], ["SopA", "CHEMICAL", 240, 244], ["SopA", "GENE_OR_GENE_PRODUCT", 51, 55], ["E2s", "GENE_OR_GENE_PRODUCT", 104, 107], ["UbcH5a", "GENE_OR_GENE_PRODUCT", 108, 114], ["UbcH5c", "GENE_OR_GENE_PRODUCT", 116, 122], ["UbcH7", "GENE_OR_GENE_PRODUCT", 128, 133], ["Salmonella strain", "ORGANISM", 169, 186], ["E3", "GENE_OR_GENE_PRODUCT", 201, 203], ["SopA", "GENE_OR_GENE_PRODUCT", 240, 244], ["PMN transepithelial", "CELL", 258, 277], ["SopA", "PROTEIN", 51, 55], ["E2s", "PROTEIN", 104, 107], ["UbcH5a", "PROTEIN", 108, 114], ["UbcH5c", "PROTEIN", 116, 122], ["UbcH7", "PROTEIN", 128, 133], ["E3 ligase", "PROTEIN", 201, 210], ["SopA", "PROTEIN", 240, 244], ["inflammation", "PROBLEM", 37, 49], ["SopA", "TREATMENT", 51, 55], ["the inflammation", "PROBLEM", 76, 92], ["UbcH5c", "TEST", 116, 122], ["ubiquitination in vitro", "PROBLEM", 138, 161], ["a Salmonella strain", "PROBLEM", 167, 186], ["SopA", "TREATMENT", 240, 244], ["inflammation", "OBSERVATION", 37, 49], ["inflammation", "OBSERVATION", 80, 92], ["less PMN", "OBSERVATION", 253, 261], ["transepithelial migration", "OBSERVATION", 262, 287]]], ["SopA could ubiquitinate bacterially derived or host proteins (or both), and identification of its physiological target(s) is now crucial in understanding its role in inflammation and enteritis.ReviewSigD/SopB is a fourth SPI-1 effector that is ubiquitinated upon translocation to the host cell.", [["cell", "ANATOMY", 289, 293], ["SopA", "CHEMICAL", 0, 4], ["inflammation", "DISEASE", 166, 178], ["enteritis", "DISEASE", 183, 192], ["SopA", "GENE_OR_GENE_PRODUCT", 0, 4], ["ReviewSigD", "GENE_OR_GENE_PRODUCT", 193, 203], ["SopB", "GENE_OR_GENE_PRODUCT", 204, 208], ["SPI-1", "GENE_OR_GENE_PRODUCT", 221, 226], ["host cell", "CELL", 284, 293], ["SopA", "PROTEIN", 0, 4], ["bacterially derived or host proteins", "PROTEIN", 24, 60], ["ReviewSigD", "PROTEIN", 193, 203], ["SopB", "PROTEIN", 204, 208], ["fourth SPI-1 effector", "PROTEIN", 214, 235], ["host cell", "CELL_TYPE", 284, 293], ["host proteins", "PROBLEM", 47, 60], ["inflammation", "PROBLEM", 166, 178], ["enteritis", "PROBLEM", 183, 192], ["inflammation", "OBSERVATION", 166, 178], ["enteritis", "OBSERVATION", 183, 192], ["host cell", "OBSERVATION", 284, 293]]], ["This inositol phosphatase localizes to the surface of the nascent SCV, where it persists for several hours .", [["surface", "ANATOMY", 43, 50], ["SCV", "ANATOMY", 66, 69], ["inositol", "CHEMICAL", 5, 13], ["inositol", "CHEMICAL", 5, 13], ["inositol", "SIMPLE_CHEMICAL", 5, 13], ["surface", "CELLULAR_COMPONENT", 43, 50], ["SCV", "CELLULAR_COMPONENT", 66, 69], ["inositol phosphatase", "PROTEIN", 5, 25], ["This inositol phosphatase", "TEST", 0, 25], ["surface", "ANATOMY_MODIFIER", 43, 50], ["nascent SCV", "OBSERVATION", 58, 69]]], ["It acts by retaining high levels of phosphatidylinositol-3-phosphate [PtdIns(3)P] in the SCV membrane and has important roles in bacterial replication (Galan and Collmer, 1999; Hernandez et al., 2004) and suppression of apoptosis in epithelial cells by activation of Akt (Knodler et al., 2005) , and membrane fission during bacterial invasion (Terebiznik et al., 2002) .", [["SCV membrane", "ANATOMY", 89, 101], ["epithelial cells", "ANATOMY", 233, 249], ["membrane", "ANATOMY", 300, 308], ["phosphatidylinositol-3-phosphate", "CHEMICAL", 36, 68], ["phosphatidylinositol-3-phosphate", "CHEMICAL", 36, 68], ["PtdIns(3)P", "CHEMICAL", 70, 80], ["phosphatidylinositol-3-phosphate", "GENE_OR_GENE_PRODUCT", 36, 68], ["PtdIns(3)P", "SIMPLE_CHEMICAL", 70, 80], ["SCV membrane", "CELLULAR_COMPONENT", 89, 101], ["epithelial cells", "CELL", 233, 249], ["Akt", "GENE_OR_GENE_PRODUCT", 267, 270], ["membrane", "CELLULAR_COMPONENT", 300, 308], ["epithelial cells", "CELL_TYPE", 233, 249], ["Akt", "PROTEIN", 267, 270], ["phosphatidylinositol-3-phosphate [PtdIns(3)P] in the SCV membrane", "TREATMENT", 36, 101], ["bacterial replication", "TREATMENT", 129, 150], ["apoptosis in epithelial cells", "PROBLEM", 220, 249], ["membrane fission", "PROBLEM", 300, 316], ["bacterial invasion", "PROBLEM", 324, 342], ["SCV membrane", "ANATOMY", 89, 101], ["bacterial replication", "OBSERVATION", 129, 150], ["epithelial cells", "OBSERVATION", 233, 249], ["bacterial invasion", "OBSERVATION", 324, 342]]], ["By 2 hr postinvasion, ubiquitin-conjugated SigD/SopB can be detected, but curiously this does not appear to lead to its degradation by the proteasome , and the functional significance of its ubiquitination (if any) is not understood.ReviewInterference with ubiquitination by Salmonella continues after the expression of the SPI-2 T3S system.", [["ubiquitin", "GENE_OR_GENE_PRODUCT", 22, 31], ["SigD", "GENE_OR_GENE_PRODUCT", 43, 47], ["SopB", "GENE_OR_GENE_PRODUCT", 48, 52], ["SPI-2", "GENE_OR_GENE_PRODUCT", 324, 329], ["ubiquitin", "PROTEIN", 22, 31], ["SigD", "PROTEIN", 43, 47], ["SopB", "PROTEIN", 48, 52], ["proteasome", "PROTEIN", 139, 149], ["SPI", "PROTEIN", 324, 327], ["T3S", "PROTEIN", 330, 333], ["ubiquitin-conjugated SigD/SopB", "TREATMENT", 22, 52], ["the proteasome", "TREATMENT", 135, 149], ["ubiquitination", "TREATMENT", 257, 271], ["Salmonella", "PROBLEM", 275, 285]]], ["SseL is a newly characterized effector of cysteine protease clan CE whose translocation onto the vacuolar membrane can be detected in epithelial cells and macrophages after approximately 6 hr following uptake of bacteria (Rytk\u00f6 nen et al., 2007) (Figure 2) .", [["vacuolar membrane", "ANATOMY", 97, 114], ["epithelial cells", "ANATOMY", 134, 150], ["macrophages", "ANATOMY", 155, 166], ["SseL", "CHEMICAL", 0, 4], ["cysteine", "CHEMICAL", 42, 50], ["SseL", "GENE_OR_GENE_PRODUCT", 0, 4], ["cysteine", "AMINO_ACID", 42, 50], ["vacuolar membrane", "CELLULAR_COMPONENT", 97, 114], ["epithelial cells", "CELL", 134, 150], ["macrophages", "CELL", 155, 166], ["SseL", "PROTEIN", 0, 4], ["cysteine protease clan CE", "PROTEIN", 42, 67], ["epithelial cells", "CELL_TYPE", 134, 150], ["macrophages", "CELL_TYPE", 155, 166], ["cysteine protease", "TREATMENT", 42, 59], ["bacteria", "PROBLEM", 212, 220], ["vacuolar membrane", "ANATOMY", 97, 114], ["epithelial cells", "OBSERVATION", 134, 150]]], ["A yeast two-hybrid screen with SseL and a HeLa cell cDNA library revealed that SseL interacts directly with Ub.", [["HeLa cell", "ANATOMY", 42, 51], ["SseL", "GENE_OR_GENE_PRODUCT", 31, 35], ["HeLa cell", "CELL", 42, 51], ["SseL", "GENE_OR_GENE_PRODUCT", 79, 83], ["SseL", "PROTEIN", 31, 35], ["HeLa cell cDNA library", "DNA", 42, 64], ["SseL", "PROTEIN", 79, 83], ["yeast", "SPECIES", 2, 7], ["yeast", "SPECIES", 2, 7], ["A yeast two-hybrid screen", "PROBLEM", 0, 25], ["a HeLa cell cDNA library", "TEST", 40, 64]]], ["A purified GST-SseL fusion protein specifically cleaved ubiquitin substrates, and infection of epithelial cells and macrophages with S. Typhimurium sseL mutant strains led to the accumulation of ubiquitinmodified proteins, indicating that SseL functions as a DUB in vivo.", [["epithelial cells", "ANATOMY", 95, 111], ["macrophages", "ANATOMY", 116, 127], ["infection", "DISEASE", 82, 91], ["GST", "GENE_OR_GENE_PRODUCT", 11, 14], ["SseL", "GENE_OR_GENE_PRODUCT", 15, 19], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 56, 65], ["epithelial cells", "CELL", 95, 111], ["macrophages", "CELL", 116, 127], ["S. Typhimurium sseL mutant strains", "ORGANISM", 133, 167], ["SseL", "GENE_OR_GENE_PRODUCT", 239, 243], ["DUB", "GENE_OR_GENE_PRODUCT", 259, 262], ["GST", "PROTEIN", 11, 14], ["SseL fusion protein", "PROTEIN", 15, 34], ["ubiquitin substrates", "PROTEIN", 56, 76], ["epithelial cells", "CELL_TYPE", 95, 111], ["macrophages", "CELL_TYPE", 116, 127], ["ubiquitinmodified proteins", "PROTEIN", 195, 221], ["SseL", "PROTEIN", 239, 243], ["DUB", "PROTEIN", 259, 262], ["S. Typhimurium", "SPECIES", 133, 147], ["S. Typhimurium", "SPECIES", 133, 147], ["A purified GST", "TEST", 0, 14], ["SseL fusion protein", "PROBLEM", 15, 34], ["cleaved ubiquitin substrates", "PROBLEM", 48, 76], ["epithelial cells", "PROBLEM", 95, 111], ["macrophages", "PROBLEM", 116, 127], ["S. Typhimurium sseL mutant strains", "PROBLEM", 133, 167], ["the accumulation of ubiquitinmodified proteins", "PROBLEM", 175, 221], ["SseL functions", "PROBLEM", 239, 253], ["ubiquitin substrates", "OBSERVATION", 56, 76], ["epithelial cells", "OBSERVATION", 95, 111]]], ["However, unlike YopJ, SseL did not influence cytokine production or interfere with activation or degradation of IkBa upon infection of macrophages. sseL mutant strains did not display an intracellular replication defect but were defective for a SPI-2-dependent latestage cytotoxic effect on macrophages and were attenuated for virulence in the systemic phase of infection in mice (Rytk\u00f6 nen et al., 2007) .", [["macrophages", "ANATOMY", 135, 146], ["intracellular", "ANATOMY", 187, 200], ["macrophages", "ANATOMY", 291, 302], ["infection", "DISEASE", 122, 131], ["infection", "DISEASE", 362, 371], ["YopJ", "GENE_OR_GENE_PRODUCT", 16, 20], ["SseL", "GENE_OR_GENE_PRODUCT", 22, 26], ["IkBa", "GENE_OR_GENE_PRODUCT", 112, 116], ["macrophages", "CELL", 135, 146], ["sseL", "GENE_OR_GENE_PRODUCT", 148, 152], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 187, 200], ["SPI-2", "GENE_OR_GENE_PRODUCT", 245, 250], ["macrophages", "CELL", 291, 302], ["mice", "ORGANISM", 375, 379], ["YopJ", "PROTEIN", 16, 20], ["SseL", "PROTEIN", 22, 26], ["cytokine", "PROTEIN", 45, 53], ["IkBa", "PROTEIN", 112, 116], ["macrophages", "CELL_TYPE", 135, 146], ["macrophages", "CELL_TYPE", 291, 302], ["mice", "SPECIES", 375, 379], ["mice", "SPECIES", 375, 379], ["IkBa", "TREATMENT", 112, 116], ["infection of macrophages", "PROBLEM", 122, 146], ["sseL mutant strains", "PROBLEM", 148, 167], ["an intracellular replication defect", "PROBLEM", 184, 219], ["a SPI", "TEST", 243, 248], ["dependent latestage cytotoxic effect on macrophages", "PROBLEM", 251, 302], ["virulence", "PROBLEM", 327, 336], ["infection", "PROBLEM", 362, 371], ["intracellular", "OBSERVATION", 187, 200], ["replication defect", "OBSERVATION", 201, 219], ["cytotoxic effect", "OBSERVATION", 271, 287], ["macrophages", "OBSERVATION", 291, 302], ["systemic phase", "OBSERVATION_MODIFIER", 344, 358], ["infection", "OBSERVATION", 362, 371]]], ["This shows that ubiquitinated proteins of host or bacterial origin accumulate on (or in close proximity to) the SCV membrane, and these are deubiquitinated by SseL.", [["SCV membrane", "ANATOMY", 112, 124], ["SCV membrane", "CELLULAR_COMPONENT", 112, 124], ["SseL", "GENE_OR_GENE_PRODUCT", 159, 163], ["ubiquitinated proteins", "PROTEIN", 16, 38], ["SseL", "PROTEIN", 159, 163], ["ubiquitinated proteins of host", "PROBLEM", 16, 46], ["bacterial origin", "PROBLEM", 50, 66], ["ubiquitinated", "OBSERVATION_MODIFIER", 16, 29], ["proteins", "OBSERVATION", 30, 38], ["host", "OBSERVATION_MODIFIER", 42, 46], ["bacterial origin", "OBSERVATION", 50, 66], ["SCV membrane", "ANATOMY", 112, 124]]], ["How this leads to cytotoxicity remains to be established, but the study provides evidence that the cytotoxic activity of Salmonella is an important component of its virulence.", [["Salmonella", "CHEMICAL", 121, 131], ["Salmonella", "SPECIES", 121, 131], ["cytotoxicity", "PROBLEM", 18, 30], ["the study", "TEST", 62, 71], ["the cytotoxic activity of Salmonella", "PROBLEM", 95, 131], ["its virulence", "PROBLEM", 161, 174], ["cytotoxic", "OBSERVATION_MODIFIER", 99, 108]]], ["It is tempting to speculate that the deubiquitinating activity of SseL might function to counteract ubiquitination and degradation of other translocated bacterial effectors by the host-cell machinery.", [["cell", "ANATOMY", 185, 189], ["SseL", "CHEMICAL", 66, 70], ["SseL", "GENE_OR_GENE_PRODUCT", 66, 70], ["cell", "CELL", 185, 189], ["SseL", "PROTEIN", 66, 70], ["translocated bacterial effectors", "PROTEIN", 140, 172], ["other translocated bacterial effectors", "PROBLEM", 134, 172], ["bacterial effectors", "OBSERVATION", 153, 172]]], ["However, this seems unlikely for two reasons.", [["seems unlikely for", "UNCERTAINTY", 14, 32]]], ["First, an important collective function of SPI-2 T3S system effectors is to enable intracellular growth (Waterman and Holden, 2003) and if SseL acted by protecting these effectors then an sseL mutant would be predicted to have an intracellular replication defect.", [["intracellular", "ANATOMY", 83, 96], ["intracellular", "ANATOMY", 230, 243], ["SPI-2", "GENE_OR_GENE_PRODUCT", 43, 48], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 83, 96], ["SseL", "GENE_OR_GENE_PRODUCT", 139, 143], ["sseL", "GENE_OR_GENE_PRODUCT", 188, 192], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 230, 243], ["SPI-2 T3S system effectors", "PROTEIN", 43, 69], ["SseL", "PROTEIN", 139, 143], ["sseL mutant", "PROTEIN", 188, 199], ["SPI", "TEST", 43, 46], ["an intracellular replication defect", "PROBLEM", 227, 262], ["intracellular", "OBSERVATION", 230, 243], ["replication defect", "OBSERVATION", 244, 262]]], ["Secondly, SseL has a clear preference for K63-linked Ub chains (Rytk\u00f6 nen et al., 2007) , indicating that it is likely to be involved in signaling events rather than interfering directly with protein degradation.ShigellaShigella flexneri is an important cause of human bacillary dysentery.", [["SseL", "CHEMICAL", 10, 14], ["bacillary dysentery", "DISEASE", 269, 288], ["SseL", "GENE_OR_GENE_PRODUCT", 10, 14], ["K63", "SIMPLE_CHEMICAL", 42, 45], ["Ub", "GENE_OR_GENE_PRODUCT", 53, 55], ["ShigellaShigella flexneri", "ORGANISM", 212, 237], ["human", "ORGANISM", 263, 268], ["SseL", "PROTEIN", 10, 14], ["K63", "PROTEIN", 42, 45], ["Ub chains", "PROTEIN", 53, 62], ["ShigellaShigella flexneri", "SPECIES", 212, 237], ["human", "SPECIES", 263, 268], ["ShigellaShigella flexneri", "SPECIES", 212, 237], ["human", "SPECIES", 263, 268], ["K63", "TEST", 42, 45], ["signaling events", "PROBLEM", 137, 153], ["protein degradation", "PROBLEM", 192, 211], ["ShigellaShigella flexneri", "PROBLEM", 212, 237], ["human bacillary dysentery", "PROBLEM", 263, 288], ["important cause of", "UNCERTAINTY", 244, 262], ["human", "OBSERVATION_MODIFIER", 263, 268], ["bacillary", "OBSERVATION_MODIFIER", 269, 278], ["dysentery", "OBSERVATION", 279, 288]]], ["The morphological features of Shigella entry into epithelial cells are similar to those induced by S. Typhimurium, and although both require T3S systems, the effector protein repertoire and infection process following invasion are distinct.", [["epithelial cells", "ANATOMY", 50, 66], ["infection", "DISEASE", 190, 199], ["Shigella", "ORGANISM", 30, 38], ["epithelial cells", "CELL", 50, 66], ["S. Typhimurium", "ORGANISM", 99, 113], ["T3S", "GENE_OR_GENE_PRODUCT", 141, 144], ["epithelial cells", "CELL_TYPE", 50, 66], ["S. Typhimurium", "SPECIES", 99, 113], ["S. Typhimurium", "SPECIES", 99, 113], ["Shigella entry into epithelial cells", "PROBLEM", 30, 66], ["S. Typhimurium", "PROBLEM", 99, 113], ["T3S systems", "TEST", 141, 152], ["the effector protein repertoire", "TREATMENT", 154, 185], ["infection process", "PROBLEM", 190, 207], ["invasion", "PROBLEM", 218, 226], ["Shigella", "OBSERVATION_MODIFIER", 30, 38], ["epithelial cells", "OBSERVATION", 50, 66], ["infection", "OBSERVATION", 190, 199]]], ["S. flexneri invades the colonic epithelium initially through M cells of Peyer's patches.", [["colonic epithelium", "ANATOMY", 24, 42], ["M cells", "ANATOMY", 61, 68], ["S. flexneri", "ORGANISM", 0, 11], ["colonic epithelium", "TISSUE", 24, 42], ["M cells", "CELL", 61, 68], ["M cells", "CELL_TYPE", 61, 68], ["S. flexneri", "SPECIES", 0, 11], ["S. flexneri", "SPECIES", 0, 11], ["Peyer's patches", "TREATMENT", 72, 87], ["flexneri", "OBSERVATION", 3, 11], ["colonic epithelium", "ANATOMY", 24, 42]]], ["Bacteria then interact with macrophages in the lymphoid follicle, and enterocytes via their basolateral membranes.", [["macrophages", "ANATOMY", 28, 39], ["lymphoid follicle", "ANATOMY", 47, 64], ["enterocytes", "ANATOMY", 70, 81], ["basolateral membranes", "ANATOMY", 92, 113], ["Bacteria", "CELL", 0, 8], ["macrophages", "CELL", 28, 39], ["lymphoid follicle", "MULTI-TISSUE_STRUCTURE", 47, 64], ["enterocytes", "CELL", 70, 81], ["basolateral membranes", "CELLULAR_COMPONENT", 92, 113], ["macrophages", "CELL_TYPE", 28, 39], ["enterocytes", "CELL_TYPE", 70, 81], ["Bacteria", "PROBLEM", 0, 8], ["macrophages", "OBSERVATION", 28, 39], ["lymphoid follicle", "OBSERVATION", 47, 64], ["enterocytes", "ANATOMY", 70, 81], ["basolateral", "ANATOMY_MODIFIER", 92, 103], ["membranes", "ANATOMY_MODIFIER", 104, 113]]], ["These interactions result in a strong proinflammatory response that exacerbates infection of the intestinal epithelium.", [["intestinal epithelium", "ANATOMY", 97, 118], ["infection", "DISEASE", 80, 89], ["intestinal epithelium", "TISSUE", 97, 118], ["a strong proinflammatory response", "PROBLEM", 29, 62], ["infection of the intestinal epithelium", "PROBLEM", 80, 118], ["infection", "OBSERVATION", 80, 89], ["intestinal epithelium", "ANATOMY", 97, 118]]], ["However, it has become clear that stimulation of proinflammatory responses is subsequently modulated by the action of several bacterial effectors (Arbibe et al., 2007; Kim et al., 2005) .", [["several bacterial effectors", "PROBLEM", 118, 145], ["clear", "OBSERVATION", 23, 28]]], ["OspG is one of approximately 20 effectors delivered to the host cells by the Shigella T3S system.", [["cells", "ANATOMY", 64, 69], ["OspG", "CHEMICAL", 0, 4], ["OspG", "GENE_OR_GENE_PRODUCT", 0, 4], ["cells", "CELL", 64, 69], ["T3S", "GENE_OR_GENE_PRODUCT", 86, 89], ["OspG", "PROTEIN", 0, 4], ["host cells", "CELL_TYPE", 59, 69], ["one", "OBSERVATION_MODIFIER", 8, 11], ["host cells", "OBSERVATION", 59, 69]]], ["A yeast two-hybrid screen showed that OspG interacts with ubiquitinylated E2 molecules, including UbcH5b (Figure 2) .", [["E2", "CHEMICAL", 74, 76], ["OspG", "SIMPLE_CHEMICAL", 38, 42], ["UbcH5b", "GENE_OR_GENE_PRODUCT", 98, 104], ["OspG", "PROTEIN", 38, 42], ["ubiquitinylated E2 molecules", "PROTEIN", 58, 86], ["UbcH5b", "PROTEIN", 98, 104], ["yeast", "SPECIES", 2, 7], ["A yeast two-hybrid screen", "TEST", 0, 25], ["ubiquitinylated E2 molecules", "TREATMENT", 58, 86]]], ["OspG was shown to have kinase activity but evidently does not phosphorylate E2 proteins.", [["OspG", "CHEMICAL", 0, 4], ["E2", "CHEMICAL", 76, 78], ["OspG", "SIMPLE_CHEMICAL", 0, 4], ["E2", "GENE_OR_GENE_PRODUCT", 76, 78], ["OspG", "PROTEIN", 0, 4], ["E2 proteins", "PROTEIN", 76, 87], ["kinase activity", "PROBLEM", 23, 38]]], ["Nevertheless, OspG can block TNF-induced IkBa degradation, a process that is dependent on UbcH5b (Kim et al., 2005) .", [["OspG", "CHEMICAL", 14, 18], ["OspG", "CHEMICAL", 14, 18], ["OspG", "SIMPLE_CHEMICAL", 14, 18], ["TNF", "GENE_OR_GENE_PRODUCT", 29, 32], ["IkBa", "GENE_OR_GENE_PRODUCT", 41, 45], ["UbcH5b", "GENE_OR_GENE_PRODUCT", 90, 96], ["OspG", "PROTEIN", 14, 18], ["TNF", "PROTEIN", 29, 32], ["IkBa", "PROTEIN", 41, 45], ["OspG can block TNF", "TREATMENT", 14, 32], ["IkBa degradation", "PROBLEM", 41, 57], ["dependent", "OBSERVATION_MODIFIER", 77, 86]]], ["This effect requires a lysine residue important for kinase activity of OspG and suggests that OspG acts at the step of phospho-IkBa ubiquitination.", [["lysine", "CHEMICAL", 23, 29], ["OspG", "CHEMICAL", 94, 98], ["lysine", "CHEMICAL", 23, 29], ["OspG", "GENE_OR_GENE_PRODUCT", 71, 75], ["OspG", "GENE_OR_GENE_PRODUCT", 94, 98], ["IkBa", "GENE_OR_GENE_PRODUCT", 127, 131], ["OspG", "PROTEIN", 71, 75], ["OspG", "PROTEIN", 94, 98], ["IkBa", "PROTEIN", 127, 131], ["a lysine residue", "TREATMENT", 21, 37], ["kinase activity of OspG", "TREATMENT", 52, 75], ["OspG acts", "TREATMENT", 94, 103]]], ["Possibly, OspG acts by phosphorylating a component of SCF b-TrCP in the context of OspG-UbcH5b.", [["OspG", "CHEMICAL", 10, 14], ["OspG", "GENE_OR_GENE_PRODUCT", 10, 14], ["SCF b-TrCP", "GENE_OR_GENE_PRODUCT", 54, 64], ["OspG-UbcH5b", "GENE_OR_GENE_PRODUCT", 83, 94], ["OspG", "PROTEIN", 10, 14], ["SCF", "PROTEIN", 54, 57], ["TrCP", "PROTEIN", 60, 64], ["OspG", "PROTEIN", 83, 87], ["UbcH5b", "PROTEIN", 88, 94], ["SCF b-TrCP", "PROBLEM", 54, 64], ["SCF b-TrCP", "OBSERVATION", 54, 64]]], ["The biochemical evidence for dampening of the inflammatory response is supported by the phenotype of an ospG mutant, which induced a much stronger inflammatory response during infection of rabbit ileal loops (Kim et al., 2005) .ShigellaIpaH9.8 is another effector delivered by Shigella into host cells, where it translocates to the nucleus (Haraga and Miller, 2003; Toyotome et al., 2001) .", [["ileal loops", "ANATOMY", 196, 207], ["cells", "ANATOMY", 296, 301], ["nucleus", "ANATOMY", 332, 339], ["infection", "DISEASE", 176, 185], ["ShigellaIpaH9.8", "CHEMICAL", 228, 243], ["ospG", "GENE_OR_GENE_PRODUCT", 104, 108], ["rabbit", "ORGANISM", 189, 195], ["ileal loops", "MULTI-TISSUE_STRUCTURE", 196, 207], ["ShigellaIpaH9.8", "GENE_OR_GENE_PRODUCT", 228, 243], ["host cells", "CELL", 291, 301], ["nucleus", "CELLULAR_COMPONENT", 332, 339], ["ospG mutant", "PROTEIN", 104, 115], ["host cells", "CELL_TYPE", 291, 301], ["rabbit", "SPECIES", 189, 195], ["rabbit", "SPECIES", 189, 195], ["dampening of the inflammatory response", "PROBLEM", 29, 67], ["an ospG mutant", "PROBLEM", 101, 115], ["a much stronger inflammatory response during infection of rabbit ileal loops", "PROBLEM", 131, 207], ["ShigellaIpa", "TREATMENT", 228, 239], ["evidence for", "UNCERTAINTY", 16, 28], ["dampening", "OBSERVATION_MODIFIER", 29, 38], ["inflammatory", "OBSERVATION", 46, 58], ["stronger", "OBSERVATION_MODIFIER", 138, 146], ["inflammatory", "OBSERVATION", 147, 159], ["infection", "OBSERVATION", 176, 185], ["ileal loops", "ANATOMY", 196, 207], ["nucleus", "ANATOMY", 332, 339]]], ["Recently it has been shown that IpaH9.8 is an E3 Ub ligase (Rohde et al., 2007) (Figure 2 ).", [["IpaH9.8", "GENE_OR_GENE_PRODUCT", 32, 39], ["E3", "GENE_OR_GENE_PRODUCT", 46, 48], ["IpaH9.8", "PROTEIN", 32, 39], ["E3 Ub ligase", "PROTEIN", 46, 58]]], ["Its biochemical characterization was achieved by using Saccharomyces both as a host for an initial phenotypic screen, and then to identify its target and biochemical function.", [["Its biochemical characterization", "TEST", 0, 32], ["an initial phenotypic screen", "TEST", 88, 116]]], ["IpaH9.8 was shown to interfere with the pheromone response signaling pathway by ubiquitinating the MAPKK Ste7, which leads to its proteasome-dependent destruction (Rohde et al., 2007) .", [["IpaH9.8", "CHEMICAL", 0, 7], ["IpaH9.8", "GENE_OR_GENE_PRODUCT", 0, 7], ["MAPKK", "GENE_OR_GENE_PRODUCT", 99, 104], ["Ste7", "GENE_OR_GENE_PRODUCT", 105, 109], ["IpaH9.8", "PROTEIN", 0, 7], ["MAPKK Ste7", "PROTEIN", 99, 109], ["proteasome", "PROTEIN", 130, 140], ["the MAPKK Ste7", "TEST", 95, 109], ["its proteasome-dependent destruction", "PROBLEM", 126, 162], ["dependent", "OBSERVATION_MODIFIER", 141, 150], ["destruction", "OBSERVATION", 151, 162]]], ["Work from another group has shown that, in mammalian cells, IpaH9.8 interacts with U2AF 35 -a component of an essential pre-mRNA splicing factor complex (Okuda et al., 2005) .", [["cells", "ANATOMY", 53, 58], ["mammalian cells", "CELL", 43, 58], ["IpaH9.8", "GENE_OR_GENE_PRODUCT", 60, 67], ["U2AF 35", "GENE_OR_GENE_PRODUCT", 83, 90], ["mammalian cells", "CELL_TYPE", 43, 58], ["IpaH9.8", "PROTEIN", 60, 67], ["U2AF 35", "PROTEIN", 83, 90], ["essential pre-mRNA splicing factor complex", "PROTEIN", 110, 152], ["pre-mRNA splicing", "OBSERVATION", 120, 137]]], ["Deletion of ipaH9.8 resulted in increased proinflammatory cytokine production and, consistent with the hypothesis that IpaH9.8 might interfere with the function of U2AF 35 , reduction of U2AF 35 expression by siRNA-mediated knockdown caused a decrease in the expression of these cytokines (Okuda et al., 2005) .", [["ipaH9.8", "GENE_OR_GENE_PRODUCT", 12, 19], ["IpaH9.8", "GENE_OR_GENE_PRODUCT", 119, 126], ["U2AF 35", "GENE_OR_GENE_PRODUCT", 164, 171], ["U2AF 35", "GENE_OR_GENE_PRODUCT", 187, 194], ["ipaH9.8", "PROTEIN", 12, 19], ["proinflammatory cytokine", "PROTEIN", 42, 66], ["IpaH9.8", "PROTEIN", 119, 126], ["U2AF 35", "PROTEIN", 164, 171], ["U2AF 35", "PROTEIN", 187, 194], ["cytokines", "PROTEIN", 279, 288], ["Deletion of ipaH9.8", "PROBLEM", 0, 19], ["increased proinflammatory cytokine production", "PROBLEM", 32, 77], ["U2AF", "TEST", 164, 168], ["reduction of U2AF", "TREATMENT", 174, 191], ["siRNA-mediated knockdown", "TREATMENT", 209, 233], ["increased", "OBSERVATION_MODIFIER", 32, 41], ["proinflammatory cytokine production", "OBSERVATION", 42, 77], ["consistent with", "UNCERTAINTY", 83, 98], ["decrease", "OBSERVATION_MODIFIER", 243, 251]]], ["It would be interesting to know if IpaH9.8 can ubiquitinate U2AF 35 , which might help to reconcile the results from these two studies.", [["IpaH9.8", "CHEMICAL", 35, 42], ["IpaH9.8", "SIMPLE_CHEMICAL", 35, 42], ["IpaH9.8", "PROTEIN", 35, 42], ["U2AF 35", "PROTEIN", 60, 67], ["these two studies", "TEST", 117, 134]]], ["The finding that IpaH9.8 is an E3 ligase has broader implications, since homologous proteins with similar domain organization and containing a critical cysteine residue are found not only in Shigella but also in several other bacterial pathogens.", [["cysteine", "CHEMICAL", 152, 160], ["IpaH9.8", "GENE_OR_GENE_PRODUCT", 17, 24], ["E3", "GENE_OR_GENE_PRODUCT", 31, 33], ["cysteine", "AMINO_ACID", 152, 160], ["IpaH9.8", "PROTEIN", 17, 24], ["E3 ligase", "PROTEIN", 31, 40], ["homologous proteins", "PROTEIN", 73, 92], ["homologous proteins", "PROBLEM", 73, 92], ["similar domain organization", "PROBLEM", 98, 125], ["a critical cysteine residue", "PROBLEM", 141, 168], ["Shigella", "PROBLEM", 191, 199], ["several other bacterial pathogens", "PROBLEM", 212, 245], ["cysteine residue", "OBSERVATION", 152, 168], ["bacterial", "OBSERVATION_MODIFIER", 226, 235], ["pathogens", "OBSERVATION", 236, 245]]], ["These proteins include Salmonella SspH1, an effector of both the SPI-1 and SPI-2 T3S systems.", [["Salmonella", "ORGANISM", 23, 33], ["SspH1", "GENE_OR_GENE_PRODUCT", 34, 39], ["SPI-1", "GENE_OR_GENE_PRODUCT", 65, 70], ["SPI-2", "GENE_OR_GENE_PRODUCT", 75, 80], ["Salmonella SspH1", "PROTEIN", 23, 39], ["SPI-1 and SPI-2 T3S systems", "DNA", 65, 92], ["These proteins", "TEST", 0, 14], ["Salmonella SspH1", "PROBLEM", 23, 39], ["the SPI", "TEST", 61, 68], ["Salmonella SspH1", "OBSERVATION", 23, 39]]], ["Purified SspH1 was shown to have E3 ligase activity on PKN1 (Rohde et al., 2007) , a host-cell kinase previously shown to interact with SspH1 (Haraga and Miller, 2006) .ChlamydiaThe availability of ubiquitin-based probes has provided useful reagents to identify new DUBs from mammalian cells and viruses Ovaa et al., 2005) .", [["cell", "ANATOMY", 90, 94], ["cells", "ANATOMY", 286, 291], ["Chlamydia", "DISEASE", 169, 178], ["SspH1", "GENE_OR_GENE_PRODUCT", 9, 14], ["E3", "GENE_OR_GENE_PRODUCT", 33, 35], ["cell", "CELL", 90, 94], ["SspH1", "GENE_OR_GENE_PRODUCT", 136, 141], ["Chlamydia", "ORGANISM", 169, 178], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 198, 207], ["DUBs", "GENE_OR_GENE_PRODUCT", 266, 270], ["mammalian cells", "CELL", 276, 291], ["SspH1", "PROTEIN", 9, 14], ["E3 ligase", "PROTEIN", 33, 42], ["host-cell kinase", "PROTEIN", 85, 101], ["SspH1", "PROTEIN", 136, 141], ["ubiquitin", "PROTEIN", 198, 207], ["DUBs", "PROTEIN", 266, 270], ["mammalian cells", "CELL_TYPE", 276, 291], ["Chlamydia", "SPECIES", 169, 178], ["E3 ligase activity", "PROBLEM", 33, 51], ["a host-cell kinase", "TEST", 83, 101], ["Chlamydia", "PROBLEM", 169, 178], ["ubiquitin-based probes", "TREATMENT", 198, 220], ["useful reagents", "TREATMENT", 234, 249], ["new DUBs from mammalian cells", "PROBLEM", 262, 291], ["ligase activity", "OBSERVATION", 36, 51]]], ["Recently, this approach was used to identify two DUBs from Chlamydia trachomatis (Misaghi et al., 2006) .", [["Chlamydia trachomatis", "DISEASE", 59, 80], ["DUBs", "GENE_OR_GENE_PRODUCT", 49, 53], ["Chlamydia trachomatis", "ORGANISM", 59, 80], ["DUBs", "PROTEIN", 49, 53], ["Chlamydia trachomatis", "SPECIES", 59, 80], ["Chlamydia trachomatis", "SPECIES", 59, 80], ["Chlamydia trachomatis", "PROBLEM", 59, 80], ["Chlamydia trachomatis", "OBSERVATION", 59, 80]]], ["Lysates of infected HeLa cells were incubated with an epitopetagged Ub-vinylmethylester conjugate, which forms a covalent adduct with the active site cysteine of DUBs (Borodovsky et al., 2001) .", [["Lysates", "ANATOMY", 0, 7], ["HeLa cells", "ANATOMY", 20, 30], ["Ub-vinylmethylester", "CHEMICAL", 68, 87], ["Ub-vinylmethylester", "CHEMICAL", 68, 87], ["cysteine", "CHEMICAL", 150, 158], ["Lysates", "ORGANISM_SUBSTANCE", 0, 7], ["HeLa cells", "CELL", 20, 30], ["Ub-vinylmethylester conjugate", "SIMPLE_CHEMICAL", 68, 97], ["cysteine", "AMINO_ACID", 150, 158], ["HeLa cells", "CELL_LINE", 20, 30], ["Ub", "PROTEIN", 68, 70], ["DUBs", "PROTEIN", 162, 166], ["infected HeLa cells", "PROBLEM", 11, 30], ["an epitopetagged Ub-vinylmethylester conjugate", "TREATMENT", 51, 97], ["infected", "OBSERVATION_MODIFIER", 11, 19], ["HeLa cells", "OBSERVATION", 20, 30], ["covalent adduct", "OBSERVATION", 113, 128], ["active", "OBSERVATION_MODIFIER", 138, 144]]], ["Following immunoprecipitation, an interacting protein was fractionated by SDS-PAGE and identified by mass spectrometry.", [["interacting protein", "PROTEIN", 34, 53], ["immunoprecipitation", "TEST", 10, 29], ["an interacting protein", "PROBLEM", 31, 53], ["mass spectrometry", "PROBLEM", 101, 118], ["mass", "OBSERVATION", 101, 105]]], ["Genome sequence analysis revealed that the gene encoding this DUB is flanked by a homolog.", [["DUB", "GENE_OR_GENE_PRODUCT", 62, 65], ["DUB", "PROTEIN", 62, 65], ["Genome sequence analysis", "TEST", 0, 24]]], ["Both corresponding proteins (named Chla-Dub1 and ChlaDub2) were shown to have deubiquitinating and deneddylating activities.", [["Chla-Dub1", "GENE_OR_GENE_PRODUCT", 35, 44], ["ChlaDub2", "GENE_OR_GENE_PRODUCT", 49, 57], ["Chla", "PROTEIN", 35, 39], ["Dub1", "PROTEIN", 40, 44], ["ChlaDub2", "PROTEIN", 49, 57]]], ["Although ChlaDub1 is clearly translocated into host cells by bacteria, its localization, biochemical target(s), and possible role during infection remain to be established.ChlamydiaEscherichia coli CNF1 toxin is produced by uropathogenic E. coli, and related toxins have been found in Y. pseudotuberculosis and Bordetella pertussis.", [["cells", "ANATOMY", 52, 57], ["infection", "DISEASE", 137, 146], ["Y. pseudotuberculosis", "DISEASE", 285, 306], ["Bordetella pertussis", "DISEASE", 311, 331], ["ChlaDub1", "GENE_OR_GENE_PRODUCT", 9, 17], ["host cells", "CELL", 47, 57], ["ChlamydiaEscherichia coli", "ORGANISM", 172, 197], ["CNF1", "GENE_OR_GENE_PRODUCT", 198, 202], ["uropathogenic E. coli", "ORGANISM", 224, 245], ["Y. pseudotuberculosis", "ORGANISM", 285, 306], ["Bordetella pertussis", "ORGANISM", 311, 331], ["ChlaDub1", "PROTEIN", 9, 17], ["host cells", "CELL_TYPE", 47, 57], ["ChlamydiaEscherichia coli CNF1 toxin", "PROTEIN", 172, 208], ["ChlamydiaEscherichia coli", "SPECIES", 172, 197], ["E. coli", "SPECIES", 238, 245], ["Y. pseudotuberculosis", "SPECIES", 285, 306], ["Bordetella pertussis", "SPECIES", 311, 331], ["ChlamydiaEscherichia coli", "SPECIES", 172, 197], ["E. coli", "SPECIES", 238, 245], ["Y. pseudotuberculosis", "SPECIES", 285, 306], ["Bordetella pertussis", "SPECIES", 311, 331], ["bacteria", "PROBLEM", 61, 69], ["role during infection", "PROBLEM", 125, 146], ["ChlamydiaEscherichia coli CNF1 toxin", "PROBLEM", 172, 208], ["uropathogenic E. coli", "PROBLEM", 224, 245], ["related toxins", "PROBLEM", 251, 265], ["Y. pseudotuberculosis", "PROBLEM", 285, 306], ["Bordetella pertussis", "PROBLEM", 311, 331], ["host cells", "OBSERVATION", 47, 57], ["bacteria", "OBSERVATION_MODIFIER", 61, 69], ["infection", "OBSERVATION", 137, 146], ["uropathogenic", "OBSERVATION_MODIFIER", 224, 237], ["E. coli", "OBSERVATION", 238, 245], ["pseudotuberculosis", "OBSERVATION", 288, 306], ["Bordetella pertussis", "OBSERVATION", 311, 331]]], ["The toxin is taken up by mammalian cells by endocytosis and then passes into the cytosol by translocation through the endosomal membrane (Boquet, 2001) .", [["cells", "ANATOMY", 35, 40], ["cytosol", "ANATOMY", 81, 88], ["endosomal membrane", "ANATOMY", 118, 136], ["mammalian cells", "CELL", 25, 40], ["cytosol", "CELLULAR_COMPONENT", 81, 88], ["endosomal membrane", "CELLULAR_COMPONENT", 118, 136], ["toxin", "PROTEIN", 4, 9], ["mammalian cells", "CELL_TYPE", 25, 40], ["The toxin", "TEST", 0, 9], ["endosomal membrane", "OBSERVATION", 118, 136]]], ["CNF1 functions by deamidating a specific glutamine residue of Rho GTPases to glutamate.", [["glutamine", "CHEMICAL", 41, 50], ["glutamate", "CHEMICAL", 77, 86], ["glutamine", "CHEMICAL", 41, 50], ["glutamate", "CHEMICAL", 77, 86], ["CNF1", "GENE_OR_GENE_PRODUCT", 0, 4], ["glutamine", "AMINO_ACID", 41, 50], ["Rho GTPases", "GENE_OR_GENE_PRODUCT", 62, 73], ["glutamate", "SIMPLE_CHEMICAL", 77, 86], ["CNF1", "PROTEIN", 0, 4], ["Rho GTPases", "PROTEIN", 62, 73], ["CNF1 functions", "TEST", 0, 14]]], ["This prevents endogenous or induced GTPase activity of these molecu-lar switches, effectively locking them into a permanently active state.", [["GTPase", "PROTEIN", 36, 42], ["molecu", "PROTEIN", 61, 67], ["these molecu-lar switches", "TREATMENT", 55, 80], ["GTPase activity", "OBSERVATION", 36, 51], ["lar", "ANATOMY", 68, 71]]], ["However, this effect is only transient, as the host cell responds by depleting the modified GTPases by ubiquitination and proteasome-mediated degradation (Doye et al., 2002) .", [["cell", "ANATOMY", 52, 56], ["host cell", "CELL", 47, 56], ["GTPases", "GENE_OR_GENE_PRODUCT", 92, 99], ["GTPases", "PROTEIN", 92, 99], ["proteasome", "PROTEIN", 122, 132], ["proteasome-mediated degradation", "TREATMENT", 122, 153], ["transient", "OBSERVATION_MODIFIER", 29, 38], ["host cell", "OBSERVATION", 47, 56]]], ["Hence, although the immediate effect of CNF1 deamidation of Rho proteins is their activation, the long-term consequence is ubiquitination and degradation.", [["CNF1", "GENE_OR_GENE_PRODUCT", 40, 44], ["Rho", "GENE_OR_GENE_PRODUCT", 60, 63], ["CNF1", "PROTEIN", 40, 44], ["Rho proteins", "PROTEIN", 60, 72], ["CNF1 deamidation of Rho proteins", "PROBLEM", 40, 72]]], ["In the case of RhoA, this is carried out by an E3 ligase called Smurf1 (Boyer et al., 2006) .ListeriaListeria monocytogenes is a Gram-positive bacterial pathogen that interacts with host-cell surface proteins to trigger signaling pathways leading to bacterial uptake.", [["cell surface", "ANATOMY", 187, 199], ["ListeriaListeria", "CHEMICAL", 93, 109], ["RhoA", "GENE_OR_GENE_PRODUCT", 15, 19], ["E3", "GENE_OR_GENE_PRODUCT", 47, 49], ["Smurf1", "GENE_OR_GENE_PRODUCT", 64, 70], ["ListeriaListeria monocytogenes", "ORGANISM", 93, 123], ["Gram-", "GENE_OR_GENE_PRODUCT", 129, 134], ["cell", "CELL", 187, 191], ["RhoA", "PROTEIN", 15, 19], ["E3 ligase", "PROTEIN", 47, 56], ["Smurf1", "PROTEIN", 64, 70], ["host-cell surface proteins", "PROTEIN", 182, 208], ["ListeriaListeria monocytogenes", "SPECIES", 93, 123], ["ListeriaListeria monocytogenes", "SPECIES", 93, 123], ["ListeriaListeria monocytogenes", "PROBLEM", 93, 123], ["a Gram-positive bacterial pathogen", "PROBLEM", 127, 161], ["host-cell surface proteins", "TEST", 182, 208], ["signaling pathways", "PROBLEM", 220, 238], ["bacterial uptake", "PROBLEM", 250, 266], ["Gram-positive", "OBSERVATION_MODIFIER", 129, 142], ["bacterial pathogen", "OBSERVATION", 143, 161], ["host-cell", "OBSERVATION", 182, 191], ["bacterial uptake", "OBSERVATION", 250, 266]]], ["One such pathway involves a bacterial cell surface-localized protein, InlB, and the growth factor receptor Met (Shen et al., 2000) .", [["cell surface", "ANATOMY", 38, 50], ["cell", "CELL", 38, 42], ["InlB", "GENE_OR_GENE_PRODUCT", 70, 74], ["Met", "GENE_OR_GENE_PRODUCT", 107, 110], ["bacterial cell surface-localized protein", "PROTEIN", 28, 68], ["InlB", "PROTEIN", 70, 74], ["growth factor receptor", "PROTEIN", 84, 106], ["a bacterial cell surface", "TEST", 26, 50], ["localized protein", "PROBLEM", 51, 68], ["InlB", "TEST", 70, 74], ["bacterial cell", "OBSERVATION", 28, 42], ["surface", "OBSERVATION_MODIFIER", 43, 50]]], ["Interaction between Met and its ligand normally triggers the recruitment of the Ub ligase Cbl, which ubiquitinates Met and leads to its endocytosis.", [["Met", "CHEMICAL", 20, 23], ["Met", "CHEMICAL", 20, 23], ["Met", "CHEMICAL", 115, 118], ["Met", "GENE_OR_GENE_PRODUCT", 20, 23], ["Ub", "GENE_OR_GENE_PRODUCT", 80, 82], ["Cbl", "GENE_OR_GENE_PRODUCT", 90, 93], ["Met", "GENE_OR_GENE_PRODUCT", 115, 118], ["Met", "PROTEIN", 20, 23], ["Ub ligase", "PROTEIN", 80, 89], ["Cbl", "PROTEIN", 90, 93], ["Met", "PROTEIN", 115, 118], ["the Ub ligase Cbl", "TEST", 76, 93], ["its endocytosis", "PROBLEM", 132, 147], ["ligase Cbl", "OBSERVATION", 83, 93]]], ["It was found recently that InlB can mediate the same process, and furthermore that the Ub-dependent endocytosis machinery is required for internalization of bacteria (Veiga and Cossart, 2005) .", [["InlB", "GENE_OR_GENE_PRODUCT", 27, 31], ["Ub", "GENE_OR_GENE_PRODUCT", 87, 89], ["InlB", "PROTEIN", 27, 31], ["Ub", "PROTEIN", 87, 89], ["the Ub-dependent endocytosis machinery", "PROBLEM", 83, 121], ["bacteria", "PROBLEM", 157, 165]]], ["While the interaction between InlB and ubiquitination machinery is indirect, this discovery reveals another means by which bacterial pathogens harness host Ub-dependent pathways to promote their virulence.", [["InlB", "GENE_OR_GENE_PRODUCT", 30, 34], ["Ub", "GENE_OR_GENE_PRODUCT", 156, 158], ["InlB", "PROTEIN", 30, 34], ["Ub", "PROTEIN", 156, 158]]], ["Following uptake into host cells, L. monocytogenes escapes its vacuole and begins to replicate and spread in the host-cell cytosol.", [["cells", "ANATOMY", 27, 32], ["vacuole", "ANATOMY", 63, 70], ["cell cytosol", "ANATOMY", 118, 130], ["host cells", "CELL", 22, 32], ["L. monocytogenes", "ORGANISM", 34, 50], ["vacuole", "CELLULAR_COMPONENT", 63, 70], ["cell cytosol", "CELLULAR_COMPONENT", 118, 130], ["host cells", "CELL_TYPE", 22, 32], ["L. monocytogenes", "SPECIES", 34, 50], ["L. monocytogenes", "SPECIES", 34, 50], ["uptake into host cells", "PROBLEM", 10, 32], ["L. monocytogenes", "PROBLEM", 34, 50], ["host cells", "OBSERVATION", 22, 32], ["L.", "OBSERVATION_MODIFIER", 34, 36], ["monocytogenes", "OBSERVATION", 37, 50], ["cell cytosol", "OBSERVATION", 118, 130]]], ["This is dependent on the action of the secreted cytolysin listeriolysin O (LLO).", [["listeriolysin O", "GENE_OR_GENE_PRODUCT", 58, 73], ["LLO", "GENE_OR_GENE_PRODUCT", 75, 78], ["cytolysin", "PROTEIN", 48, 57], ["listeriolysin O", "PROTEIN", 58, 73], ["LLO", "PROTEIN", 75, 78], ["dependent", "OBSERVATION_MODIFIER", 8, 17]]], ["LLO is potentially damaging to the host-cell plasma membrane, and to ensure that bacteria remain intracellular, the activity of LLO must be restricted to the vacuolar membrane.", [["cell plasma membrane", "ANATOMY", 40, 60], ["intracellular", "ANATOMY", 97, 110], ["vacuolar membrane", "ANATOMY", 158, 175], ["LLO", "GENE_OR_GENE_PRODUCT", 0, 3], ["cell", "CELL", 40, 44], ["plasma membrane", "CELLULAR_COMPONENT", 45, 60], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 97, 110], ["LLO", "GENE_OR_GENE_PRODUCT", 128, 131], ["vacuolar membrane", "CELLULAR_COMPONENT", 158, 175], ["LLO", "PROTEIN", 0, 3], ["LLO", "PROTEIN", 128, 131], ["cell plasma membrane", "TEST", 40, 60], ["bacteria", "PROBLEM", 81, 89], ["bacteria", "OBSERVATION", 81, 89], ["vacuolar membrane", "OBSERVATION", 158, 175]]], ["By mechanisms that are still unclear, LLO is rapidly ubiquitinated and degraded by the proteasome machinery (Schnupf et al., 2006) .Plant PathogensBacterial plant pathogens also use specialized secretion systems to deliver effector proteins into host cells.", [["cells", "ANATOMY", 251, 256], ["LLO", "GENE_OR_GENE_PRODUCT", 38, 41], ["host cells", "CELL", 246, 256], ["LLO", "PROTEIN", 38, 41], ["proteasome", "PROTEIN", 87, 97], ["effector proteins", "PROTEIN", 223, 240], ["host cells", "CELL_TYPE", 246, 256], ["Plant PathogensBacterial plant pathogens", "PROBLEM", 132, 172], ["specialized secretion systems", "TREATMENT", 182, 211], ["rapidly", "OBSERVATION_MODIFIER", 45, 52], ["ubiquitinated", "OBSERVATION_MODIFIER", 53, 66], ["Pathogens", "OBSERVATION_MODIFIER", 138, 147], ["Bacterial plant pathogens", "OBSERVATION", 147, 172], ["host cells", "OBSERVATION", 246, 256]]], ["As with animal pathogens, the processes of activation, conjugation, and deconjugation of Ub and Ubls all appear to be targeted by bacterial effector proteins.", [["Ub", "GENE_OR_GENE_PRODUCT", 89, 91], ["Ubls", "GENE_OR_GENE_PRODUCT", 96, 100], ["Ub", "PROTEIN", 89, 91], ["Ubls", "PROTEIN", 96, 100], ["bacterial effector proteins", "PROTEIN", 130, 157], ["animal pathogens", "PROBLEM", 8, 24], ["conjugation", "TREATMENT", 55, 66], ["deconjugation of Ub and Ubls", "PROBLEM", 72, 100], ["bacterial effector proteins", "PROBLEM", 130, 157], ["pathogens", "OBSERVATION", 15, 24]]], ["VirF of Agrobacterium is one of several proteins involved in transfer of T-DNA from this bacterium into plant cells.", [["cells", "ANATOMY", 110, 115], ["VirF", "CHEMICAL", 0, 4], ["VirF", "GENE_OR_GENE_PRODUCT", 0, 4], ["T-", "GENE_OR_GENE_PRODUCT", 73, 75], ["DNA", "CELLULAR_COMPONENT", 75, 78], ["plant cells", "CELL", 104, 115], ["VirF", "PROTEIN", 0, 4], ["T-DNA", "DNA", 73, 78], ["plant cells", "CELL_TYPE", 104, 115], ["this bacterium into plant cells", "PROBLEM", 84, 115], ["Agrobacterium", "OBSERVATION", 8, 21], ["plant cells", "OBSERVATION", 104, 115]]], ["It localizes to the plant cell nucleus, where it causes the degradation of a plant protein VIP1.", [["cell nucleus", "ANATOMY", 26, 38], ["cell nucleus", "CELLULAR_COMPONENT", 26, 38], ["VIP1", "GENE_OR_GENE_PRODUCT", 91, 95], ["VIP1", "PROTEIN", 91, 95], ["a plant protein VIP1", "TREATMENT", 75, 95], ["plant cell nucleus", "OBSERVATION", 20, 38]]], ["This is thought to be mediated by an F box motif in VirF that binds the plant homolog of Skp1, a component of SCF in some E3 ligase complexes (Tzfira et al., 2004) .", [["VirF", "GENE_OR_GENE_PRODUCT", 52, 56], ["Skp1", "GENE_OR_GENE_PRODUCT", 89, 93], ["SCF", "GENE_OR_GENE_PRODUCT", 110, 113], ["E3", "GENE_OR_GENE_PRODUCT", 122, 124], ["F box motif", "DNA", 37, 48], ["VirF", "PROTEIN", 52, 56], ["Skp1", "PROTEIN", 89, 93], ["SCF", "PROTEIN", 110, 113], ["E3 ligase complexes", "PROTEIN", 122, 141], ["an F box motif in VirF", "TREATMENT", 34, 56], ["SCF", "PROBLEM", 110, 113], ["thought to be", "UNCERTAINTY", 8, 21], ["component", "OBSERVATION_MODIFIER", 97, 106], ["SCF", "OBSERVATION", 110, 113], ["ligase complexes", "OBSERVATION", 125, 141]]], ["AvrPtoB is a T3S effector translocated into tomato cells by Pseudomonas syringae, where it inhibits hypersensitivity-a plant immune response involving rapid localized host-cell death at the site of infection.", [["tomato cells", "ANATOMY", 44, 56], ["cell", "ANATOMY", 172, 176], ["AvrPtoB", "CHEMICAL", 0, 7], ["hypersensitivity", "DISEASE", 100, 116], ["death", "DISEASE", 177, 182], ["infection", "DISEASE", 198, 207], ["AvrPtoB", "GENE_OR_GENE_PRODUCT", 0, 7], ["T3S", "GENE_OR_GENE_PRODUCT", 13, 16], ["tomato cells", "CELL", 44, 56], ["Pseudomonas syringae", "ORGANISM", 60, 80], ["cell", "CELL", 172, 176], ["AvrPtoB", "PROTEIN", 0, 7], ["T3S effector", "PROTEIN", 13, 25], ["tomato cells", "CELL_TYPE", 44, 56], ["tomato", "SPECIES", 44, 50], ["Pseudomonas syringae", "SPECIES", 60, 80], ["tomato", "SPECIES", 44, 50], ["Pseudomonas syringae", "SPECIES", 60, 80], ["a T3S effector", "PROBLEM", 11, 25], ["Pseudomonas syringae", "PROBLEM", 60, 80], ["hypersensitivity", "PROBLEM", 100, 116], ["rapid localized host-cell death", "PROBLEM", 151, 182], ["infection", "PROBLEM", 198, 207], ["Pseudomonas syringae", "OBSERVATION", 60, 80], ["rapid", "OBSERVATION_MODIFIER", 151, 156], ["localized", "OBSERVATION_MODIFIER", 157, 166], ["host-cell death", "OBSERVATION", 167, 182], ["infection", "OBSERVATION", 198, 207]]], ["The amino acid sequence of AvrPtoB provided no information as to its function, but the crystal structure of the C-terminal domain of AvrPtoB revealed striking similarity to U box and RING finger components of E3 ligases (Janjusevic et al., 2006) .", [["amino acid", "CHEMICAL", 4, 14], ["amino acid", "CHEMICAL", 4, 14], ["C", "CHEMICAL", 112, 113], ["amino acid", "AMINO_ACID", 4, 14], ["AvrPtoB", "GENE_OR_GENE_PRODUCT", 27, 34], ["AvrPtoB", "GENE_OR_GENE_PRODUCT", 133, 140], ["U box", "GENE_OR_GENE_PRODUCT", 173, 178], ["E3", "GENE_OR_GENE_PRODUCT", 209, 211], ["amino acid sequence", "PROTEIN", 4, 23], ["AvrPtoB", "PROTEIN", 27, 34], ["C-terminal domain", "PROTEIN", 112, 129], ["AvrPtoB", "PROTEIN", 133, 140], ["U box", "DNA", 173, 178], ["RING finger components", "PROTEIN", 183, 205], ["E3 ligases", "PROTEIN", 209, 219], ["The amino acid sequence", "TEST", 0, 23], ["U box", "TREATMENT", 173, 178], ["RING", "ANATOMY_MODIFIER", 183, 187], ["finger", "ANATOMY", 188, 194], ["E3 ligases", "OBSERVATION", 209, 219]]], ["Purified AvrPtoB was shown to have E3 ligase activity in vitro, and putative E2 binding site residues were shown to be critical for suppression of the plant hypersensitive response (Janjusevic et al., 2006) .", [["E2", "CHEMICAL", 77, 79], ["AvrPtoB", "GENE_OR_GENE_PRODUCT", 9, 16], ["E3", "GENE_OR_GENE_PRODUCT", 35, 37], ["E2", "GENE_OR_GENE_PRODUCT", 77, 79], ["AvrPtoB", "PROTEIN", 9, 16], ["E3", "PROTEIN", 35, 37], ["E3 ligase activity in vitro", "PROBLEM", 35, 62], ["putative E2 binding site residues", "PROBLEM", 68, 101], ["the plant hypersensitive response", "PROBLEM", 147, 180], ["ligase activity", "OBSERVATION", 38, 53], ["hypersensitive response", "OBSERVATION", 157, 180]]], ["Presumably, AvrPtoB recruits E2 partners and substrates and transfers Ub to host-cell proteins(s) that positively regulate the plant defense response.", [["cell", "ANATOMY", 81, 85], ["AvrPtoB", "CHEMICAL", 12, 19], ["E2", "CHEMICAL", 29, 31], ["AvrPtoB", "GENE_OR_GENE_PRODUCT", 12, 19], ["E2", "GENE_OR_GENE_PRODUCT", 29, 31], ["Ub", "GENE_OR_GENE_PRODUCT", 70, 72], ["host-cell proteins", "GENE_OR_GENE_PRODUCT", 76, 94], ["AvrPtoB", "PROTEIN", 12, 19], ["E2 partners", "PROTEIN", 29, 40], ["Ub", "PROTEIN", 70, 72], ["host-cell proteins", "PROTEIN", 76, 94], ["plant", "OBSERVATION", 127, 132], ["defense response", "OBSERVATION", 133, 149]]], ["However, the cellular substrate(s) of this activity have not yet been identified.", [["cellular", "ANATOMY", 13, 21], ["cellular", "CELL", 13, 21]]], ["Xanthomonas campestris is a related pathogen of solanaceous plants; one of its T3S system effectors, XopD, has been characterized as a cysteine protease of clan CE, family 48.", [["Xanthomonas campestris", "CHEMICAL", 0, 22], ["XopD", "CHEMICAL", 101, 105], ["cysteine", "CHEMICAL", 135, 143], ["Xanthomonas campestris", "ORGANISM", 0, 22], ["solanaceous plants", "ORGANISM", 48, 66], ["T3S", "GENE_OR_GENE_PRODUCT", 79, 82], ["XopD", "GENE_OR_GENE_PRODUCT", 101, 105], ["T3S system effectors", "PROTEIN", 79, 99], ["XopD", "PROTEIN", 101, 105], ["cysteine protease", "PROTEIN", 135, 152], ["Xanthomonas campestris", "SPECIES", 0, 22], ["Xanthomonas campestris", "SPECIES", 0, 22], ["Xanthomonas campestris", "PROBLEM", 0, 22], ["solanaceous plants", "PROBLEM", 48, 66], ["solanaceous plants", "OBSERVATION", 48, 66]]], ["This effector localizes to the plant cell nucleus, where it cleaves (as yet uncharacterized) sumoylated proteins (Hotson et al., 2003) .", [["cell nucleus", "ANATOMY", 37, 49], ["plant cell nucleus", "CELLULAR_COMPONENT", 31, 49], ["sumoylated proteins", "PROTEIN", 93, 112], ["plant cell nucleus", "OBSERVATION", 31, 49]]], ["XopD appears to have a strict preference for plant SUMOs and was recently used to obtain insight into substrate specificity of ULPs (Chosed et al., 2007) .", [["XopD", "CHEMICAL", 0, 4], ["XopD", "GENE_OR_GENE_PRODUCT", 0, 4], ["SUMOs", "GENE_OR_GENE_PRODUCT", 51, 56], ["ULPs", "SIMPLE_CHEMICAL", 127, 131], ["XopD", "PROTEIN", 0, 4], ["SUMOs", "PROTEIN", 51, 56]]], ["Several other bacterial plant pathogens and symbionts are predicted to contain proteins that have been classified as members of clan CE, family 48 proteases.", [["clan CE, family 48 proteases", "PROTEIN", 128, 156], ["Several other bacterial plant pathogens", "PROBLEM", 0, 39], ["bacterial", "OBSERVATION_MODIFIER", 14, 23], ["plant pathogens", "OBSERVATION", 24, 39]]], ["These include Acidovorax avenae, Bradyrhizobium japonicum, Mesorhizobium loti, and Rhizobium leguminosarum (http://merops.sanger.ac.uk/index.htm).Viral InterventionAlthough this review focuses on bacteria, several viruses are also known to interfere with different steps in the ubiquitin pathway.", [["Acidovorax avenae", "ORGANISM", 14, 31], ["Bradyrhizobium japonicum", "ORGANISM", 33, 57], ["Mesorhizobium loti", "ORGANISM", 59, 77], ["Rhizobium leguminosarum", "ORGANISM", 83, 106], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 278, 287], ["Acidovorax avenae", "SPECIES", 14, 31], ["Bradyrhizobium japonicum", "SPECIES", 33, 57], ["Mesorhizobium loti", "SPECIES", 59, 77], ["Rhizobium leguminosarum", "SPECIES", 83, 106], ["Acidovorax avenae", "SPECIES", 14, 31], ["Bradyrhizobium japonicum", "SPECIES", 33, 57], ["Mesorhizobium loti", "SPECIES", 59, 77], ["Rhizobium leguminosarum", "SPECIES", 83, 106], ["Acidovorax avenae", "PROBLEM", 14, 31], ["Bradyrhizobium japonicum", "TEST", 33, 57], ["Mesorhizobium loti", "TEST", 59, 77], ["bacteria", "PROBLEM", 196, 204], ["several viruses", "PROBLEM", 206, 221], ["Acidovorax avenae", "OBSERVATION", 14, 31], ["Mesorhizobium loti", "OBSERVATION", 59, 77], ["viruses", "OBSERVATION", 214, 221]]], ["Some encode proteins that modify cullinlike RING Ub ligases by interacting with substrate adaptors, redirecting the Ub ligase complex to new targets, or protecting cellular proteins from ubiquitination (Barry and Fruh, 2006) .", [["cellular", "ANATOMY", 164, 172], ["Ub", "GENE_OR_GENE_PRODUCT", 49, 51], ["Ub", "GENE_OR_GENE_PRODUCT", 116, 118], ["cellular", "CELL", 164, 172], ["cullinlike RING Ub ligases", "PROTEIN", 33, 59], ["substrate adaptors", "PROTEIN", 80, 98], ["Ub ligase complex", "PROTEIN", 116, 133], ["cellular proteins", "PROTEIN", 164, 181], ["Some encode proteins", "PROBLEM", 0, 20], ["RING Ub ligases", "TREATMENT", 44, 59], ["substrate adaptors", "TREATMENT", 80, 98], ["the Ub ligase complex", "PROBLEM", 112, 133], ["proteins", "OBSERVATION", 12, 20], ["ligases", "OBSERVATION_MODIFIER", 52, 59]]], ["Both the Herpes and Poxvirus families encode proteins with E3 ligase activity.", [["Herpes", "DISEASE", 9, 15], ["Herpes", "ORGANISM", 9, 15], ["Poxvirus", "GENE_OR_GENE_PRODUCT", 20, 28], ["E3", "GENE_OR_GENE_PRODUCT", 59, 61], ["Herpes and Poxvirus families", "PROTEIN", 9, 37], ["E3 ligase", "PROTEIN", 59, 68], ["E3 ligase activity", "TREATMENT", 59, 77], ["Herpes", "OBSERVATION", 9, 15], ["ligase activity", "OBSERVATION", 62, 77]]], ["These E3 ligases promote ubiquitination of MHC-1, B7.2, ICAM-1, and CD4, resulting in removal of these cell surface molecules and obstruction of host immune responses (Coscoy et al., 2001; Duncan et al., 2006; Hewitt et al., 2002; Mansouri et al., 2003) .", [["cell surface", "ANATOMY", 103, 115], ["E3", "GENE_OR_GENE_PRODUCT", 6, 8], ["MHC-1", "GENE_OR_GENE_PRODUCT", 43, 48], ["B7.2", "GENE_OR_GENE_PRODUCT", 50, 54], ["ICAM-1", "GENE_OR_GENE_PRODUCT", 56, 62], ["CD4", "GENE_OR_GENE_PRODUCT", 68, 71], ["cell", "CELL", 103, 107], ["E3 ligases", "PROTEIN", 6, 16], ["MHC", "PROTEIN", 43, 46], ["B7.2", "PROTEIN", 50, 54], ["ICAM", "PROTEIN", 56, 60], ["CD4", "PROTEIN", 68, 71], ["cell surface molecules", "PROTEIN", 103, 125], ["MHC", "TEST", 43, 46], ["B7.2", "TEST", 50, 54], ["ICAM", "TEST", 56, 60], ["CD4", "TEST", 68, 71], ["removal", "TREATMENT", 86, 93], ["these cell surface molecules", "PROBLEM", 97, 125], ["obstruction of host immune responses", "PROBLEM", 130, 166], ["ubiquitination", "OBSERVATION_MODIFIER", 25, 39], ["cell", "OBSERVATION", 103, 107], ["surface molecules", "OBSERVATION", 108, 125], ["obstruction", "OBSERVATION", 130, 141]]], ["Other viruses produce E3 ligases that interfere with apoptosis and interferon (IFN) production (Halford et al., 2006; Melroe et al., 2004; Taylor and Barry, 2006) .", [["E3", "GENE_OR_GENE_PRODUCT", 22, 24], ["interferon", "GENE_OR_GENE_PRODUCT", 67, 77], ["IFN", "GENE_OR_GENE_PRODUCT", 79, 82], ["E3 ligases", "PROTEIN", 22, 32], ["interferon", "PROTEIN", 67, 77], ["IFN", "PROTEIN", 79, 82], ["apoptosis", "PROBLEM", 53, 62], ["interferon (IFN)", "TREATMENT", 67, 83], ["E3 ligases", "OBSERVATION", 22, 32]]], ["Recently, it has become clear that some viruses, including herpesvirus, cytomegalovirus, adenovirus, and coronaviruses also encode DUBs; however, the targets for most of these DUBs have not yet been identified (Kattenhorn et al., 2005; Balakirev et al., 2002; Barretto et al., 2005; Sulea et al., 2006; Wang et al., 2006) .ConclusionsFrom the work reviewed above and elsewhere (Boyer and Lemichez, 2004; Angot et al., 2007) , it is clear that interference of ubiquitination and deubiquitination plays an important role in the virulence of several bacterial pathogens and frequently influences host immune responses.", [["herpesvirus, cytomegalovirus, adenovirus, and coronaviruses", "DISEASE", 59, 118], ["herpesvirus", "ORGANISM", 59, 70], ["cytomegalovirus", "ORGANISM", 72, 87], ["adenovirus", "ORGANISM", 89, 99], ["DUBs", "GENE_OR_GENE_PRODUCT", 131, 135], ["DUBs", "GENE_OR_GENE_PRODUCT", 176, 180], ["DUBs", "PROTEIN", 131, 135], ["DUBs", "PROTEIN", 176, 180], ["adenovirus", "SPECIES", 89, 99], ["some viruses", "PROBLEM", 35, 47], ["herpesvirus", "PROBLEM", 59, 70], ["cytomegalovirus", "PROBLEM", 72, 87], ["adenovirus", "PROBLEM", 89, 99], ["coronaviruses", "PROBLEM", 105, 118], ["these DUBs", "TEST", 170, 180], ["ubiquitination and deubiquitination", "PROBLEM", 459, 494], ["several bacterial pathogens", "PROBLEM", 539, 566], ["clear", "OBSERVATION", 24, 29], ["viruses", "OBSERVATION", 40, 47], ["cytomegalovirus", "OBSERVATION", 72, 87]]], ["Although the current list of bacterial effectors involved in these processes is relatively short, they would appear to fall into three general categories: those that act directly on pathways by ''mimicking'' host-cell proteins (e.g., E3 ligases and DUBs), those that act indirectly (e.g., E. coli CNF1 and Shigella OspG), and those that are themselves subject to ubiquitination in ways that influence bacterial virulence (e.g., Salmonella SopE).", [["cell", "ANATOMY", 213, 217], ["cell", "CELL", 213, 217], ["E3", "GENE_OR_GENE_PRODUCT", 234, 236], ["DUBs", "GENE_OR_GENE_PRODUCT", 249, 253], ["E. coli", "ORGANISM", 289, 296], ["CNF1", "GENE_OR_GENE_PRODUCT", 297, 301], ["Shigella OspG", "GENE_OR_GENE_PRODUCT", 306, 319], ["Salmonella SopE", "ORGANISM", 428, 443], ["bacterial effectors", "PROTEIN", 29, 48], ["host-cell proteins", "PROTEIN", 208, 226], ["E3 ligases", "PROTEIN", 234, 244], ["DUBs", "PROTEIN", 249, 253], ["CNF1", "PROTEIN", 297, 301], ["Shigella OspG", "PROTEIN", 306, 319], ["E. coli", "SPECIES", 289, 296], ["E. coli", "SPECIES", 289, 296], ["bacterial effectors", "PROBLEM", 29, 48], ["DUBs", "TEST", 249, 253], ["E. coli CNF1", "TEST", 289, 301], ["bacterial virulence", "PROBLEM", 401, 420], ["bacterial effectors", "OBSERVATION", 29, 48]]], ["Much of our (albeit limited) understanding of this aspect of bacterial virulence has been gained in the last few years, and it therefore seems likely that the number of bacterial proteins that either mimic or modulate host-cell proteins involved in Ub pathways will increase considerably in the future.", [["cell", "ANATOMY", 223, 227], ["cell", "CELL", 223, 227], ["Ub", "GENE_OR_GENE_PRODUCT", 249, 251], ["bacterial proteins", "PROTEIN", 169, 187], ["host-cell proteins", "PROTEIN", 218, 236], ["Ub", "PROTEIN", 249, 251], ["bacterial virulence", "PROBLEM", 61, 80], ["bacterial proteins", "PROBLEM", 169, 187], ["bacterial virulence", "OBSERVATION", 61, 80], ["seems likely", "UNCERTAINTY", 137, 149], ["bacterial proteins", "OBSERVATION", 169, 187]]], ["Of the bacterial DUBs that have been identified to date, none have the same architecture as the ''classic'' eukaryotic DUBs (clan CA); they are all members of clan CE proteases.", [["DUBs", "GENE_OR_GENE_PRODUCT", 17, 21], ["DUBs", "GENE_OR_GENE_PRODUCT", 119, 123], ["clan CA", "GENE_OR_GENE_PRODUCT", 125, 132], ["bacterial DUBs", "PROTEIN", 7, 21], ["eukaryotic DUBs", "PROTEIN", 108, 123], ["clan CA", "PROTEIN", 125, 132], ["clan CE proteases", "PROTEIN", 159, 176], ["the bacterial DUBs", "PROBLEM", 3, 21], ["bacterial DUBs", "OBSERVATION", 7, 21], ["eukaryotic DUBs", "OBSERVATION", 108, 123]]], ["As our knowledge of the clan organization of DUBs and ULPs increases (Hotson and Mudgett, 2004) , it will become easier to identify putative new Ub-or ULPspecific proteases among both plant and animal pathogens.", [["DUBs", "GENE_OR_GENE_PRODUCT", 45, 49], ["ULPs", "GENE_OR_GENE_PRODUCT", 54, 58], ["Ub", "GENE_OR_GENE_PRODUCT", 145, 147], ["DUBs", "PROTEIN", 45, 49], ["Ub", "PROTEIN", 145, 147], ["ULPspecific proteases", "PROTEIN", 151, 172], ["ULPspecific proteases", "PROBLEM", 151, 172], ["animal pathogens", "PROBLEM", 194, 210], ["DUBs", "OBSERVATION", 45, 49]]], ["However, identifying new modifiers of the Ub conjugation machinery is unlikely to be straightforward, since the bacterial E3 ligases identified to date do not display striking amino acid sequence similarities, either between themselves or with their mammalian counterparts.", [["amino acid", "CHEMICAL", 176, 186], ["amino acid", "CHEMICAL", 176, 186], ["Ub", "GENE_OR_GENE_PRODUCT", 42, 44], ["E3", "GENE_OR_GENE_PRODUCT", 122, 124], ["amino acid", "AMINO_ACID", 176, 186], ["Ub", "PROTEIN", 42, 44], ["bacterial E3 ligases", "PROTEIN", 112, 132], ["the Ub conjugation machinery", "TREATMENT", 38, 66], ["the bacterial E3 ligases", "TEST", 108, 132], ["striking amino acid sequence similarities", "PROBLEM", 167, 208], ["new", "OBSERVATION_MODIFIER", 21, 24], ["unlikely to be", "UNCERTAINTY", 70, 84]]], ["A major problem is that the targets of most of these bacterial effectors are currently unknown, and identifying them can be fraught with difficulty: many of these effectors are very potent, are produced transiently, and localize to specific regions of the infected cell.", [["cell", "ANATOMY", 265, 269], ["cell", "CELL", 265, 269], ["infected cell", "CELL_TYPE", 256, 269], ["A major problem", "PROBLEM", 0, 15], ["these bacterial effectors", "PROBLEM", 47, 72], ["the infected cell", "PROBLEM", 252, 269], ["major", "OBSERVATION_MODIFIER", 2, 7], ["problem", "OBSERVATION", 8, 15], ["infected cell", "OBSERVATION", 256, 269]]], ["Specificity could therefore be achieved by precise spatiotemporal control of effector delivery rather than being an intrinsic property of the effectors.", [["effector delivery", "TREATMENT", 77, 94]]], ["The controversial literature regarding the function of YopJ emphasizes the need for careful biochemical analysis of putative cysteine proteases to reveal their physiological functions in vivo.", [["cysteine", "CHEMICAL", 125, 133], ["YopJ", "GENE_OR_GENE_PRODUCT", 55, 59], ["cysteine proteases", "GENE_OR_GENE_PRODUCT", 125, 143], ["YopJ", "PROTEIN", 55, 59], ["cysteine proteases", "PROTEIN", 125, 143], ["careful biochemical analysis", "TEST", 84, 112], ["putative cysteine proteases", "TREATMENT", 116, 143]]], ["Ideally, this involves the study of the protein in the natural context of infection, as opposed to analysis following its overexpression either in vitro or in vivo, but obviously this is not feasible in many instances.", [["infection", "DISEASE", 74, 83], ["the study", "TEST", 23, 32], ["infection", "PROBLEM", 74, 83], ["analysis", "TEST", 99, 107], ["infection", "OBSERVATION", 74, 83]]], ["Notwithstanding these concerns, the growing literature on bacterial manipulation of Ub pathways reflects a very important and widespread aspect of bacterial pathogenesis, and future research in this area will provide exciting new insights into the mechanisms underlying bacterial virulence.", [["Ub", "GENE_OR_GENE_PRODUCT", 84, 86], ["Ub", "PROTEIN", 84, 86], ["bacterial manipulation of Ub pathways", "PROBLEM", 58, 95], ["bacterial pathogenesis", "PROBLEM", 147, 169], ["bacterial virulence", "PROBLEM", 270, 289], ["bacterial pathogenesis", "OBSERVATION", 147, 169], ["bacterial virulence", "OBSERVATION", 270, 289]]]], "98857f720402ca1ab30091192e821321116f2d9e": [["Yet, knowledge of secondary structure provides important insights into the biological function of RNAs by allowing the study of physical properties, such as for instance molecular interactions 2 .", [["RNAs", "RNA", 98, 102], ["the study", "TEST", 115, 124]]], ["In most cases, information about the RNA folding complements sequence analysis 3 and is useful to understand mechanisms of action: microRNA precursors, for example, are processed by DGCR8 if folded in specific hairpin loop structures 4 .", [["DGCR8", "GENE_OR_GENE_PRODUCT", 182, 187], ["DGCR8", "PROTEIN", 182, 187], ["the RNA folding complements sequence analysis", "TEST", 33, 78], ["hairpin loop", "OBSERVATION", 210, 222]]], ["Similarly, the architecture of ribosomal RNAs evolves in a self-contained way through conservation of stem loops present in ancient species 5,6 , indicating distinct requirements for structural elements.IntroductionLong non-coding RNAs (lncRNAs) are regarded as a mystery in terms of sequence and structural conservation 7 .", [["ribosomal", "ANATOMY", 31, 40], ["stem loops", "ANATOMY", 102, 112], ["ribosomal", "CELLULAR_COMPONENT", 31, 40], ["ribosomal RNAs", "RNA", 31, 45], ["IntroductionLong non-coding RNAs", "RNA", 203, 235], ["lncRNAs", "DNA", 237, 244], ["ribosomal RNAs", "PROBLEM", 31, 45], ["ribosomal RNAs", "OBSERVATION", 31, 45], ["stem loops", "OBSERVATION", 102, 112], ["distinct requirements", "OBSERVATION", 157, 178], ["structural elements", "OBSERVATION", 183, 202]]], ["The vast majority of lncRNAs evolve under little or no selective constraints, undergo almost no purifying selection, are poorly expressed and without easily identifiable orthologues 7, 8 .", [["lncRNAs", "DNA", 21, 28], ["orthologues 7, 8", "DNA", 170, 186], ["lncRNAs", "OBSERVATION", 21, 28]]], ["The average sequence homology of evolutionarily conserved lncRNAs is only 20% between human and mouse and drops to 5% between human and fish 7 .", [["human", "ORGANISM", 86, 91], ["mouse", "ORGANISM", 96, 101], ["human", "ORGANISM", 126, 131], ["evolutionarily conserved lncRNAs", "DNA", 33, 65], ["human", "SPECIES", 86, 91], ["mouse", "SPECIES", 96, 101], ["human", "SPECIES", 126, 131], ["human", "SPECIES", 86, 91], ["mouse", "SPECIES", 96, 101], ["human", "SPECIES", 126, 131], ["human and mouse and drops", "TREATMENT", 86, 111], ["conserved lncRNAs", "OBSERVATION", 48, 65]]], ["Thus, primary structure does not provide relevant information on lncRNA conservation and secondary structure should be used for better characterization.", [["lncRNA conservation", "TREATMENT", 65, 84]]], ["In addition to lncRNAs, the transcriptomes of single-stranded RNA (ssRNA) viruses retain their fold even if sequences mutate rapidly 9 , which indicates that secondary structure investigation can reveal important properties.IntroductionTo study the structural conservation of RNA molecules, we developed the CROSSalign method.IntroductionCROSSalign, available at our webpages http://service.tartaglialab.com//new_submission/crossalign, is based on the combination of two methods: 1) Computational Recognition Of Secondary Structure (CROSS), which is an algorithm trained on experimental data to predict RNA secondary profiles without sequence length restrictions and at single-nucleotide resolution 10 ; 2) the Dynamic Time Warping (DTW) algorithm to assess the similarity of two profiles of different lengths 11 .", [["single-stranded RNA", "GENE_OR_GENE_PRODUCT", 46, 65], ["lncRNAs", "DNA", 15, 22], ["RNA molecules", "PROTEIN", 276, 289], ["single-stranded RNA (ssRNA) viruses", "TREATMENT", 46, 81], ["secondary structure investigation", "PROBLEM", 158, 191], ["RNA molecules", "PROBLEM", 276, 289], ["the CROSSalign method", "TREATMENT", 304, 325], ["experimental data", "TEST", 574, 591], ["sequence length restrictions", "TREATMENT", 634, 662], ["algorithm", "TEST", 738, 747], ["lncRNAs", "OBSERVATION", 15, 22], ["RNA molecules", "OBSERVATION", 276, 289], ["Secondary Structure", "OBSERVATION", 512, 531]]], ["DTW flexibility allows managing profiles of different length without having to sacrifice computational time.IntroductionWe applied CROSSalign on lncRNAs of different species as well as ssRNA viruses.IntroductionCROSSalign is able to find structural homologues among millions of possible matches identifying structural domains with great accuracy.ResultsTo test the performances and functionality of CROSS combined with DTW ( Supplementary Figures 1 and 2 Figures 5B and 6) .", [["CROSSalign", "DNA", 131, 141], ["lncRNAs", "DNA", 145, 152], ["IntroductionWe", "TREATMENT", 108, 122], ["different species", "PROBLEM", 156, 173], ["ssRNA viruses", "PROBLEM", 185, 198], ["DTW", "TEST", 419, 422], ["ssRNA viruses", "OBSERVATION", 185, 198]]], ["By contrast, calculating sequence similarity with respect to human XIST (computed with EMBOSS; see Material and Methods), we could not identify a specific cluster for primates (Supplementary Figure 5) .", [["human", "ORGANISM", 61, 66], ["XIST", "GENE_OR_GENE_PRODUCT", 67, 71], ["human XIST", "DNA", 61, 71], ["human", "SPECIES", 61, 66], ["human", "SPECIES", 61, 66]]], ["Thus, our results indicate that secondary structure shows a higher degree of conservation than sequence.ResultsWe then selected RepA of orangutan and searched for structural similarities in all human intergenic lncRNAs (lincRNAs 8176 sequences; ENSEMBLE 82).", [["RepA", "GENE_OR_GENE_PRODUCT", 128, 132], ["orangutan", "ORGANISM", 136, 145], ["human", "ORGANISM", 194, 199], ["RepA", "DNA", 128, 132], ["human intergenic lncRNAs", "DNA", 194, 218], ["lincRNAs 8176 sequences", "DNA", 220, 243], ["ENSEMBLE 82", "DNA", 245, 256], ["human", "SPECIES", 194, 199], ["human", "SPECIES", 194, 199], ["secondary structure", "PROBLEM", 32, 51], ["higher degree", "OBSERVATION_MODIFIER", 60, 73]]], ["XIST was ranked as the best significant match in the pool (structural distance 0.01; p-value < 10 -6 ) and RepA was correctly identified (predicted coordinates: 328-764; 95% overlap with the query region; Figure 2A ; Supplementary Table 1) .", [["XIST", "DNA", 0, 4], ["RepA", "DNA", 107, 111], ["p-value", "TEST", 85, 92], ["RepA", "TEST", 107, 111]]], ["Same results were observed for baboon RepA (best result: 0.032; 86% overlap with the query region) and lemur RepA (best result: 0.075; p-value; 97% overlap with the query region), suggesting a strong structural conservation within primates ( Figure 2B ).", [["baboon", "ORGANISM", 31, 37], ["baboon RepA", "DNA", 31, 42], ["lemur RepA", "DNA", 103, 113], ["lemur RepA", "TEST", 103, 113], ["p-value", "TEST", 135, 142], ["strong", "OBSERVATION_MODIFIER", 193, 199], ["structural conservation", "OBSERVATION", 200, 223]]], ["By contrast, human and mouseResultsRepA showed larger distance in terms of both structural and sequence similarity, which is in agreement with previous studies on lncRNA conservation 16 .ResultsWe used CROSSalign to search human RepA in all mouse lncRNAs and identified XIST as the 5 th best hit (structural distance 0.085; p-value < 10 -6 ; Figure 3A ).", [["human", "ORGANISM", 13, 18], ["mouseResultsRepA", "GENE_OR_GENE_PRODUCT", 23, 39], ["human", "ORGANISM", 223, 228], ["RepA", "GENE_OR_GENE_PRODUCT", 229, 233], ["mouse", "ORGANISM", 241, 246], ["XIST", "GENE_OR_GENE_PRODUCT", 270, 274], ["human and mouseResultsRepA", "DNA", 13, 39], ["lncRNA conservation 16", "DNA", 163, 185], ["human RepA", "DNA", 223, 233], ["mouse lncRNAs", "DNA", 241, 254], ["XIST", "DNA", 270, 274], ["5 th best hit", "DNA", 282, 295], ["human", "SPECIES", 13, 18], ["human", "SPECIES", 223, 228], ["mouse", "SPECIES", 241, 246], ["human", "SPECIES", 13, 18], ["human", "SPECIES", 223, 228], ["mouse", "SPECIES", 241, 246], ["previous studies", "TEST", 143, 159], ["lncRNA conservation", "TREATMENT", 163, 182], ["human RepA", "TREATMENT", 223, 233], ["p-value", "TEST", 324, 331], ["larger", "OBSERVATION_MODIFIER", 47, 53]]], ["In this case, the position of RepA was not correctly assigned (coordinates: 10306-10698; 0% overlap) but the best match falls in the regulatory region of exon 7 and the structural relation between RepA and exon 7 has been reported 17 .", [["RepA", "GENE_OR_GENE_PRODUCT", 30, 34], ["RepA", "GENE_OR_GENE_PRODUCT", 197, 201], ["RepA", "DNA", 30, 34], ["regulatory region", "DNA", 133, 150], ["exon 7", "DNA", 154, 160], ["RepA", "DNA", 197, 201], ["exon 7", "DNA", 206, 212]]], ["Importantly, the correct coordinates of human RepA within mouse XIST rank second in our analysis (structural distance 0.086; p-value < 10 -6 ), while the best match is a miRNA-containing gene Mirg (ENSMUSG00000097391) and the two secondary structure profiles show a strong correlation of 0.92 ( Figure 3B) .", [["human", "ORGANISM", 40, 45], ["RepA", "GENE_OR_GENE_PRODUCT", 46, 50], ["mouse", "ORGANISM", 58, 63], ["XIST", "GENE_OR_GENE_PRODUCT", 64, 68], ["human RepA", "DNA", 40, 50], ["XIST", "DNA", 64, 68], ["miRNA-containing gene Mirg", "DNA", 170, 196], ["ENSMUSG00000097391", "DNA", 198, 216], ["human", "SPECIES", 40, 45], ["mouse", "SPECIES", 58, 63], ["human", "SPECIES", 40, 45], ["mouse", "SPECIES", 58, 63], ["human RepA", "TREATMENT", 40, 50], ["our analysis", "TEST", 84, 96], ["structural distance", "TEST", 98, 117], ["p-value", "TEST", 125, 132], ["a miRNA", "TEST", 168, 175]]], ["Interestingly, even if little information is available on Mirg, it is be prevalently expressed in the embryo 18 .", [["embryo", "ANATOMY", 102, 108], ["Mirg", "GENE_OR_GENE_PRODUCT", 58, 62], ["embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 102, 108], ["Mirg", "PROTEIN", 58, 62]]], ["This result unveils a previously unreported relationship between XIST and Mirg, in which structural and functional homologies can be linked.", [["XIST", "GENE_OR_GENE_PRODUCT", 65, 69], ["Mirg", "GENE_OR_GENE_PRODUCT", 74, 78], ["XIST", "DNA", 65, 69], ["Mirg", "DNA", 74, 78]]], ["Intriguingly, also the second best result, Rian (ENSMUSG00000097451), is expressed in embryo, while no information is available on the third and fourth hits (ENSMUSG00000107391 and ENSMUSG00000085312).ResultsWe note that the five matches here are not listed in the top 20 hits obtained by analysis of sequence similarity (<34%).ResultsOur results suggest that RepA secondary structure is conserved among primates, and diverges between human and mouse.", [["embryo", "ANATOMY", 86, 92], ["embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 86, 92], ["RepA", "GENE_OR_GENE_PRODUCT", 360, 364], ["human", "ORGANISM", 435, 440], ["mouse", "ORGANISM", 445, 450], ["RepA", "PROTEIN", 360, 364], ["human", "SPECIES", 435, 440], ["mouse", "SPECIES", 445, 450], ["human", "SPECIES", 435, 440], ["mouse", "SPECIES", 445, 450], ["sequence similarity", "TEST", 301, 320], ["RepA secondary structure", "PROBLEM", 360, 384]]], ["However, analyzing the information contained in structured nucleotides (i.e., nucleotides with CROSS score < 0 are set to 0) we could identify XIST as the 1 st best hit of human RepA in all mouse lncRNAs (structural distance 0.034; p-value < 10 -6 ; Figure 3C ).", [["nucleotides", "CHEMICAL", 59, 70], ["nucleotides", "CHEMICAL", 78, 89], ["XIST", "GENE_OR_GENE_PRODUCT", 143, 147], ["human", "ORGANISM", 172, 177], ["RepA", "GENE_OR_GENE_PRODUCT", 178, 182], ["mouse", "ORGANISM", 190, 195], ["XIST", "DNA", 143, 147], ["1 st best hit", "DNA", 155, 168], ["human RepA", "DNA", 172, 182], ["mouse lncRNAs", "DNA", 190, 203], ["human", "SPECIES", 172, 177], ["mouse", "SPECIES", 190, 195], ["human", "SPECIES", 172, 177], ["mouse", "SPECIES", 190, 195], ["CROSS score", "TEST", 95, 106], ["human RepA", "TREATMENT", 172, 182], ["structural distance", "TEST", 205, 224], ["p-value", "TEST", 232, 239]]], ["This result indicates that double-stranded regions are more conserved than single-stranded regions.", [["double-stranded regions", "DNA", 27, 50], ["single-stranded regions", "DNA", 75, 98], ["double-stranded regions", "PROBLEM", 27, 50], ["double", "OBSERVATION_MODIFIER", 27, 33], ["stranded", "OBSERVATION", 34, 42], ["more conserved", "OBSERVATION_MODIFIER", 55, 69], ["stranded", "OBSERVATION", 82, 90]]], ["In addition, we note that the sequence identity ranks XIST as the 14 th hit of human RepA in all mouse lncRNAs, thusResultsshowing significantly lower ability to identify structural homologues.HOTAIRWe selected the D2 domain of HOTAIR (predicted by CROSS to be highly structured;Supplementary Figure 7)to measure its conservation in 10 species 15 using CROSSalign (Supplementary Figure 8A) .", [["XIST", "GENE_OR_GENE_PRODUCT", 54, 58], ["human", "ORGANISM", 79, 84], ["RepA", "GENE_OR_GENE_PRODUCT", 85, 89], ["mouse", "ORGANISM", 97, 102], ["HOTAIR", "GENE_OR_GENE_PRODUCT", 228, 234], ["XIST", "DNA", 54, 58], ["14 th hit", "DNA", 66, 75], ["human RepA", "DNA", 79, 89], ["mouse lncRNAs", "DNA", 97, 110], ["D2 domain", "PROTEIN", 215, 224], ["HOTAIR", "DNA", 228, 234], ["CROSS", "PROTEIN", 249, 254], ["human", "SPECIES", 79, 84], ["mouse", "SPECIES", 97, 102], ["human", "SPECIES", 79, 84], ["mouse", "SPECIES", 97, 102], ["human RepA", "TREATMENT", 79, 89], ["HOTAIR", "PROBLEM", 228, 234], ["mouse lncRNAs", "OBSERVATION", 97, 110]]], ["As for XIST, structural distance analysis indicates that primates cluster close to human and other species are more distant (Supplementary Figure 8B) .Supplementary Figure 7)Orangutan D2 was searched in all human lncRNAs and HOTAIR was identified as the best match (structural distance 0.032; p-value < 10 -6 ) with overlapping coordinates (nucleotides: 666-1191; 78% overlap with the query region; Figure 4A ).", [["XIST", "GENE_OR_GENE_PRODUCT", 7, 11], ["human", "ORGANISM", 83, 88], ["Orangutan D2", "GENE_OR_GENE_PRODUCT", 174, 186], ["human", "ORGANISM", 207, 212], ["HOTAIR", "GENE_OR_GENE_PRODUCT", 225, 231], ["XIST", "DNA", 7, 11], ["human lncRNAs", "DNA", 207, 220], ["HOTAIR", "DNA", 225, 231], ["nucleotides: 666-1191", "DNA", 341, 362], ["human", "SPECIES", 83, 88], ["human", "SPECIES", 207, 212], ["human", "SPECIES", 83, 88], ["human", "SPECIES", 207, 212], ["XIST", "PROBLEM", 7, 11], ["structural distance analysis", "TEST", 13, 41], ["primates cluster close to human and other species", "PROBLEM", 57, 106], ["Orangutan D2", "TREATMENT", 174, 186], ["HOTAIR", "TREATMENT", 225, 231], ["p-value", "TEST", 293, 300], ["nucleotides", "TEST", 341, 352]]], ["Searching mouse D2 in all human lncRNAs, HOTAIR was found as the best (0.092; p-value < 10 -suggest that D2 secondary structure is not only conserved in primates but also in mouse.Supplementary Figure 7)To further investigate HOTAIR secondary structure, we selected the D4 (Supplementary Figure 9 ) domain that is predicted by CROSS to be poorly structured (Supplementary Figure 7) .Supplementary Figure 7)Orangutan D4 is the best results among all human lncRNA (structural distance 0.023; pvalue < 10 -6 ) and correctly matching in sequence position (predicted coordinates: 1650-2291; overlap of 79%; Figure 5A ).", [["mouse", "ORGANISM", 10, 15], ["D2", "GENE_OR_GENE_PRODUCT", 16, 18], ["human", "ORGANISM", 26, 31], ["HOTAIR", "GENE_OR_GENE_PRODUCT", 41, 47], ["mouse", "ORGANISM", 174, 179], ["HOTAIR", "GENE_OR_GENE_PRODUCT", 226, 232], ["Orangutan D4", "GENE_OR_GENE_PRODUCT", 406, 418], ["human", "ORGANISM", 449, 454], ["mouse D2", "DNA", 10, 18], ["human lncRNAs", "DNA", 26, 39], ["HOTAIR", "DNA", 41, 47], ["D2", "PROTEIN", 105, 107], ["HOTAIR", "DNA", 226, 232], ["D4 (Supplementary Figure 9 ) domain", "PROTEIN", 270, 305], ["CROSS", "PROTEIN", 327, 332], ["human lncRNA", "DNA", 449, 461], ["mouse", "SPECIES", 10, 15], ["human", "SPECIES", 26, 31], ["mouse", "SPECIES", 174, 179], ["human", "SPECIES", 449, 454], ["mouse", "SPECIES", 10, 15], ["human", "SPECIES", 26, 31], ["mouse", "SPECIES", 174, 179], ["human", "SPECIES", 449, 454], ["HOTAIR", "TEST", 41, 47], ["p-value", "TEST", 78, 85], ["D2 secondary structure", "PROBLEM", 105, 127], ["HOTAIR secondary structure", "PROBLEM", 226, 252], ["the D4 (Supplementary Figure 9 ) domain", "TREATMENT", 266, 305], ["secondary structure", "OBSERVATION", 233, 252]]], ["By contrast, mouse D4 shows poor ranking (1849 th Figure 6A ).", [["mouse", "ORGANISM", 13, 18], ["mouse D4", "PROTEIN", 13, 21], ["mouse", "SPECIES", 13, 18], ["mouse", "SPECIES", 13, 18]]], ["This result indicates that the secondary structure of this region is not only necessary for HIV encapsidation 23 , but is also essential for the activity of other viruses.Supplementary Figure 7)We also compared structural distances and sequence similarities of all HIV strains (4804; see Material and Methods).", [["HIV", "SPECIES", 92, 95], ["HIV", "SPECIES", 265, 268], ["the secondary structure of this region", "PROBLEM", 27, 65], ["HIV encapsidation", "PROBLEM", 92, 109], ["all HIV strains", "PROBLEM", 261, 276], ["secondary", "OBSERVATION_MODIFIER", 31, 40], ["not only necessary", "UNCERTAINTY", 69, 87]]], ["We found two clusters (brown and red; Figure 6B )Supplementary Figure 7)that are similar in terms of structure (~0.06 structural distance; p-value < 10 -6 ) andSupplementary Figure 7)sequence (95%-80% sequence similarity).", [["p-value", "TEST", 139, 146], ["sequence", "TEST", 183, 191], ["two", "OBSERVATION_MODIFIER", 9, 12], ["clusters", "OBSERVATION_MODIFIER", 13, 21], ["brown", "OBSERVATION_MODIFIER", 23, 28], ["similar", "OBSERVATION_MODIFIER", 81, 88]]], ["Other clusters (red and green; Figure 6B ) showed significant distance in structure (from 0.06 to 0.09 of structural distance; pvalue < 10 -6 ) that is not identifiable by sequence similarity (~85% sequence similarity).Supplementary Figure 7)This result suggests that HIV could have evolved maintaining a similar sequence but different structures, as previously reported in literature 24 .DiscussionWe developed the CROSSalign method based on the combination of the CROSS algorithm to predict the RNA secondary structure at single-nucleotide resolution 10 and the Dynamic Time Warping (DTW) algorithm to align profiles of different lengths 11 .", [["HIV", "ORGANISM", 268, 271], ["HIV", "SPECIES", 268, 271], ["Figure 6B", "TEST", 31, 40], ["significant distance in structure", "PROBLEM", 50, 83], ["pvalue", "TEST", 127, 133], ["HIV", "PROBLEM", 268, 271], ["the CROSSalign method", "TREATMENT", 412, 433], ["the CROSS algorithm", "TEST", 462, 481], ["the Dynamic Time Warping (DTW) algorithm", "TREATMENT", 560, 600], ["significant", "OBSERVATION_MODIFIER", 50, 61], ["distance", "OBSERVATION_MODIFIER", 62, 70], ["not identifiable", "UNCERTAINTY", 152, 168], ["HIV", "OBSERVATION", 268, 271], ["different", "OBSERVATION_MODIFIER", 622, 631], ["lengths", "OBSERVATION_MODIFIER", 632, 639]]], ["DTW has been previously applied in different fields, especially pattern recognition and data mining 25,26 , but has never been used to investigate structural alignments.", [["DTW", "CHEMICAL", 0, 3], ["DTW", "PROTEIN", 0, 3]]], ["Since CROSS has no sequence length restrictions and shows strong performances on both coding and non-coding RNAs 10 the combination with DTW allows very accurate comparisons of structural profiles.", [["CROSS", "CHEMICAL", 6, 11], ["CROSS", "DNA", 6, 11], ["DTW", "DNA", 137, 140], ["non-coding RNAs", "TREATMENT", 97, 112]]], ["Other thermodynamic approaches, such as RNAstructure 14 or RNAfold 12 cannot be directly used for such task since they are restricted on the sequence length (typically <1000 nt) 27 .DiscussionWe applied CROSSalign to investigate the structural conservation of lncRNAs in different species and the complete genomes of ssRNA viruses.", [["RNAstructure 14", "DNA", 40, 55], ["RNAfold 12", "PROTEIN", 59, 69], ["lncRNAs", "DNA", 260, 267], ["RNAstructure", "TEST", 40, 52], ["the sequence length", "TEST", 137, 156], ["CROSSalign", "TREATMENT", 203, 213], ["lncRNAs in different species", "PROBLEM", 260, 288], ["ssRNA viruses", "PROBLEM", 317, 330], ["thermodynamic approaches", "OBSERVATION", 6, 30], ["lncRNAs", "OBSERVATION", 260, 267], ["ssRNA viruses", "OBSERVATION", 317, 330]]], ["We found that the algorithm is able to find structural homologues between thousands of possible matches correctly identifying the regions of similarity between profiles of different length.", [["different", "OBSERVATION_MODIFIER", 172, 181], ["length", "OBSERVATION_MODIFIER", 182, 188]]], ["The results of our analysis reveal a structural conservation between know lncRNA domains including XIST RepA (1/8176 best hit; 95% overlap with the query region) and HOTAIR D2 (1/8176 best hit; 78% overlap with the query region), but also identify structural similarities between regulatory regions of HIV and other ssRNA viruses, opening new questions regarding similar mechanisms mediated by the secondary structure.Discussionfunction computed with RNAstructure, we calculated the AUC for each structure with and without CROSS constraints and observed an improvement from 0.81 to 0.86 when CROSS is integrated in the algorithm.", [["XIST", "GENE_OR_GENE_PRODUCT", 99, 103], ["HOTAIR D2", "GENE_OR_GENE_PRODUCT", 166, 175], ["HIV", "ORGANISM", 302, 305], ["lncRNA domains", "DNA", 74, 88], ["XIST RepA", "DNA", 99, 108], ["1/8176 best hit", "DNA", 110, 125], ["HOTAIR D2", "DNA", 166, 175], ["1/8176 best hit", "DNA", 177, 192], ["regulatory regions", "DNA", 280, 298], ["HIV", "SPECIES", 302, 305], ["HIV", "SPECIES", 302, 305], ["our analysis", "TEST", 15, 27], ["XIST RepA", "TEST", 99, 108], ["HOTAIR D2", "PROBLEM", 166, 175], ["HIV", "PROBLEM", 302, 305], ["other ssRNA viruses", "PROBLEM", 310, 329], ["the AUC", "TEST", 479, 486], ["CROSS constraints", "TEST", 523, 540], ["lncRNA", "OBSERVATION", 74, 80], ["HIV", "OBSERVATION", 302, 305], ["ssRNA viruses", "OBSERVATION", 316, 329], ["secondary structure", "OBSERVATION", 398, 417], ["improvement", "OBSERVATION_MODIFIER", 557, 568]]], ["On the test set 12 , we found a similar trend using RNAfold 12 (the PPV increases from 0.67 to 0.70 using Global Score and the AUC remains at 0.85).DiscussionIn this study, all the profiles were computed using the Global Score module without smoothing: nucleotides with a score higher then 0 are predicted to be double-stranded and structured, while nucleotides with a score lower than 0 are single-stranded.", [["nucleotides", "CHEMICAL", 253, 264], ["nucleotides", "CHEMICAL", 350, 361], ["Global Score module", "DNA", 214, 233], ["the test set", "TEST", 3, 15], ["the PPV", "TEST", 64, 71], ["Global Score", "TEST", 106, 118], ["the AUC", "TEST", 123, 130], ["this study", "TEST", 161, 171], ["a score", "TEST", 270, 277], ["a score", "TEST", 367, 374], ["similar", "OBSERVATION_MODIFIER", 32, 39], ["trend", "OBSERVATION_MODIFIER", 40, 45], ["stranded", "OBSERVATION", 319, 327]]], ["Since the algorithm has no sequence length restriction and shows strong performances on both coding and non-coding RNAs 10 it was combined with DTW for pairwise comparison of structural profiles.", [["non-coding RNAs", "RNA", 104, 119], ["DTW", "DNA", 144, 147], ["sequence length restriction", "TEST", 27, 54], ["strong", "OBSERVATION_MODIFIER", 65, 71]]], ["Thermodynamic approaches, such as RNAstructure 14 or RNAfold 12 , could not be directly used for such task since they are restricted on the sequence length (maximum ~1000nt).", [["RNAstructure 14", "DNA", 34, 49], ["RNAfold 12", "PROTEIN", 53, 63], ["RNAstructure", "TEST", 34, 46], ["the sequence length", "TEST", 136, 155]]], ["IDTW is used to compare profile of similar length (i.e., one sequence is less than 3 times longer than the other), while OBE-DTW is preferred to search modules inside bigger profiles (e.g., RepA inside the complete XIST sequence; ~45 times bigger).Comparison of structural profiles: DTWThe structural distance is computed with an asymmetric pattern and using the Manhattan distance, which is optimal for comparing profiles of different length.", [["RepA", "GENE_OR_GENE_PRODUCT", 190, 194], ["IDTW", "PROTEIN", 0, 4], ["OBE-DTW", "DNA", 121, 128], ["RepA", "DNA", 190, 194], ["XIST sequence", "DNA", 215, 228], ["structural", "OBSERVATION_MODIFIER", 290, 300], ["distance", "OBSERVATION_MODIFIER", 301, 309], ["asymmetric", "OBSERVATION_MODIFIER", 330, 340], ["pattern", "OBSERVATION_MODIFIER", 341, 348], ["length", "OBSERVATION_MODIFIER", 436, 442]]], ["The function index was used to visualize the optimal path and to extract the matching coordinates between the two profiles.Statistical analysisTo compute the significance of a specific DTW score, we analyzed the statistical distributions generated using human lncRNAs of different lengths (200, 500, 1000, 5000 nucleotides).", [["human", "ORGANISM", 254, 259], ["human lncRNAs", "DNA", 254, 267], ["human", "SPECIES", 254, 259], ["human", "SPECIES", 254, 259], ["The function index", "TEST", 0, 18], ["a specific DTW score", "TEST", 174, 194]]], ["The distributions are set as a reference to compute the p-values in new analyses (Supplementary Table 3 )Datasets\u2022 lncRNA sequences were downloaded from ENSEBLE 82 using Biomart and specifying lincRNAs, for a total of 4427 sequences for mouse and 8176 for human.Datasets\u2022 The complete viral genomes were downloaded from NCBI selecting ssRNA viruses having as host human or primates (for SIV), for a total of 292 complete genomes.Datasets\u2022 The complete rRNA sequences were downloaded from NCBI.Datasets\u2022 RepA, D2 and D4 were selected from the data publicly available from the work of Rivas et al., 2016 15 .", [["mouse", "ORGANISM", 237, 242], ["human", "ORGANISM", 256, 261], ["human", "ORGANISM", 364, 369], ["primates", "ORGANISM", 373, 381], ["SIV", "ORGANISM", 387, 390], ["RepA", "GENE_OR_GENE_PRODUCT", 503, 507], ["lncRNA sequences", "DNA", 115, 131], ["ENSEBLE 82", "DNA", 153, 163], ["Biomart", "DNA", 170, 177], ["lincRNAs", "DNA", 193, 201], ["4427 sequences", "DNA", 218, 232], ["viral genomes", "DNA", 285, 298], ["rRNA sequences", "DNA", 452, 466], ["RepA", "DNA", 503, 507], ["D2", "DNA", 509, 511], ["D4", "DNA", 516, 518], ["mouse", "SPECIES", 237, 242], ["human", "SPECIES", 256, 261], ["human", "SPECIES", 364, 369], ["mouse", "SPECIES", 237, 242], ["human", "SPECIES", 256, 261], ["human", "SPECIES", 364, 369], ["SIV", "SPECIES", 387, 390], ["Datasets\u2022 lncRNA sequences", "TEST", 105, 131], ["Datasets", "TREATMENT", 262, 270], ["The complete viral genomes", "PROBLEM", 272, 298], ["The complete rRNA sequences", "TEST", 439, 466], ["viral genomes", "OBSERVATION", 285, 298]]], ["When this was not possible we selected similar species (rat and mouse, orangutan and chimpanzee, lemur and sloth).Datasets\u2022 The HIV strains were downloaded from HIV databases (https://www.hiv.lanl.gov/), selecting only complete genomes for a total of 4804 sequences processable by CROSS.Sequence alignmentTo compute the sequence alignments we used the browser version of EMBOSSneedleall, public available at http://www.bioinformatics.nl/cgi-bin/emboss/needleall.Sequence alignmentThe tool was used with standard settings to speed-up the calculation.", [["rat", "ORGANISM", 56, 59], ["mouse", "ORGANISM", 64, 69], ["orangutan", "ORGANISM", 71, 80], ["chimpanzee", "ORGANISM", 85, 95], ["lemur", "ORGANISM", 97, 102], ["HIV", "ORGANISM", 128, 131], ["4804 sequences", "DNA", 251, 265], ["CROSS", "PROTEIN", 281, 286], ["rat", "SPECIES", 56, 59], ["mouse", "SPECIES", 64, 69], ["HIV", "SPECIES", 128, 131], ["rat", "SPECIES", 56, 59], ["mouse", "SPECIES", 64, 69], ["HIV", "SPECIES", 128, 131], ["HIV", "SPECIES", 161, 164], ["The HIV strains", "PROBLEM", 124, 139], ["HIV databases", "TEST", 161, 174], ["Sequence alignment", "TEST", 287, 305], ["EMBOSSneedleall", "TREATMENT", 371, 386], ["standard settings", "TREATMENT", 503, 520], ["not possible", "UNCERTAINTY", 14, 26]]], ["The sequence identity was retrieved from the corresponding field from EMBOSS multiple output.InputThe user should paste one or two RNA sequences in FASTA format into the dedicated form, providing an email address (optional) to receive a notification when the job is completed.", [["RNA sequences", "DNA", 131, 144], ["multiple", "OBSERVATION_MODIFIER", 77, 85], ["output", "OBSERVATION_MODIFIER", 86, 92]]], ["The algorithm can be launched in 4 different modes, each of them being a specific variation of the DTW algorithm (Supplementary Figure 1) .Input\u2022 The standard-DTW is recommended to compare profile of similar length RNAs (i.e., one sequence is less than 2 times longer than the other).Input\u2022 OBE-DTW (open begins and ends) is a specific mode to search a smaller profile inside a bigger one.", [["DTW", "DNA", 159, 162], ["length RNAs", "RNA", 208, 219], ["OBE-DTW", "DNA", 291, 298]]], ["This is the recommended modality when comparing profile of very different sizes (i.e., one sequence is more than 5 times longer than the other).", [["sizes", "OBSERVATION_MODIFIER", 74, 79]]], ["Please keep in mind that the sequence in the form of RNA input 1 will be searched in RNA input 2, so the sequence in RNA input 1 should be smaller than the other.Input\u2022 The fragmented OBE-DTW is a specific modality to search unknown secondary structure domains of one profile inside the other.", [["DTW", "DNA", 188, 191], ["secondary structure domains", "PROTEIN", 233, 260], ["RNA input", "TREATMENT", 53, 62], ["smaller", "OBSERVATION_MODIFIER", 139, 146], ["fragmented", "OBSERVATION_MODIFIER", 173, 183]]], ["The secondary structure of RNA input 1 will be fragmented with a non-overlapping window of 200 nucleotides [optimal size to search secondary structure domains in large RNAs 32,33 ] Each fragment of one sequence be then searched against the other sequence.", [["nucleotides", "CHEMICAL", 95, 106], ["The secondary structure of RNA input", "PROBLEM", 0, 36], ["a non-overlapping window of 200 nucleotides", "TREATMENT", 63, 106], ["secondary structure domains in large RNAs", "PROBLEM", 131, 172], ["RNA input", "OBSERVATION", 27, 36]]], ["A minimum length of 600 nucleotides is recommended for fragmentation.Input\u2022 The dataset mode allows the user to search a single sequence inside all the lincRNAs of a specific organism.", [["nucleotides", "CHEMICAL", 24, 35], ["lincRNAs", "DNA", 152, 160], ["A minimum length of 600 nucleotides", "TREATMENT", 0, 35], ["fragmentation", "PROBLEM", 55, 68], ["a single sequence", "TREATMENT", 119, 136]]], ["The shorter profile of each couple will be searched in the larger one following the OBE-DTW procedure.", [["the OBE-DTW procedure", "TREATMENT", 80, 101]]], ["The organisms available are Human, Mouse, Rat, Macaque and Zebrafish.", [["Human", "ORGANISM", 28, 33], ["Mouse", "ORGANISM", 35, 40], ["Macaque", "ORGANISM", 47, 54], ["Zebrafish", "ORGANISM", 59, 68], ["Human", "SPECIES", 28, 33], ["Mouse", "SPECIES", 35, 40], ["Rat", "SPECIES", 42, 45], ["Zebrafish", "SPECIES", 59, 68]]], ["The lincRNAs where downloaded using Biomart (Ensemble 82).", [["lincRNAs", "DNA", 4, 12], ["lincRNAs", "OBSERVATION", 4, 12]]], ["New organisms and updated versions will be regularly added.OutputWe report the CROSSalign score that measures the structural distance between two structures.", [["New organisms", "PROBLEM", 0, 13], ["the CROSSalign score", "PROBLEM", 75, 95], ["organisms", "OBSERVATION", 4, 13], ["structural", "OBSERVATION_MODIFIER", 114, 124], ["distance", "OBSERVATION_MODIFIER", 125, 133]]], ["The closer the score is to 0, the higher the similarity in terms of secondary structure.", [["secondary structure", "OBSERVATION", 68, 87]]], ["According to our statistical analysis, RNA molecules with a structural distance of 0.10 or higher are to be considered different in term of secondary structure (see Documentation).OutputThe main image shows the overall structural similarity of the two profiles employed to calculate CROSSalign score (Supplementary Figure 2A) .", [["RNA molecules", "PROTEIN", 39, 52], ["CROSSalign", "PROTEIN", 283, 293], ["our statistical analysis", "TEST", 13, 37], ["RNA molecules", "PROBLEM", 39, 52], ["a structural distance", "TEST", 58, 79], ["Output", "TEST", 180, 186], ["The main image", "TEST", 186, 200], ["secondary structure", "OBSERVATION", 140, 159], ["main", "OBSERVATION_MODIFIER", 190, 194], ["overall", "OBSERVATION_MODIFIER", 211, 218], ["structural similarity", "OBSERVATION", 219, 240]]], ["On the two axes the user will see the structural profiles obtained with CROSS for the two RNA sequences in input (score >0 means a double-stranded nucleotide; <0 single-stranded;).", [["nucleotide", "CHEMICAL", 147, 157], ["CROSS", "DNA", 72, 77], ["RNA sequences", "DNA", 90, 103], ["the two RNA sequences", "TEST", 82, 103], ["score", "TEST", 114, 119], ["a double-stranded nucleotide", "TEST", 129, 157]]], ["For a better visualization, the profiles are smoothed using a function previously defined 10OutputThe similarity is represented by the red path in the figure, obtained with the index function of the dtw package.", [["10Output", "DNA", 90, 98], ["a better visualization", "TEST", 4, 26]]], ["The closer the path is to the diagonal, the more similar Red and green boxes indicate strains whose structural difference cannot be identified through sequence analysis, while brown and red boxes as well as green and yellow boxes identify strains with similar structures and different sequences.", [["Red and green boxes", "DNA", 57, 76], ["brown and red boxes", "DNA", 176, 195], ["green and yellow boxes", "DNA", 207, 229], ["strains", "PROBLEM", 86, 93], ["sequence analysis", "TEST", 151, 168], ["brown and red boxes", "PROBLEM", 176, 195], ["green and yellow boxes identify strains", "PROBLEM", 207, 246], ["diagonal", "ANATOMY_MODIFIER", 30, 38]]], ["RepA-Orangutan VS all lincRNA-Human RepA-Baboon VS all lincRNA-Human", [["RepA", "GENE_OR_GENE_PRODUCT", 0, 4], ["RepA", "DNA", 0, 4], ["lincRNA-Human RepA-Baboon VS", "DNA", 22, 50], ["RepA", "TEST", 0, 4], ["RepA", "TEST", 36, 40]]]], "e770d1a56fd61852b17c235fa40a7cb3b829b036": [["IntroductionA cluster outbreak of pneumonia now known as the novel coronavirus infectious disease occurred in Wuhan City, Hubei Province of China, beginning in December 2019 (Lu, et al. 2020) .", [["pneumonia", "DISEASE", 34, 43], ["coronavirus infectious disease", "DISEASE", 67, 97], ["coronavirus", "ORGANISM", 67, 78], ["coronavirus", "SPECIES", 67, 78], ["pneumonia", "PROBLEM", 34, 43], ["the novel coronavirus infectious disease", "PROBLEM", 57, 97], ["pneumonia", "OBSERVATION", 34, 43], ["coronavirus", "OBSERVATION_MODIFIER", 67, 78], ["infectious", "OBSERVATION", 79, 89]]], ["The WHO has named the pneumonia caused by this coronavirus Coronavirus Disease 2019 and declared COVID-19 as a global health emergency.", [["pneumonia", "DISEASE", 22, 31], ["coronavirus Coronavirus Disease", "DISEASE", 47, 78], ["coronavirus", "SPECIES", 47, 58], ["the pneumonia", "PROBLEM", 18, 31], ["this coronavirus Coronavirus Disease", "PROBLEM", 42, 78], ["pneumonia", "OBSERVATION", 22, 31], ["coronavirus Coronavirus", "OBSERVATION", 47, 70]]], ["As of June 2nd, 2020, there are more than 6,430,000 patients confirmed to have COVID-19 and 385,000 deaths worldwide.", [["deaths", "DISEASE", 100, 106], ["patients", "ORGANISM", 52, 60], ["patients", "SPECIES", 52, 60], ["COVID", "TEST", 79, 84]]], ["Nearly 14% of the patients need ICU management because of severe acute respiratory distress syndrome (ARDS) (Wu and Mcgoogan 2020) .IntroductionCT (computerized tomography) scan is the key imaging modality for these patients (Chung, et al. 2020 , Pan, et al. 2020 .", [["respiratory", "ANATOMY", 71, 82], ["acute respiratory distress syndrome", "DISEASE", 65, 100], ["ARDS", "DISEASE", 102, 106], ["patients", "ORGANISM", 18, 26], ["patients", "ORGANISM", 216, 224], ["patients", "SPECIES", 18, 26], ["patients", "SPECIES", 216, 224], ["ICU management", "TREATMENT", 32, 46], ["severe acute respiratory distress syndrome", "PROBLEM", 58, 100], ["ARDS", "PROBLEM", 102, 106], ["computerized tomography) scan", "TEST", 148, 177], ["severe", "OBSERVATION_MODIFIER", 58, 64], ["acute", "OBSERVATION_MODIFIER", 65, 70], ["respiratory", "ANATOMY", 71, 82], ["distress syndrome", "OBSERVATION", 83, 100]]], ["However, the disadvantages of a CT scan include the need to transport the patient to the CT room, radiation exposure and, most importantly, the risk of virus dissemination.", [["patient", "ORGANISM", 74, 81], ["patient", "SPECIES", 74, 81], ["a CT scan", "TEST", 30, 39], ["radiation exposure", "TREATMENT", 98, 116], ["virus dissemination", "PROBLEM", 152, 171], ["virus dissemination", "OBSERVATION", 152, 171]]], ["As a result, lung ultrasound seems to be a safer and more convenient alternative to CT scans in a transportation-limited setting such as when mechanical ventilation or even extracorporeal membrane oxygenation (ECMO) are needed.", [["lung", "ANATOMY", 13, 17], ["extracorporeal membrane", "ANATOMY", 173, 196], ["lung", "ORGAN", 13, 17], ["extracorporeal membrane", "MULTI-TISSUE_STRUCTURE", 173, 196], ["lung ultrasound", "TEST", 13, 28], ["CT scans", "TEST", 84, 92], ["mechanical ventilation", "TREATMENT", 142, 164], ["extracorporeal membrane oxygenation", "TREATMENT", 173, 208], ["ECMO)", "TREATMENT", 210, 215], ["lung", "ANATOMY", 13, 17]]], ["In an urgent situation when a patient's situation deteriorates, a rapid imaging tool is urgently needed.", [["patient", "ORGANISM", 30, 37], ["patient", "SPECIES", 30, 37], ["a patient's situation", "PROBLEM", 28, 49], ["a rapid imaging tool", "TEST", 64, 84]]], ["Lung ultrasound has evolved in recent decades, especially in critical care and emergency management.", [["Lung", "ANATOMY", 0, 4], ["Lung", "ORGAN", 0, 4], ["Lung ultrasound", "TEST", 0, 15], ["emergency management", "TREATMENT", 79, 99]]], ["Studies of lung ultrasound have proven the value of this imaging modality in identifying pulmonary diseases including pulmonary edema and pneumonia, especially in the emergency and intensive care settings (Lichtenstein and Meziere 2008, Lichtenstein 2009 ).", [["lung", "ANATOMY", 11, 15], ["pulmonary", "ANATOMY", 89, 98], ["pulmonary", "ANATOMY", 118, 127], ["pulmonary diseases", "DISEASE", 89, 107], ["pulmonary edema", "DISEASE", 118, 133], ["pneumonia", "DISEASE", 138, 147], ["lung", "ORGAN", 11, 15], ["pulmonary", "ORGAN", 89, 98], ["pulmonary", "ORGAN", 118, 127], ["lung ultrasound", "TEST", 11, 26], ["this imaging modality", "TEST", 52, 73], ["pulmonary diseases", "PROBLEM", 89, 107], ["pulmonary edema", "PROBLEM", 118, 133], ["pneumonia", "PROBLEM", 138, 147], ["Lichtenstein and Meziere", "TREATMENT", 206, 230], ["Lichtenstein", "TREATMENT", 237, 249], ["lung", "ANATOMY", 11, 15], ["pulmonary", "ANATOMY", 89, 98], ["diseases", "OBSERVATION", 99, 107], ["pulmonary", "ANATOMY", 118, 127], ["edema", "OBSERVATION", 128, 133], ["pneumonia", "OBSERVATION", 138, 147]]], ["We have introduced bedside ultrasound for the imaging assessment of patients with severe COVID-19 to evaluate the severity of pneumonia.", [["pneumonia", "DISEASE", 126, 135], ["patients", "ORGANISM", 68, 76], ["patients", "SPECIES", 68, 76], ["bedside ultrasound", "TEST", 19, 37], ["the imaging assessment", "TEST", 42, 64], ["severe COVID", "TEST", 82, 94], ["pneumonia", "PROBLEM", 126, 135], ["pneumonia", "OBSERVATION", 126, 135]]], ["(1) severe type: respiratory distress with a respiratory rate \u2265 30 times/min and an oxygen saturation\u226493% and a PaO2/FiO2 \u2264 300 mmHG in a resting state; (2) critical type: respiratory failure requiring mechanical ventilation, shock and other organ failure requiring ICU monitoring and treatment; (3) refractory type: refractory respiratory failure with a PaO2/FiO2\u2264100 mmHG or patients who were treated with ECMO.", [["respiratory", "ANATOMY", 17, 28], ["respiratory", "ANATOMY", 45, 56], ["respiratory", "ANATOMY", 172, 183], ["organ", "ANATOMY", 242, 247], ["respiratory", "ANATOMY", 328, 339], ["respiratory distress", "DISEASE", 17, 37], ["oxygen", "CHEMICAL", 84, 90], ["respiratory failure", "DISEASE", 172, 191], ["shock", "DISEASE", 226, 231], ["organ failure", "DISEASE", 242, 255], ["respiratory failure", "DISEASE", 328, 347], ["oxygen", "CHEMICAL", 84, 90], ["oxygen", "SIMPLE_CHEMICAL", 84, 90], ["organ", "ORGAN", 242, 247], ["patients", "ORGANISM", 377, 385], ["patients", "SPECIES", 377, 385], ["respiratory distress", "PROBLEM", 17, 37], ["a respiratory rate", "TEST", 43, 61], ["an oxygen saturation", "TEST", 81, 101], ["a PaO2", "TEST", 110, 116], ["FiO2", "TEST", 117, 121], ["respiratory failure", "PROBLEM", 172, 191], ["mechanical ventilation", "TREATMENT", 202, 224], ["shock", "PROBLEM", 226, 231], ["other organ failure", "PROBLEM", 236, 255], ["ICU monitoring", "TREATMENT", 266, 280], ["treatment", "TREATMENT", 285, 294], ["refractory respiratory failure", "PROBLEM", 317, 347], ["a PaO2", "TEST", 353, 359], ["FiO2", "TEST", 360, 364], ["ECMO", "TREATMENT", 408, 412], ["respiratory distress", "OBSERVATION", 17, 37], ["respiratory failure", "OBSERVATION", 172, 191], ["mechanical ventilation", "OBSERVATION", 202, 224], ["organ", "ANATOMY", 242, 247], ["failure", "OBSERVATION", 248, 255], ["refractory", "OBSERVATION_MODIFIER", 317, 327], ["respiratory failure", "OBSERVATION", 328, 347]]], ["We included patients with refractory-type disease in the refractory group and those with severe-type and critical-type disease in the nonrefractory group.", [["critical-type disease", "DISEASE", 105, 126], ["patients", "ORGANISM", 12, 20], ["patients", "SPECIES", 12, 20], ["refractory-type disease", "PROBLEM", 26, 49], ["severe-type and critical-type disease", "PROBLEM", 89, 126], ["severe", "OBSERVATION_MODIFIER", 89, 95], ["critical", "OBSERVATION_MODIFIER", 105, 113], ["-type", "OBSERVATION_MODIFIER", 113, 118], ["disease", "OBSERVATION", 119, 126]]], ["The lung ultrasound features and scores were studied and compared between the two groups.Materials and MethodsLung ultrasound assessment: All ultrasound evaluations were performed at the bedside by three physicians with over 5 years of critical care experience.", [["lung", "ANATOMY", 4, 8], ["lung", "ORGAN", 4, 8], ["The lung ultrasound features", "TEST", 0, 28], ["scores", "TEST", 33, 39], ["MethodsLung ultrasound assessment", "TEST", 103, 136], ["All ultrasound evaluations", "TEST", 138, 164], ["critical care experience", "TREATMENT", 236, 260], ["lung", "ANATOMY", 4, 8]]], ["Operators were dressed in protective clothing, gloves and goggles to enter the isolation ward.", [["protective clothing", "TREATMENT", 26, 45], ["gloves", "TREATMENT", 47, 53], ["goggles", "TREATMENT", 58, 65]]], ["All precautions for respiratory, droplet and contact isolation were provided in this ward.", [["respiratory", "ANATOMY", 20, 31], ["All precautions", "TREATMENT", 0, 15], ["respiratory, droplet", "TREATMENT", 20, 40], ["contact isolation", "TREATMENT", 45, 62]]], ["The ultrasound probe was placed in a sterile plastic sleeve or sterile glove.", [["The ultrasound probe", "TREATMENT", 0, 20], ["a sterile plastic sleeve", "TREATMENT", 35, 59], ["sterile glove", "TREATMENT", 63, 76], ["plastic sleeve", "OBSERVATION", 45, 59], ["sterile glove", "OBSERVATION", 63, 76]]], ["The operator used a convex probe to perform an ultrasound of the lungs.", [["lungs", "ANATOMY", 65, 70], ["lungs", "ORGAN", 65, 70], ["a convex probe", "TREATMENT", 18, 32], ["an ultrasound of the lungs", "TEST", 44, 70], ["lungs", "ANATOMY", 65, 70]]], ["Pulmonary ultrasound was screened first longitudinally and then transversely according to BLUE protocol (Lichtenstein 2009 ).", [["Pulmonary", "ANATOMY", 0, 9], ["Pulmonary", "ORGAN", 0, 9], ["Pulmonary ultrasound", "TEST", 0, 20]]], ["The longitudinal examination began by finding the sonogram of the ribs and the pleural line between the two ribs to identify the lung tissue.", [["ribs", "ANATOMY", 66, 70], ["pleural line", "ANATOMY", 79, 91], ["ribs", "ANATOMY", 108, 112], ["lung tissue", "ANATOMY", 129, 140], ["ribs", "ORGAN", 66, 70], ["pleural line", "CELL", 79, 91], ["ribs", "ORGAN", 108, 112], ["lung tissue", "TISSUE", 129, 140], ["The longitudinal examination", "TEST", 0, 28], ["the sonogram", "TEST", 46, 58], ["the pleural line", "TREATMENT", 75, 91], ["ribs", "ANATOMY", 66, 70], ["pleural", "ANATOMY", 79, 86], ["line", "OBSERVATION", 87, 91], ["two", "ANATOMY_MODIFIER", 104, 107], ["ribs", "ANATOMY", 108, 112], ["lung", "ANATOMY", 129, 133], ["tissue", "ANATOMY_MODIFIER", 134, 140]]], ["A transverse examination was then performed to further clarify the images of the lungs.", [["lungs", "ANATOMY", 81, 86], ["lungs", "ORGAN", 81, 86], ["A transverse examination", "TEST", 0, 24], ["the images", "TEST", 63, 73], ["lungs", "ANATOMY", 81, 86]]], ["Image data were frozen and saved after obtaining the desired image, and the patient's name and examination location were marked.", [["patient", "ORGANISM", 76, 83], ["patient", "SPECIES", 76, 83], ["Image data", "TEST", 0, 10], ["the desired image", "TEST", 49, 66], ["examination location", "TEST", 95, 115]]], ["At the end of the procedure, we sterilize the probe in a dedicated area and placed the sterile plastic bag or sterile gloves in a medical recycling bag.", [["the procedure", "TREATMENT", 14, 27], ["the probe", "TREATMENT", 42, 51], ["the sterile plastic bag", "TREATMENT", 83, 106], ["sterile gloves", "TREATMENT", 110, 124], ["a medical recycling bag", "TREATMENT", 128, 151], ["plastic bag", "OBSERVATION", 95, 106]]], ["All images were reviewed and scored by two physicians with over 5 years of critical care ultrasound experience with the operator.", [["All images", "TEST", 0, 10]]], ["An M7 Expert ultrasound system with a 5-MHz curved (C60x) transducer was used for lung ultrasound assessment (Mindray Investment Co, Ltd, China).", [["lung", "ANATOMY", 82, 86], ["lung", "ORGAN", 82, 86], ["An M7 Expert ultrasound system", "TEST", 0, 30], ["a 5-MHz curved (C60x) transducer", "TREATMENT", 36, 68], ["lung ultrasound assessment", "TEST", 82, 108], ["lung", "ANATOMY", 82, 86]]], ["We examined each side of the chest wall in 5 examination zones: the anterosuperior and anteroinferior zones were the second and fifth intercostal space in the midclavicular line; the laterosuperior and lateroinferior zones were the same cross-sections at the midaxillary line; and the posterior zone was the subscapularis area on the back.", [["chest wall", "ANATOMY", 29, 39], ["anterosuperior", "ANATOMY", 68, 82], ["anteroinferior zones", "ANATOMY", 87, 107], ["fifth intercostal space", "ANATOMY", 128, 151], ["midclavicular line", "ANATOMY", 159, 177], ["laterosuperior", "ANATOMY", 183, 197], ["lateroinferior zones", "ANATOMY", 202, 222], ["cross-sections", "ANATOMY", 237, 251], ["midaxillary line", "ANATOMY", 259, 275], ["posterior zone", "ANATOMY", 285, 299], ["subscapularis area", "ANATOMY", 308, 326], ["back", "ANATOMY", 334, 338], ["chest wall", "MULTI-TISSUE_STRUCTURE", 29, 39], ["anterosuperior", "CANCER", 68, 82], ["intercostal space", "MULTI-TISSUE_STRUCTURE", 134, 151], ["midclavicular line", "CELL", 159, 177], ["laterosuperior", "CANCER", 183, 197], ["lateroinferior zones", "CANCER", 202, 222], ["-sections", "MULTI-TISSUE_STRUCTURE", 242, 251], ["midaxillary line", "CELL", 259, 275], ["posterior zone", "MULTI-TISSUE_STRUCTURE", 285, 299], ["subscapularis area", "TISSUE", 308, 326], ["5 examination zones", "TEST", 43, 62], ["chest", "ANATOMY", 29, 34], ["wall", "ANATOMY_MODIFIER", 35, 39], ["anterosuperior", "ANATOMY_MODIFIER", 68, 82], ["anteroinferior", "ANATOMY_MODIFIER", 87, 101], ["zones", "ANATOMY_MODIFIER", 102, 107], ["second", "ANATOMY_MODIFIER", 117, 123], ["fifth", "ANATOMY_MODIFIER", 128, 133], ["intercostal", "ANATOMY_MODIFIER", 134, 145], ["space", "ANATOMY_MODIFIER", 146, 151], ["midclavicular", "ANATOMY", 159, 172], ["line", "ANATOMY_MODIFIER", 173, 177], ["laterosuperior", "ANATOMY_MODIFIER", 183, 197], ["lateroinferior", "ANATOMY_MODIFIER", 202, 216], ["zones", "ANATOMY_MODIFIER", 217, 222], ["midaxillary", "ANATOMY", 259, 270], ["line", "ANATOMY_MODIFIER", 271, 275], ["posterior", "ANATOMY_MODIFIER", 285, 294], ["zone", "ANATOMY_MODIFIER", 295, 299], ["subscapularis", "ANATOMY", 308, 321], ["area", "ANATOMY_MODIFIER", 322, 326], ["back", "ANATOMY", 334, 338]]], ["In total, 10 zones were examined on every patient's chest wall.", [["chest wall", "ANATOMY", 52, 62], ["patient", "ORGANISM", 42, 49], ["chest wall", "MULTI-TISSUE_STRUCTURE", 52, 62], ["patient", "SPECIES", 42, 49], ["total", "OBSERVATION_MODIFIER", 3, 8], ["10 zones", "OBSERVATION_MODIFIER", 10, 18], ["chest", "ANATOMY", 52, 57], ["wall", "ANATOMY_MODIFIER", 58, 62]]], ["Patients were investigated in a semirecumbent or supine position.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8]]], ["We focused on the following patterns, and a numeric value was assigned according to the most severe finding: (1) 0 points, normal pattern with a smooth and sliding pleural line with parallel A-lines; (2) 1 point, B-line patterns:Materials and MethodsB-lines were defined as discrete laser-like vertical hyperechoic artifacts arising from the pleural line and extending to the bottom of the image without fading (Lichtenstein, et al. 1997 ); (3) 2 points, ground-glass sign with B-lines occupying the entire screen; (3) 3 points, shred sign that was fragmented similar to small consolidation under the pleural line; (4) 4 points, liver tissue-like consolidation sign; and (4) 4 points, pleural effusion.", [["pleural line", "ANATOMY", 164, 176], ["pleural line", "ANATOMY", 342, 354], ["B-lines", "ANATOMY", 478, 485], ["pleural line", "ANATOMY", 601, 613], ["liver tissue", "ANATOMY", 629, 641], ["pleural effusion", "ANATOMY", 685, 701], ["pleural effusion", "DISEASE", 685, 701], ["B-lines", "CELL", 478, 485], ["liver tissue", "TISSUE", 629, 641], ["pleural", "PATHOLOGICAL_FORMATION", 685, 692], ["MethodsB-lines", "CELL_LINE", 243, 257], ["B-lines", "CELL_LINE", 478, 485], ["a numeric value", "TEST", 42, 57], ["a smooth and sliding pleural line", "TREATMENT", 143, 176], ["parallel A-lines", "TREATMENT", 182, 198], ["MethodsB-lines", "TREATMENT", 243, 257], ["discrete laser-like vertical hyperechoic artifacts", "PROBLEM", 274, 324], ["ground-glass sign", "TEST", 455, 472], ["B-lines", "TREATMENT", 478, 485], ["shred sign", "PROBLEM", 529, 539], ["small consolidation under the pleural line", "PROBLEM", 571, 613], ["liver tissue-like consolidation sign", "PROBLEM", 629, 665], ["pleural effusion", "PROBLEM", 685, 701], ["normal", "OBSERVATION", 123, 129], ["smooth", "OBSERVATION_MODIFIER", 145, 151], ["pleural", "ANATOMY", 164, 171], ["line", "OBSERVATION", 172, 176], ["discrete", "OBSERVATION_MODIFIER", 274, 282], ["laser", "OBSERVATION_MODIFIER", 283, 288], ["vertical", "OBSERVATION_MODIFIER", 294, 302], ["hyperechoic", "OBSERVATION_MODIFIER", 303, 314], ["artifacts", "OBSERVATION", 315, 324], ["pleural", "ANATOMY", 342, 349], ["line", "OBSERVATION", 350, 354], ["bottom", "ANATOMY_MODIFIER", 376, 382], ["without", "UNCERTAINTY", 396, 403], ["fading", "OBSERVATION_MODIFIER", 404, 410], ["Lichtenstein", "OBSERVATION", 412, 424], ["glass sign", "OBSERVATION", 462, 472], ["small", "OBSERVATION_MODIFIER", 571, 576], ["consolidation", "OBSERVATION", 577, 590], ["pleural", "ANATOMY", 601, 608], ["line", "OBSERVATION", 609, 613], ["liver", "ANATOMY", 629, 634], ["tissue", "ANATOMY_MODIFIER", 635, 641], ["consolidation", "OBSERVATION", 647, 660], ["pleural", "ANATOMY", 685, 692], ["effusion", "OBSERVATION", 693, 701]]], ["For one patient, the sum of the 10 zone numbers was recorded as the LUS score, which ranged from 0 to 40.", [["patient", "ORGANISM", 8, 15], ["patient", "SPECIES", 8, 15], ["the LUS score", "TEST", 64, 77]]], ["The affected zones of each pattern were also recorded.", [["affected", "OBSERVATION_MODIFIER", 4, 12], ["zones", "OBSERVATION_MODIFIER", 13, 18]]], ["This scoring system referenced some previously published scoring systems (Bouhemad, et al. 2011 , Soldati, et al. 2020 , Volpicelli, et al. 2020 ).Statistical analysis:We compared the demographical and LUS data between the nonrefractory group and the refractory group.", [["LUS data", "TEST", 202, 210], ["refractory", "OBSERVATION_MODIFIER", 251, 261]]], ["Statistical analysis was performed with Rstudio 1.2.1335 (RStudio, Inc., Boston, MA, USA).", [["Statistical analysis", "TEST", 0, 20], ["Rstudio", "TEST", 40, 47], ["RStudio", "TEST", 58, 65]]], ["Normally distributed data are expressed as the mean (SD) and were analyzed by Student's t-test.", [["Student's t-test", "TEST", 78, 94]]], ["Nonnormally distributed data are expressed as the median (interquartile range [IQR] ) and were analyzed by the Wilcoxon test.", [["the Wilcoxon test", "TEST", 107, 124]]], ["Proportions are expressed as numbers (percentages) and were compared by the chi-square test or Fisher's exact test.", [["the chi-square test", "TEST", 72, 91], ["Fisher's exact test", "TEST", 95, 114]]], ["Linear regression was used to evaluate the relationship between LUS and PaO2/FiO2.", [["PaO2", "CHEMICAL", 72, 76], ["FiO2", "CHEMICAL", 77, 81], ["Linear regression", "PROBLEM", 0, 17], ["LUS", "TEST", 64, 67], ["PaO2", "TEST", 72, 76], ["FiO2", "TREATMENT", 77, 81], ["regression", "OBSERVATION", 7, 17]]], ["Receiver operating characteristic (ROC) curves were plotted to illustrate the accuracy in recognizing patients with refractory pneumonia.Patient selection and demographic informationA total of 35 patients were enrolled in this study.", [["pneumonia", "DISEASE", 127, 136], ["patients", "ORGANISM", 102, 110], ["patients", "ORGANISM", 196, 204], ["patients", "SPECIES", 102, 110], ["Patient", "SPECIES", 137, 144], ["patients", "SPECIES", 196, 204], ["refractory pneumonia", "PROBLEM", 116, 136], ["this study", "TEST", 222, 232], ["refractory", "OBSERVATION_MODIFIER", 116, 126], ["pneumonia", "OBSERVATION", 127, 136]]], ["In total, 28 patients were in the nonrefractory group, and 7 were in the refractory group.", [["patients", "ORGANISM", 13, 21], ["patients", "SPECIES", 13, 21]]], ["As shown in Table 1 , the mean age was not significantly different between the groups.", [["significantly different", "OBSERVATION_MODIFIER", 43, 66]]], ["In the nonrefractory group, there were 8 patients on mechanical ventilation, and 20 on HFNC.", [["patients", "ORGANISM", 41, 49], ["patients", "SPECIES", 41, 49], ["mechanical ventilation", "TREATMENT", 53, 75], ["HFNC", "TREATMENT", 87, 91], ["mechanical ventilation", "OBSERVATION", 53, 75]]], ["In the refractory group, all 7 patients were on ECMO in the end.", [["patients", "ORGANISM", 31, 39], ["patients", "SPECIES", 31, 39], ["ECMO", "TREATMENT", 48, 52], ["refractory", "OBSERVATION_MODIFIER", 7, 17]]], ["In total, there were 15 patients who were mechanically ventilated.", [["patients", "ORGANISM", 24, 32], ["patients", "SPECIES", 24, 32], ["mechanically ventilated", "OBSERVATION", 42, 65]]], ["There were 7 patients from Wuhan and 5 patients who had traveled to Wuhan within 14 days (Table 1) .Lung ultrasound imaging findingsUltrasound morphology features and their distributions are shown in Table 2 .", [["Lung", "ANATOMY", 100, 104], ["patients", "ORGANISM", 13, 21], ["patients", "ORGANISM", 39, 47], ["Lung", "ORGAN", 100, 104], ["patients", "SPECIES", 13, 21], ["patients", "SPECIES", 39, 47], ["Lung ultrasound imaging findings", "TEST", 100, 132], ["Ultrasound morphology", "TEST", 132, 153]]], ["The B-line pattern ( Fig 1B) and shred sign ( Fig 1D) were the most typical ultrasound features that were frequently found in both groups.", [["B-line", "ANATOMY", 4, 10], ["B-line", "CELL", 4, 10], ["The B-line pattern", "TEST", 0, 18]]], ["The median number of zones that showed a shred sign was 6 [IQR 6-7] in the refractory group and 8 [IQR 7-9] in the nonrefractory group.", [["a shred sign", "TEST", 39, 51], ["IQR", "TEST", 59, 62], ["IQR", "TEST", 99, 102], ["zones", "ANATOMY_MODIFIER", 21, 26], ["refractory", "OBSERVATION_MODIFIER", 75, 85]]], ["Patients in the refractory group showed less B-line patterns than those in the nonrefractory group (4 [IQR 2-7] vs 6 [IQR 6-7], p = 0.046).", [["B-line", "ANATOMY", 45, 51], ["Patients", "ORGANISM", 0, 8], ["B-line", "CELL", 45, 51], ["Patients", "SPECIES", 0, 8], ["less B-line patterns", "PROBLEM", 40, 60], ["IQR", "TEST", 103, 106], ["IQR", "TEST", 118, 121]]], ["The ground-glass pattern ( Fig 1C) occurred significantly more frequently in the refractory group than in the nonrefractory group (6 [IQR 2.5-6.5] vs 0 [IQR 0-3]).", [["The ground-glass pattern", "TEST", 0, 24], ["IQR", "TEST", 134, 137], ["ground-", "OBSERVATION_MODIFIER", 4, 11], ["glass pattern", "OBSERVATION", 11, 24], ["more frequently", "OBSERVATION_MODIFIER", 58, 73], ["refractory", "OBSERVATION_MODIFIER", 81, 91]]], ["Although the consolidation pattern ( Fig 1E) was not that frequently found in both groups, it seemed that the refractory group had significantly more consolidation patterns.", [["the consolidation pattern", "PROBLEM", 9, 34], ["significantly more consolidation patterns", "PROBLEM", 131, 172], ["consolidation", "OBSERVATION", 13, 26], ["refractory", "OBSERVATION_MODIFIER", 110, 120], ["significantly", "OBSERVATION_MODIFIER", 131, 144], ["more", "OBSERVATION_MODIFIER", 145, 149], ["consolidation", "OBSERVATION", 150, 163]]], ["For the effusion pattern (Fig 1F) , there were significantly more patients with this pattern in the refractory group than in the nonrefractory group (5 [IQR 1.5-6] vs 0 [IQR 0-0.25]).Lung ultrasound score in differentiating critical patientsThe refractory group showed a higher LUS score than the nonrefractory group ( Fig 2 A) .", [["Lung", "ANATOMY", 183, 187], ["patients", "ORGANISM", 66, 74], ["Lung", "ORGAN", 183, 187], ["patients", "ORGANISM", 233, 241], ["patients", "SPECIES", 66, 74], ["patients", "SPECIES", 233, 241], ["the effusion pattern", "PROBLEM", 4, 24], ["IQR", "TEST", 153, 156], ["Lung ultrasound score", "TEST", 183, 204], ["a higher LUS score", "PROBLEM", 269, 287], ["effusion", "OBSERVATION", 8, 16], ["refractory", "OBSERVATION_MODIFIER", 245, 255]]], ["In different scanning zones, the refractory group always have a higher LUS score (Fig 2 B) .", [["zones", "OBSERVATION_MODIFIER", 22, 27], ["refractory", "OBSERVATION_MODIFIER", 33, 43]]], ["The scores in the nonrefractory group were equal between zones.", [["The scores", "TEST", 0, 10], ["equal", "OBSERVATION", 43, 48], ["zones", "ANATOMY_MODIFIER", 57, 62]]], ["In the refractory group, the scores were higher in the gravity-dependent zones.", [["the scores", "TEST", 25, 35], ["refractory", "OBSERVATION_MODIFIER", 7, 17], ["higher", "OBSERVATION_MODIFIER", 41, 47], ["gravity", "OBSERVATION", 55, 62], ["dependent", "OBSERVATION_MODIFIER", 63, 72], ["zones", "ANATOMY_MODIFIER", 73, 78]]], ["However, Wilcoxon analysis found no significant difference between zones in patients with refractory disease.", [["patients", "ORGANISM", 76, 84], ["patients", "SPECIES", 76, 84], ["Wilcoxon analysis", "TEST", 9, 26], ["significant difference between zones", "PROBLEM", 36, 72], ["refractory disease", "PROBLEM", 90, 108], ["no", "UNCERTAINTY", 33, 35], ["significant", "OBSERVATION_MODIFIER", 36, 47], ["difference", "OBSERVATION", 48, 58], ["refractory", "OBSERVATION_MODIFIER", 90, 100], ["disease", "OBSERVATION", 101, 108]]], ["When LUS was utilized in distinguishing patients with refractory disease, the cutoff point was 32 points (Fig 3A) .", [["patients", "ORGANISM", 40, 48], ["patients", "SPECIES", 40, 48], ["LUS", "TEST", 5, 8], ["refractory disease", "PROBLEM", 54, 72], ["the cutoff point", "TEST", 74, 90]]], ["At this point, predicting a refractory situation had a specificity of 0.893 and a sensitivity of 0.571.", [["a refractory situation", "PROBLEM", 26, 48], ["a specificity", "TEST", 53, 66], ["a sensitivity", "TEST", 80, 93], ["refractory", "OBSERVATION_MODIFIER", 28, 38]]], ["The ROC curve of the PaO2/FiO2 is also shown in Fig 3, and the cutoff point is 114 , with a specificity of 0.74 and a sensitivity of 100%.", [["The ROC curve", "TEST", 0, 13], ["the PaO2/FiO2", "TEST", 17, 30], ["a specificity", "TEST", 90, 103], ["a sensitivity", "TEST", 116, 129]]], ["The AUC of the PaO2/FiO2 ROC was 0.894.", [["The AUC", "TEST", 0, 7], ["the PaO2", "TEST", 11, 19], ["FiO2 ROC", "TEST", 20, 28]]], ["However, LUS did not differentiate well between the two severe and critical groups of patients, with an AUC of only 0.52 (Fig 3B) .DiscussionCOVID-19 has already involved nearly 6,430,000 people all over the world.", [["patients", "ORGANISM", 86, 94], ["people", "ORGANISM", 188, 194], ["patients", "SPECIES", 86, 94], ["people", "SPECIES", 188, 194], ["LUS", "TEST", 9, 12], ["an AUC", "TEST", 101, 107], ["severe", "OBSERVATION_MODIFIER", 56, 62]]], ["Although CT is the most important imaging modality for viral pneumonia, the high risk of transporting ventilated patients or patients on ECMO with hemodynamic failure makes CT have limited availability.", [["pneumonia", "DISEASE", 61, 70], ["patients", "ORGANISM", 113, 121], ["patients", "ORGANISM", 125, 133], ["patients", "SPECIES", 113, 121], ["patients", "SPECIES", 125, 133], ["CT", "TEST", 9, 11], ["viral pneumonia", "PROBLEM", 55, 70], ["ECMO", "TREATMENT", 137, 141], ["hemodynamic failure", "PROBLEM", 147, 166], ["CT", "TEST", 173, 175], ["viral", "OBSERVATION_MODIFIER", 55, 60], ["pneumonia", "OBSERVATION", 61, 70]]], ["Furthermore, the risk of the contagiousness of the coronavirus should be evaluated before transportation.", [["coronavirus", "DISEASE", 51, 62], ["coronavirus", "ORGANISM", 51, 62], ["the coronavirus", "PROBLEM", 47, 62]]], ["In addition, in the ICU, protective clothing makes stethoscopes have limited utility. `Lung ultrasound has significantly evolved in the critical care and emergency department due to its theoretical and practical aspects.", [["Lung", "ANATOMY", 87, 91], ["Lung", "ORGAN", 87, 91], ["protective clothing", "TREATMENT", 25, 44], ["Lung ultrasound", "TEST", 87, 102], ["Lung", "ANATOMY", 87, 91]]], ["We introduced ultrasound for the examination of COVID-19 lesions because in critical care, ultrasound is an optimal tool for patients on mechanical ventilation or ECMO.", [["COVID-19 lesions", "ANATOMY", 48, 64], ["COVID-19 lesions", "CANCER", 48, 64], ["patients", "ORGANISM", 125, 133], ["patients", "SPECIES", 125, 133], ["ultrasound", "TEST", 14, 24], ["the examination", "TEST", 29, 44], ["COVID", "TEST", 48, 53], ["19 lesions", "PROBLEM", 54, 64], ["ultrasound", "TEST", 91, 101], ["mechanical ventilation", "TREATMENT", 137, 159], ["ECMO", "TREATMENT", 163, 167], ["lesions", "OBSERVATION", 57, 64]]], ["Both convex and linear probes can be used for ultrasound of the lungs (Radzina and Biederer 2019 , Soldati, et al. 2019 .", [["lungs", "ANATOMY", 64, 69], ["lungs", "ORGAN", 64, 69], ["ultrasound of the lungs", "TEST", 46, 69], ["convex", "OBSERVATION_MODIFIER", 5, 11], ["linear", "OBSERVATION_MODIFIER", 16, 22], ["lungs", "ANATOMY", 64, 69]]], ["However, because the convex probe may be more suitable for obese patients, it can also be used for abdominal and even cardiac examinations; thus, a convex probe was used in this study instead of a linear probe.", [["abdominal", "ANATOMY", 99, 108], ["cardiac", "ANATOMY", 118, 125], ["patients", "ORGANISM", 65, 73], ["abdominal", "ORGANISM_SUBDIVISION", 99, 108], ["cardiac", "ORGAN", 118, 125], ["patients", "SPECIES", 65, 73], ["the convex probe", "TREATMENT", 17, 33], ["abdominal and even cardiac examinations", "TEST", 99, 138], ["a convex probe", "TREATMENT", 146, 160], ["this study", "TEST", 173, 183], ["a linear probe", "TREATMENT", 195, 209]]], ["Both Bounsenso and Soldati have suggested that wireless probes and tablets represent the most appropriate ultrasound equipment , Soldati, et al. 2020 ).", [["wireless probes", "TREATMENT", 47, 62], ["tablets", "TREATMENT", 67, 74]]], ["These devices can easily be wrapped in single use plastic covers to reduce the risk of contamination and allow simple sterilization procedures.", [["These devices", "TREATMENT", 0, 13], ["contamination", "PROBLEM", 87, 100], ["simple sterilization procedures", "TREATMENT", 111, 142], ["contamination", "OBSERVATION", 87, 100]]], ["However, the unavailability of these devices limited our choice.", [["these devices", "TREATMENT", 31, 44]]], ["Daily assessment of the lungs can provide an assessment of the severity of lung disease since patients with refractory disease have more decreased lung aeration that can be evaluated by the lung ultrasound score.", [["lungs", "ANATOMY", 24, 29], ["lung", "ANATOMY", 75, 79], ["lung", "ANATOMY", 147, 151], ["lung", "ANATOMY", 190, 194], ["lung disease", "DISEASE", 75, 87], ["lungs", "ORGAN", 24, 29], ["lung", "ORGAN", 75, 79], ["patients", "ORGANISM", 94, 102], ["lung", "ORGAN", 147, 151], ["lung", "ORGAN", 190, 194], ["patients", "SPECIES", 94, 102], ["Daily assessment", "TEST", 0, 16], ["an assessment", "TEST", 42, 55], ["lung disease", "PROBLEM", 75, 87], ["refractory disease", "PROBLEM", 108, 126], ["more decreased lung aeration", "PROBLEM", 132, 160], ["the lung ultrasound score", "TEST", 186, 211], ["lungs", "ANATOMY", 24, 29], ["lung", "ANATOMY", 75, 79], ["disease", "OBSERVATION", 80, 87], ["refractory", "OBSERVATION_MODIFIER", 108, 118], ["disease", "OBSERVATION", 119, 126], ["more", "OBSERVATION_MODIFIER", 132, 136], ["decreased", "OBSERVATION_MODIFIER", 137, 146], ["lung", "ANATOMY", 147, 151], ["aeration", "OBSERVATION", 152, 160], ["lung", "ANATOMY", 190, 194]]], ["The LUS could differentiate between the two groups when they were divided into refractory and nonrefractory groups (p = 0.047).", [["LUS", "MULTI-TISSUE_STRUCTURE", 4, 7], ["The LUS", "TEST", 0, 7]]], ["We haven't divided the patients into three groups (the severe group, the critical group and the refractory group) because the lung ultrasound score (LUS) could not differentiate well between the severe group and the critical group (p = 0.18).DiscussionMore ground-glass patterns and pleural effusions may indicate a more critical status.DiscussionGround-glass sign indicates a high ratio of fluid to air.", [["lung", "ANATOMY", 126, 130], ["pleural effusions", "ANATOMY", 283, 300], ["pleural effusions", "DISEASE", 283, 300], ["patients", "ORGANISM", 23, 31], ["lung", "ORGAN", 126, 130], ["pleural effusions", "CANCER", 283, 300], ["patients", "SPECIES", 23, 31], ["the lung ultrasound score", "TEST", 122, 147], ["LUS", "TEST", 149, 152], ["pleural effusions", "PROBLEM", 283, 300], ["Ground-glass sign", "TEST", 347, 364], ["lung", "ANATOMY", 126, 130], ["severe", "OBSERVATION_MODIFIER", 195, 201], ["glass patterns", "OBSERVATION", 264, 278], ["pleural", "ANATOMY", 283, 290], ["effusions", "OBSERVATION", 291, 300], ["fluid", "OBSERVATION", 391, 396]]], ["This pattern was more frequently found in the refractory group.", [["more frequently", "OBSERVATION_MODIFIER", 17, 32], ["refractory", "OBSERVATION_MODIFIER", 46, 56]]], ["Previous CT studies have found few effusions (Chung, et al. 2020 , Fang, et al. 2020 , Pan, et al. 2020 .", [["effusions", "DISEASE", 35, 44], ["Previous CT studies", "TEST", 0, 19], ["few effusions", "PROBLEM", 31, 44], ["few", "OBSERVATION_MODIFIER", 31, 34], ["effusions", "OBSERVATION", 35, 44]]], ["However, in the current study, more pleural effusions may have been related to refractory respiratory failure.", [["pleural effusions", "ANATOMY", 36, 53], ["respiratory", "ANATOMY", 90, 101], ["pleural effusions", "DISEASE", 36, 53], ["respiratory failure", "DISEASE", 90, 109], ["pleural effusions", "CANCER", 36, 53], ["the current study", "TEST", 12, 29], ["more pleural effusions", "PROBLEM", 31, 53], ["refractory respiratory failure", "PROBLEM", 79, 109], ["pleural", "ANATOMY", 36, 43], ["effusions", "OBSERVATION", 44, 53], ["may have been related to", "UNCERTAINTY", 54, 78], ["refractory", "OBSERVATION_MODIFIER", 79, 89], ["respiratory failure", "OBSERVATION", 90, 109]]], ["The reason may be that patients with refractory disease in this study had more severe disease or were in progressed stages, and mechanical ventilation may have further injured the lungs of these patients.", [["lungs", "ANATOMY", 180, 185], ["patients", "ORGANISM", 23, 31], ["lungs", "ORGAN", 180, 185], ["patients", "ORGANISM", 195, 203], ["patients", "SPECIES", 23, 31], ["patients", "SPECIES", 195, 203], ["refractory disease", "PROBLEM", 37, 55], ["this study", "TEST", 59, 69], ["more severe disease", "PROBLEM", 74, 93], ["mechanical ventilation", "TREATMENT", 128, 150], ["refractory", "OBSERVATION_MODIFIER", 37, 47], ["disease", "OBSERVATION", 48, 55], ["severe", "OBSERVATION_MODIFIER", 79, 85], ["disease", "OBSERVATION", 86, 93], ["mechanical ventilation", "OBSERVATION", 128, 150], ["lungs", "ANATOMY", 180, 185]]], ["When the density of the lung increases to that of solid tissue, consolidation appears.", [["lung", "ANATOMY", 24, 28], ["solid tissue", "ANATOMY", 50, 62], ["lung", "ORGAN", 24, 28], ["solid tissue", "TISSUE", 50, 62], ["solid tissue", "PROBLEM", 50, 62], ["consolidation", "PROBLEM", 64, 77], ["density", "OBSERVATION", 9, 16], ["lung", "ANATOMY", 24, 28], ["increases", "OBSERVATION_MODIFIER", 29, 38], ["solid tissue", "OBSERVATION", 50, 62], ["consolidation", "OBSERVATION", 64, 77]]], ["Although there were more consolidation patterns in the refractory group, consolidation patterns were not so frequently found in either groups.", [["consolidation patterns", "PROBLEM", 73, 95], ["more", "OBSERVATION_MODIFIER", 20, 24], ["consolidation", "OBSERVATION", 25, 38], ["refractory", "OBSERVATION_MODIFIER", 55, 65], ["consolidation", "OBSERVATION", 73, 86]]], ["Previous CT studies have also found few consolidation patterns (Chung, et al. 2020 , Fang, et al. 2020 , Pan, et al. 2020 ).DiscussionThe shred sign and B-line patterns were the most typical ultrasound features but were not specific to distinguish patients with refractory disease because we found many B-lines and shred signs in both groups.", [["B-lines", "ANATOMY", 303, 310], ["B-line", "CELL", 153, 159], ["patients", "ORGANISM", 248, 256], ["B-lines", "CELL", 303, 310], ["B-lines", "CELL_LINE", 303, 310], ["patients", "SPECIES", 248, 256], ["Previous CT studies", "TEST", 0, 19], ["few consolidation patterns", "PROBLEM", 36, 62], ["The shred sign", "TEST", 134, 148], ["refractory disease", "PROBLEM", 262, 280], ["many B-lines and shred signs in both groups", "PROBLEM", 298, 341], ["few", "OBSERVATION_MODIFIER", 36, 39], ["consolidation", "OBSERVATION", 40, 53]]], ["Previous literature regarding CT scan disclosed that COVID-19 lesions are always distributed at the peripheral part of the lungs (Pan, et al. 2020 ).", [["COVID-19 lesions", "ANATOMY", 53, 69], ["peripheral part", "ANATOMY", 100, 115], ["lungs", "ANATOMY", 123, 128], ["COVID-19 lesions", "CANCER", 53, 69], ["peripheral part", "MULTI-TISSUE_STRUCTURE", 100, 115], ["lungs", "ORGAN", 123, 128], ["CT scan", "TEST", 30, 37], ["COVID", "TEST", 53, 58], ["19 lesions", "PROBLEM", 59, 69], ["lesions", "OBSERVATION", 62, 69], ["peripheral", "ANATOMY_MODIFIER", 100, 110], ["lungs", "ANATOMY", 123, 128]]], ["This characteristic is beneficial for lung ultrasound to detect small fragments such as the shred sign in the shallow part of the lungs.", [["lung", "ANATOMY", 38, 42], ["fragments", "ANATOMY", 70, 79], ["lungs", "ANATOMY", 130, 135], ["lung", "ORGAN", 38, 42], ["lungs", "ORGAN", 130, 135], ["lung ultrasound", "TEST", 38, 53], ["small fragments", "PROBLEM", 64, 79], ["the shred sign", "TEST", 88, 102], ["small", "OBSERVATION_MODIFIER", 64, 69], ["fragments", "OBSERVATION", 70, 79], ["shallow", "ANATOMY_MODIFIER", 110, 117], ["lungs", "ANATOMY", 130, 135]]], ["The B-line pattern is considered to be highly reliable in diagnosing interstitial lesions and viral etiologies (Lichtenstein, et al. 1997 , Cortellaro, et al. 2012 ) such as H1N1 and H7N9 (Testa, et al. 2012 , Tsai, et al. 2014 ).", [["B-line", "ANATOMY", 4, 10], ["interstitial lesions", "ANATOMY", 69, 89], ["B-line", "CELL", 4, 10], ["interstitial lesions", "PATHOLOGICAL_FORMATION", 69, 89], ["H7N9", "SPECIES", 183, 187], ["The B-line pattern", "TREATMENT", 0, 18], ["interstitial lesions", "PROBLEM", 69, 89], ["viral etiologies", "PROBLEM", 94, 110], ["H1N1", "PROBLEM", 174, 178], ["H7N9", "PROBLEM", 183, 187], ["-line", "OBSERVATION_MODIFIER", 5, 10], ["interstitial", "ANATOMY_MODIFIER", 69, 81], ["lesions", "OBSERVATION", 82, 89], ["viral", "OBSERVATION_MODIFIER", 94, 99]]], ["However, this pattern is not related to a more critical status in COVID-19 patients.", [["patients", "ORGANISM", 75, 83], ["patients", "SPECIES", 75, 83], ["not related to", "UNCERTAINTY", 25, 39]]], ["The reason may be that the number of B-lines was not described and analyzed in detail in this study.DiscussionThe lung ultrasound score exhibits a high specificity of 89.4% in distinguishing refractory respiratory failure in COVID-19 patients.", [["B-lines", "ANATOMY", 37, 44], ["lung", "ANATOMY", 114, 118], ["respiratory", "ANATOMY", 202, 213], ["respiratory failure", "DISEASE", 202, 221], ["B-lines", "CELL", 37, 44], ["lung", "ORGAN", 114, 118], ["patients", "ORGANISM", 234, 242], ["B-lines", "CELL_LINE", 37, 44], ["patients", "SPECIES", 234, 242], ["B-lines", "TREATMENT", 37, 44], ["this study", "TEST", 89, 99], ["The lung ultrasound score", "TEST", 110, 135], ["refractory respiratory failure", "PROBLEM", 191, 221], ["lung", "ANATOMY", 114, 118], ["refractory", "OBSERVATION_MODIFIER", 191, 201], ["respiratory failure", "OBSERVATION", 202, 221]]], ["Although the AUC of the LUS is lower than that of the PaO2/FiO2, the LUS exerts a much higher specificity than the PaO2/FiO2.", [["PaO2", "CHEMICAL", 54, 58], ["FiO2", "CHEMICAL", 59, 63], ["PaO2", "CHEMICAL", 115, 119], ["FiO2", "CHEMICAL", 120, 124], ["the AUC", "TEST", 9, 16], ["the LUS", "TEST", 20, 27], ["the PaO2", "TEST", 50, 58], ["FiO2", "TREATMENT", 59, 63], ["the LUS", "TEST", 65, 72], ["the PaO2", "TEST", 111, 119], ["FiO2", "TREATMENT", 120, 124], ["lower", "OBSERVATION_MODIFIER", 31, 36]]], ["If we combined the high specificity of the LUS and the high sensitivity of the PaO2/FiO2, we may have a much more reliable diagnosis.", [["LUS", "MULTI-TISSUE_STRUCTURE", 43, 46], ["the LUS", "TEST", 39, 46], ["the PaO2/FiO2", "TREATMENT", 75, 88]]], ["While one patient had a PaO2/FiO2 lower than 114, we had a 100% sensitivity in distinguishing patients with refractory disease.", [["FiO2", "CHEMICAL", 29, 33], ["patient", "ORGANISM", 10, 17], ["patients", "ORGANISM", 94, 102], ["patient", "SPECIES", 10, 17], ["patients", "SPECIES", 94, 102], ["a PaO2/FiO2", "TEST", 22, 33], ["refractory disease", "PROBLEM", 108, 126], ["refractory disease", "OBSERVATION", 108, 126]]], ["A further LUS assessment of more than 32 points on the LUS can improve the specificity to nearly 90%.DiscussionThus, we can have a more accurate model to differentiate refractory respiratory failure among patients who might need urgent life-saving maneuvers such as ECMO.", [["respiratory", "ANATOMY", 179, 190], ["respiratory failure", "DISEASE", 179, 198], ["LUS", "MULTI-TISSUE_STRUCTURE", 55, 58], ["patients", "ORGANISM", 205, 213], ["patients", "SPECIES", 205, 213], ["A further LUS assessment", "TEST", 0, 24], ["the LUS", "TEST", 51, 58], ["refractory respiratory failure", "PROBLEM", 168, 198], ["urgent life-saving maneuvers", "TREATMENT", 229, 257], ["ECMO", "TREATMENT", 266, 270], ["respiratory failure", "OBSERVATION", 179, 198]]], ["ECMO was recommended by the WHO interim guidelines for eligible COVID-19 patients who had developed refractory ARDS (Ramanathan, et al. 2020) .", [["ARDS", "DISEASE", 111, 115], ["patients", "ORGANISM", 73, 81], ["patients", "SPECIES", 73, 81], ["ECMO", "TREATMENT", 0, 4], ["refractory ARDS", "PROBLEM", 100, 115], ["refractory", "OBSERVATION_MODIFIER", 100, 110], ["ARDS", "OBSERVATION", 111, 115]]], ["Available evidence from similar patient populations suggests that carefully selected patients with severe ARDS who do not benefit from conventional treatment might be successfully supported with venovenous ECMO.", [["ARDS", "DISEASE", 106, 110], ["patient", "ORGANISM", 32, 39], ["patients", "ORGANISM", 85, 93], ["patient", "SPECIES", 32, 39], ["patients", "SPECIES", 85, 93], ["severe ARDS", "PROBLEM", 99, 110], ["conventional treatment", "TREATMENT", 135, 157], ["venovenous ECMO", "TREATMENT", 195, 210], ["ARDS", "OBSERVATION", 106, 110]]], ["In this study, the patients in the refractory group were all put on venovenous ECMO, and the lung ultrasound score exhibited a high specificity of 89.4% in distinguishing refractory respiratory failure in COVID-19 patients.", [["lung", "ANATOMY", 93, 97], ["respiratory", "ANATOMY", 182, 193], ["respiratory failure", "DISEASE", 182, 201], ["patients", "ORGANISM", 19, 27], ["lung", "ORGAN", 93, 97], ["patients", "ORGANISM", 214, 222], ["patients", "SPECIES", 19, 27], ["patients", "SPECIES", 214, 222], ["this study", "TEST", 3, 13], ["venovenous ECMO", "TREATMENT", 68, 83], ["the lung ultrasound score", "TEST", 89, 114], ["refractory respiratory failure", "PROBLEM", 171, 201], ["COVID", "TEST", 205, 210], ["lung", "ANATOMY", 93, 97], ["refractory", "OBSERVATION_MODIFIER", 171, 181], ["respiratory failure", "OBSERVATION", 182, 201]]], ["A previous study disclosed that lung ultrasound is a valuable tool for bedside assessment of lung aeration in subjects supported by ECMO (Lu, et al. 2019) .DiscussionHowever, such a practice has not been reported in COVID-19 patients.DiscussionBased on ultrasound findings, we have utilized lung ultrasound in the following routine works: (1) daily assessment of the severity of lung lesions: B-lines gradually disappear and are replaced by A-lines, and consolidation that progressively disappears might indicate an improvement in the lungs, while more interstitial syndrome or more consolidation may indicate progression of the disease; (2) management of ECMO patients in put-on or weaning: an LUS more than 32 might indicate a refractory status in this patient; namely, more interstitial syndrome and more consolidations detected by the LUS are directly correlated with the severity of the lung injury, which may indicate the need for venovenous ECMO; (3) diagnosis of the reason for rapid deterioration among patients; and (4) reducing the need for CT scan.DiscussionOur study has limitations.", [["lung", "ANATOMY", 32, 36], ["lung", "ANATOMY", 93, 97], ["lung", "ANATOMY", 291, 295], ["lung lesions", "ANATOMY", 379, 391], ["B-lines", "ANATOMY", 393, 400], ["lungs", "ANATOMY", 535, 540], ["interstitial", "ANATOMY", 553, 565], ["interstitial", "ANATOMY", 777, 789], ["lung", "ANATOMY", 892, 896], ["lung lesions", "DISEASE", 379, 391], ["interstitial syndrome", "DISEASE", 553, 574], ["interstitial syndrome", "DISEASE", 777, 798], ["lung injury", "DISEASE", 892, 903], ["lung", "ORGAN", 32, 36], ["lung", "ORGAN", 93, 97], ["patients", "ORGANISM", 225, 233], ["lung", "ORGAN", 291, 295], ["lung lesions", "PATHOLOGICAL_FORMATION", 379, 391], ["B-lines", "CELL", 393, 400], ["lungs", "ORGAN", 535, 540], ["patients", "ORGANISM", 661, 669], ["patient", "ORGANISM", 755, 762], ["LUS", "MULTI-TISSUE_STRUCTURE", 839, 842], ["lung", "ORGAN", 892, 896], ["patients", "ORGANISM", 1012, 1020], ["B-lines", "CELL_LINE", 393, 400], ["patients", "SPECIES", 225, 233], ["patients", "SPECIES", 661, 669], ["patient", "SPECIES", 755, 762], ["patients", "SPECIES", 1012, 1020], ["A previous study", "TEST", 0, 16], ["lung ultrasound", "TEST", 32, 47], ["bedside assessment", "TEST", 71, 89], ["lung aeration", "TREATMENT", 93, 106], ["ultrasound findings", "TEST", 253, 272], ["lung ultrasound", "TEST", 291, 306], ["daily assessment", "TEST", 343, 359], ["lung lesions", "PROBLEM", 379, 391], ["B-lines", "TREATMENT", 393, 400], ["consolidation", "PROBLEM", 454, 467], ["interstitial syndrome", "PROBLEM", 553, 574], ["more consolidation", "PROBLEM", 578, 596], ["the disease", "PROBLEM", 625, 636], ["ECMO", "TREATMENT", 656, 660], ["an LUS", "TEST", 692, 698], ["a refractory status", "PROBLEM", 727, 746], ["interstitial syndrome", "PROBLEM", 777, 798], ["more consolidations", "PROBLEM", 803, 822], ["the LUS", "TEST", 835, 842], ["the lung injury", "PROBLEM", 888, 903], ["venovenous ECMO", "TREATMENT", 937, 952], ["rapid deterioration", "PROBLEM", 986, 1005], ["CT scan", "TEST", 1052, 1059], ["DiscussionOur study", "TEST", 1060, 1079], ["lung", "ANATOMY", 32, 36], ["lung", "ANATOMY", 93, 97], ["aeration", "OBSERVATION", 98, 106], ["lung", "ANATOMY", 291, 295], ["lung", "ANATOMY", 379, 383], ["lesions", "OBSERVATION", 384, 391], ["lines", "OBSERVATION_MODIFIER", 395, 400], ["gradually", "OBSERVATION_MODIFIER", 401, 410], ["consolidation", "OBSERVATION", 454, 467], ["improvement", "OBSERVATION_MODIFIER", 516, 527], ["lungs", "ANATOMY", 535, 540], ["interstitial syndrome", "OBSERVATION", 553, 574], ["more", "OBSERVATION_MODIFIER", 578, 582], ["consolidation", "OBSERVATION", 583, 596], ["may indicate", "UNCERTAINTY", 597, 609], ["progression", "OBSERVATION_MODIFIER", 610, 621], ["disease", "OBSERVATION", 629, 636], ["refractory", "OBSERVATION_MODIFIER", 729, 739], ["interstitial syndrome", "OBSERVATION", 777, 798], ["more", "OBSERVATION_MODIFIER", 803, 807], ["consolidations", "OBSERVATION", 808, 822], ["lung", "ANATOMY", 892, 896], ["injury", "OBSERVATION", 897, 903]]], ["First, this is a retrospective experience-based study with a small sample size; thus, the extrapolations of the conclusion may not be strong enough to be suitable for other critical COVID-19 patients.", [["patients", "ORGANISM", 191, 199], ["patients", "SPECIES", 191, 199], ["based study", "TEST", 42, 53], ["a small sample size", "PROBLEM", 59, 78], ["small", "OBSERVATION_MODIFIER", 61, 66], ["size", "OBSERVATION_MODIFIER", 74, 78]]], ["Second, the acoustic beam cannot reach the deeper part of the lungs, and ultrasound features are always indirect artifacts of the lesions.DiscussionThird, with ultrasound, some parts of the thorax cannot be screened, especially the back because patients with severe disease are always in the supine position.", [["lungs", "ANATOMY", 62, 67], ["lesions", "ANATOMY", 130, 137], ["thorax", "ANATOMY", 190, 196], ["lungs", "ORGAN", 62, 67], ["lesions", "PATHOLOGICAL_FORMATION", 130, 137], ["thorax", "ORGAN", 190, 196], ["patients", "ORGANISM", 245, 253], ["patients", "SPECIES", 245, 253], ["the acoustic beam", "TEST", 8, 25], ["ultrasound features", "TEST", 73, 92], ["the lesions", "PROBLEM", 126, 137], ["ultrasound", "TEST", 160, 170], ["severe disease", "PROBLEM", 259, 273], ["acoustic beam", "OBSERVATION", 12, 25], ["deeper", "ANATOMY_MODIFIER", 43, 49], ["lungs", "ANATOMY", 62, 67], ["lesions", "OBSERVATION", 130, 137], ["thorax", "ANATOMY", 190, 196], ["severe", "OBSERVATION_MODIFIER", 259, 265], ["disease", "OBSERVATION", 266, 273]]], ["According to Soldati's recommendation (Soldati, et al. 2020) , all patients should have a lung ultrasound at 14 sites.DiscussionHowever, 15 patients in this study were mechanically ventilated, and a good ultrasound examination of the back could not be obtained.", [["lung", "ANATOMY", 90, 94], ["patients", "ORGANISM", 67, 75], ["lung", "ORGAN", 90, 94], ["patients", "ORGANISM", 140, 148], ["patients", "SPECIES", 67, 75], ["patients", "SPECIES", 140, 148], ["a lung ultrasound", "TEST", 88, 105], ["this study", "TEST", 152, 162], ["mechanically ventilated", "TREATMENT", 168, 191], ["a good ultrasound examination", "TEST", 197, 226], ["lung", "ANATOMY", 90, 94], ["ventilated", "OBSERVATION", 181, 191], ["back", "ANATOMY", 234, 238]]], ["Therefore, we focused only on evaluating lung ultrasound in the lower back segment in all patients.", [["lung", "ANATOMY", 41, 45], ["lower back segment", "ANATOMY", 64, 82], ["lung", "ORGAN", 41, 45], ["lower back", "ORGANISM_SUBDIVISION", 64, 74], ["patients", "ORGANISM", 90, 98], ["patients", "SPECIES", 90, 98], ["evaluating lung ultrasound", "TEST", 30, 56], ["lung", "ANATOMY", 41, 45], ["lower", "ANATOMY_MODIFIER", 64, 69], ["back", "ANATOMY", 70, 74], ["segment", "ANATOMY_MODIFIER", 75, 82]]], ["There were 4 fewer sites examined than Soldati's recommendation; thus, the patient score may have been underestimated.", [["patient", "ORGANISM", 75, 82], ["patient", "SPECIES", 75, 82]]], ["Even though we used conservative fluid therapy for all of our patients, we were still not completely sure if the patient had fluid overload and congestive heart failure.", [["fluid", "ANATOMY", 125, 130], ["heart", "ANATOMY", 155, 160], ["fluid overload", "DISEASE", 125, 139], ["congestive heart failure", "DISEASE", 144, 168], ["patients", "ORGANISM", 62, 70], ["patient", "ORGANISM", 113, 120], ["fluid", "ORGANISM_SUBSTANCE", 125, 130], ["heart", "ORGAN", 155, 160], ["patients", "SPECIES", 62, 70], ["patient", "SPECIES", 113, 120], ["conservative fluid therapy", "TREATMENT", 20, 46], ["fluid overload", "PROBLEM", 125, 139], ["congestive heart failure", "PROBLEM", 144, 168], ["fluid overload", "OBSERVATION", 125, 139], ["congestive", "OBSERVATION_MODIFIER", 144, 154], ["heart", "ANATOMY", 155, 160], ["failure", "OBSERVATION", 161, 168]]], ["These conditions might also influence the B-lines and the analysis of the lung ultrasound scores.DiscussionIn summary, COVID-19 patients share common ultrasound patterns such as B-lines and shred signs.", [["B-lines", "ANATOMY", 42, 49], ["lung", "ANATOMY", 74, 78], ["B-lines", "ANATOMY", 178, 185], ["B-lines", "CELL", 42, 49], ["lung", "ORGAN", 74, 78], ["patients", "ORGANISM", 128, 136], ["B-lines", "CELL", 178, 185], ["B-lines", "CELL_LINE", 42, 49], ["B-lines", "CELL_LINE", 178, 185], ["patients", "SPECIES", 128, 136], ["the B-lines", "TREATMENT", 38, 49], ["the analysis", "TEST", 54, 66], ["the lung ultrasound scores", "TEST", 70, 96], ["common ultrasound patterns", "TEST", 143, 169], ["B-lines", "TREATMENT", 178, 185], ["shred signs", "TEST", 190, 201], ["lung", "ANATOMY", 74, 78]]], ["However, patients with refractory COVID-19 have more ground-glass signs, consolidation patterns and pleural effusion.", [["pleural", "ANATOMY", 100, 107], ["COVID", "DISEASE", 34, 39], ["pleural effusion", "DISEASE", 100, 116], ["patients", "ORGANISM", 9, 17], ["pleural effusion", "PATHOLOGICAL_FORMATION", 100, 116], ["patients", "SPECIES", 9, 17], ["refractory COVID", "TEST", 23, 39], ["more ground-glass signs", "PROBLEM", 48, 71], ["consolidation patterns", "PROBLEM", 73, 95], ["pleural effusion", "PROBLEM", 100, 116], ["ground-glass signs", "OBSERVATION", 53, 71], ["consolidation", "OBSERVATION", 73, 86], ["pleural", "ANATOMY", 100, 107], ["effusion", "OBSERVATION", 108, 116]]], ["The lung ultrasound score can be utilized to distinguish critical patients who might need ECMO with a high specificity of 90%.DiscussionUltrasound can be used as a routine tool for daily assessment of the lung aeration of severely critical COVID-19 patients.Conflicts of interest declarationThe authors declare that they have no potential financial or ethical conflicts of interest regarding the contents of this manuscript. ultrasound score in the refractory group was higher than that in the nonrefractory group.", [["lung", "ANATOMY", 4, 8], ["lung", "ANATOMY", 205, 209], ["lung", "ORGAN", 4, 8], ["patients", "ORGANISM", 66, 74], ["lung", "ORGAN", 205, 209], ["patients", "ORGANISM", 249, 257], ["patients", "SPECIES", 66, 74], ["patients", "SPECIES", 249, 257], ["The lung ultrasound score", "TEST", 0, 25], ["ECMO", "TREATMENT", 90, 94], ["DiscussionUltrasound", "TEST", 126, 146], ["a routine tool", "TEST", 162, 176], ["daily assessment", "TEST", 181, 197], ["the lung aeration", "TEST", 201, 218], ["ultrasound score", "TEST", 425, 441], ["lung", "ANATOMY", 4, 8], ["lung", "ANATOMY", 205, 209], ["aeration", "OBSERVATION", 210, 218], ["refractory", "OBSERVATION_MODIFIER", 449, 459], ["higher", "OBSERVATION_MODIFIER", 470, 476]]], ["B In most scanning zones, the LUS was higher in the refractory group than in the non-ECMO group.", [["non-ECMO", "CANCER", 81, 89], ["the LUS", "TEST", 26, 33], ["higher", "OBSERVATION_MODIFIER", 38, 44], ["refractory", "OBSERVATION_MODIFIER", 52, 62]]], ["In refractory group, grand glass pattern, consolidation pattern and pleural effusions were significantly more than in the non-refractory group.", [["pleural effusions", "ANATOMY", 68, 85], ["pleural effusions", "DISEASE", 68, 85], ["pleural effusions", "CANCER", 68, 85], ["grand glass pattern", "PROBLEM", 21, 40], ["consolidation pattern", "PROBLEM", 42, 63], ["pleural effusions", "PROBLEM", 68, 85], ["refractory", "OBSERVATION_MODIFIER", 3, 13], ["grand glass pattern", "OBSERVATION", 21, 40], ["consolidation", "OBSERVATION", 42, 55], ["pleural", "ANATOMY", 68, 75], ["effusions", "OBSERVATION", 76, 85], ["significantly", "OBSERVATION_MODIFIER", 91, 104], ["more", "OBSERVATION_MODIFIER", 105, 109]]]], "8fb24f1b94e8bff0fdbc612929d6152135bf242c": [["IntroductionIn response to the COVID-19 global pandemic, many countries have implemented large-scale physical (\"social\") distancing measures.", [["the COVID", "TEST", 27, 36], ["distancing measures", "TREATMENT", 121, 140], ["large", "OBSERVATION_MODIFIER", 89, 94]]], ["Accordingly, countries experiencing increasing case counts have considered, and will continue to need to consider, what degree of distancing measures to implement in order to reduce disease spread whilst maintaining public compliance and minimising negative effects of distancing (such as adverse health and economic impacts).", [["increasing case counts", "PROBLEM", 36, 58], ["distancing measures", "TREATMENT", 130, 149], ["disease spread", "PROBLEM", 182, 196]]], ["Quantifying the effect and time scale of such relaxations will contribute to health care capacity forecasting, and delivery of timely advice and instructions to communities.IntroductionA number of recent studies have examined the effectiveness of government control measures on the spread of COVID-19 [2, 8, 34, 35, 23, 32, 18, 9] .", [["COVID-19", "CHEMICAL", 292, 300], ["such relaxations", "TREATMENT", 41, 57], ["recent studies", "TEST", 197, 211], ["government control measures", "TREATMENT", 247, 274], ["COVID", "TEST", 292, 297]]], ["One approach has been to retrospectively compare observed data to baseline model output [34, 8] .", [["baseline model output", "TEST", 66, 87]]], ["Many studies have also focused on estimating changes in the effective reproduction number over time [11, 6, 35] .", [["Many studies", "TEST", 0, 12]]], ["Similarly, [2] directly estimates the impact of control measures on COVID-19 transmission patterns using a Bayesian model with explicit physical distancing.", [["COVID", "TEST", 68, 73], ["a Bayesian model", "TREATMENT", 105, 121]]], ["However, these studies do not focus on reporting the time until a given amount of change is predicted between many simulations of future case counts.", [["these studies", "TEST", 9, 22]]], ["In-stead, they compare simulations to a constant baseline, or report quantitative measures on only a few simulations.IntroductionIn this work, we use a likelihood-based approach to determine when we may expect to see the effects of implementing or relaxing physical distancing measures using case count data.", [["physical distancing measures", "TREATMENT", 257, 285], ["case count data", "TEST", 292, 307]]], ["This is in contrast to the work described above which focuses on quantifying the effect of such measures.", [["such measures", "TREATMENT", 91, 104]]], ["We further use this method to estimate the changes in growth rate that would be expected after beginning to strengthen or relax physical distancing.", [["this method", "TREATMENT", 15, 26], ["the changes in growth rate", "PROBLEM", 39, 65]]], ["We use the SEIR-type model developed in [2] to simulate scenarios over a broad range of simulation parameters and strengths of distancing.", [["the SEIR-type model", "TREATMENT", 7, 26], ["simulation parameters", "TEST", 88, 109]]], ["We consider the impact on the time to detect a change in distancing of data collection delays and inconsistencies, and apply our methods to publicly available case count data from British Columbia, Canada.", [["a change in distancing of data collection delays", "PROBLEM", 45, 93]]], ["While we focus here on the \"first\" implementation and relaxation of physical distancing for COVID-19, these methods can also be used to detect the first time we would expect to see a change in reported case counts in response to modifications of any non-pharmaceutical intervention (NPI).", [["COVID", "TEST", 92, 97], ["a change in reported case counts", "PROBLEM", 181, 213], ["any non-pharmaceutical intervention", "TREATMENT", 246, 281]]], ["For example, we could use this model to explore the effects of introducing digital contact tracing or improved testing.Transmission modelWe use a compartmental model describing susceptible, exposed, infectious and removed individuals (SEIR) [2] .", [["this model", "TREATMENT", 26, 36], ["digital contact tracing", "TEST", 75, 98], ["infectious", "OBSERVATION_MODIFIER", 199, 209]]], ["We fit the model to data on daily case counts, and incorporate knowledge of the incubation period and duration of the infectious period in the model.", [["daily case counts", "TEST", 28, 45], ["infectious", "OBSERVATION", 118, 128]]], ["The model includes a fixed proportion of the population who are willing and able to practise physical distancing, although individuals can transition between distancing and non-distancing modes.", [["distancing and non-distancing modes", "TREATMENT", 158, 193]]], ["Upon infectious contact, individuals move from a susceptible state (S) to an exposed state (E 1 ).", [["infectious", "OBSERVATION", 5, 15]]], ["From here, the disease progresses through the infectious, pre-symptomatic state (E 2 ), to infectious and symptomatic (I), and finally to removed (R).", [["the disease", "PROBLEM", 11, 22], ["disease", "OBSERVATION", 15, 22], ["infectious", "OBSERVATION_MODIFIER", 46, 56], ["infectious", "OBSERVATION_MODIFIER", 91, 101], ["symptomatic", "OBSERVATION_MODIFIER", 106, 117]]], ["Removed individuals are assumed to be not susceptible.", [["assumed to be not", "UNCERTAINTY", 24, 41]]], ["The model furthermore incorporates a possible quarantined state (Q) following symptom onset, in which individuals are still infected but are unable to infect others.", [["individuals", "ORGANISM", 102, 113], ["quarantined state", "PROBLEM", 46, 63], ["symptom onset", "PROBLEM", 78, 91], ["infected", "PROBLEM", 124, 132], ["possible", "UNCERTAINTY", 37, 45], ["infected", "OBSERVATION", 124, 132]]], ["For each state, there is a corresponding \"distanced\" state.", [["a corresponding \"distanced\" state", "PROBLEM", 25, 58]]], ["A schematic for this model is shown in Figure 1 .Transmission modelThe differential equations for the non-distancing compartments are given as follows:Transmission modelThe differential equations for individuals practising physical distancing are analogous:Transmission modelIn these equations, the strength of physical distancing is represented by the parameter 0 \u2264 f (t) \u2264 1, with f (t) = 1 indicating no physical distancing.", [["The differential equations", "TEST", 67, 93], ["The differential equations", "TEST", 169, 195], ["physical distancing", "PROBLEM", 407, 426], ["no", "UNCERTAINTY", 404, 406]]], ["This parameter modulates transmission within the distancing compartments.", [["distancing compartments", "OBSERVATION", 49, 72]]], ["In addition, individuals in the distancing compartments are less likely to be encountered by others, and so contribute a reduced portion of the force of infection as well.", [["infection", "DISEASE", 153, 162], ["infection", "PROBLEM", 153, 162], ["less likely", "UNCERTAINTY", 60, 71], ["reduced", "OBSERVATION_MODIFIER", 121, 128], ["infection", "OBSERVATION", 153, 162]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)Transmission modelThe copyright holder for this preprint this version posted June 16, 2020. . https://doi.org/10.1101/2020.06.14.20131177 doi: medRxiv preprint Figure 1 : Schematic of the epidemiological model from [2] .", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 217, 237], ["med", "ANATOMY", 102, 105]]], ["Compartments are: susceptible to the virus (S); exposed (E 1 ); exposed, pre-symptomatic, and infectious (E 2 ); symptomatic and infectious (I); quarantined (Q); and removed (recovered or deceased; R).", [["the virus", "PROBLEM", 33, 42], ["pre-symptomatic", "PROBLEM", 73, 88], ["symptomatic", "PROBLEM", 113, 124], ["infectious", "OBSERVATION_MODIFIER", 94, 104], ["symptomatic", "OBSERVATION_MODIFIER", 113, 124], ["infectious", "OBSERVATION_MODIFIER", 129, 139]]], ["The reverse transition occurs at rate u r .", [["The reverse transition", "PROBLEM", 0, 22]]], ["The red and tinted red squares represent the compartments that we identify as active cases.", [["The red and tinted red squares", "TREATMENT", 0, 30], ["red", "OBSERVATION", 4, 7], ["tinted red", "OBSERVATION", 12, 22]]], ["The orange/orange tinted and red/red tinted compartments indicate infectious cases.Transmission modelwho became symptomatic at some time s days ago:Transmission modelHere w c represents the distribution of delay between the onset of symptoms and a positive test being reported and \u03c8 t is the fraction of eligible cases on day t that will be tested and reported.", [["red/red tinted compartments", "PROBLEM", 29, 56], ["infectious cases", "PROBLEM", 66, 82], ["symptomatic", "PROBLEM", 112, 123], ["symptoms", "PROBLEM", 233, 241], ["a positive test", "PROBLEM", 246, 261], ["orange tinted", "OBSERVATION", 11, 24], ["infectious", "OBSERVATION", 66, 76], ["symptomatic", "OBSERVATION_MODIFIER", 112, 123]]], ["The upper limit on the integral, M , represents the maximum possible delay in days between onset and reporting, for which we use twice the mean delay.", [["upper limit", "OBSERVATION_MODIFIER", 4, 15]]], ["We seek to determine how soon changes in distancing measures will cause substantial changes in the number of prevalent cases.", [["distancing measures", "TREATMENT", 41, 60], ["substantial changes", "PROBLEM", 72, 91]]], ["And then, determine how well we may be able to estimate the strength of these measures given the delay and noise in the reported case counts and uncertainty about the model parameters.", [["these measures", "TREATMENT", 72, 86], ["the delay and noise", "PROBLEM", 93, 112]]], ["Given a set of daily case count data {C t }, where C t is the number of cases identified on day t, we use a negative binomial likelihood with mean \u00b5 t and dispersion parameter \u03c6, NB(C t | \u00b5 t , \u03c6) as in [2] , to write the likelihood of the data given the model parameters accounting for dispersion:Transmission modelHere T is the final day for which case counts are available (or, of concern), f = (f 0 , f 1 , f 2 ),5.", [["daily case count data", "TEST", 15, 36], ["t", "TEST", 190, 191], ["the data", "TEST", 236, 244]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)5The copyright holder for this preprint this version posted June 16, 2020. . and \u03b8 = (u d , u r , q, D, k 1 , k 2 , \u03c8 t ) are the remaining model parameters, which are assumed to be fixed in all of our experiments except for the simulations in Figure S6 .", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 200, 220], ["u d , u r", "TEST", 285, 294], ["k", "TEST", 303, 304], ["k", "TEST", 309, 310], ["med", "ANATOMY", 102, 105]]], ["In this parameterization of the negative binomial distribution, the variance scales with the mean according to the dispersion parameter \u03c6: Var[{C t }] = \u00b5 + \u00b5 2 /\u03c6.", [["the dispersion parameter", "TEST", 111, 135], ["Var[", "TEST", 139, 143], ["t", "TEST", 146, 147], ["\u00b5", "TEST", 153, 154], ["negative", "OBSERVATION_MODIFIER", 32, 40], ["binomial distribution", "OBSERVATION", 41, 62]]], ["Values of the model parameters for our analysis using British Columbia case count data are provided in Table S1 .Time to pairwise model divergenceThe ODEs described above require parameters which can be sampled from prior distributions.", [["our analysis", "TEST", 35, 47], ["British Columbia case count data", "TEST", 54, 86]]], ["We use uncertainty in R 0 to capture uncertainty in transmission and duration of infection simultaneously: given information about the duration, the transmission parameter \u03b2 can simply be scaled in order to match the exponential growth phase of a dataset.", [["infection", "DISEASE", 81, 90], ["infection", "PROBLEM", 81, 90], ["the transmission parameter", "TREATMENT", 145, 171], ["infection", "OBSERVATION", 81, 90]]], ["This procedure induces a distribution over the case counts seen on each day.Time to pairwise model divergenceWe introduce a method for determining the first date at which the case counts of two models begin to diverge.", [["This procedure", "TREATMENT", 0, 14], ["the case counts", "TEST", 43, 58], ["a method", "TREATMENT", 122, 130], ["distribution", "OBSERVATION_MODIFIER", 25, 37]]], ["The simulated datasets for a model are treated as random samples from a distribution of prevalence in each component of the ODE.", [["random samples", "TEST", 50, 64]]], ["To compute the empirical probability that a substantial difference occurs on a given day after introducing distancing measures, we consider the proportion of simulated samples for which the model with physical distancing shows fewer infected counts than the non-distancing model by at least 10.", [["distancing measures", "TREATMENT", 107, 126], ["fewer infected counts", "PROBLEM", 227, 248], ["the non-distancing model", "TEST", 254, 278], ["substantial", "OBSERVATION_MODIFIER", 44, 55], ["difference", "OBSERVATION", 56, 66], ["fewer", "OBSERVATION_MODIFIER", 227, 232], ["infected", "OBSERVATION", 233, 241]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)Time to pairwise model divergenceThe copyright holder for this preprint this version posted June 16, 2020. .", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 232, 252], ["med", "ANATOMY", 102, 105]]], ["We investigate situations in which the amount of physical distancing is modulated on May 17th (the strategy for restarting British Columbia through relaxation of physical distancing recommendations began in the middle of May [28] ) through a forcing of the ODE parameter f 2 , and in which many of the ODE parameters are modulated through grid-searches.", [["amount", "OBSERVATION_MODIFIER", 39, 45]]], ["We also consider a retrospective analysis of the introduction of physical distancing in British Columbia, assuming that physical distancing is introduced in mid-March (March 18th) by modulation of parameter f from f 0 = 1 to f 1 = 0.4 and f 1 = 0.7, and compare to a baseline model in which f remains at 1.", [["a retrospective analysis", "TEST", 17, 41], ["a baseline model", "TEST", 265, 281]]], ["We investigate 25% to 50% confidence intervals around the number of active case in early/mid-April, by considering 100 replicates in the ODE simulations, each with a value of R 0 drawn independently from the prior.Time to pairwise model divergenceIn Section 2.3, we provide some evidence that the physical distancing undertaken by people in British Columbia corresponds to a modeled value for f 1 of 0.36.", [["people", "ORGANISM", 331, 337], ["people", "SPECIES", 331, 337], ["a value", "TEST", 164, 171]]], ["We consider alternative relaxation models in which the value of f changes from f 1 = 0.36 to either f 2 = 0.5 (weak relaxation), f 2 = 0.65 (medium relaxation) or f 2 = 0.9 (strong relaxation) on May 17th.", [["alternative relaxation models", "TREATMENT", 12, 41]]], ["For each condition, we again consider 100 replicates each with a value of R 0 drawn from the prior.Time to observe a change in the strength of distancingIn addition to estimating the first time at which we would expect a substantial difference in incidence to occur after a change in physical distancing, we also aim to understand the time it would take to observe such a difference in reported case counts.", [["a change", "PROBLEM", 115, 123], ["substantial", "OBSERVATION_MODIFIER", 221, 232], ["difference", "OBSERVATION", 233, 243]]], ["We use a likelihood-based approach to estimate if a change in distancing measures is yet having an effect on observed case counts, and to estimate the size of this effect.Time to observe a change in the strength of distancingThe likelihood expression, as described in Section 2.1, relates predicted case counts from the SEIR-type model to reported case counts, over time and corrected for the delay between symptomonset and reporting which is assumed to have a Weibull distribution (w c ).", [["a change in distancing measures", "PROBLEM", 50, 81], ["a change", "PROBLEM", 187, 195], ["size", "OBSERVATION_MODIFIER", 151, 155], ["likelihood expression", "OBSERVATION", 229, 250]]], ["Since case count data can be quite noisy, there can also be considerable variation in the day-by-day MLEs.", [["case count data", "TEST", 6, 21], ["considerable", "OBSERVATION_MODIFIER", 60, 72], ["variation", "OBSERVATION_MODIFIER", 73, 82]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 16, 2020. . https://doi.org/10.1101/2020.06.14.20131177 doi: medRxiv preprint can have a large impact on the MLE for f X .", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 198, 218], ["med", "ANATOMY", 102, 105], ["large", "OBSERVATION_MODIFIER", 351, 356]]], ["We find a credible band by simulating the SEIR model with 50 different values of the baseline R 0 parameter, normally distributed about the mean R 0 = 2.57 estimated by a pre-distancing model fit, and with standard deviation 0.05.(which was not certified by peer review)Although, as of the time of writing, we have only started to see the effects of relaxing physical distancing in British Columbia, we simulate the effects of relaxing distancing to 65% of the normal (unrelaxed) level, under the assumption that the noise and delay in observing case counts remains as during March/April in British Columbia (\u03c6 = 5, delay shape parameter 9.85, delay scale parameter 1.73 as estimated in [2] ).", [["a credible band", "TEST", 8, 23], ["the SEIR model", "TEST", 38, 52], ["the noise", "PROBLEM", 513, 522], ["delay shape parameter", "TEST", 616, 637], ["delay scale parameter", "TEST", 644, 665]]], ["We also consider other levels of distancing relaxation (50%, 90%) and record the resulting impact on the number of days n to accept the MLE f n .", [["distancing relaxation", "TREATMENT", 33, 54]]], ["For the credible bands, we increased the standard deviation to 0.15 to obtain a similar level of variation in the model fit as compared to the introduction-of-distancing estimation (the majority of individuals distancing causes the overall reproduction number to be lower).(which was not certified by peer review)We also explore the impact of changing the noise/delay of case count reporting on the time to detect a change in the strength of physical distancing.", [["the credible bands", "PROBLEM", 4, 22], ["the standard deviation", "TREATMENT", 37, 59], ["distancing estimation", "TEST", 159, 180], ["case count", "TEST", 371, 381], ["model fit", "OBSERVATION", 114, 123]]], ["In this investigation, we control the variance in the number of daily reported cases: note that this is not the same as the dispersion parameter about R 0 , commonly referred to as k.", [["this investigation", "TEST", 3, 21]]], ["We also control the shape and scale parameters of the onset-to-reporting Weibull distribution.", [["shape", "OBSERVATION_MODIFIER", 20, 25]]], ["We then perform the same daily MLE estimation procedure on these simulated time series.", [["the same daily MLE estimation procedure", "TREATMENT", 16, 55]]], ["Note that this back-estimation requires the assumption that the true noise level and delay are known.", [["the true noise level", "PROBLEM", 60, 80]]], ["If we did not have estimates of these quantities in reality, we would need to co-estimate them along with the strength of distancing, which may introduce identifiability issues or a longer time to acceptance.(which was not certified by peer review)All statistical analysis was performed in R [24] , and datasets and R code are available * on GitHub under an open source license.ResultsWe find that it takes 21-23 days (March 18th until April 9th or 11th) before there is a substantial difference between the baseline trajectory (the exponential growth phase of the SEIR-type model) and a trajectory with distancing measures of f 1 = 0.4, 0.7.", [["identifiability issues", "PROBLEM", 154, 176], ["All statistical analysis", "TEST", 248, 272], ["substantial", "OBSERVATION_MODIFIER", 473, 484], ["difference", "OBSERVATION_MODIFIER", 485, 495]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 16, 2020. . takes approximately 45 days before a substantial difference arises due to relaxing distancing from f 1 = 0.36 to f 2 = 0.65, and 23 days to detect such a difference using observed cases.", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 198, 218], ["a substantial difference", "PROBLEM", 309, 333], ["med", "ANATOMY", 102, 105]]], ["Figure 2 shows rising case trajectories for which distancing is introduced, and declining ones in which distancing is relaxed, and illustrates the dependence of the timing on the severity of the change.", [["rising case trajectories", "PROBLEM", 15, 39], ["relaxed", "OBSERVATION_MODIFIER", 118, 125]]], ["If the change is weak (e.g., a weak relaxation from f 1 = 0.36 to f 2 = 0.5) there is no discernible difference between the trajectories before July 1 (47 days).", [["a weak relaxation", "PROBLEM", 29, 46], ["weak", "OBSERVATION_MODIFIER", 17, 21], ["no", "UNCERTAINTY", 86, 88], ["discernible", "OBSERVATION_MODIFIER", 89, 100], ["difference", "OBSERVATION", 101, 111]]], ["The time until a substantial difference arises naturally depends on what is considered a substantial difference, and on the underlying uncertainty.", [["substantial", "OBSERVATION_MODIFIER", 89, 100], ["difference", "OBSERVATION", 101, 111]]], ["We explore the impact of the threshold choice 9 .", [["the threshold choice", "TREATMENT", 25, 45]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 16, 2020. . and strength of relaxation ( Figure 3) ; naturally, stronger relaxation (all the way to baseline contact levels with f = 1) produces a difference quickly (10-20 days) .", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 198, 218], ["med", "ANATOMY", 102, 105]]], ["Similarly a smaller threshold difference of 5 cases is reached relatively soon.", [["a smaller threshold difference of 5 cases", "PROBLEM", 10, 51], ["smaller", "OBSERVATION_MODIFIER", 12, 19], ["threshold", "OBSERVATION_MODIFIER", 20, 29], ["difference", "OBSERVATION_MODIFIER", 30, 40]]], ["The uncertainty in R 0 and other parameters also impacts the time before there is a substantial difference in trajectories ( Figure S6 ).", [["substantial", "OBSERVATION_MODIFIER", 84, 95], ["difference", "OBSERVATION_MODIFIER", 96, 106]]], ["Uncertainty in other fixed parameters does not have a strong impact on the time ( Figure S6 ) unless the relaxation conditions are strong (f 2 > 0.7).", [["Uncertainty in other fixed parameters", "PROBLEM", 0, 37], ["the relaxation conditions", "TEST", 101, 126]]], ["Epidemiological parameters are now somewhat well-established for COVID-19 [26] , but we can be less certain of the true value of more behaviour-influenced parameters (q, u r , u d ).", [["Epidemiological parameters", "TEST", 0, 26], ["COVID", "TEST", 65, 70]]], ["We explicitly explore the impact of the incubation period on the time until a substantial difference arises, and find little impact ( Figure S7 ), largely because a few days' uncertainty in the incubation period is overwhelmed by the the overall time scale and threshold of 10 cases to define a substantial difference.", [["a substantial difference", "PROBLEM", 293, 317], ["substantial", "OBSERVATION_MODIFIER", 295, 306], ["difference", "OBSERVATION", 307, 317]]], ["In some instances we cannot differentiate between trajectories for the models with distancing and the models without distancing (these are the missing values in the related figures).", [["the missing values", "PROBLEM", 139, 157]]], ["Also, if the standard deviation in the underlying parameter R 0 is too large, a substantial difference may not be possible to predict in the time frame of interest.(which was not certified by peer review)We have conceptually separated the time until there is any substantial difference in model trajectories and the time until we would be able to estimate the impact of a change in distancing, using reported case counts under conditions in British Columbia.", [["the standard deviation", "PROBLEM", 9, 31], ["too large", "OBSERVATION_MODIFIER", 67, 76]]], ["These times may differ as a result of reporting delay, but also in some circumstances it may be sufficient to observe signal of a change in distancing under a lower probability or a lower case threshold.", [["a change", "PROBLEM", 128, 136]]], ["Several larger cluster outbreaks had begun to be observed in British Columbia by this time [4] , which may have contributed to this increase in the estimated distancing parameter.(which was not certified by peer review)In the first few days after the introduction of distancing, we see considerable noise in the daily MLEs.", [["Several larger cluster outbreaks", "PROBLEM", 0, 32], ["larger", "OBSERVATION_MODIFIER", 8, 14], ["cluster", "OBSERVATION_MODIFIER", 15, 22], ["outbreaks", "OBSERVATION", 23, 32]]], ["This is expected, as limited data observed in those first few days implies that even small variations in the case counts can have a large effect.", [["small variations in the case counts", "PROBLEM", 85, 120], ["small", "OBSERVATION_MODIFIER", 85, 90], ["variations", "OBSERVATION_MODIFIER", 91, 101], ["large", "OBSERVATION_MODIFIER", 132, 137], ["effect", "OBSERVATION_MODIFIER", 138, 144]]], ["The likelihood is flat for a period around the first week after distancing is introduced.", [["flat", "OBSERVATION_MODIFIER", 18, 22]]], ["The time at which the credible interval no longer includes 1.0 may indicate the time at which we are confident that distancing has a positive effect (even if we cannot yet determine the size of this effect).", [["no longer", "UNCERTAINTY", 40, 49]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.", [["CC", "CHEMICAL", 0, 2], ["med", "ANATOMY", 102, 105]]], ["Figure 3 : The size of the threshold used to define \"substantial differences\" impacts the time until such a difference occurs, as does the severity of the change in contact rate f .", [["size", "OBSERVATION_MODIFIER", 15, 19]]], ["The baseline model has f 1 = 0.36 (on May 17th), and so a change to f 2 = 1 is a complete relaxation of distancing measures, and is detected sooner than a partial relaxation.", [["partial relaxation", "OBSERVATION", 155, 173]]], ["Each density is produced based on the assumption that R 0 is normally distributed with a mean 2.5 and a standard deviation of 0.15.", [["a standard deviation", "TEST", 102, 122], ["density", "OBSERVATION", 5, 12], ["normally", "OBSERVATION_MODIFIER", 61, 69], ["distributed", "OBSERVATION_MODIFIER", 70, 81]]], ["Missing values on the y-axis (for example for values of the active cases level of 0.6) indicate that our methods cannot differentiate between the models with and without relaxed physical distancing when the active cases threshold is 15 or 20 cases.", [["Missing values", "PROBLEM", 0, 14], ["the y-axis", "TEST", 18, 28], ["values", "TEST", 46, 52], ["the active cases level", "TEST", 56, 78], ["the active cases threshold", "TEST", 203, 229]]], ["For each f 2 and threshold level, we simulate 10,000 ODEs with random initial R 0 values drawn independently from a normal distribution with mean 2.5 and variance 0.15, and for each group of 100 simulated ODEs, we compute the days since May 17th until the excess active cases threshold is detected between the baseline and the condition. the 26 days to accept the MLE estimate.", [["mean", "TEST", 141, 145], ["variance", "TEST", 154, 162], ["the excess active cases threshold", "PROBLEM", 252, 285], ["normal", "OBSERVATION", 116, 122]]], ["Under the assumption that the noise and delay in observing the true outbreak process remains constant, we estimate that it would take 23 days from initiating relaxation of distancing until accepting the MLE f n .", [["the noise", "PROBLEM", 26, 35], ["the true outbreak process", "PROBLEM", 59, 84]]], ["We also performed the same analysis with f 2 = 0.9 and f 2 = 0.5, and estimated 23 days and 30 days respectively.", [["the same analysis", "TEST", 18, 35]]], ["The time until the 95% quantile for R t drops below 1.0 is 14 days after distancing was introduced (April 1), and it takes 18, 24 days after distancing is relaxed for R t 's 95% quantile to be above 1.0 (f 2 = 0.9, 0.65).", [["R t drops", "TREATMENT", 36, 45], ["R t 's", "TEST", 167, 173], ["quantile", "TEST", 178, 186]]], ["Even with weekly smoothing, the R t values fluctuate greatly, particularly after relaxation of distancing.", [["the R t values", "TEST", 28, 42], ["distancing", "OBSERVATION", 95, 105]]], ["In contrast, the estimates of f 1 and f 2 do not.", [["f 2", "GENE_OR_GENE_PRODUCT", 38, 41]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 16, 2020. . https://doi.org/10.1101/2020.06.14.20131177 doi: medRxiv preprint 12 .", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 198, 218], ["medRxiv preprint", "TREATMENT", 323, 339], ["med", "ANATOMY", 102, 105]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 16, 2020. . case counts and the delay between symptom onset and reporting.", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 198, 218], ["case counts", "TEST", 274, 285], ["med", "ANATOMY", 102, 105]]], ["As the noise in the daily case counts is reduced (Figure 5a) , so is the time to detect the strength of distancing.", [["the daily case counts", "TEST", 16, 37], ["reduced", "OBSERVATION_MODIFIER", 41, 48]]], ["Under a level of noise realistic for observed case counts in BC (\u03c6 = 5), we estimated 26 days to accept f n .", [["case counts", "TEST", 46, 57], ["BC", "TEST", 61, 63]]], ["Under the most optimistic scenario, where there is no noise (but when there is still an average 8.7 day delay), the time-to-accept is 15 days.(which was not certified by peer review)As would be expected, a longer delay between symptom onset and case reporting also results in a longer time taken to estimate the strength of distancing (Figure 5b) .", [["noise", "PROBLEM", 54, 59], ["a longer delay between symptom onset", "PROBLEM", 204, 240], ["no", "UNCERTAINTY", 51, 53]]], ["With a Weibull distributed delay of shape 1.73 and scale 9.85 (mean 8.78, variance 27.4) and \u03c6 = 5, as estimated for British Columbia in [2] , we estimate 32 days to accept the MLE of f 1 .", [["shape", "TEST", 36, 41], ["scale", "TEST", 51, 56], ["mean", "TEST", 63, 67], ["variance", "TEST", 74, 82], ["\u03c6", "TEST", 93, 94]]], ["If the delay is reduced to shape 2 and scale 5 (mean 4.43, variance 5.37), the time to accept is 20 days.", [["the delay", "PROBLEM", 3, 12], ["scale", "TEST", 39, 44], ["mean", "TEST", 48, 52], ["variance", "TEST", 59, 67]]], ["Lastly, with a delay shape 10 and scale 1 (mean 0.95, variance 0.013), the time to accept is 15 days.DiscussionAs jurisdictions begin to ease physical distancing measures, we must understand how long it may take to observe a statistically significant difference in reported case counts.", [["a delay shape", "TEST", 13, 26], ["scale", "TEST", 34, 39], ["mean", "TEST", 43, 47]]], ["We find that it generally takes between 10-60 days before changes in distancing have a substantial, detectable impact on the reported case counts.", [["substantial", "OBSERVATION_MODIFIER", 87, 98]]], ["In certain cases, we find that these methods are unable to differentiate between the relaxed and unrelaxed scenarios; for example, if the deviation in R 0 is high and the relative change in physical distancing is low.", [["the deviation in R 0", "TEST", 134, 154], ["the relative change in physical distancing", "PROBLEM", 167, 209], ["high", "OBSERVATION_MODIFIER", 158, 162], ["change", "OBSERVATION_MODIFIER", 180, 186], ["low", "OBSERVATION_MODIFIER", 213, 216]]], ["Halving the case count variance or the mean onset-to-reporting delay in British Columbia during March and April could have reduced the time taken to understand the strength of social distancing by approximately 20% and 38%, respectively.", [["the case count variance", "TEST", 8, 31]]], ["Such lines of work include Simultaneous Equations Models (SEM), a field within econometrics [25] and growth rates in bacterial culture [16] .", [["Simultaneous Equations Models", "TEST", 27, 56], ["a field within econometrics", "TEST", 64, 91], ["growth rates", "TEST", 101, 113], ["bacterial culture", "TEST", 117, 134]]], ["These are distinct from the methodology we introduce in this work in that that they focus on inference of the true number of cases at a particular time from the observed num-13 .", [["distinct", "OBSERVATION_MODIFIER", 10, 18]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 16, 2020.", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 198, 218], ["med", "ANATOMY", 102, 105]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 16, 2020. . ber.", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 198, 218], ["med", "ANATOMY", 102, 105]]], ["In contrast, we work backwards from observed cases, using a model which takes observation delay and imperfect sampling into account, to understand the impact of physical distancing on COVID-19.(which was not certified by peer review)Our analysis has a number of limitations.", [["COVID-19", "DNA", 184, 192], ["COVID", "TEST", 184, 189], ["Our analysis", "TEST", 233, 245]]], ["Although policy changes happen at defined times, distancing behaviour and other COVID-19 control practices do not change instantaneously, and the time frame to detect changes may therefore be longer than we have estimated.", [["distancing behaviour", "TEST", 49, 69], ["other COVID-19 control practices", "TREATMENT", 74, 106]]], ["The transmission model used is a deterministic SEIR variant, and does not include stochastic effects (except in the observation model), or age or risk structure.", [["SEIR variant", "CELL_LINE", 47, 59], ["a deterministic SEIR variant", "PROBLEM", 31, 59], ["stochastic effects", "PROBLEM", 82, 100]]], ["The model includes a fraction of the population practising physical distancing, thereby reducing their contact rates, but does not otherwise include heterogeneity in contact patterns.", [["fraction", "OBSERVATION_MODIFIER", 21, 29]]], ["In particular, we focus on the case onset-toreporting delay, but certain high-risk groups such as healthcare workers may be more likely to get tested and have expedited testing available.", [["expedited testing", "TEST", 159, 176]]], ["Indeed, any disease model will include exponential growth and decay, and this work is somewhat modelagnostic in that, whatever level of detail goes into producing this exponential behaviour, we can still perform the same eventual inference.(which was not certified by peer review)Our approach to determining when the effect of modifying measures is observable relies on using case count data as the indicator for increased community-based transmission.", [["any disease model", "PROBLEM", 8, 25], ["exponential growth", "PROBLEM", 39, 57], ["modifying measures", "TREATMENT", 327, 345], ["case count data", "TEST", 376, 391], ["disease", "OBSERVATION", 12, 19]]], ["Changes in these smaller outbreaks may be detected much faster than our 3 week estimates, but it remains the case that measures directed towards the general population are the main intervention for COVID-19.", [["Changes in these smaller outbreaks", "PROBLEM", 0, 34], ["COVID", "TEST", 198, 203], ["smaller", "OBSERVATION_MODIFIER", 17, 24], ["outbreaks", "OBSERVATION", 25, 34], ["may be", "UNCERTAINTY", 35, 41], ["main", "OBSERVATION_MODIFIER", 176, 180]]], ["Sentinel surveillance systems, contact tracing and outbreak detection are among the tools used by public health agencies to gather rapid and more detailed information than case counts during a disease outbreak.", [["Sentinel surveillance systems", "TEST", 0, 29], ["contact tracing", "TEST", 31, 46], ["outbreak detection", "TEST", 51, 69], ["a disease outbreak", "PROBLEM", 191, 209]]], ["These form multi-faceted surveillance networks-including hospitals, primary care, symptom trackers-which may often be faster than confirmed and lab-tested cases.", [["symptom trackers", "TEST", 82, 98]]], ["Confirmed case counts remain a widely used source for population-level understanding of COVID-19 control, particular for those seeking a broad assessment of COVID-19 in multiple jurisdictions to support policy on borders and travel or to compare effectiveness of control measures.(which was not certified by peer review)While we focus on data from British Columbia in this work, our methods may be applied to any region or country with case reporting to determine the relevant time lags and interpret reported cases accordingly.", [["case counts", "TEST", 10, 21], ["COVID-19 control", "TREATMENT", 88, 104], ["a broad assessment", "TEST", 135, 153], ["COVID", "TEST", 157, 162], ["control measures", "TREATMENT", 263, 279], ["our methods", "TREATMENT", 379, 390]]], ["In addition, SEIR-type models are used to forecast COVID-19 in all 15 .", [["SEIR", "PROTEIN", 13, 17], ["COVID-19", "DNA", 51, 59], ["SEIR", "TEST", 13, 17], ["forecast COVID", "TEST", 42, 56]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 16, 2020. .", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 198, 218], ["med", "ANATOMY", 102, 105]]], ["50 US states with the Covid Act Now project [15] : each state is associated with a COVID-19 risk level based on how soon their projections arrive at certain constant thresholds on measures such as case counts and ICU headroom used.", [["a COVID", "TEST", 81, 88], ["case counts", "TEST", 197, 208]]], ["Our methods could improve such region-based work by allowing the parameters and baselines to be calibrated, reflecting population density, testing protocols, demographics and cultural factors regarding social contact.", [["Our methods", "TREATMENT", 0, 11], ["testing protocols", "TEST", 139, 156]]], ["The times to observe the impacts of changes in control measures are likely to be region specific.(which was not certified by peer review)We have found in this work that the time-to-detection for a return to widespread transmission owing to relaxed physical distancing measures can be long, indeed considerably longer than than the mean incubation period [26, 14] or often used 14 day time period [5, 27, 17] .", [["changes in control measures", "TREATMENT", 36, 63]]], ["In order to decrease the time-to-detection, we need less noisy testing and faster ways to monitor community transmission.", [["less noisy testing", "TEST", 52, 70]]], ["Outbreaks within communities contribute both to \"noise\" in case counts and to uncertainty in R 0 , particularly if they reveal areas of previous under-detection.", [["case counts", "TEST", 59, 70]]], ["Other surveillance techniques could facilitate faster and smoother case detection, but suffer from their own limitations.", [["Other surveillance techniques", "TEST", 0, 29]]], ["Consistent sentinel surveillance, e.g. as are seen in influenza-like-illness data, may have a slightly longer delay, but ultimately less noise.", [["influenza-like-illness", "DISEASE", 54, 76], ["sentinel surveillance", "TEST", 11, 32], ["influenza", "PROBLEM", 54, 63], ["a slightly longer delay", "PROBLEM", 92, 115], ["sentinel surveillance", "OBSERVATION", 11, 32], ["influenza", "OBSERVATION", 54, 63], ["slightly longer", "OBSERVATION_MODIFIER", 94, 109], ["less noise", "OBSERVATION_MODIFIER", 132, 142]]], ["Symptom tracker apps could show changes in incidence sooner than laboratory-confirmed case counts, but could suffer from false positives and may be affected by coverage and usage limitations.", [["Symptom tracker apps", "TEST", 0, 20], ["case counts", "TEST", 86, 97], ["false positives", "PROBLEM", 121, 136], ["false positives", "OBSERVATION", 121, 136]]], ["Digital contact tracing may also support rapid case finding, but will likely ultimately rely on testing data for confirmation.", [["Digital contact tracing", "TEST", 0, 23], ["testing data", "TEST", 96, 108], ["confirmation", "TEST", 113, 125]]], ["However, case confirmation delays in a contact tracing context are often considerably shorter than through symptom-based testing [3] .", [["a contact tracing", "TEST", 37, 54]]], ["Promising recent research has also investigated detection of SARS-CoV-2 in wastewater [22, 1] , which, although potentially not revealing of individual-level infection, may bypass case detection delays and provide an early warning system.", [["SARS", "DISEASE", 61, 65], ["infection", "DISEASE", 158, 167], ["SARS-CoV", "SPECIES", 61, 69], ["SARS", "TEST", 61, 65], ["CoV", "TEST", 66, 69], ["individual-level infection", "PROBLEM", 141, 167], ["an early warning system", "PROBLEM", 214, 237], ["infection", "OBSERVATION", 158, 167]]], ["Similarly, investigation of live mobility data during the disease outbreak [10, 13] may reveal changes in population behaviour, even if such work requires some assumptions about the link to changes in incidence.", [["the disease outbreak", "PROBLEM", 54, 74], ["changes in population behaviour", "PROBLEM", 95, 126]]], ["Given the long time frames for reported case count data it is urgent that robust combinations of diverse surveillance systems be developed, and for those seeking an overview of COVID-19 trajectories without reference to multi-faceted local surveillance data (perhaps at the national level or to support decisions about travel to and from other jurisdictions), it is important not to over-interpret short-term fluctuations in reported case counts.Impact of uncertainty in model parametersWe consider two experiments wherein the uncertainty about the ODE parameters are modulated, and record the time to detect a threshold of excess in the active cases above baseline models.", [["case count data", "TEST", 40, 55], ["diverse surveillance systems", "TEST", 97, 125], ["multi-faceted local surveillance data", "TEST", 220, 257], ["short-term fluctuations", "PROBLEM", 398, 421], ["active", "OBSERVATION_MODIFIER", 638, 644]]], ["In the main text, we consider ODEs in which the R 0 parameter is initialized to a draw from a normal distribution with mean 2.5 and standard deviation 0.15.", [["mean", "TEST", 119, 123], ["main", "OBSERVATION_MODIFIER", 7, 11], ["normal", "OBSERVATION", 94, 100]]], ["In all conditions, the baseline indicates a situation in which physical distancing is not relaxed, and remains in effect.Impact of uncertainty in model parametersIf the standard deviation is varied away from 0.15, then the days until the threshold is reached (i.e., a significant difference between the baseline and a relaxed condition is seen) is affected.", [["a relaxed condition", "PROBLEM", 316, 335], ["significant", "OBSERVATION_MODIFIER", 268, 279]]], ["The results of varying the standard deviation between 0.01 and 0.4 (considering the values in the set {0.01, 0.11, 0.21, 0.31, 0.41}) are shown in Figure S6a .", [["the values", "TEST", 80, 90], ["varying", "OBSERVATION_MODIFIER", 15, 22]]], ["In that Figure, we see that the days until a significant increase in the active cases can vary from 10 to 50 days.", [["significant", "OBSERVATION_MODIFIER", 45, 56], ["increase", "OBSERVATION_MODIFIER", 57, 65], ["active", "OBSERVATION_MODIFIER", 73, 79]]], ["Missing values in the lines in this plot indicate that our methods cannot determine whether or not the condition will ever differ from the baseline: if the standard deviation of R 0 is > 0.11, we do not predict that a weak relaxation of physical distancing to f 2 = 0.6 will result in a substantial increase in active cases.", [["Missing values", "PROBLEM", 0, 14], ["a substantial increase in active cases", "PROBLEM", 285, 323], ["substantial", "OBSERVATION_MODIFIER", 287, 298], ["increase", "OBSERVATION_MODIFIER", 299, 307], ["active", "OBSERVATION_MODIFIER", 311, 317], ["cases", "OBSERVATION", 318, 323]]], ["However, if the standard deviation of R 0 is < 0.11 a relaxation of physical distancing to f 2 = 0.6 could lead to a significant increase in active case count after 20 or 40 days.21.", [["a significant increase in active case count", "PROBLEM", 115, 158], ["significant", "OBSERVATION_MODIFIER", 117, 128], ["increase", "OBSERVATION_MODIFIER", 129, 137], ["active", "OBSERVATION_MODIFIER", 141, 147]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 16, 2020. . https://doi.org/10.1101/2020.06.14.20131177 doi: medRxiv preprint Figure S6 : (a) Days until active cases in the relaxed model exceeds the baseline model (y-axis), with varying levels of the standard deviation for R 0 (x-axis).", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 198, 218], ["active cases", "PROBLEM", 367, 379], ["med", "ANATOMY", 102, 105]]], ["There are four relaxation levels (all starting relaxation on May 17th).", [["four relaxation levels", "PROBLEM", 10, 32], ["four", "OBSERVATION_MODIFIER", 10, 14], ["relaxation", "OBSERVATION_MODIFIER", 15, 25], ["levels", "OBSERVATION_MODIFIER", 26, 32]]], ["Parameter settings are identical to other figures aside from sd.(which was not certified by peer review)The missing values indicate that our methods could not differentiate between the models. (b) The variables D, k 1 , k 2 , q, u d and u r are all varied between 10% and 30% around their fitted values (with the three levels described in the legend).", [["Parameter settings", "TREATMENT", 0, 18], ["our methods", "TEST", 137, 148], ["k", "TEST", 214, 215], ["k", "TEST", 220, 221], ["u d and u r", "TEST", 229, 240]]], ["So, R 0 is sampled at ODE initialization, but so too now are the 6 variables mentioned (with independent draws from the uniform distribution).", [["R 0", "GENE_OR_GENE_PRODUCT", 4, 7]]], ["For each f 2 level, 100 iterations are considered each with 100 replicates.(which was not certified by peer review)In another experiment, we consider variation of the ODE parameters D, k 1 , k 2 , q, u d and u r .", [["k", "TEST", 185, 186], ["k", "TEST", 191, 192], ["u d and u r", "TEST", 200, 211]]], ["We vary each of these parameters around their default values (given in Table S1 ) by X%, with X varied in the set {10, 20, 30}.", [["these parameters", "TEST", 16, 32]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 16, 2020. .", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 198, 218], ["med", "ANATOMY", 102, 105]]], ["ODE is initialized with random parameters.", [["random parameters", "TEST", 24, 41]]], ["For the basic reproduction number, R 0 is initialized as a normal distribution with mean 2.5 and variance 0.15 (as is done in the main text), and for the parameters D, k 1 , k 2 , q, u d and u r we initialize each parameter by drawing from a uniform distribution.", [["mean", "TEST", 84, 88], ["variance", "TEST", 97, 105], ["k", "TEST", 168, 169], ["k", "TEST", 174, 175], ["u r", "TEST", 191, 194], ["normal", "OBSERVATION", 59, 65], ["uniform", "OBSERVATION_MODIFIER", 242, 249], ["distribution", "OBSERVATION_MODIFIER", 250, 262]]], ["For each parameter, the range of the uniform distribution has a minimum value of the 'default' value of that parameter (given by Table S1 ) minus X% of the default value, and maximum value of the 'default' plus X%.", [["the default value", "TEST", 152, 169], ["maximum value", "TEST", 175, 188], ["uniform", "OBSERVATION_MODIFIER", 37, 44], ["distribution", "OBSERVATION_MODIFIER", 45, 57]]], ["The number of iterations and the number of replicates is identical to Figure 3 (described in the main text).", [["number", "OBSERVATION_MODIFIER", 4, 10]]], ["Density plots for the number of days until the threshold on the excess of active case counts are shown in Figure S6b for a variety of relaxation levels.", [["S6b", "PROTEIN", 113, 116], ["Density plots", "PROBLEM", 0, 13], ["active case counts", "TEST", 74, 92]]], ["Figure S7 : The incubation period has a limited effect on the time before a substantial difference occurs between two simulated scenarios.", [["a substantial difference", "PROBLEM", 74, 98]]], ["The initial value f 1 is 0.36.", [["The initial value f", "TEST", 0, 19]]], ["The curves are obtained under the uncertainty assumption that R 0 is normally distributed with a mean 2.5, and a standard deviation of 0.15.", [["normally", "OBSERVATION_MODIFIER", 69, 77], ["distributed", "OBSERVATION_MODIFIER", 78, 89]]], ["For each setting of the incubation period, we rescale k 1 and k 2 evenly from their fitted values (k 1 = 1 and k 2 = 1/5) to achieve the incubation period in days. (e.g., for an incubation period of 7 days 1/k 1 + 1/k 2 = 7, and so the values for k 1 and k 2 used are 1 * (6/7) and 1/5 * (6/7) respectively.)", [["k", "TEST", 54, 55], ["k", "TEST", 62, 63], ["k", "TEST", 99, 100], ["k", "TEST", 111, 112], ["k", "TEST", 208, 209], ["the values", "TEST", 232, 242], ["k", "TEST", 247, 248], ["k", "TEST", 255, 256]]], ["Missing values indicate that our methods cannot distinguish between simulations in which physical distancing is relaxed and simulations in which physical distancing is not relaxed (indicating that a relaxation of f 2 to 0.6 may not have an effect for much of the range of incubation periods considered)(which was not certified by peer review)The above results indicate that uncertainty about the model parameters substantially increases the number of days until definitive statements about the effects of relaxing social distancing can be made, with the total range of the number of days until effects are seen varying between 20 and 70.23.", [["the model parameters", "TEST", 392, 412]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)23The copyright holder for this preprint this version posted June 16, 2020. .Effect of the incubation periodWe vary the incubation period to explore the impact on the time before the active cases threshold of 10 is reached.", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 201, 221], ["the incubation period", "TREATMENT", 286, 307], ["med", "ANATOMY", 102, 105]]], ["The incubation period is defined as 1/k 1 +1/k 2 , with default values k 1 = 1/5 and k 2 = 1 throughout this work.", [["k", "TEST", 45, 46], ["default values k", "TEST", 56, 72], ["k", "TEST", 85, 86]]], ["We vary the incubation period between 6 and 10 days by modulating k 1 and k 2 appropriately (with the same scaling factor for each) and show the results in Figure S7 .Effect of the incubation periodFor each incubation period and relaxation f 2 level, we perform 50 replicates and plot the median number of days until the active cases threshold is reached.", [["the incubation period", "TREATMENT", 177, 198], ["relaxation f 2 level", "TEST", 229, 249], ["Figure S7", "OBSERVATION", 156, 165]]], ["This suggests that the variance in active case due to uncertainty about R 0 may overwhelm variation in the incubation period over the range considered.Estimation of R tFor comparison with the daily MLE method applied to British Columbia case count data in Figure 4 , we also perform estimation of R t using EpiEstim package [7] in R. Results are shown in Figure S8 .", [["R tFor", "GENE_OR_GENE_PRODUCT", 165, 171], ["R tFor", "DNA", 165, 171], ["R t", "DNA", 297, 300], ["the daily MLE method", "TREATMENT", 188, 208], ["R t using EpiEstim package", "TREATMENT", 297, 323]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)24The copyright holder for this preprint this version posted June 16, 2020.", [["CC", "CHEMICAL", 0, 2], ["med", "ANATOMY", 102, 105]]], ["Figure S8 : Median estimates of the time-dependent reproduction number R t in British Columbia, using a weekly sliding window and assumed serial interval of 5 (sd 1) days.", [["a weekly sliding window", "TREATMENT", 102, 125]]], ["Top panel: after implementing distancing, using true observed case counts (14 days until R t < 1 at the 95% level).", [["Top panel", "TEST", 0, 9]]], ["Bottom panel: after relaxing distancing, using simulated data (18, 25 days until R t > 1 at the 95% level for f 2 = 0.9, 0.65, respectively), under the assumption that f 1 = 0.36 and observation noise and delay remain as pre-relaxation during March/April in BC.", [["BC", "CANCER", 258, 260], ["Bottom panel", "TEST", 0, 12], ["simulated data", "TEST", 47, 61], ["observation noise", "TEST", 183, 200]]], ["Coloured bands correspond to 95% quantiles.25.", [["Coloured bands", "TEST", 0, 14]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)25The copyright holder for this preprint this version posted June 16, 2020. . https://doi.org/10.1101/2020.06.14.20131177 doi: medRxiv preprint", [["CC", "CHEMICAL", 0, 2], ["medRxiv", "TREATMENT", 326, 333], ["med", "ANATOMY", 102, 105]]]], "d4f77703bbee2e31e43494282cfa346c85825cab": [["The objective of this study was to develop a mathematical model to predict the epidemic in Sri Lanka incorporating measures taken for social distancing and prevention of social gatherings.MethodsA hybrid model incorporating both exponential and polynomial features was developed and parameters were estimated.", [["this study", "TEST", 17, 27], ["MethodsA hybrid model", "TREATMENT", 188, 209], ["both", "OBSERVATION_MODIFIER", 224, 228], ["exponential", "OBSERVATION_MODIFIER", 229, 240]]], ["Additional features were incorporated to the model to examine the effects of current control measures.FindingsSri Lanka will have a peak of 177 COVID-19 active cases at the end of second incubation period from the index case of our projection, if the same trend continues.", [["current control measures", "TREATMENT", 77, 101]]], ["At 10% risk, we project a peak of 263 COVID-19 active cases at the end of third incubation period, and a peak of 353 at the end of fourth incubation period.", [["COVID", "TEST", 38, 43], ["a peak", "TEST", 103, 109]]], ["Should the risk level reach 20%, the peak will be above 1000 active cases after 90 days.", [["the risk level", "TEST", 7, 21]]], ["Simulations incorporating control measures predict that, deviation from the control measures currently in place could trigger exponential behaviour of the epidemic.InterpretationThe hybrid model combining exponential and polynomial functions showed promising results to predict COVID-19 epidemic.", [["Simulations incorporating control measures", "TREATMENT", 0, 42], ["the control measures", "TREATMENT", 72, 92], ["COVID", "TEST", 278, 283], ["epidemic", "PROBLEM", 287, 295], ["exponential", "OBSERVATION_MODIFIER", 126, 137], ["epidemic", "OBSERVATION_MODIFIER", 155, 163]]], ["Projections indicate that any early relaxation of control measures is not advisable.", [["any early relaxation of control measures", "TREATMENT", 26, 66]]], ["This methodological approach can be replicated in other settings at the initial stages of the epidemic.IntroductionThe global COVID-19 caseload had exceeded over one million and sixty thousand deaths by 4 th of April 2020 [1] .", [["deaths", "DISEASE", 193, 199], ["This methodological approach", "TREATMENT", 0, 28], ["The global COVID", "TEST", 115, 131]]], ["It is still spreading across countries and communities.", [["spreading", "OBSERVATION_MODIFIER", 12, 21]]], ["Health systems are overwhelmed due to the high caseload.", [["the high caseload", "PROBLEM", 38, 55]]], ["Hence, lowering and flattening of the epidemic peak is particularly important, as it reduces the acute pressure on healthcare systems [2] .IntroductionSeveral methods of community mitigation strategies are heavily advocated as the key prevention methods.", [["flattening of the epidemic peak", "PROBLEM", 20, 51], ["the acute pressure on healthcare systems", "PROBLEM", 93, 133], ["community mitigation strategies", "TREATMENT", 170, 201], ["lowering", "OBSERVATION_MODIFIER", 7, 15], ["flattening", "OBSERVATION_MODIFIER", 20, 30], ["epidemic peak", "OBSERVATION", 38, 51], ["acute", "OBSERVATION_MODIFIER", 97, 102], ["pressure", "OBSERVATION_MODIFIER", 103, 111]]], ["These include cancellation and suspension of events with super spreader potential, use of social distancing measures to reduce direct and close contact between people in the community, travel restrictions including reduced flights, suspension of public transport and route restrictions without compromising the work of essential services, voluntary home quarantine of contacts, and clear communication (e.g. on aspects of hygiene) from health authorities to ensure verified information to the community [3] .IntroductionProjections on the behaviour of an epidemic is extremely useful in planning the responses of the community, health services, and in general all sectors directly and indirectly partnering in the mitigation process.", [["people", "SPECIES", 160, 166], ["social distancing measures", "TREATMENT", 90, 116], ["public transport", "TREATMENT", 246, 262]]], ["A few mathematical models and projections presented to date have attempted to understand the COVID-19 pandemic in detail, particularly based on data from cases in Wuhan in China (where the virus began) and from those returning from China to other countries.", [["the virus", "PROBLEM", 185, 194], ["few", "OBSERVATION_MODIFIER", 2, 5]]], ["Those models have concentrated on early dynamics of transmission, epidemic behaviour with the application of different preventive measures, and infectivity dynamics of the pathogen [2, 4, 5] .", [["epidemic behaviour", "PROBLEM", 66, 84], ["different preventive measures", "TREATMENT", 109, 138], ["concentrated", "OBSERVATION_MODIFIER", 18, 30]]], ["In addition, attempts to predict resource need in healthcare to face the challenges of COVID-19 are emerging [6] .Introduction.", [["COVID-19", "CHEMICAL", 87, 95], ["COVID", "TREATMENT", 87, 92]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)IntroductionThe copyright holder for this preprint this version posted May 1, 2020. . https://doi.org/10.1101/2020.04.27.20082537 doi: medRxiv preprint Sri Lanka is in a unique position in this epidemic; being an island with a population of 21 million.", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 214, 234], ["med", "ANATOMY", 105, 108], ["position", "OBSERVATION_MODIFIER", 379, 387], ["epidemic", "OBSERVATION_MODIFIER", 396, 404], ["island", "OBSERVATION_MODIFIER", 415, 421]]], ["Sri Lanka provides free of charge healthcare at the point of delivery to the total population in the state hospitals.", [["delivery", "TREATMENT", 61, 69]]], ["However, the majority of Sri Lankan hospitals provide non-specialised primary care and have very limited facilities and staff to manage conditions at an advanced stage such as severe respiratory distress.", [["respiratory", "ANATOMY", 183, 194], ["respiratory distress", "DISEASE", 183, 203], ["Sri Lankan", "ORGANISM", 25, 35], ["severe respiratory distress", "PROBLEM", 176, 203], ["severe", "OBSERVATION_MODIFIER", 176, 182], ["respiratory distress", "OBSERVATION", 183, 203]]], ["Prevention, notification and control action on communicable diseases is one of the key functions of the MOHs.", [["communicable diseases", "DISEASE", 47, 68], ["communicable diseases", "PROBLEM", 47, 68]]], ["Sri Lanka recorded its first case of COVID-19 on the 27 th January 2020.", [["COVID", "TEST", 37, 42]]], ["As of 4 th of April 2020, Sri Lanka has recorded 159 COVID-19 cases, with five deaths [10].IntroductionData from Sri Lanka on COVID-19 shows that it is still within a specific cluster (4 th of April 2020) where contact history can be traced; those who contacted the disease from outside the country, their close relatives or those associated with the index case.", [["deaths", "DISEASE", 79, 85], ["COVID", "TEST", 53, 58], ["COVID", "TEST", 126, 131]]], ["However, with increasing number of contacts to a single case, the field level difficulties in tracing each and every contact poses a threat of initiating community transmission.", [["increasing", "OBSERVATION_MODIFIER", 14, 24]]], ["The Sri Lankan government initiated measures to prevent the COVID-19 epidemic even before the first case was detected in January 2020.", [["the COVID", "TEST", 56, 65]]], ["Those measures were gradually strengthened through mandatory thermal screening at the points of entry to the country, followed by self-quarantine of those returning from designated countries from the beginning of March 2020.", [["mandatory thermal screening", "TEST", 51, 78]]], ["An island wide curfew was imposed on 20 th March to implement strict social distancing.", [["An island wide curfew", "PROBLEM", 0, 21], ["island", "OBSERVATION_MODIFIER", 3, 9], ["wide", "OBSERVATION_MODIFIER", 10, 14], ["curfew", "OBSERVATION", 15, 21]]], ["These measures continue at the time of writing (figure 1), (S1 Appendix).", [["S1 Appendix", "ANATOMY", 60, 71]]], ["Hence, Sri Lankan preparedness and preventive/ control measures for COVID-19 were unique compared with most other countries.IntroductionAs stated above, Sri Lanka initiated stringent measures even before a community outbreak of COVID-19 was evident.", [["COVID-19", "CHEMICAL", 228, 236], ["Sri Lankan preparedness", "TREATMENT", 7, 30], ["preventive/ control measures", "TREATMENT", 35, 63], ["COVID", "TEST", 68, 73], ["stringent measures", "TREATMENT", 173, 191], ["COVID", "TEST", 228, 233]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)IntroductionThe copyright holder for this preprint this version posted May 1, 2020. .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 214, 234], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)IntroductionThe copyright holder for this preprint this version posted May 1, 2020.MethodsIn this study, a mathematical model was developed and applied to COVID-19 active cases in China, Republic of Korea, and Italy, parameters were also estimated using existing active COVID-19 data from these respective countries where data was available in the public domainMethods[11] The developed model was validated for those three countries.", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 214, 234], ["this study", "TEST", 295, 305], ["a mathematical model", "TEST", 307, 327], ["COVID", "TEST", 357, 362], ["existing active COVID", "TREATMENT", 456, 477], ["med", "ANATOMY", 105, 108]]], ["The model development, parameter estimation and model validation process are described in detail below.Development of Mathematical ModelIn the model development process, we assumed that all the clinically tested positive cases for COVID-19 are homogeneous with no impact of age, sex and history of chronic diseases on the disease progression.", [["chronic diseases", "DISEASE", 298, 314], ["parameter estimation", "TEST", 23, 43], ["model validation process", "PROBLEM", 48, 72], ["Mathematical ModelIn the model development process", "PROBLEM", 118, 168], ["COVID", "TEST", 231, 236], ["chronic diseases", "PROBLEM", 298, 314], ["the disease progression", "PROBLEM", 318, 341], ["model validation", "OBSERVATION", 48, 64], ["Mathematical ModelIn", "OBSERVATION", 118, 138], ["chronic", "OBSERVATION_MODIFIER", 298, 305], ["diseases", "OBSERVATION", 306, 314], ["disease", "OBSERVATION_MODIFIER", 322, 329], ["progression", "OBSERVATION_MODIFIER", 330, 341]]], ["Conventional compartmental transmission models assume exponential growth for the number of infectious cases during the early stage of a well-mixed epidemic [13, 14] .", [["exponential growth", "PROBLEM", 54, 72], ["exponential", "OBSERVATION_MODIFIER", 54, 65], ["growth", "OBSERVATION_MODIFIER", 66, 72], ["infectious", "OBSERVATION", 91, 101]]], ["Therefore, the growth pattern of infectious disease outbreaks has been studied using exponential and/or extended versions of exponential models in the absence of control strategies [13] [14] [15] [16] .", [["infectious disease", "DISEASE", 33, 51], ["[13] [14] [15] [16]", "SIMPLE_CHEMICAL", 181, 200], ["infectious disease outbreaks", "PROBLEM", 33, 61], ["infectious", "OBSERVATION", 33, 43]]], ["In the present study, we propose a combined hybrid type model which has both exponential and polynomial features with control levels.", [["a combined hybrid type model", "TREATMENT", 33, 61], ["exponential", "OBSERVATION_MODIFIER", 77, 88]]], ["Generally, exponential models describe either a growth or a decay process depending on the nature of the exponential parameter; polynomial models describe the turning points of a behaviour.", [["a growth", "PROBLEM", 46, 54], ["a decay process", "PROBLEM", 58, 73], ["polynomial models", "PROBLEM", 128, 145]]], ["The experience gathered from the existing data on COVID-19 shows that pure exponential models may not be able to explain the behaviour of this epidemic.", [["COVID-19", "DNA", 50, 58], ["COVID", "TEST", 50, 55], ["pure exponential models", "PROBLEM", 70, 93]]], ["Hence, we designed a hybrid model by combining both exponential and .", [["a hybrid model", "TREATMENT", 19, 33]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 1, 2020. . https://doi.org/10.1101/2020.04.27.20082537 doi: medRxiv preprint polynomial models which may be more suited to explain the realistic behaviour of the COVID-19 epidemic in the early stages.(which was not certified by peer review)Based on the aforementioned theoretical underpinnings, the number of active infected cases (C(t)) may be modelled combining quadric and exponential behaviours and is given as follows:(which was not certified by peer review)where C(t) describes the cumulative number of active cases at time t, is a positive parameter, and b is either a positive or a negative parameter which depends on trends of the existing data.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["medRxiv preprint polynomial models", "TREATMENT", 324, 358], ["the COVID", "TEST", 422, 431], ["the existing data", "TEST", 900, 917], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108], ["active", "OBSERVATION_MODIFIER", 573, 579], ["infected", "OBSERVATION_MODIFIER", 580, 588], ["active", "OBSERVATION_MODIFIER", 773, 779]]], ["Parameter Q is a free parameter which can be determined based on control strategies and /or community responses.Parameter EstimationParameters and b can be estimated using nonlinear least-squares curve fitting techniques through the active cases curve modelled by C(t).We use the MATLAB in-built function lsqcurvefit which enables us to fit parameterized nonlinear functions to data.", [["Parameter EstimationParameters", "TEST", 112, 142], ["nonlinear least-squares curve fitting techniques", "TREATMENT", 172, 220]]], ["The parameter Q was chosen by imposing control strategies and/or social distance norms.Parameter Estimation.", [["The parameter Q", "TREATMENT", 0, 15], ["Parameter Estimation", "TEST", 87, 107]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 1, 2020. . https://doi.org/10.1101/2020.04.27.20082537 doi: medRxiv preprintModel ValidationIn real time modelling situations, model validation cannot be carried out using traditional techniques as Sri Lanka is still in the initial stages of the epidemic due to having only a small number of cases [16] .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["medRxiv", "TREATMENT", 324, 331], ["traditional techniques", "TREATMENT", 436, 458], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["However, we studied the behaviour of the COVID-19 epidemic in three countries, namely, China, Republic of Korea, and Italy.", [["the COVID", "TEST", 37, 46]]], ["These three countries are currently in three different stages of the epidemic; COVID-19 in China is mostly under control, Republic of Korea is likely to be approaching control status, and Italy is still in a full blown community epidemic.", [["COVID-19", "CHEMICAL", 79, 87], ["COVID", "TEST", 79, 84], ["likely to be", "UNCERTAINTY", 143, 155]]], ["We used three data sets from China, Republic Korea, and Italy that are available in the public domain for the purpose of model validation [11] (S2-S4 Appendix).Model ValidationThe objectives of the model validation process are as follows: (1) to determine whether our model captures the epidemic behaviour of the three reference countries, and (2) to determine the effectiveness of control measures, and the duration needed to observe the impact of the control measures on the epidemic curve.Model validation using the data from China, Republic of Korea, and ItalyFour simulations were performed using reported active COVID-19 cases from China in four different time periods (Table 1) .", [["model validation", "TEST", 121, 137], ["control measures", "TREATMENT", 382, 398], ["the control measures", "TREATMENT", 449, 469], ["the epidemic curve", "TEST", 473, 491], ["Appendix", "ANATOMY", 150, 158]]], ["Similarly, three simulations were performed using active COVID-19 cases from Republic of Korea and Italy in three different time periods (Table 1) .Model validation using the data from China, Republic of Korea, and ItalyModel parameters (a and b) were estimated in each simulation and predicted using the fitted model.", [["active COVID", "TREATMENT", 50, 62]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 1, 2020. .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 1, 2020. .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 1, 2020.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["In the graphs of all three countries, the gaps between the curves show the impact of the control strategies-i.e. how effective such controls were and the time duration needed for these to be effective.(which was not certified by peer review).", [["the curves", "TEST", 55, 65], ["the control strategies", "TREATMENT", 85, 107]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 1, 2020.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["The R-square values of all simulated models are higher than 0.91 and are presented in Table 2 .ResultsSimulations were performed using the reported active COVID-19 cases obtained from the Epidemiology unit, Sri Lanka, for the following period: 11-30 March 2020.", [["The R-square values", "TEST", 0, 19], ["R", "ANATOMY_MODIFIER", 4, 5], ["higher", "OBSERVATION_MODIFIER", 48, 54]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 1, 2020. .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["When the risk level reaches 20% according to the simulation, the peak of the curve will be above 1000 active cases after 90 days.(which was not certified by peer review).", [["the risk level", "TEST", 5, 19], ["the curve", "TEST", 73, 82]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 1, 2020. .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 1, 2020. . https://doi.org/10.1101/2020.04.27.20082537 doi: medRxiv preprint Figure 6 Definition of risk levels .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["medRxiv preprint Figure", "TREATMENT", 324, 347], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 1, 2020. . https://doi.org/10.1101/2020.04.27.20082537 doi: medRxiv preprint Figure 7 presents the curves shown in Figure 5 separately for each occasion.Figure 7 Simulation results for different risk levels and active COVID-19 cases reported in SriLanka-expanded A-Simulation for present situation without a risk definition B-Simulation with 10% risk C-Simulation with 15% risk D-Simulation with 20% risk Figure 8 presents simulations performed according to the degree of different preventive measures targeting social distancing and hygiene.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["medRxiv preprint Figure", "TREATMENT", 324, 347], ["different risk levels", "TEST", 449, 470], ["active COVID", "TEST", 475, 487], ["Simulation", "TEST", 617, 627], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["We considered three main factors as control measures, namely keeping social distance (l1), prevention of social gatherings (l2) and practising sanitary advisors (l3).", [["l3", "ANATOMY", 162, 164]]], ["Keeping social distance of one metre is enforced even when the communities are provided with opportunities to obtain essential services to prevent the spread of infection.", [["infection", "DISEASE", 161, 170], ["essential services", "TREATMENT", 117, 135], ["infection", "PROBLEM", 161, 170], ["infection", "OBSERVATION", 161, 170]]], ["The combined effect of these three control measures may be modelled using an algebraic product as follows:Figure 7 Simulation results for different risk levels and active COVID-19 cases reported in Sri.", [["Sri.", "SPECIES", 198, 202], ["different risk levels", "TEST", 138, 159], ["active COVID", "TEST", 164, 176]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 1, 2020. figure 8 show that if the current measures are fully adhered to (100%), then the number of active cases depicted by the dotted blue line stabilizes (177 COVID-19 cases by 11th April 2020) and then declines.", [["CC", "CHEMICAL", 0, 2], ["dotted blue line", "CELL_LINE", 393, 409], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108], ["blue line", "OBSERVATION", 400, 409]]], ["However, deviations from 100% adherence, as depicted by the dotted red (75%) and red (50%) lines, show an increasing trend of active cases that approaches an exponential behaviour.(which was not certified by peer review).", [["an increasing trend of active cases", "PROBLEM", 103, 138], ["increasing", "OBSERVATION_MODIFIER", 106, 116], ["trend", "OBSERVATION_MODIFIER", 117, 122], ["active", "OBSERVATION_MODIFIER", 126, 132], ["exponential", "OBSERVATION_MODIFIER", 158, 169]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 1, 2020. .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 1, 2020. active cases on May 8th (15%), and above 1000 active cases after 90 days (20% risk).", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["In addition, our model projects that the direction of the epidemic curve will change depending on relaxation or on the degree of compliance to the current control measures, resulting in an exponential behaviour for the scenarios of lower compliance.(which was not certified by peer review)Earlier this year, Sri Lanka imposed gradual control measures to prevent COVID-19 imported cases, even before the first case was detected in late January.", [["the epidemic curve", "PROBLEM", 54, 72], ["the current control measures", "TREATMENT", 143, 171], ["gradual control measures", "TREATMENT", 326, 350]]], ["The first case did not establish local transmission of the disease and the second case, a contact with a foreigner, was detected six weeks later.", [["the disease", "PROBLEM", 55, 66], ["disease", "OBSERVATION", 59, 66]]], ["Following the detection of a second COVID-19 case and the arrival of more infected returnees from overseas, initiation of local transmission was seen among their immediate contacts establishing a local cluster epidemic.", [["a second COVID", "TEST", 27, 41], ["more infected returnees", "PROBLEM", 69, 92], ["local transmission", "TREATMENT", 122, 140], ["infected", "OBSERVATION", 74, 82]]], ["This observation goes along with a recent study which found that a single case introduced to a new location would not necessarily initiate an epidemic, but that several introductions are needed for an outbreak to occur [4] .", [["a recent study", "TEST", 33, 47], ["epidemic", "OBSERVATION", 142, 150]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 1, 2020. . https://doi.org/10.1101/2020.04.27.20082537 doi: medRxiv preprint the measures already taken, namely self or institutionalized quarantine, those sporadic cases did not spill over to the community, thereby restricting the transmission to within a group of immediate contacts.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["medRxiv", "TREATMENT", 324, 331], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["This is a unique situation that allowed Sri Lanka to observe a cluster epidemic still on 4 th of April 2020.(which was not certified by peer review)Predicting the behaviour of the COVID-19 epidemic in this unique situation incorporating the potential risk of infection spilling over to the community through extended contacts needed a fresh approach.", [["infection", "DISEASE", 259, 268], ["the COVID", "TEST", 176, 185], ["infection spilling", "PROBLEM", 259, 277], ["a fresh approach", "TREATMENT", 333, 349], ["infection", "OBSERVATION", 259, 268]]], ["Development of our model through a hybrid approach fulfilled this necessity.(which was not certified by peer review)Validation of a mathematical model improves the credibility of projections on the future behaviour of the epidemic.", [["a hybrid approach", "TREATMENT", 33, 50]]], ["We used existing data from three countries to test our model with promising results (Rsquare above 0.9 for all simulations) [14] [15] [16] .(which was not certified by peer review)The infectivity, thus the basic reproduction number (R0) of an epidemic could change with time, and R0 will have more reliable estimates with more case data and data on the effects of interventions.", [["The infectivity", "PROBLEM", 180, 195], ["interventions", "TREATMENT", 364, 377], ["infectivity", "OBSERVATION", 184, 195]]], ["In a review examining COVID-19, R0 estimates ranged from 1.5 to 6.47 [5] .", [["COVID-19", "DNA", 22, 30], ["COVID", "TEST", 22, 27], ["R0 estimates", "TEST", 32, 44]]], ["Transmission of COVID-19 to immediate contacts and to their extended contacts will have a bearing on the propagation of the epidemic.", [["COVID-19", "CHEMICAL", 16, 24], ["COVID-19", "DNA", 16, 24], ["COVID", "TEST", 16, 21]]], ["In consideration of the available estimates of R0 and the contact cluster sizes observed in Sri Lanka, the risk levels were defined as 10%, 15%, and 20% in order to simulate the projections.", [["R0", "TREATMENT", 47, 49], ["the risk levels", "TEST", 103, 118], ["sizes", "OBSERVATION_MODIFIER", 74, 79]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 1, 2020.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["The effects of current public health measures towards the behaviour of the epidemic is important for decision makers.", [["current public health measures", "TREATMENT", 15, 45]]], ["Continuity or discontinuity of such measures warrant evidence [2] .", [["such measures", "TREATMENT", 31, 44]]], ["In the absence of many options to mitigate the COVID-19 epidemic, it is vital to examine the available methods to manage and reduce the caseload that are currently in use [3] .", [["the COVID", "TEST", 43, 52], ["the caseload", "TREATMENT", 132, 144]]], ["Our projections clearly show that the COVID-19 epidemic in Sri Lanka has a slow progression under control conditions.", [["Sri Lanka", "ORGANISM", 59, 68], ["the COVID", "TEST", 34, 43], ["a slow progression under control conditions", "PROBLEM", 73, 116], ["slow", "OBSERVATION_MODIFIER", 75, 79], ["progression", "OBSERVATION_MODIFIER", 80, 91]]], ["However, based on the three defined risk levels (variation in the levels of contacts being infected), the active caseload shows an increasing trend.", [["infected", "PROBLEM", 91, 99], ["an increasing trend", "PROBLEM", 128, 147], ["increasing", "OBSERVATION_MODIFIER", 131, 141], ["trend", "OBSERVATION_MODIFIER", 142, 147]]], ["Under a scenario of 20% risk, the trajectory of the number of active infected cases curve show stabilizing trend only after 90 days (over 1000 active cases) from the initial case.", [["active infected cases curve", "PROBLEM", 62, 89], ["active", "OBSERVATION_MODIFIER", 62, 68], ["infected", "OBSERVATION", 69, 77]]], ["The results of the projections thus shows the importance of preventive measures to minimize transmission to immediate contacts and thereby reducing the possibility of secondary transmission to extended contacts.", [["preventive measures", "TREATMENT", 60, 79]]], ["Failure to prevent this transmission could lead to a spill over of the infection to the community.", [["infection", "DISEASE", 71, 80], ["Failure", "PROBLEM", 0, 7], ["the infection", "PROBLEM", 67, 80], ["spill", "OBSERVATION", 53, 58], ["infection", "OBSERVATION", 71, 80]]], ["When the number of active cases increases, isolation and protective procedures will be less effective to control the epidemic, needing interventions in the curative side [18] .", [["isolation", "TREATMENT", 43, 52], ["protective procedures", "TREATMENT", 57, 78], ["interventions", "TREATMENT", 135, 148], ["active", "OBSERVATION_MODIFIER", 19, 25]]], ["In addition, practical difficulties would also arise in implementing effective quarantine for even the immediate contacts.(which was not certified by peer review)Non pharmacological intervention based on sustained physical distancing have a strong potential to reduce the magnitude of the epidemic curve and lead to a small number of total cases [2] .", [["practical difficulties", "PROBLEM", 13, 35], ["Non pharmacological intervention", "TREATMENT", 162, 194]]], ["In practice, physical distancing has been implemented through closing of schools and other educational institutions, closure of non-essential work settings and allowing employees to work .", [["closure", "TREATMENT", 117, 124]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 1, 2020. . https://doi.org/10.1101/2020.04.27.20082537 doi: medRxiv preprint from home, advocating social distancing through prevention of social gatherings, and imposing curfew or physical lockdown of geographical territories [3, 4, 18] .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["Although curfew was relaxed for essential services for few hours in between, the trend of the epidemic curve accommodated the effect of those measures during the last ten days of our data set (20-30 th of March 2020).", [["the epidemic curve", "PROBLEM", 90, 108], ["those measures", "TREATMENT", 136, 150]]], ["Thus, the parameters in our model captured the effects of those control measures in the simulation to provide a reasonable projection.", [["those control measures", "TREATMENT", 58, 80]]], ["However, realizing that behavioural variations need to be accommodated, particularly on keeping at least one metre distance, the breaching of social gathering prohibitions when curfew is relaxed, and by citizens not fully complying on hygiene practices, separate simulations were done to examine the epidemic behaviour.", [["behavioural variations", "PROBLEM", 24, 46], ["hygiene practices", "TREATMENT", 235, 252]]], ["This is to provide additional time and opportunity for healthcare systems to respond [2] .(which was not certified by peer review)The projections have an additional utility in deciding when and how to relax control measures, particularly physical distance maintenance, to prevent another surge in the epidemic.", [["physical distance maintenance", "TREATMENT", 238, 267]]], ["The limited literature available at present suggest that a premature and sudden lifting of interventions could lead an early secondary peak and that this can be prevented by a staggered lifting of control measures [2, 3] .", [["a premature", "PROBLEM", 57, 68], ["interventions", "TREATMENT", 91, 104], ["a staggered lifting of control measures", "TREATMENT", 174, 213]]], ["Our projections on relaxing or noncompliance of control measures clearly confirm this upward surge.", [["noncompliance of control measures", "TREATMENT", 31, 64]]], ["Hence, Sri Lanka needs to be extra cautious when making decisions on the existing control measures.(which was not certified by peer review).", [["the existing control measures", "TREATMENT", 69, 98]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)(which was not certified by peer review)The copyright holder for this preprint this version posted May 1, 2020. . https://doi.org/10.1101/2020.04.27.20082537 doi: medRxiv preprintStrengths and limitationsThis is the first known prediction model for the COVID-19 epidemic in Sri Lanka based on local data and case contact data.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 242, 262], ["medRxiv preprintStrengths", "TREATMENT", 365, 390], ["the COVID", "TEST", 451, 460], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["The model showed excellent goodness of fit with all three data sets.", [["excellent goodness", "OBSERVATION", 17, 35]]], ["Additionally, incorporating control measures to the model helped us to examine the contribution of those in mitigating the epidemic.Strengths and limitationsThe dataset in Sri Lanka is still relatively small, hence traditional in built methods of model validation were not possible.", [["model validation", "TEST", 247, 263], ["relatively", "OBSERVATION_MODIFIER", 191, 201], ["small", "OBSERVATION_MODIFIER", 202, 207], ["not possible", "UNCERTAINTY", 269, 281]]], ["Further, incorporation of cluster size of contacts into the model had to be limited to three categories due to the small numbers in the dataset.", [["the small numbers in the dataset", "PROBLEM", 111, 143], ["cluster", "OBSERVATION_MODIFIER", 26, 33], ["size", "OBSERVATION_MODIFIER", 34, 38], ["small", "OBSERVATION_MODIFIER", 115, 120], ["numbers", "OBSERVATION", 121, 128]]], ["Our projections based on a homogenous population could be limited to some extent due to the varying behaviour of transmission within different clusters owing to demographic, health seeking, and cultural practices.Study implicationsProjections of this model are already being used for the mitigation activities of COVID-19 by the Sri Lankan health authorities.", [["COVID-19", "CHEMICAL", 313, 321], ["COVID-19", "CHEMICAL", 313, 321], ["this model", "TREATMENT", 246, 256], ["COVID", "TEST", 313, 318], ["homogenous", "OBSERVATION_MODIFIER", 27, 37], ["population", "OBSERVATION", 38, 48], ["varying", "OBSERVATION_MODIFIER", 92, 99], ["behaviour", "OBSERVATION_MODIFIER", 100, 109]]], ["These projections have supported decision makers to plan testing facilities, health care provision and human resource management strategies.", [["human", "ORGANISM", 103, 108], ["human", "SPECIES", 103, 108], ["human", "SPECIES", 103, 108], ["health care provision", "TREATMENT", 77, 98], ["human resource management strategies", "TREATMENT", 103, 139]]], ["The methodological approach used in developing this method can be replicated in other settings with low caseload at the initial stages of the epidemic to project their behaviour, which will be useful for decision makers.Study implications.", [["The methodological approach", "TREATMENT", 0, 27], ["this method", "TREATMENT", 47, 58]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)Study implicationsThe copyright holder for this preprint this version posted May 1, 2020. . https://doi.org/10.1101/2020.04.27.20082537 doi: medRxiv preprintConclusionsIn conclusion, the hybrid model developed combining exponential and polynomial functions showed promising results to predict the trends of the COVID-19 epidemic.", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 220, 240], ["medRxiv", "TREATMENT", 343, 350], ["the hybrid model", "PROBLEM", 385, 401], ["polynomial functions", "TEST", 438, 458], ["the COVID", "TEST", 509, 518], ["epidemic", "PROBLEM", 522, 530], ["med", "ANATOMY", 105, 108]]], ["Further, additional simulations incorporating control measures clearly showed that deviations in the levels of compliance could trigger a higher number of active cases and bring upon the exponential features of the epidemic.", [["additional simulations incorporating control measures", "TREATMENT", 9, 62], ["the epidemic", "PROBLEM", 211, 223], ["epidemic", "OBSERVATION", 215, 223]]], ["At this stage our evidence indicates that early relaxation of the control measures that are in place is not advisable.ContributorsSNP and MCW conceptualized the study.", [["the control measures", "TREATMENT", 62, 82], ["the study", "TEST", 157, 166], ["evidence indicates", "UNCERTAINTY", 18, 36], ["early", "OBSERVATION_MODIFIER", 42, 47], ["relaxation", "OBSERVATION_MODIFIER", 48, 58], ["not advisable", "UNCERTAINTY", 104, 117]]], ["SNP and NCG performed mathematical modelling.ContributorsMCW and DDS provided epidemiological inputs.", [["SNP", "CHEMICAL", 0, 3], ["NCG", "DNA", 8, 11], ["SNP", "TREATMENT", 0, 3]]], ["SNP, MCW, DDS, and NCG interpreted the results and wrote the article.Declaration of interestsWe declare no competing interests.", [["SNP", "CHEMICAL", 0, 3]]]], "0ac30466bb6fcd6da6d05611cbb25dfb38dbd6d9": [["50Chile and study the effectiveness of control interventions by conducting short-term forecasts 51 based on early transmission dynamics of COVID-19.", [["control interventions", "TREATMENT", 39, 60], ["COVID", "TEST", 139, 144]]], ["The incidence curve displays sub-52 exponential growth dynamics with the scaling of growth parameter, , estimated at 0.8 (95% CI: 53 0.7, 0.8) and the reproduction number estimated at 1.6 (95% CI: 1.5, 1.6).", [["The incidence curve", "TEST", 0, 19], ["sub", "TEST", 29, 32], ["exponential growth dynamics", "PROBLEM", 36, 63], ["CI", "TEST", 126, 128], ["CI", "TEST", 193, 195], ["sub", "OBSERVATION_MODIFIER", 29, 32], ["exponential", "OBSERVATION_MODIFIER", 36, 47], ["growth", "OBSERVATION_MODIFIER", 48, 54], ["growth", "OBSERVATION_MODIFIER", 84, 90]]], ["The sub-epidemic CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 18, 2020. .71The coronavirus disease 2019 caused by Severe Acute Respiratory Syndrome 72 Coronavirus 2 (SARS-CoV-2) was declared a global pandemic by the WHO (World Health 73 Organization) on March 11 th , 2020 (1).", [["CC", "CHEMICAL", 17, 19], ["coronavirus disease", "DISEASE", 292, 311], ["Acute Respiratory Syndrome", "DISEASE", 334, 360], ["coronavirus", "ORGANISM", 292, 303], ["SARS-CoV-2", "ORGANISM", 379, 389], ["Severe Acute Respiratory Syndrome 72", "SPECIES", 327, 363], ["SARS-CoV-2", "SPECIES", 379, 389], ["The sub-epidemic CC", "TEST", 0, 19], ["The copyright holder", "TREATMENT", 212, 232], ["The coronavirus disease", "PROBLEM", 288, 311], ["Severe Acute Respiratory Syndrome", "PROBLEM", 327, 360], ["Coronavirus", "PROBLEM", 364, 375], ["med", "ANATOMY", 116, 119], ["coronavirus disease", "OBSERVATION", 292, 311], ["Severe", "OBSERVATION_MODIFIER", 327, 333], ["Acute", "OBSERVATION_MODIFIER", 334, 339], ["Respiratory Syndrome", "OBSERVATION", 340, 360]]], ["This highly contagious unprecedented virus has impacted 74 government and public institutions, strained the health care systems, restricted people in their 75 homes and caused country-wide lock downs resulting in a global economic crisis.", [["people", "ORGANISM", 140, 146], ["people", "SPECIES", 140, 146], ["a global economic crisis", "PROBLEM", 213, 237], ["contagious", "OBSERVATION_MODIFIER", 12, 22], ["global", "OBSERVATION_MODIFIER", 215, 221], ["economic crisis", "OBSERVATION", 222, 237]]], ["Moreover, as of 76 May 2 nd , 2020, more than 3 million COVID-19 cases in 210 countries and territories have been 77 recorded, including more than 200,000 deaths (2).", [["deaths", "DISEASE", 155, 161], ["COVID", "TEST", 56, 61]]], ["The social, economic and psychological impact 78 of this pandemic on much of the world's population is profound (3).", [["profound", "OBSERVATION_MODIFIER", 103, 111]]], ["79 Soon after its initial rapid spread in China, the first case of novel coronavirus beyond China 80 was reported in Thailand on January 13 th , 2020 (4).", [["coronavirus", "DISEASE", 73, 84], ["coronavirus", "ORGANISM", 73, 84], ["novel coronavirus", "PROBLEM", 67, 84]]], ["The first case in the USA was not identified 81 until January 20 th , 2020 followed by the detection of the first cases in the European territory on 82 January 24 th , 2020 (5, 6 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)71The copyright holder for this preprint this version posted May 18, 2020 . . https://doi.org/10.1101 /2020 Chile in phase 4 of the pandemic and surpassing 1000 reported cases of the novel coronavirus on 92 March 25 th , 2020 (9).", [["https://doi.org/10.1101 /2020", "CHEMICAL", 392, 421], ["coronavirus", "DISEASE", 503, 514], ["The copyright holder", "TREATMENT", 316, 336], ["the novel coronavirus", "PROBLEM", 493, 514], ["med", "ANATOMY", 217, 220]]], ["However, since the early phase of the outbreak, Chile has employed 96 an agile public health response by announcing a ban on large public health gatherings of more than 97 500 people on March 13 th , 2020 when the nationwide cumulative case count reached 44 reported 98 cases (11).", [["people", "SPECIES", 176, 182], ["cumulative case count", "TEST", 225, 246]]], ["This was followed by the announcement to close country borders 100 on March 18 th , 2020, and the declaration of national emergency on the same date, which was 101 accompanied with several concrete interventions to further contain the outbreak in the region (12, 102 13).", [["region", "ANATOMY_MODIFIER", 251, 257]]], ["Chile has accumulated a total of 14365 reported 106 cases including 207 deaths as of April 28 th , 2020.", [["deaths", "DISEASE", 72, 78]]], ["The majority of these cases are concentrated in 107 Chile's capital, Santiago, with 8300 reported cases and the Araucan\u00eda in Southern Chile with 1251 108 reported cases (14).", [["concentrated", "OBSERVATION_MODIFIER", 32, 44]]], ["110 In this study we estimate the transmission potential of COVID-19, including the effective 111 reproduction number, R, during the early transmission phase of the COVID-19 epidemic in Chile 112 that can guide the magnitude and intensity of control interventions to combat the epidemic (15, 113 16).", [["COVID-19", "CELL", 60, 68], ["this study", "TEST", 7, 17], ["COVID", "TEST", 60, 65], ["the COVID", "TEST", 161, 170], ["control interventions", "TREATMENT", 242, 263]]], ["Moreover, we can study the effectiveness of control interventions in Chile, including closure 114 .", [["control interventions", "TREATMENT", 44, 65], ["closure", "TREATMENT", 86, 93]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 18, 2020 . . https://doi.org/10.1101 /2020 of country borders, schools and non-essential businesses and the implementation of night time 115 curfew among others (see Table 1 ) on the transmission rate by conducting short-term forecasts 116 calibrated using the trajectory of the epidemic (17).", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 195, 215], ["med", "ANATOMY", 99, 102], ["non-essential businesses", "OBSERVATION", 333, 357]]], ["119 We obtained updates on the daily series of COVID-19 cases as of April 28 th , 2020 from 120 the publicly available data from the Github repository created by the government of Chile (8).121Incidence case data by the date of reporting, confirmed by PCR (polymerase chain reaction) tests 122 from March 3 rd -April 28 th , 2020 were analyzed.", [["COVID", "TEST", 47, 52], ["PCR", "TEST", 252, 255], ["polymerase chain reaction", "TEST", 257, 282], ["tests", "TEST", 284, 289]]], ["The daily testing and positivity rates available 123 from April 9 th -April 28 th , 2020 were also analyzed.", [["The daily testing", "TEST", 0, 17], ["positivity rates", "TEST", 22, 38]]], ["125 We generate short term forecasts in real time using the generalized growth model (GGM) 126 that characterizes the early ascending phase of the epidemic by estimating two parameters: (1) the 127 intrinsic growth rate, ; and (2) a dimensionless \"deceleration of growth\" parameter, .", [["intrinsic growth rate", "TEST", 198, 219], ["a dimensionless \"deceleration of growth\" parameter", "PROBLEM", 231, 281], ["short term", "OBSERVATION_MODIFIER", 16, 26], ["early", "OBSERVATION_MODIFIER", 118, 123], ["ascending phase", "OBSERVATION_MODIFIER", 124, 139]]], ["This model 128 allows to capture a range of epidemic growth profiles, by modulating parameter , including sub-129 exponential (polynomial) (0< <1) and exponential growth trends ( =1).", [["This model", "TEST", 0, 10], ["epidemic growth profiles", "PROBLEM", 44, 68], ["sub", "TEST", 106, 109], ["exponential growth trends", "TEST", 151, 176]]], ["The GGM model is 130 given by the following differential equation: 137 .", [["The GGM model", "TEST", 0, 13]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 18, 2020. . https://doi.org/10.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 195, 215], ["med", "ANATOMY", 99, 102]]], ["1101 /2020 Sub-epidemic wave model 138 We also fit the sub-epidemic model to the daily incidence of COVID-19, that depicts is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 18, 2020. . https://doi.org/10.", [["COVID", "TREATMENT", 100, 105], ["The copyright holder", "TREATMENT", 257, 277], ["med", "ANATOMY", 161, 164]]], ["Moreover, for the subsequently 158 occurring sub-epidemics, the size of the th sub-epidemic ( : ) declines exponentially at a rate q 159 because of multiple factors such as the effect of interventions, behavior changes and changes in 160 disease transmission dependent on seasonality, we have, 167 168 We calibrate the GGM model and the sub-epidemic wave model to the daily incidence180.", [["multiple factors", "PROBLEM", 148, 164], ["interventions", "TREATMENT", 187, 200], ["behavior changes", "PROBLEM", 202, 218], ["changes in 160 disease transmission dependent", "PROBLEM", 223, 268], ["the GGM model", "TREATMENT", 315, 328], ["size", "OBSERVATION_MODIFIER", 64, 68]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 18, 2020. . https://doi.org/10.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 195, 215], ["med", "ANATOMY", 99, 102]]], ["The initial condition is fixed to the first observation in the data 182 set.", [["the data", "TEST", 59, 67]]], ["Next, we utilize a parametric 183 bootstrapping approach assuming Poisson error structure for the sub-epidemic model and the 184 negative binomial error structure for the GGM model to derive uncertainty in the parameters 185 obtained by non-linear least square fit of the data as previously described (18, 21) .", [["a parametric 183 bootstrapping approach", "TREATMENT", 17, 56], ["the GGM model", "TEST", 167, 180], ["binomial error", "OBSERVATION", 138, 152]]], ["The model 186 confidence intervals of parameters and the 95% prediction intervals of model fit are also obtained 187 using the parametric bootstrap approach (18).", [["parameters", "TEST", 38, 48], ["the parametric bootstrap approach", "TEST", 123, 156]]], ["189 The reproduction number, R, is defined as the average number of secondary cases 190 generated by a primary case during the early ascending phase of an outbreak.", [["ascending phase", "OBSERVATION_MODIFIER", 133, 148]]], ["This is a crucial 191 quantity to identify the intensity of interventions required to contain an epidemic (22, 23).192Estimates of effective R indicate if the disease transmission continues (R>1) or if the active disease 193 transmission ceases (R<1).", [["interventions", "TREATMENT", 60, 73], ["the disease transmission", "PROBLEM", 155, 179], ["the active disease", "PROBLEM", 202, 220], ["epidemic", "OBSERVATION_MODIFIER", 97, 105], ["active", "OBSERVATION_MODIFIER", 206, 212], ["disease", "OBSERVATION", 213, 220]]], ["Therefore, in order to contain an outbreak, we need to maintain R<1.", [["outbreak", "OBSERVATION", 34, 42]]], ["194 We estimate the reproduction number by calibrating the GGM to the early growth phase of the 195 epidemic (28 days) (19).", [["early", "OBSERVATION_MODIFIER", 70, 75], ["growth", "OBSERVATION_MODIFIER", 76, 82]]], ["We model the generation interval of SARS-CoV-2 assuming gamma 196 distribution with a mean of 4.41 days and a standard deviation of 3.17 days (24-28).", [["SARS", "DISEASE", 36, 40], ["gamma 196", "PROTEIN", 56, 65], ["SARS-CoV", "SPECIES", 36, 44], ["SARS", "TEST", 36, 40], ["CoV", "TEST", 41, 44]]], ["We estimate 197 the growth rate parameter, r, and the deceleration of growth parameter, p, as described above.", [["the growth rate parameter", "TEST", 16, 41], ["the deceleration of growth parameter", "PROBLEM", 50, 86], ["deceleration", "OBSERVATION_MODIFIER", 54, 66], ["growth parameter", "OBSERVATION", 70, 86]]], ["Then CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 18, 2020. . https://doi.org/10.", [["CC", "CHEMICAL", 5, 7], ["The copyright holder", "TREATMENT", 200, 220], ["med", "ANATOMY", 104, 107]]], ["Next, we derive the uncertainty bounds around the curve of 5 directly 207 from the uncertainty associated with the parameter estimates (r, p).", [["the curve", "TEST", 46, 55]]], ["We estimate 5 for 300 208 simulated curves assuming a negative binomial error structure (18).", [["binomial error", "OBSERVATION", 63, 77]]], ["223 We estimate the reproduction number for the first 28 epidemic days incorporating the 224 effects of the social distancing interventions as explained in Table 1 .", [["the social distancing interventions", "TREATMENT", 104, 139]]], ["The incidence curve displays 225 .", [["The incidence curve", "TEST", 0, 19]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 18, 2020 . . https://doi.org/10.1101 /2020 sub-exponential growth dynamics with the scaling of growth parameter, p, estimated at 0.8 (95% 226 CI: 0.7, 0.9) and the intrinsic growth rate, r, estimated at 0.8 (95% CI: 0.7, 0.9).", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 195, 215], ["CI", "TEST", 400, 402], ["the intrinsic growth rate", "TEST", 418, 443], ["CI", "TEST", 470, 472], ["med", "ANATOMY", 99, 102]]], ["The reproduction 227 number for the early transmission phase was estimated at 1.6 (95% CI: 1.5, 1.6) (Figure 3) .228Assessing the impact of social distancing interventions 229 To assess the impact of social distancing interventions in Chile given in Table 1, The current estimates of the early transmission potential in Chile for the first 28 days of 246 the epidemic indicates sustained local transmission in the country with the estimate of reproduction 247 number at ~1.6 (95% CI: 1.5, 1.6) which is in accordance with the lower estimates of the 248 .", [["CI", "TEST", 87, 89], ["Figure", "TEST", 102, 108], ["social distancing interventions", "TREATMENT", 140, 171], ["social distancing interventions", "TREATMENT", 200, 231], ["CI", "TEST", 480, 482]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 18, 2020 . . https://doi.org/10.1101 /2020 reproduction numbers from studies conducted in China, Brazil, Korea, Peru, South Africa and Iran 249 that lie in the range of 1.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 195, 215], ["med", "ANATOMY", 99, 102]]], ["In contrast, the even lower estimates of R (<1) that have 250 been reported in Singapore and Australia can be correlated with the implementation of early social 251 distancing interventions in these countries (38, 39) .", [["lower", "OBSERVATION_MODIFIER", 22, 27]]], ["252 The initial scaling of the growth parameter in Chile indicates a sub-exponential growth 253 pattern (~0.8), consistent with sub-exponential growth patterns of COVID-19 that have been CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 18, 2020 . . https://doi.org/10.1101 /2020 of ~441 cases per day), highlighting the positive effects of quarantine and lockdowns in the 271 country, case counts continue to accrue.292.", [["CC", "CHEMICAL", 187, 189], ["COVID", "TEST", 163, 168], ["CC", "TEST", 187, 189], ["The copyright holder", "TREATMENT", 382, 402], ["quarantine", "TREATMENT", 549, 559], ["lockdowns", "TREATMENT", 564, 573], ["case counts", "TEST", 594, 605], ["sub", "OBSERVATION_MODIFIER", 69, 72], ["consistent with", "UNCERTAINTY", 112, 127], ["exponential", "OBSERVATION_MODIFIER", 132, 143], ["growth", "OBSERVATION_MODIFIER", 144, 150], ["med", "ANATOMY", 286, 289]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 18, 2020 . . https://doi.org/10.1101 /2020 This study has some limitations.", [["CC", "CHEMICAL", 0, 2], ["https://doi.org/10.1101 /2020", "CHEMICAL", 271, 300], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 195, 215], ["This study", "TEST", 301, 311], ["med", "ANATOMY", 99, 102]]], ["First our study analyzes cases by the dates of reporting 293 while it is ideal to analyze the cases by the dates of onset or after adjusting for reporting delays.294On the other hand, a substantial fraction of the COVID-19 infections exhibit very mild or no 295 symptoms at all, which may not be reflected by data (26).", [["infections", "DISEASE", 223, 233], ["the COVID", "TEST", 210, 219], ["19 infections", "PROBLEM", 220, 233], ["295 symptoms", "PROBLEM", 258, 270], ["substantial", "OBSERVATION_MODIFIER", 186, 197], ["fraction", "OBSERVATION", 198, 206], ["mild", "OBSERVATION_MODIFIER", 247, 251], ["may not be", "UNCERTAINTY", 285, 295]]], ["Second, the data is not stratified by local 296 vs. imported cases, therefore, we assume that all cases contribute equally to the transmission 297 dynamics of COVID-19.", [["COVID-19", "DNA", 159, 167], ["COVID", "TEST", 159, 164]]], ["Finally, the extent of selective underreporting, and its impact on these 298 results, is difficult to assess.300In this study we estimate the early transmission potential of SARS-CoV-2 in Chile.", [["SARS", "DISEASE", 174, 178], ["SARS-CoV-2", "ORGANISM", 174, 184], ["SARS-CoV", "SPECIES", 174, 182], ["this study", "TEST", 115, 125], ["SARS", "PROBLEM", 174, 178], ["extent", "OBSERVATION_MODIFIER", 13, 19], ["selective", "OBSERVATION_MODIFIER", 23, 32]]], ["Our CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)300The copyright holder for this preprint this version posted May 18, 2020.", [["CC", "CHEMICAL", 4, 6], ["The copyright holder", "TREATMENT", 203, 223], ["med", "ANATOMY", 103, 106]]]], "PMC7518799": [["Authors\u2019 contributionKS, DS, SK and NKV conceived the idea; VKS, KS and AM compiled the literature; VKS, KS, AM, YKR, DS and NKV wrote the manuscript; KS, DS, SK and NKV reviewed the manuscript; all authors have approved the final version of manuscript.FundingThis research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.Declaration of Competing InterestThe authors report no declarations of interest.", [["VKS", "TEST", 60, 63], ["VKS", "TEST", 100, 103]]]], "3c31b1dd002899846b274e39ae27424b1d7c1ea7": [["Introduction:The novel beta-coronavirus SARS-CoV-2 is believed to have emerged last year in 2019 in Wuhan from Bats, crossing the species barrier it entered human beings with further human to human transmission.", [["beta-coronavirus SARS-CoV-2", "ORGANISM", 23, 50], ["human", "ORGANISM", 157, 162], ["human", "ORGANISM", 183, 188], ["human", "ORGANISM", 192, 197], ["human", "SPECIES", 157, 162], ["human", "SPECIES", 183, 188], ["human", "SPECIES", 192, 197], ["human", "SPECIES", 157, 162], ["human", "SPECIES", 183, 188], ["human", "SPECIES", 192, 197]]], ["The beta-coronaviruses have jumped between the species and have caused three zoonotic outbreaks namely, SARS CoV (2002-03), MERS-CoV (2012), and SARS-CoV-2 (2019till date) in the last 2 decades.", [["SARS", "DISEASE", 104, 108], ["SARS", "DISEASE", 145, 149], ["beta-coronaviruses", "GENE_OR_GENE_PRODUCT", 4, 22], ["SARS CoV", "SPECIES", 104, 112], ["MERS-CoV", "SPECIES", 124, 132], ["SARS-CoV-2", "SPECIES", 145, 155], ["The beta-coronaviruses", "TEST", 0, 22], ["SARS CoV", "TEST", 104, 112], ["SARS", "TEST", 145, 149], ["CoV", "TEST", 150, 153], ["zoonotic", "OBSERVATION_MODIFIER", 77, 85], ["outbreaks", "OBSERVATION", 86, 95]]], ["The existence of a myriad of coronaviruses in bats, including many SARS-related CoV (Severe Acute Respiratory Syndrome related Coronaviruses) and the sporadic crossing of the species barriers of the coronaviruses to humans, suggest the future occurrences of zoonotic transmission events may sustain (1) .Introduction:Since its emergence in Nov 2019, it has spread to 188 countries and 25 territories around the globe, despite elaborate efforts by WHO and Governments to contain the infection, owing to the highly infectious nature of this virus (2; 3).", [["SARS", "DISEASE", 67, 71], ["Acute Respiratory Syndrome", "DISEASE", 92, 118], ["Coronaviruses", "DISEASE", 127, 140], ["infection", "DISEASE", 482, 491], ["coronaviruses", "ORGANISM", 29, 42], ["SARS-related CoV", "ORGANISM", 67, 83], ["coronaviruses", "ORGANISM", 199, 212], ["humans", "ORGANISM", 216, 222], ["humans", "SPECIES", 216, 222], ["humans", "SPECIES", 216, 222], ["coronaviruses in bats", "PROBLEM", 29, 50], ["many SARS-related CoV (Severe Acute Respiratory Syndrome", "PROBLEM", 62, 118], ["Coronaviruses", "PROBLEM", 127, 140], ["zoonotic transmission events", "PROBLEM", 258, 286], ["the infection", "PROBLEM", 478, 491], ["this virus", "PROBLEM", 534, 544], ["myriad", "OBSERVATION_MODIFIER", 19, 25], ["coronaviruses", "OBSERVATION", 29, 42], ["Severe", "OBSERVATION_MODIFIER", 85, 91], ["Acute", "OBSERVATION_MODIFIER", 92, 97], ["Respiratory Syndrome", "OBSERVATION", 98, 118], ["globe", "ANATOMY", 411, 416], ["infection", "OBSERVATION", 482, 491], ["highly", "OBSERVATION_MODIFIER", 506, 512], ["infectious", "OBSERVATION", 513, 523]]], ["As of 2 July 2020, 10,533,779 cases have been reported globally with 512,842 deaths (4) .", [["deaths", "DISEASE", 77, 83]]], ["There has been a monumental increase in the number of infected patients, with a 7-day moving average of 210,209 cases per day, as of 2 July 2020 (2) .", [["patients", "ORGANISM", 63, 71], ["patients", "SPECIES", 63, 71], ["a monumental increase", "PROBLEM", 15, 36], ["monumental", "OBSERVATION_MODIFIER", 17, 27], ["increase", "OBSERVATION_MODIFIER", 28, 36], ["number", "OBSERVATION_MODIFIER", 44, 50], ["infected", "OBSERVATION_MODIFIER", 54, 62]]], ["SARS-CoV-2, a highly contagious virus, tends to spread by the inhalation of the respiratory aerosols, direct human contact, and via fomites.", [["respiratory", "ANATOMY", 80, 91], ["SARS", "DISEASE", 0, 4], ["SARS-CoV-2", "ORGANISM", 0, 10], ["human", "ORGANISM", 109, 114], ["human", "SPECIES", 109, 114], ["SARS-CoV-2", "SPECIES", 0, 10], ["human", "SPECIES", 109, 114], ["a highly contagious virus", "PROBLEM", 12, 37], ["contagious", "OBSERVATION_MODIFIER", 21, 31], ["virus", "OBSERVATION", 32, 37], ["respiratory", "ANATOMY", 80, 91]]], ["Social distancing, personal hygiene, frequent hand washing or sanitizing using the alcohol (61-70%) based hand-sanitizers, and disinfection of the surfaces are some steps which can protect the individuals from getting infected (5) .", [["hand", "ANATOMY", 46, 50], ["hand", "ANATOMY", 106, 110], ["alcohol", "CHEMICAL", 83, 90], ["alcohol", "CHEMICAL", 83, 90], ["hand", "ORGANISM_SUBDIVISION", 46, 50], ["alcohol", "SIMPLE_CHEMICAL", 83, 90], ["frequent hand washing", "TREATMENT", 37, 58], ["disinfection", "TREATMENT", 127, 139]]], ["R0 is an epidemiological scale; used to measure the contagiousness of an infectious agent.", [["an epidemiological scale", "TEST", 6, 30], ["an infectious agent", "TREATMENT", 70, 89], ["infectious", "OBSERVATION", 73, 83]]], ["Its magnitude depends upon various biological, environmental, and socio-behavioral factors.", [["magnitude", "OBSERVATION_MODIFIER", 4, 13]]], ["SARS-CoV-2 has an R0 value range of 2-3 (7) which is much higher in comparison to Spanish flu for which the R0 was recorded at 0.9-2.1 (8) .", [["SARS", "DISEASE", 0, 4], ["SARS-CoV", "TEST", 0, 8], ["an R0 value range", "TEST", 15, 32], ["higher", "OBSERVATION_MODIFIER", 58, 64]]], ["According to WHO, people living with non-communicable diseases (co-morbid conditions) are prone to severe illness due to COVID-19 infection.", [["non-communicable diseases", "DISEASE", 37, 62], ["illness", "DISEASE", 106, 113], ["COVID-19", "CHEMICAL", 121, 129], ["infection", "DISEASE", 130, 139], ["people", "ORGANISM", 18, 24], ["people", "SPECIES", 18, 24], ["non-communicable diseases (co-morbid conditions", "PROBLEM", 37, 84], ["severe illness", "PROBLEM", 99, 113], ["COVID-19 infection", "PROBLEM", 121, 139], ["infection", "OBSERVATION", 130, 139]]], ["The incubation period of the virus ranges from 2-14 days with a median of 5.1 days (9) .", [["the virus ranges", "TEST", 25, 41]]], ["The symptoms include fever, dry cough, fatigue, shortness of breath, chills, muscles pain, headache, gastric disturbances and weight loss (10) .", [["muscles", "ANATOMY", 77, 84], ["gastric", "ANATOMY", 101, 108], ["fever", "DISEASE", 21, 26], ["dry cough", "DISEASE", 28, 37], ["fatigue", "DISEASE", 39, 46], ["shortness of breath", "DISEASE", 48, 67], ["chills", "DISEASE", 69, 75], ["muscles pain", "DISEASE", 77, 89], ["headache", "DISEASE", 91, 99], ["gastric disturbances", "DISEASE", 101, 121], ["weight loss", "DISEASE", 126, 137], ["muscles", "ORGANISM_SUBDIVISION", 77, 84], ["gastric", "ORGAN", 101, 108], ["The symptoms", "PROBLEM", 0, 12], ["fever", "PROBLEM", 21, 26], ["dry cough", "PROBLEM", 28, 37], ["fatigue", "PROBLEM", 39, 46], ["shortness of breath", "PROBLEM", 48, 67], ["chills", "PROBLEM", 69, 75], ["muscles pain", "PROBLEM", 77, 89], ["headache", "PROBLEM", 91, 99], ["gastric disturbances", "PROBLEM", 101, 121], ["weight loss", "PROBLEM", 126, 137], ["cough", "OBSERVATION", 32, 37], ["muscles", "ANATOMY", 77, 84], ["gastric", "ANATOMY", 101, 108], ["disturbances", "OBSERVATION", 109, 121]]], ["Some patients may have lymphopenia and bilateral ground-glass opacity changes in the chest CT scans.", [["lymphopenia", "DISEASE", 23, 34], ["patients", "ORGANISM", 5, 13], ["patients", "SPECIES", 5, 13], ["lymphopenia", "PROBLEM", 23, 34], ["bilateral ground-glass opacity changes", "PROBLEM", 39, 77], ["the chest CT scans", "TEST", 81, 99], ["lymphopenia", "OBSERVATION", 23, 34], ["bilateral", "ANATOMY_MODIFIER", 39, 48], ["ground", "OBSERVATION_MODIFIER", 49, 55], ["glass opacity", "OBSERVATION", 56, 69], ["chest", "ANATOMY", 85, 90]]], ["The histological examinations of the lungs' biopsy samples have shown a bilaterally diffused alveolar damage with cellular fibromyxoid exudates.", [["lungs' biopsy samples", "ANATOMY", 37, 58], ["alveolar", "ANATOMY", 93, 101], ["cellular fibromyxoid exudates", "ANATOMY", 114, 143], ["alveolar damage", "DISEASE", 93, 108], ["lungs", "ORGAN", 37, 42], ["biopsy samples", "CANCER", 44, 58], ["alveolar", "TISSUE", 93, 101], ["cellular fibromyxoid exudates", "TISSUE", 114, 143], ["The histological examinations", "TEST", 0, 29], ["the lungs' biopsy samples", "TEST", 33, 58], ["a bilaterally diffused alveolar damage", "PROBLEM", 70, 108], ["cellular fibromyxoid exudates", "PROBLEM", 114, 143], ["lungs", "ANATOMY", 37, 42], ["bilaterally", "ANATOMY_MODIFIER", 72, 83], ["diffused", "OBSERVATION_MODIFIER", 84, 92], ["alveolar damage", "OBSERVATION", 93, 108], ["cellular", "OBSERVATION_MODIFIER", 114, 122], ["fibromyxoid exudates", "OBSERVATION", 123, 143]]], ["A few interstitial mononuclear inflammatory infiltrates were observed both in the liver and the heart specimens (11) .", [["interstitial mononuclear", "ANATOMY", 6, 30], ["liver", "ANATOMY", 82, 87], ["heart specimens", "ANATOMY", 96, 111], ["interstitial mononuclear", "CELL", 6, 30], ["liver", "ORGAN", 82, 87], ["heart specimens", "CANCER", 96, 111], ["A few interstitial mononuclear inflammatory infiltrates", "PROBLEM", 0, 55], ["the heart specimens", "TEST", 92, 111], ["few", "OBSERVATION_MODIFIER", 2, 5], ["interstitial", "OBSERVATION_MODIFIER", 6, 18], ["mononuclear", "OBSERVATION_MODIFIER", 19, 30], ["inflammatory", "OBSERVATION_MODIFIER", 31, 43], ["infiltrates", "OBSERVATION", 44, 55], ["liver", "ANATOMY", 82, 87], ["heart", "ANATOMY", 96, 101]]], ["However, a large population of the infected patients have no or mild symptoms and remain asymptomatic (12) .Introduction:Structurally coronaviruses are pleomorphic, enveloped viruses with a characteristic fringe of projections composed of S protein on their surface.", [["surface", "ANATOMY", 258, 265], ["patients", "ORGANISM", 44, 52], ["coronaviruses", "ORGANISM", 134, 147], ["S protein", "GENE_OR_GENE_PRODUCT", 239, 248], ["surface", "CELLULAR_COMPONENT", 258, 265], ["S protein", "PROTEIN", 239, 248], ["patients", "SPECIES", 44, 52], ["mild symptoms", "PROBLEM", 64, 77], ["asymptomatic", "PROBLEM", 89, 101], ["pleomorphic", "PROBLEM", 152, 163], ["large", "OBSERVATION_MODIFIER", 11, 16], ["population", "OBSERVATION_MODIFIER", 17, 27], ["infected", "OBSERVATION", 35, 43], ["mild", "OBSERVATION_MODIFIER", 64, 68], ["symptoms", "OBSERVATION", 69, 77], ["S protein", "OBSERVATION_MODIFIER", 239, 248]]], ["These viruses are equipped with a positive sense ssRNA genome, which is complexed with the nucleocapsid (N) protein forming helical nucleocapsids.", [["nucleocapsids", "ANATOMY", 132, 145], ["positive sense ssRNA genome", "DNA", 34, 61], ["nucleocapsid (N) protein", "PROTEIN", 91, 115], ["These viruses", "PROBLEM", 0, 13], ["a positive sense ssRNA genome", "PROBLEM", 32, 61], ["the nucleocapsid (N) protein forming helical nucleocapsids", "PROBLEM", 87, 145], ["viruses", "OBSERVATION", 6, 13], ["ssRNA genome", "OBSERVATION", 49, 61]]], ["The genome is both capped and polyadenylated (13) .", [["genome", "CELLULAR_COMPONENT", 4, 10], ["both", "OBSERVATION_MODIFIER", 14, 18], ["capped", "OBSERVATION_MODIFIER", 19, 25]]], ["The genetic analysis of SARS-CoV-2 and SARS-like coronaviruses has revealed that there is a total of 380 amino acid substitutions condensed mainly within the NSP genes.", [["amino acid", "CHEMICAL", 105, 115], ["amino acid", "CHEMICAL", 105, 115], ["SARS-CoV-2", "ORGANISM", 24, 34], ["SARS-like coronaviruses", "ORGANISM", 39, 62], ["amino acid", "AMINO_ACID", 105, 115], ["NSP", "GENE_OR_GENE_PRODUCT", 158, 161], ["NSP genes", "DNA", 158, 167], ["SARS-CoV", "SPECIES", 24, 32], ["The genetic analysis", "TEST", 0, 20], ["SARS", "TEST", 24, 28], ["CoV", "TEST", 29, 32], ["SARS", "PROBLEM", 39, 43], ["coronaviruses", "PROBLEM", 49, 62], ["amino acid substitutions", "PROBLEM", 105, 129], ["acid substitutions", "OBSERVATION", 111, 129], ["NSP genes", "OBSERVATION", 158, 167]]], ["Out of these substitutions, there are 27 amino acid replacements in the immune-dominant S protein while 102 and 61 amino acid substitutions are found in the NSP3 and NSP2.", [["amino acid", "CHEMICAL", 41, 51], ["amino acid", "CHEMICAL", 115, 125], ["amino acid", "CHEMICAL", 41, 51], ["amino acid", "CHEMICAL", 115, 125], ["amino acid", "AMINO_ACID", 41, 51], ["amino acid", "AMINO_ACID", 115, 125], ["NSP3", "GENE_OR_GENE_PRODUCT", 157, 161], ["NSP2", "GENE_OR_GENE_PRODUCT", 166, 170], ["immune-dominant S protein", "PROTEIN", 72, 97], ["NSP3", "PROTEIN", 157, 161], ["NSP2", "PROTEIN", 166, 170], ["27 amino acid replacements", "TREATMENT", 38, 64], ["amino acid substitutions", "PROBLEM", 115, 139], ["the NSP3", "TREATMENT", 153, 161], ["NSP2", "PROBLEM", 166, 170], ["acid substitutions", "OBSERVATION", 121, 139]]], ["Whereas, NSP7, NSP13, E protein, and some accessory proteins are devoid of any amino acid substitutions (14) .", [["amino acid", "CHEMICAL", 79, 89], ["amino acid", "CHEMICAL", 79, 89], ["NSP7", "GENE_OR_GENE_PRODUCT", 9, 13], ["NSP13", "GENE_OR_GENE_PRODUCT", 15, 20], ["E", "GENE_OR_GENE_PRODUCT", 22, 23], ["amino acid", "AMINO_ACID", 79, 89], ["NSP7", "PROTEIN", 9, 13], ["NSP13", "PROTEIN", 15, 20], ["E protein", "PROTEIN", 22, 31], ["accessory proteins", "PROTEIN", 42, 60], ["NSP7", "TEST", 9, 13], ["NSP13", "TEST", 15, 20], ["E protein", "TEST", 22, 31], ["some accessory proteins", "PROBLEM", 37, 60], ["any amino acid substitutions", "PROBLEM", 75, 103]]], ["SARS-CoV and SARS-CoV-2 share a common host receptor, hACE2, to gain entry into the cell (SARS-CoV-2 binds with a higher affinity than the SARS-CoV), while MERS-CoV uses Dipeptidyl Peptidase 4 (DPP4) (15) .", [["cell", "ANATOMY", 84, 88], ["SARS", "DISEASE", 0, 4], ["SARS-CoV", "ORGANISM", 0, 8], ["SARS-CoV-2", "ORGANISM", 13, 23], ["hACE2", "GENE_OR_GENE_PRODUCT", 54, 59], ["cell", "CELL", 84, 88], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 90, 100], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 139, 147], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 156, 164], ["Dipeptidyl Peptidase 4", "GENE_OR_GENE_PRODUCT", 170, 192], ["DPP4", "GENE_OR_GENE_PRODUCT", 194, 198], ["hACE2", "PROTEIN", 54, 59], ["MERS", "PROTEIN", 156, 160], ["Dipeptidyl Peptidase 4", "PROTEIN", 170, 192], ["DPP4", "PROTEIN", 194, 198], ["SARS-CoV", "SPECIES", 0, 8], ["SARS-CoV", "SPECIES", 13, 21], ["SARS-CoV", "SPECIES", 139, 147], ["MERS-CoV", "SPECIES", 156, 164], ["SARS", "TEST", 0, 4], ["SARS", "PROBLEM", 13, 17], ["CoV", "TEST", 18, 21], ["CoV", "TEST", 95, 98], ["a higher affinity", "PROBLEM", 112, 129], ["Dipeptidyl Peptidase 4 (DPP4)", "TREATMENT", 170, 199], ["cell", "ANATOMY", 84, 88]]], ["Sequence analysis has revealed that the SARS-CoV-2 has around 79% similarity with the SARS-CoV while it is found to be quite distantly related to the MERS-CoV with around 50% similarity (16) .Introduction:The genome of SARS-CoV-2 is transcribed in at least 10 Open Reading Frames (ORFs).", [["SARS", "DISEASE", 86, 90], ["SARS-CoV-2", "ORGANISM", 40, 50], ["SARS-CoV", "ORGANISM", 86, 94], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 150, 158], ["SARS-CoV-2", "ORGANISM", 219, 229], ["SARS-CoV-2", "DNA", 40, 50], ["MERS-CoV", "DNA", 150, 158], ["SARS-CoV-2", "DNA", 219, 229], ["Open Reading Frames", "DNA", 260, 279], ["ORFs", "DNA", 281, 285], ["SARS-CoV", "SPECIES", 40, 48], ["SARS-CoV", "SPECIES", 86, 94], ["MERS-CoV", "SPECIES", 150, 158], ["SARS-CoV", "SPECIES", 219, 227], ["Sequence analysis", "TEST", 0, 17], ["the SARS", "TEST", 36, 44], ["CoV", "TEST", 45, 48], ["the SARS-CoV", "PROBLEM", 82, 94]]], ["ORF1ab translates into a polyprotein which is processed into 16 non-structural proteins (NSPs) (17) .", [["ORF1ab", "CHEMICAL", 0, 6], ["ORF1ab", "GENE_OR_GENE_PRODUCT", 0, 6], ["ORF1ab", "PROTEIN", 0, 6], ["16 non-structural proteins", "PROTEIN", 61, 87], ["NSPs", "PROTEIN", 89, 93], ["ORF1ab", "TREATMENT", 0, 6], ["a polyprotein", "TREATMENT", 23, 36]]], ["The NSPs perform various functions like genome replication, inducing the cleavage of host mRNA, membrane rearrangement, generation of the autophagosome, cleavage of the NSP polyprotein, capping, tailing, methylation, unwinding of the RNA duplex, etc. which are essential for the viral life cycle (18).", [["membrane", "ANATOMY", 96, 104], ["autophagosome", "ANATOMY", 138, 151], ["NSPs", "GENE_OR_GENE_PRODUCT", 4, 8], ["genome", "CELLULAR_COMPONENT", 40, 46], ["membrane", "CELLULAR_COMPONENT", 96, 104], ["autophagosome", "CELLULAR_COMPONENT", 138, 151], ["NSP", "GENE_OR_GENE_PRODUCT", 169, 172], ["NSPs", "PROTEIN", 4, 8], ["host mRNA", "RNA", 85, 94], ["NSP polyprotein", "PROTEIN", 169, 184], ["RNA duplex", "RNA", 234, 244], ["genome replication", "TREATMENT", 40, 58], ["host mRNA", "PROBLEM", 85, 94], ["membrane rearrangement", "PROBLEM", 96, 118], ["the autophagosome", "PROBLEM", 134, 151], ["the NSP polyprotein", "TREATMENT", 165, 184], ["capping", "TREATMENT", 186, 193], ["methylation", "TREATMENT", 204, 215], ["the RNA duplex", "TEST", 230, 244], ["genome replication", "OBSERVATION", 40, 58], ["host mRNA", "OBSERVATION", 85, 94], ["membrane rearrangement", "OBSERVATION", 96, 118]]], ["Besides, the SARS-CoV-2 virus contains four structural proteins namely, spike (S), nucleocapsid (N), envelope (E), and membrane (M) proteins which are encoded by the 3'-end of the viral genome (19) .", [["membrane", "ANATOMY", 119, 127], ["SARS", "DISEASE", 13, 17], ["SARS-CoV-2 virus", "ORGANISM", 13, 29], ["spike (S)", "GENE_OR_GENE_PRODUCT", 72, 81], ["nucleocapsid (N), envelope (E)", "GENE_OR_GENE_PRODUCT", 83, 113], ["membrane", "CELLULAR_COMPONENT", 119, 127], ["structural proteins", "PROTEIN", 44, 63], ["spike (S)", "PROTEIN", 72, 81], ["nucleocapsid (N), envelope (E), and membrane (M) proteins", "PROTEIN", 83, 140], ["3'-end", "DNA", 166, 172], ["viral genome", "DNA", 180, 192], ["CoV-2 virus", "SPECIES", 18, 29], ["SARS-CoV-2 virus", "SPECIES", 13, 29], ["the SARS", "TEST", 9, 17], ["CoV", "TEST", 18, 21], ["four structural proteins", "PROBLEM", 39, 63], ["spike (S), nucleocapsid (N), envelope (E), and membrane (M) proteins", "PROBLEM", 72, 140], ["the viral genome", "PROBLEM", 176, 192], ["viral genome", "OBSERVATION", 180, 192]]], ["Amongst the 4 structural proteins the S glycoprotein, being a large multifunctional trans-membrane protein, plays the vital role of viral attachment, fusion, and entry into the host cell (19) .", [["cell", "ANATOMY", 182, 186], ["S glycoprotein", "GENE_OR_GENE_PRODUCT", 38, 52], ["host cell", "CELL", 177, 186], ["structural proteins", "PROTEIN", 14, 33], ["S glycoprotein", "PROTEIN", 38, 52], ["multifunctional trans-membrane protein", "PROTEIN", 68, 106], ["a large multifunctional trans-membrane protein", "TREATMENT", 60, 106], ["viral attachment, fusion", "TREATMENT", 132, 156], ["large", "OBSERVATION_MODIFIER", 62, 67], ["membrane protein", "OBSERVATION", 90, 106], ["viral attachment", "OBSERVATION", 132, 148], ["host cell", "OBSERVATION", 177, 186]]], ["The S protein consists of S1 and S2 subunits, which are further split into different functional domains.", [["S1", "GENE_OR_GENE_PRODUCT", 26, 28], ["S2", "GENE_OR_GENE_PRODUCT", 33, 35], ["S protein", "PROTEIN", 4, 13], ["S1", "PROTEIN", 26, 28], ["S2 subunits", "PROTEIN", 33, 44], ["functional domains", "PROTEIN", 85, 103], ["The S protein", "TEST", 0, 13], ["S1 and S2 subunits", "TREATMENT", 26, 44], ["S2", "ANATOMY", 33, 35]]], ["The S1 subunit has two functional domains viz.", [["S1", "GENE_OR_GENE_PRODUCT", 4, 6], ["S1 subunit", "PROTEIN", 4, 14], ["two", "OBSERVATION_MODIFIER", 19, 22], ["functional domains", "OBSERVATION", 23, 41]]], ["N-terminal Domain (NTD) and Receptor Binding Domain (RBD) and the latter contains conserved receptor binding motif (RBM) (20) .", [["N", "CHEMICAL", 0, 1], ["Receptor Binding Domain", "GENE_OR_GENE_PRODUCT", 28, 51], ["N-terminal Domain", "PROTEIN", 0, 17], ["NTD", "PROTEIN", 19, 22], ["Receptor Binding Domain", "PROTEIN", 28, 51], ["RBD", "PROTEIN", 53, 56], ["conserved receptor binding motif", "PROTEIN", 82, 114], ["terminal Domain (NTD)", "TREATMENT", 2, 23], ["Receptor Binding Domain (RBD", "TREATMENT", 28, 56]]], ["The alignment studies have revealed that the region of RBD sequence lies between the residues 331 and 524 of the S protein (21) .", [["RBD sequence", "PROTEIN", 55, 67], ["S protein", "PROTEIN", 113, 122], ["The alignment studies", "TEST", 0, 21], ["RBD sequence", "TEST", 55, 67], ["the S protein", "TEST", 109, 122], ["RBD", "OBSERVATION", 55, 58]]], ["Whereas, the S2 subunit has three operational domains namely, fusion peptide (FP), heptad repeat (HR) 1, and 2.", [["S2", "GENE_OR_GENE_PRODUCT", 13, 15], ["S2 subunit", "PROTEIN", 13, 23], ["heptad repeat", "PROTEIN", 83, 96], ["fusion peptide", "TREATMENT", 62, 76], ["heptad repeat (HR", "TEST", 83, 100]]], ["The S1 protein trimer aligns itself at the top of the trimeric S2 stalk to form the immune-dominant S protein (20) .", [["S1", "GENE_OR_GENE_PRODUCT", 4, 6], ["S2", "GENE_OR_GENE_PRODUCT", 63, 65], ["S1 protein trimer", "PROTEIN", 4, 21], ["trimeric S2 stalk", "PROTEIN", 54, 71], ["immune-dominant S protein", "PROTEIN", 84, 109], ["S1", "ANATOMY_MODIFIER", 4, 6], ["protein trimer aligns", "OBSERVATION", 7, 28], ["top", "OBSERVATION_MODIFIER", 43, 46], ["trimeric S2", "ANATOMY", 54, 65]]], ["Interestingly, J o u r n a l P r e -p r o o f a furin cleavage site is observed within the spike protein of SARS-CoV-2 while it is absent in the SARS-CoV which may be a possible explanation of the variation in the pathogenicity of the virus (22) .", [["SARS", "DISEASE", 145, 149], ["furin", "GENE_OR_GENE_PRODUCT", 48, 53], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 108, 118], ["SARS-CoV", "ORGANISM", 145, 153], ["furin cleavage site", "DNA", 48, 67], ["spike protein", "PROTEIN", 91, 104], ["SARS-CoV", "SPECIES", 108, 116], ["SARS-CoV", "SPECIES", 145, 153], ["a furin cleavage site", "PROBLEM", 46, 67], ["SARS", "TEST", 108, 112], ["CoV", "TEST", 113, 116], ["the variation", "PROBLEM", 193, 206], ["the pathogenicity of the virus", "PROBLEM", 210, 240], ["may be a possible", "UNCERTAINTY", 160, 177]]], ["A host trans-membrane protease serine 2, (TMPRSS2) is responsible for the initial priming of the spike protein.", [["serine", "CHEMICAL", 31, 37], ["trans-membrane protease serine 2", "GENE_OR_GENE_PRODUCT", 7, 39], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 42, 49], ["TMPRSS2", "PROTEIN", 42, 49], ["spike protein", "PROTEIN", 97, 110], ["A host trans-membrane protease serine", "TREATMENT", 0, 37], ["TMPRSS2", "TEST", 42, 49], ["the spike protein", "PROBLEM", 93, 110]]], ["The virus can utilize both TMPRSS2 and endosomal cysteine proteases cathepsin B and L (CatB/L) to gain entry into the cell.", [["endosomal", "ANATOMY", 39, 48], ["cell", "ANATOMY", 118, 122], ["cysteine", "CHEMICAL", 49, 57], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 27, 34], ["endosomal", "CELLULAR_COMPONENT", 39, 48], ["cathepsin B", "GENE_OR_GENE_PRODUCT", 68, 79], ["L (CatB/L)", "GENE_OR_GENE_PRODUCT", 84, 94], ["cell", "CELL", 118, 122], ["TMPRSS2", "PROTEIN", 27, 34], ["endosomal cysteine proteases", "PROTEIN", 39, 67], ["cathepsin B", "PROTEIN", 68, 79], ["L (CatB/L)", "PROTEIN", 84, 94], ["The virus", "PROBLEM", 0, 9], ["TMPRSS2", "TEST", 27, 34], ["endosomal cysteine proteases cathepsin B and L (CatB/L)", "TREATMENT", 39, 94], ["virus", "OBSERVATION", 4, 9], ["cell", "ANATOMY", 118, 122]]], ["The TMPRSS2 is responsible for the cleavage of the S protein to expose the FP region of the S2 subunit which is responsible for the initiation of the endosome mediated entry into the host cell.", [["endosome", "ANATOMY", 150, 158], ["cell", "ANATOMY", 188, 192], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 4, 11], ["S2", "GENE_OR_GENE_PRODUCT", 92, 94], ["endosome", "CELLULAR_COMPONENT", 150, 158], ["cell", "CELL", 188, 192], ["TMPRSS2", "PROTEIN", 4, 11], ["S protein", "PROTEIN", 51, 60], ["FP region", "PROTEIN", 75, 84], ["S2 subunit", "PROTEIN", 92, 102], ["host cell", "CELL_TYPE", 183, 192], ["The TMPRSS2", "TEST", 0, 11], ["the cleavage of the S protein", "PROBLEM", 31, 60], ["responsible for", "UNCERTAINTY", 15, 30], ["FP", "ANATOMY_MODIFIER", 75, 77], ["region", "ANATOMY_MODIFIER", 78, 84], ["S2", "ANATOMY", 92, 94], ["subunit", "ANATOMY_MODIFIER", 95, 102], ["host cell", "OBSERVATION", 183, 192]]], ["This indicates that TMPRSS2 is a host factor that is essential for viral entry; therefore, the drugs approved for the inhibition of this protease (like camostatmesylate) could be used for therapeutic purposes (23) .", [["camostatmesylate", "CHEMICAL", 152, 168], ["camostatmesylate", "CHEMICAL", 152, 168], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 20, 27], ["camostatmesylate", "SIMPLE_CHEMICAL", 152, 168], ["TMPRSS2", "PROTEIN", 20, 27], ["protease", "PROTEIN", 137, 145], ["TMPRSS2", "PROBLEM", 20, 27], ["a host factor", "PROBLEM", 31, 44], ["viral entry", "PROBLEM", 67, 78], ["the drugs", "TREATMENT", 91, 100], ["this protease (like camostatmesylate)", "TREATMENT", 132, 169]]], ["SARS-CoV-2 uses the human angiotensin-converting enzyme 2 (hACE2) receptor to seize the target cell through the spike glycoprotein (S-Protein), to enter the cell.", [["cell", "ANATOMY", 95, 99], ["cell", "ANATOMY", 157, 161], ["SARS", "DISEASE", 0, 4], ["angiotensin", "CHEMICAL", 26, 37], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 0, 10], ["human", "ORGANISM", 20, 25], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 26, 57], ["hACE2", "GENE_OR_GENE_PRODUCT", 59, 64], ["cell", "CELL", 95, 99], ["S-Protein", "GENE_OR_GENE_PRODUCT", 132, 141], ["cell", "CELL", 157, 161], ["human angiotensin-converting enzyme 2 (hACE2) receptor", "PROTEIN", 20, 74], ["spike glycoprotein", "PROTEIN", 112, 130], ["S-Protein", "PROTEIN", 132, 141], ["human", "SPECIES", 20, 25], ["human", "SPECIES", 20, 25], ["the human angiotensin", "TREATMENT", 16, 37], ["enzyme 2 (hACE2) receptor", "TREATMENT", 49, 74], ["target cell", "OBSERVATION", 88, 99], ["cell", "ANATOMY", 157, 161]]], ["It has been suggested that the coronaviruses exercise the use of conformational masking and glycan shielding of the spike protein to circumvent the host immune cells.", [["immune cells", "ANATOMY", 153, 165], ["coronaviruses", "ORGANISM", 31, 44], ["immune cells", "CELL", 153, 165], ["spike protein", "PROTEIN", 116, 129], ["host immune cells", "CELL_TYPE", 148, 165], ["the coronaviruses exercise", "PROBLEM", 27, 53], ["conformational masking", "TREATMENT", 65, 87], ["glycan shielding", "TREATMENT", 92, 108], ["the spike protein", "PROBLEM", 112, 129], ["host immune cells", "OBSERVATION", 148, 165]]], ["The Cryo-EM structures have revealed the presence of two distinct: closed and open conformations of the S-Protein ectodomain trimer, as a consequence of the opening of the structure at the trimer apex.", [["S-Protein ectodomain trimer", "PROTEIN", 104, 131], ["trimer apex", "PROTEIN", 189, 200], ["the S-Protein ectodomain trimer", "TREATMENT", 100, 131], ["two", "OBSERVATION_MODIFIER", 53, 56], ["distinct", "OBSERVATION_MODIFIER", 57, 65], ["closed", "OBSERVATION", 67, 73], ["S-Protein ectodomain trimer", "OBSERVATION", 104, 131], ["opening", "OBSERVATION", 157, 164], ["trimer", "ANATOMY_MODIFIER", 189, 195], ["apex", "ANATOMY_MODIFIER", 196, 200]]], ["This conformational diversification is necessary for the receptor binding as the trimer opening exposes the RBM which is present at the interface between the protomers in the closed trimers (24) .Introduction:The E protein that forms E channels (called the viroporins), is involved in a myriad of functions in the viral replication cycle involving assembly, the release of virus particles, pathogenesis, etc. (25).", [["E", "GENE_OR_GENE_PRODUCT", 234, 235], ["viroporins", "GENE_OR_GENE_PRODUCT", 257, 267], ["RBM", "PROTEIN", 108, 111], ["E protein", "PROTEIN", 213, 222], ["E channels", "PROTEIN", 234, 244], ["viroporins", "PROTEIN", 257, 267], ["This conformational diversification", "TREATMENT", 0, 35], ["the receptor binding", "PROBLEM", 53, 73], ["the viral replication cycle", "TREATMENT", 310, 337], ["virus particles", "PROBLEM", 373, 388], ["pathogenesis", "PROBLEM", 390, 402], ["RBM", "OBSERVATION", 108, 111], ["closed trimers", "OBSERVATION", 175, 189]]], ["These reprobate ion channels exist in the form of homo-pentamers with each subunit containing 50-120 amino acids.", [["amino acids", "CHEMICAL", 101, 112], ["amino acids", "CHEMICAL", 101, 112], ["amino acids", "AMINO_ACID", 101, 112], ["reprobate ion channels", "PROTEIN", 6, 28], ["homo-pentamers", "PROTEIN", 50, 64], ["homo-pentamers", "TREATMENT", 50, 64]]], ["E channels contain at least one trans-membrane domain (TMD) which facilitates the linkage in host cell membranes.", [["cell membranes", "ANATOMY", 98, 112], ["cell membranes", "CELLULAR_COMPONENT", 98, 112], ["E channels", "PROTEIN", 0, 10], ["trans-membrane domain", "PROTEIN", 32, 53], ["TMD", "PROTEIN", 55, 58], ["the linkage in host cell membranes", "PROBLEM", 78, 112], ["at least", "OBSERVATION_MODIFIER", 19, 27], ["host cell membranes", "OBSERVATION", 93, 112]]], ["SARS CoVs generally contain three categories of ion channels namely: E, 8a, and 3a.", [["SARS", "DISEASE", 0, 4], ["SARS CoVs", "PROBLEM", 0, 9]]], ["The E and 8a ion channels contain the PDZ (Post Synaptic Density Protein; Disc Large Tumor Suppressor; Zonula Occludens-1 Protein) Domain Binding Motif (PBM) which is responsible for the over-expression of the inflammatory cytokines which may result in the cytokine storm (26) .", [["PDZ", "GENE_OR_GENE_PRODUCT", 38, 41], ["Zonula Occludens-1 Protein) Domain Binding Motif", "GENE_OR_GENE_PRODUCT", 103, 151], ["PBM", "GENE_OR_GENE_PRODUCT", 153, 156], ["E and 8a ion channels", "PROTEIN", 4, 25], ["PDZ", "PROTEIN", 38, 41], ["Post Synaptic Density Protein; Disc Large Tumor Suppressor; Zonula Occludens-1 Protein) Domain Binding Motif", "PROTEIN", 43, 151], ["PBM", "PROTEIN", 153, 156], ["inflammatory cytokines", "PROTEIN", 210, 232], ["cytokine", "PROTEIN", 257, 265], ["The E and 8a ion channels", "TREATMENT", 0, 25], ["the PDZ (Post Synaptic Density Protein", "TREATMENT", 34, 72], ["Disc Large Tumor Suppressor", "TREATMENT", 74, 101], ["Zonula Occludens", "TREATMENT", 103, 119], ["Domain Binding Motif (PBM", "TREATMENT", 131, 156], ["the inflammatory cytokines", "PROBLEM", 206, 232], ["Disc", "ANATOMY", 74, 78], ["Large", "OBSERVATION_MODIFIER", 79, 84], ["Tumor", "OBSERVATION", 85, 90], ["inflammatory", "OBSERVATION", 210, 222]]], ["From the sequence alignment study of the E protein, it was observed that a negatively charged glutamate residue (E69) in SARS-CoV corresponds to a positively charged arginine residue (R69) in SARS-CoV-2 (17) .", [["glutamate", "CHEMICAL", 94, 103], ["SARS", "DISEASE", 121, 125], ["arginine", "CHEMICAL", 166, 174], ["glutamate", "CHEMICAL", 94, 103], ["arginine", "CHEMICAL", 166, 174], ["glutamate", "SIMPLE_CHEMICAL", 94, 103], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 121, 129], ["arginine", "AMINO_ACID", 166, 174], ["E protein", "PROTEIN", 41, 50], ["SARS-CoV", "SPECIES", 121, 129], ["the sequence alignment study", "TEST", 5, 33], ["a negatively charged glutamate residue", "PROBLEM", 73, 111], ["SARS", "PROBLEM", 121, 125], ["a positively charged arginine residue", "PROBLEM", 145, 182], ["SARS", "TEST", 192, 196], ["CoV", "TEST", 197, 200]]], ["However, this mutation is remote from the inhibitor binding site; therefore, E protein can be used as a pharmaceutical target (26) .Introduction:The M protein, the central organizer of CoV assembly, is most abundant in the virus particle.", [["E protein", "GENE_OR_GENE_PRODUCT", 77, 86], ["CoV", "GENE_OR_GENE_PRODUCT", 185, 188], ["inhibitor binding site", "DNA", 42, 64], ["E protein", "PROTEIN", 77, 86], ["M protein", "PROTEIN", 149, 158], ["this mutation", "PROBLEM", 9, 22], ["E protein", "TREATMENT", 77, 86], ["The M protein", "TREATMENT", 145, 158], ["central", "ANATOMY_MODIFIER", 164, 171], ["CoV", "OBSERVATION", 185, 188], ["virus particle", "OBSERVATION", 223, 237]]], ["It functions crucially in the morphogenesis and assembly of the SARS-CoV-2 by interacting with the essential structural proteins (27) .", [["SARS", "DISEASE", 64, 68], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 64, 74], ["essential structural proteins", "PROTEIN", 99, 128], ["the SARS", "PROBLEM", 60, 68]]], ["The binding of the M and N protein stabilizes the N protein and RNA complex and the internal core of the virus.", [["M and N protein", "PROTEIN", 19, 34], ["N protein", "PROTEIN", 50, 59], ["RNA complex", "PROTEIN", 64, 75], ["the M and N protein", "TEST", 15, 34], ["RNA complex", "PROBLEM", 64, 75], ["the virus", "PROBLEM", 101, 110], ["virus", "OBSERVATION", 105, 110]]], ["In SARS-CoV, the M protein has also been shown to induce the process of apoptosis (17) .Introduction:In addition to stabilizing the ssRNA genome of the virus particle, the N protein is an antagonist of the antiviral RNAi.", [["SARS", "DISEASE", 3, 7], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 3, 11], ["M protein", "PROTEIN", 17, 26], ["ssRNA genome", "DNA", 132, 144], ["N protein", "PROTEIN", 172, 181], ["SARS-CoV", "SPECIES", 3, 11], ["the M protein", "TEST", 13, 26], ["apoptosis", "PROBLEM", 72, 81], ["the virus particle", "PROBLEM", 148, 166], ["the N protein", "TEST", 168, 181], ["the antiviral RNAi", "TREATMENT", 202, 220], ["ssRNA genome", "OBSERVATION", 132, 144], ["virus particle", "OBSERVATION", 152, 166], ["antiviral RNAi", "OBSERVATION", 206, 220]]], ["It is responsible for the inhibition of the cell cycle of the host cell as it can inhibit the entry of the cell into the S-phase (17) .Introduction:Immunotherapy is considered as an effective method for the treatment of various infectious diseases and cancers, which involves the artificial triggering of the immune system to elicit the immune response (28) .", [["cell", "ANATOMY", 44, 48], ["cell", "ANATOMY", 67, 71], ["cell", "ANATOMY", 107, 111], ["cancers", "ANATOMY", 252, 259], ["immune system", "ANATOMY", 309, 322], ["infectious diseases", "DISEASE", 228, 247], ["cancers", "DISEASE", 252, 259], ["cell", "CELL", 44, 48], ["host cell", "CELL", 62, 71], ["cell", "CELL", 107, 111], ["cancers", "CANCER", 252, 259], ["Immunotherapy", "TREATMENT", 148, 161], ["an effective method", "TREATMENT", 179, 198], ["the treatment", "TREATMENT", 203, 216], ["various infectious diseases", "PROBLEM", 220, 247], ["cancers", "PROBLEM", 252, 259], ["cell cycle", "OBSERVATION", 44, 54], ["host cell", "OBSERVATION", 62, 71], ["infectious", "OBSERVATION", 228, 238], ["cancers", "OBSERVATION", 252, 259]]], ["A vaccine that elicits the production of S protein neutralizing antibodies in the vaccinated subjects is the primary aim of all the programs for COVID-19 vaccines.", [["S protein", "GENE_OR_GENE_PRODUCT", 41, 50], ["S protein neutralizing antibodies", "PROTEIN", 41, 74], ["A vaccine", "TREATMENT", 0, 9], ["S protein neutralizing antibodies", "PROBLEM", 41, 74], ["COVID-19 vaccines", "TREATMENT", 145, 162]]], ["Studies have revealed that there is a limited to no cross-neutralization between the sera of SARS-CoV and SARS-CoV-2, indicating that recovery from one infection may not shield against the other (1).", [["sera", "ANATOMY", 85, 89], ["SARS", "DISEASE", 93, 97], ["infection", "DISEASE", 152, 161], ["sera", "ORGANISM_SUBSTANCE", 85, 89], ["SARS-CoV", "ORGANISM", 93, 101], ["SARS-CoV-2", "ORGANISM", 106, 116], ["SARS-CoV", "SPECIES", 93, 101], ["SARS-CoV", "SPECIES", 106, 114], ["cross-neutralization", "TREATMENT", 52, 72], ["SARS", "TEST", 93, 97], ["SARS", "TEST", 106, 110], ["CoV", "TEST", 111, 114], ["one infection", "PROBLEM", 148, 161], ["infection", "OBSERVATION", 152, 161]]], ["Furthermore, a database of approximately 5500 full-length genomes of SARS-CoV-2 isolated from various countries is now available at NCBI which facilitates delineating the polymorphisms in S protein and other important proteins of the virus concerning vaccine development.", [["SARS-CoV-2", "ORGANISM", 69, 79], ["S protein", "GENE_OR_GENE_PRODUCT", 188, 197], ["5500 full-length genomes", "DNA", 41, 65], ["S protein", "PROTEIN", 188, 197], ["SARS-CoV", "SPECIES", 69, 77], ["a database", "TEST", 13, 23], ["SARS", "PROBLEM", 69, 73], ["CoV", "TEST", 74, 77], ["the polymorphisms in S protein", "PROBLEM", 167, 197], ["the virus", "TREATMENT", 230, 239]]], ["The rationale for writing this review is to gather all the information about the COVID-19 vaccine development programs and give the readers and researchers insight into types of vaccines being worked upon and the current status of the clinical trials of these vaccines for ready reference.Vaccination strategiesMany efforts have been directed towards the development of the vaccines against the COVID-19, to avert the pandemic and most of the developing vaccine candidates have been using the S-protein of SARS-CoV-2 (29) .", [["SARS-CoV-2", "ORGANISM", 506, 516], ["SARS-CoV-2", "SPECIES", 506, 516], ["the COVID-19 vaccine development programs", "TREATMENT", 77, 118], ["vaccines", "TREATMENT", 178, 186], ["these vaccines", "TREATMENT", 254, 268], ["Vaccination strategies", "TREATMENT", 289, 311], ["the vaccines", "TREATMENT", 370, 382], ["the COVID", "TEST", 391, 400], ["the developing vaccine", "TREATMENT", 439, 461], ["the S-protein of SARS", "TEST", 489, 510], ["CoV", "TEST", 511, 514]]], ["As of July 2, 2020, the worldwide SARS-CoV-2 vaccine landscape includes 158 vaccine candidates, out of which 135 are in the preclinical or the exploratory stage of their development.", [["SARS", "DISEASE", 34, 38], ["SARS-CoV-2", "ORGANISM", 34, 44], ["the worldwide SARS", "TEST", 20, 38], ["CoV-2 vaccine landscape", "TREATMENT", 39, 62]]], ["Currently, mRNA-1273 (Moderna), Ad5-nCoV (CanSino Biologicals), INO-4800 (Inovio, Inc.), LV-SMENP-DC, and Pathogen-specific aAPC (ShinzenGeno-Immune Medical Institute), and ChAdOx1 (University of Oxford) have entered the phase I/II clinical trials (30) .", [["DC", "ANATOMY", 98, 100], ["INO-4800", "CHEMICAL", 64, 72], ["mRNA-1273", "GENE_OR_GENE_PRODUCT", 11, 20], ["Ad5-nCoV", "GENE_OR_GENE_PRODUCT", 32, 40], ["INO-4800", "GENE_OR_GENE_PRODUCT", 64, 72], ["DC", "CELL_TYPE", 98, 100], ["Ad5", "SPECIES", 32, 35], ["mRNA", "TEST", 11, 15], ["Moderna", "TEST", 22, 29], ["Ad5", "TEST", 32, 35], ["INO", "TEST", 64, 67], ["Inovio", "TEST", 74, 80], ["LV", "TEST", 89, 91], ["Pathogen", "PROBLEM", 106, 114], ["LV", "ANATOMY", 89, 91]]], ["The vaccines which are in the conduit are based upon inactivated or live attenuated viruses, protein sub-unit, virus-like particles (VLP), viral vectors (replicating and non-replicating), DNA, RNA, nanoparticles, etc. (31) .", [["conduit", "TISSUE", 30, 37], ["virus-like particles", "ORGANISM", 111, 131], ["VLP", "ORGANISM", 133, 136], ["DNA", "CELLULAR_COMPONENT", 188, 191], ["protein sub-unit", "DNA", 93, 109], ["viral vectors", "DNA", 139, 152], ["The vaccines", "TREATMENT", 0, 12], ["the conduit", "TREATMENT", 26, 37], ["live attenuated viruses", "PROBLEM", 68, 91], ["virus", "TREATMENT", 111, 116], ["viral vectors", "TREATMENT", 139, 152], ["conduit", "OBSERVATION", 30, 37], ["viral vectors", "OBSERVATION", 139, 152]]], ["To enhance the immunogenicity, various adjuvant technologies like AS03 (GSK), MF-59 (Novartis), CpG 1018 (Dynavax), etc. are now accessible to the researchers for the vaccine development (32) .", [["AS03", "CHEMICAL", 66, 70], ["CpG 1018", "CHEMICAL", 96, 104], ["AS03", "SIMPLE_CHEMICAL", 66, 70], ["GSK", "GENE_OR_GENE_PRODUCT", 72, 75], ["MF-59", "ORGANISM", 78, 83], ["various adjuvant technologies", "TREATMENT", 31, 60], ["MF", "TEST", 78, 80]]], ["The immuno-informatics approach is also used for the epitope identification for the SARS-CoV-2 vaccine candidates.", [["SARS-CoV-2", "ORGANISM", 84, 94], ["SARS-CoV", "SPECIES", 84, 92], ["The immuno-informatics approach", "TREATMENT", 0, 31], ["the epitope identification", "TEST", 49, 75], ["the SARS", "TEST", 80, 88], ["CoV-2 vaccine candidates", "TREATMENT", 89, 113]]], ["It can be used to identify the significant cytotoxic T cell and B-cell epitopes in the viral S-Protein (33).", [["T cell", "ANATOMY", 53, 59], ["B-cell", "ANATOMY", 64, 70], ["T cell", "CELL", 53, 59], ["B-cell", "CELL", 64, 70], ["cytotoxic T cell", "CELL_TYPE", 43, 59], ["B-cell epitopes", "PROTEIN", 64, 79], ["the significant cytotoxic T cell", "PROBLEM", 27, 59], ["B-cell epitopes", "TEST", 64, 79], ["the viral S-Protein", "TEST", 83, 102], ["significant", "OBSERVATION_MODIFIER", 31, 42], ["cytotoxic T cell", "OBSERVATION", 43, 59], ["cell epitopes", "OBSERVATION", 66, 79]]], ["J o u r n a l P r e -p r o o f \uf0b7 LAV requires an extensive accessory testing to establish safety and efficacy. \uf0b7 There is a probability of nucleotide substitution during viral replication, resulting in the creation of recombinants postvaccination.Inactivated Virus Vaccine\uf0b7 Stable and safer as compared to the LAVs. \uf0b7 It has the pre-existing technology and infrastructure required for its development. \uf0b7 Has already been tested for SARS-CoV and various other diseases. \uf0b7 It can be used along with adjuvants to increase their immunogenicity.Inactivated Virus Vaccine\uf0b7 Require the booster shots to keep the immunity. \uf0b7 Furthermore, large amounts of viruses need to be handled and the integrity of the immunogenic particles must be maintained.Inactivated Virus Vaccine3 Sub-unit Vaccine \uf0b7 Do not have any live component of the viral particle. \uf0b7 Thus, it is safe with fewer side-effects.Inactivated Virus Vaccine\uf0b7 Induce an immune response. \uf0b7 Memory for future responses is doubtful.Viral vectorbased vaccine\uf0b7 Show a highly specific gene delivery into the host cell with a vigorous immune response. \uf0b7 Avoids handling of any infectious particle and it has been used widely for MERS-CoV with positive results from the trials.Viral vectorbased vaccine\uf0b7 The host may possess immunity against the vector due to prior exposure, reducing the efficacy. \uf0b7 May lead to cancer due to the integration of the viral genome into the host genome.DNA Vaccines\uf0b7 The synthetic DNA is temperature stable and cold-chain free \uf0b7 It can be developed at an accelerated pace. \uf0b7 It does not require the handling of the infectious viral particle.DNA Vaccines\uf0b7 Though it elicits both Cytotoxic and humoral immunity, the titers remain low. \uf0b7 Insertion of foreign DNA into the host genome may cause abnormalities in the cell. \uf0b7 May induce the antibody production against itself.", [["cell", "ANATOMY", 1057, 1061], ["cancer", "ANATOMY", 1355, 1361], ["cell", "ANATOMY", 1785, 1789], ["nucleotide", "CHEMICAL", 139, 149], ["SARS-CoV", "DISEASE", 432, 440], ["cancer", "DISEASE", 1355, 1361], ["nucleotide", "CHEMICAL", 139, 149], ["Virus", "ORGANISM", 259, 264], ["SARS-CoV", "ORGANISM", 432, 440], ["Virus", "ORGANISM", 552, 557], ["Virus", "ORGANISM", 752, 757], ["Inactivated Virus", "ORGANISM", 883, 900], ["host cell", "CELL", 1052, 1061], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 1172, 1180], ["cancer", "CANCER", 1355, 1361], ["DNA", "CELLULAR_COMPONENT", 1426, 1429], ["DNA", "CELLULAR_COMPONENT", 1454, 1457], ["DNA", "CELLULAR_COMPONENT", 1614, 1617], ["DNA", "CELLULAR_COMPONENT", 1729, 1732], ["cell", "CELL", 1785, 1789], ["viral genome", "DNA", 1392, 1404], ["host genome", "DNA", 1414, 1425], ["foreign DNA", "DNA", 1721, 1732], ["host genome", "DNA", 1742, 1753], ["SARS-CoV", "SPECIES", 432, 440], ["MERS-CoV", "SPECIES", 1172, 1180], ["LAV", "PROBLEM", 33, 36], ["an extensive accessory testing", "TEST", 46, 76], ["nucleotide substitution", "TREATMENT", 139, 162], ["viral replication", "TREATMENT", 170, 187], ["Inactivated Virus Vaccine\uf0b7", "TREATMENT", 247, 273], ["SARS", "PROBLEM", 432, 436], ["CoV", "PROBLEM", 437, 440], ["various other diseases", "PROBLEM", 445, 467], ["adjuvants", "TREATMENT", 497, 506], ["Inactivated Virus Vaccine", "TREATMENT", 540, 565], ["large amounts of viruses", "PROBLEM", 630, 654], ["the immunogenic particles", "TREATMENT", 695, 720], ["Inactivated Virus Vaccine3 Sub-unit Vaccine", "TREATMENT", 740, 783], ["the viral particle", "PROBLEM", 820, 838], ["Inactivated Virus Vaccine", "TREATMENT", 883, 908], ["Viral vectorbased vaccine", "TREATMENT", 979, 1004], ["any infectious particle", "PROBLEM", 1116, 1139], ["Viral vectorbased vaccine", "TREATMENT", 1219, 1244], ["cancer", "PROBLEM", 1355, 1361], ["DNA Vaccines", "TREATMENT", 1426, 1438], ["an accelerated pace", "TREATMENT", 1525, 1544], ["the infectious viral particle", "PROBLEM", 1584, 1613], ["DNA Vaccines", "TREATMENT", 1614, 1626], ["the titers", "TEST", 1683, 1693], ["Insertion of foreign DNA", "TREATMENT", 1708, 1732], ["abnormalities in the cell", "PROBLEM", 1764, 1789], ["the antibody production", "PROBLEM", 1804, 1827], ["\uf0b7 LAV", "ANATOMY", 31, 36], ["nucleotide substitution", "OBSERVATION", 139, 162], ["viral replication", "OBSERVATION", 170, 187], ["diseases", "OBSERVATION", 459, 467], ["large", "OBSERVATION_MODIFIER", 630, 635], ["amounts", "OBSERVATION_MODIFIER", 636, 643], ["viruses", "OBSERVATION", 647, 654], ["viral particle", "OBSERVATION", 824, 838], ["host cell", "OBSERVATION", 1052, 1061], ["infectious", "OBSERVATION", 1120, 1130], ["cancer", "OBSERVATION", 1355, 1361], ["viral genome", "OBSERVATION", 1392, 1404], ["host genome", "OBSERVATION", 1414, 1425], ["accelerated", "OBSERVATION_MODIFIER", 1528, 1539], ["pace", "OBSERVATION", 1540, 1544], ["infectious", "OBSERVATION", 1588, 1598], ["Cytotoxic", "OBSERVATION_MODIFIER", 1651, 1660], ["humoral immunity", "OBSERVATION", 1665, 1681], ["foreign DNA", "OBSERVATION", 1721, 1732], ["host genome", "OBSERVATION", 1742, 1753], ["may cause", "UNCERTAINTY", 1754, 1763], ["abnormalities", "OBSERVATION", 1764, 1777], ["cell", "ANATOMY", 1785, 1789], ["antibody production", "OBSERVATION", 1808, 1827]]], ["6 RNA Vaccines \uf0b7 The translation of mRNA occurs in the cytosol of the host cell averting the risk of any sort of integration into the host genome.Protein Sub-unit vaccineA subunit vaccine is the one which is based on the synthetic peptides or recombinant antigenic proteins, which are necessary for invigorating long-lasting protective and/or therapeutic immune response (31) .", [["cytosol", "ANATOMY", 55, 62], ["cell", "ANATOMY", 75, 79], ["cytosol", "CELLULAR_COMPONENT", 55, 62], ["host cell", "CELL", 70, 79], ["mRNA", "RNA", 36, 40], ["host genome", "DNA", 134, 145], ["recombinant antigenic proteins", "PROTEIN", 243, 273], ["RNA Vaccines", "TREATMENT", 2, 14], ["Protein Sub-unit vaccineA subunit vaccine", "TREATMENT", 146, 187], ["the synthetic peptides", "TREATMENT", 217, 239], ["recombinant antigenic proteins", "PROBLEM", 243, 273], ["host cell", "OBSERVATION", 70, 79], ["host genome", "OBSERVATION", 134, 145]]], ["The subunit vaccine, however, exhibits low immunogenicity and requires auxiliary support of an adjuvant to potentiate the vaccine-induced immune responses.", [["The subunit vaccine", "TREATMENT", 0, 19], ["low immunogenicity", "PROBLEM", 39, 57], ["auxiliary support", "TREATMENT", 71, 88], ["an adjuvant", "TREATMENT", 92, 103], ["the vaccine", "TREATMENT", 118, 129], ["low immunogenicity", "OBSERVATION_MODIFIER", 39, 57]]], ["An adjuvant may enhance the biological half-life of the antigenic material, or it may ameliorate the immunomodulatory cytokine response.", [["cytokine", "PROTEIN", 118, 126], ["An adjuvant", "TREATMENT", 0, 11]]], ["The addition of an adjuvant, therefore, helps in overcoming the shortcomings of the protein subunit vaccines (35).", [["an adjuvant", "TREATMENT", 16, 27], ["the protein subunit vaccines", "TREATMENT", 80, 108]]], ["The S protein of the SARS-CoV-2 is the most suitable antigen to induce the neutralizing antibodies against the pathogen.", [["SARS-CoV-2", "ORGANISM", 21, 31], ["S protein", "PROTEIN", 4, 13], ["neutralizing antibodies", "PROTEIN", 75, 98], ["SARS-CoV", "SPECIES", 21, 29], ["The S protein", "TEST", 0, 13], ["the SARS", "TEST", 17, 25], ["CoV", "TEST", 26, 29], ["the neutralizing antibodies", "TEST", 71, 98], ["the pathogen", "PROBLEM", 107, 119]]], ["The S Protein consists of two subunits.", [["S Protein", "PROTEIN", 4, 13], ["The S Protein", "TEST", 0, 13]]], ["The S1 subunit has the NTD, RBD, and RBM domains while the S2 subunit comprises of FP, HR 1, &2 (1).", [["S1", "GENE_OR_GENE_PRODUCT", 4, 6], ["S1 subunit", "PROTEIN", 4, 14], ["NTD", "PROTEIN", 23, 26], ["RBD", "PROTEIN", 28, 31], ["RBM domains", "PROTEIN", 37, 48], ["S2 subunit", "PROTEIN", 59, 69], ["RBD", "PROBLEM", 28, 31], ["FP", "TEST", 83, 85], ["HR", "TEST", 87, 89], ["NTD", "OBSERVATION", 23, 26], ["RBD", "OBSERVATION", 28, 31]]], ["The virus enters into the cell via endocytosis by utilizing the S-Protein mediated binding to the hACE2 receptor.", [["cell", "ANATOMY", 26, 30], ["cell", "CELL", 26, 30], ["S-Protein", "GENE_OR_GENE_PRODUCT", 64, 73], ["hACE2 receptor", "GENE_OR_GENE_PRODUCT", 98, 112], ["hACE2 receptor", "PROTEIN", 98, 112], ["The virus", "PROBLEM", 0, 9], ["the S-Protein mediated binding", "TREATMENT", 60, 90], ["virus", "OBSERVATION", 4, 9], ["cell", "ANATOMY_MODIFIER", 26, 30], ["endocytosis", "OBSERVATION", 35, 46]]], ["Therefore, the S-Protein and its antigenic fragments are the prime targets for the institution of the subunit vaccine (31) .", [["S-Protein", "GENE_OR_GENE_PRODUCT", 15, 24], ["S-Protein", "PROTEIN", 15, 24], ["the S-Protein", "TREATMENT", 11, 24], ["its antigenic fragments", "TREATMENT", 29, 52], ["the subunit vaccine", "TREATMENT", 98, 117], ["antigenic fragments", "OBSERVATION", 33, 52]]], ["The S glycoprotein is a dynamic protein, possessing two conformational states i.e. pre-fusion and postfusion state.", [["S glycoprotein", "GENE_OR_GENE_PRODUCT", 4, 18], ["S glycoprotein", "PROTEIN", 4, 18], ["dynamic protein", "PROTEIN", 24, 39], ["pre-fusion and postfusion state", "PROBLEM", 83, 114]]], ["Therefore, the antigen must maintain its surface chemistry and profile of the original pre-fusion spike protein to preserve the epitopes for igniting good quality antibody responses (36) .", [["surface", "ANATOMY", 41, 48], ["pre-fusion spike protein", "PROTEIN", 87, 111], ["epitopes", "PROTEIN", 128, 136], ["the antigen", "TEST", 11, 22], ["the original pre-fusion spike protein", "PROBLEM", 74, 111]]], ["Moreover, means to target the masked RBM as an antigen will enhance the neutralizing antibody response and improve the overall efficacy of the vaccine.NVX-CoV2373 (Novavax, Inc.| Emergent BioSolutions)NVX-CoV2373 is a nano-particle based immunogenic vaccine which is based upon the recombinant expression of the stable pre-fusion, coronavirus S-Protein (37) .", [["NVX-CoV2373", "CHEMICAL", 151, 162], ["NVX-CoV2373", "CHEMICAL", 201, 212], ["nano-particle", "CHEMICAL", 218, 231], ["NVX", "CHEMICAL", 151, 154], ["Co", "CHEMICAL", 155, 157], ["NVX-CoV2373", "CHEMICAL", 201, 212], ["RBM", "GENE_OR_GENE_PRODUCT", 37, 40], ["NVX-CoV2373", "SIMPLE_CHEMICAL", 151, 162], ["NVX-CoV2373", "SIMPLE_CHEMICAL", 201, 212], ["nano-particle", "SIMPLE_CHEMICAL", 218, 231], ["RBM", "PROTEIN", 37, 40], ["the masked RBM", "PROBLEM", 26, 40], ["an antigen", "TEST", 44, 54], ["the neutralizing antibody response", "PROBLEM", 68, 102], ["the vaccine", "TREATMENT", 139, 150], ["NVX", "TEST", 151, 154], ["Novavax", "TREATMENT", 164, 171], ["NVX", "TEST", 201, 204], ["a nano-particle based immunogenic vaccine", "TREATMENT", 216, 257], ["coronavirus S-Protein", "TEST", 331, 352], ["stable", "OBSERVATION_MODIFIER", 312, 318]]], ["The protein was stably expressed in the Baculovirus system (38) .", [["Baculovirus", "ORGANISM", 40, 51], ["The protein", "TEST", 0, 11]]], ["The company plans to use the Matrix-M adjuvant to enhance the immune response against SARS-CoV-2 spike protein by the induction of high levels of neutralizing antibodies.", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 86, 96], ["SARS-CoV-2 spike protein", "PROTEIN", 86, 110], ["neutralizing antibodies", "PROTEIN", 146, 169], ["SARS-CoV", "SPECIES", 86, 94], ["the Matrix-M adjuvant", "TREATMENT", 25, 46], ["the immune response", "TEST", 58, 77], ["SARS", "PROBLEM", 86, 90], ["CoV", "TEST", 91, 94], ["2 spike protein", "PROBLEM", 95, 110], ["neutralizing antibodies", "PROBLEM", 146, 169]]], ["In the animal models, a single immunization resulted in the high level of anti-spike protein antibodies which blocked the hACE2 receptor binding domain activity and could elicit SARS-CoV-2 wild type virus-neutralizing antibodies (39).Molecular Clamp Stabilized spike protein vaccine candidateIt is being developed by the University of Queensland in collaboration with GSK and Dynavax.", [["hACE2 receptor", "GENE_OR_GENE_PRODUCT", 122, 136], ["SARS-CoV-2 wild type virus", "ORGANISM", 178, 204], ["GSK", "GENE_OR_GENE_PRODUCT", 368, 371], ["anti-spike protein antibodies", "PROTEIN", 74, 103], ["hACE2 receptor binding domain", "PROTEIN", 122, 151], ["neutralizing antibodies", "PROTEIN", 205, 228], ["a single immunization", "TREATMENT", 22, 43], ["anti-spike protein antibodies", "PROBLEM", 74, 103], ["SARS", "TEST", 178, 182], ["CoV", "TEST", 183, 186], ["wild type virus", "PROBLEM", 189, 204], ["neutralizing antibodies", "TEST", 205, 228], ["Molecular Clamp", "TREATMENT", 234, 249], ["protein vaccine", "TREATMENT", 267, 282], ["Dynavax", "TREATMENT", 376, 383]]], ["The University will have access to vaccine adjuvant platform technology (AS03 Adjuvant system), which is believed to strengthen the vaccine response and minimize the amount of vaccine required per dose (40) .", [["vaccine adjuvant platform technology", "TREATMENT", 35, 71], ["AS03 Adjuvant system", "TREATMENT", 73, 93], ["the amount of vaccine", "TREATMENT", 162, 183]]], ["The University is developing a stabilized pre-fusion, recombinant viral protein subunit vaccine which is based upon the Molecular Clamp technology.", [["recombinant viral protein subunit", "PROTEIN", 54, 87], ["a stabilized pre-fusion", "TREATMENT", 29, 52], ["recombinant viral protein subunit vaccine", "TREATMENT", 54, 95], ["stabilized", "OBSERVATION", 31, 41]]], ["This technology has been proved to induce the production of the neutralizing antibodies (38)PittCoVacc (University of Pittsburgh)It is a Micro-Needle Array (MNA) based recombinant SARS-CoV-2 vaccine which involves the administration of rSARS-CoV-2 S1 and rSARS-CoV-2-S1fRS09 (recombinant immunogens).", [["SARS-CoV-2", "ORGANISM", 180, 190], ["rSARS-CoV-2 S1", "ORGANISM", 236, 250], ["rSARS-CoV-2", "ORGANISM", 255, 266], ["S1fRS09", "GENE_OR_GENE_PRODUCT", 267, 274], ["neutralizing antibodies", "PROTEIN", 64, 87], ["rSARS", "PROTEIN", 236, 241], ["rSARS", "PROTEIN", 255, 260], ["CoV", "PROTEIN", 261, 264], ["S1fRS09", "PROTEIN", 267, 274], ["recombinant immunogens", "PROTEIN", 276, 298], ["the neutralizing antibodies", "TEST", 60, 87], ["a Micro-Needle Array (MNA)", "TREATMENT", 135, 161], ["recombinant SARS-CoV-2 vaccine", "TREATMENT", 168, 198], ["rSARS", "TEST", 236, 241], ["CoV", "TEST", 242, 245], ["rSARS", "TEST", 255, 260], ["CoV", "TEST", 261, 264], ["S1fRS09 (recombinant immunogens", "TREATMENT", 267, 298]]], ["A substantial increase in the antigen specific antibodies with a statistical significance was observed in the pre-clinical trials at the end of two weeks in the mice models.", [["mice", "ORGANISM", 161, 165], ["antigen specific antibodies", "PROTEIN", 30, 57], ["mice", "SPECIES", 161, 165], ["mice", "SPECIES", 161, 165], ["A substantial increase", "PROBLEM", 0, 22], ["the antigen specific antibodies", "PROBLEM", 26, 57], ["substantial", "OBSERVATION_MODIFIER", 2, 13], ["increase", "OBSERVATION_MODIFIER", 14, 22]]], ["Furthermore, the immunogenicity of the vaccine was maintained after the sterilization using gamma radiation.", [["the vaccine", "TREATMENT", 35, 46], ["the sterilization", "TREATMENT", 68, 85], ["gamma radiation", "TREATMENT", 92, 107]]], ["The statistically significant titers of antibodies at the early stages and also before boosting, support the feasibility of the MNA-SARS-CoV-2 vaccine (41).Triple Antigen Vaccine (Premas Biotech, India)It is a multi-antigenic VLP vaccine prototype wherein the recombinant spike, membrane, and envelope protein of SARS-CoV-2 have been co-expressed in an engineered Saccharomyces cerevisiae expression platform (D-Crypt\u2122).", [["membrane", "ANATOMY", 279, 287], ["CoV-2", "ORGANISM", 137, 142], ["membrane", "CELLULAR_COMPONENT", 279, 287], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 313, 323], ["Saccharomyces cerevisiae", "ORGANISM", 364, 388], ["D-Crypt\u2122", "SIMPLE_CHEMICAL", 410, 418], ["antibodies", "PROTEIN", 40, 50], ["recombinant spike, membrane, and envelope protein", "PROTEIN", 260, 309], ["Saccharomyces cerevisiae", "SPECIES", 364, 388], ["SARS-CoV", "SPECIES", 313, 321], ["Saccharomyces cerevisiae", "SPECIES", 364, 388], ["The statistically significant titers of antibodies", "PROBLEM", 0, 50], ["the MNA", "TEST", 124, 131], ["CoV-2 vaccine", "TREATMENT", 137, 150], ["Triple Antigen Vaccine", "TREATMENT", 156, 178], ["a multi-antigenic VLP vaccine", "TREATMENT", 208, 237], ["SARS", "PROBLEM", 313, 317], ["CoV", "TEST", 318, 321], ["significant", "OBSERVATION_MODIFIER", 18, 29], ["titers", "OBSERVATION", 30, 36]]], ["The TEM and allied analytical data simultaneously furnished the biophysical characterization of the VLP.", [["the biophysical characterization", "TEST", 60, 92]]], ["This prototype has the potential to enter the pre-clinical trials as a vaccine candidate after further research and development.", [["a vaccine", "TREATMENT", 69, 78]]], ["Furthermore, it is thought to be safe and easy to manufacture on a mass scale, in a cost-effective manner (42).Viral Vectored vaccinesA vaccine based on viral vectors is the prophylactic solution against a pathogen, which works by prompting the humoral immune response.", [["a mass scale", "TREATMENT", 65, 77], ["Viral Vectored vaccinesA vaccine", "TREATMENT", 111, 143], ["viral vectors", "TREATMENT", 153, 166], ["the prophylactic solution", "TREATMENT", 170, 195], ["a pathogen", "PROBLEM", 204, 214], ["thought to be", "UNCERTAINTY", 19, 32]]], ["These vaccines are highly specific in delivering the genes to the target cells, highly efficient in the gene transduction, and efficiently induce the immune response, thereby increasing the immunity (43) .", [["cells", "ANATOMY", 73, 78], ["cells", "CELL", 73, 78], ["target cells", "CELL_TYPE", 66, 78], ["These vaccines", "TREATMENT", 0, 14]]], ["They offer a long term and high level of antigenic protein expression and therefore, they have a great potential for prophylactic use as these vaccines trigger and prime the cytotoxic T cells (CTL) which ultimately leads to the elimination of the virus infected cells (32).Ad5-nCoV (CanSino Biologics Inc | Beijing Institute of Biotechnology)It is a recombinant, replication defective adenovirus type-5 vector (Ad5) expressing the recombinant spike protein of SARS-CoV-2.", [["cytotoxic T cells", "ANATOMY", 174, 191], ["CTL", "ANATOMY", 193, 196], ["cells", "ANATOMY", 262, 267], ["cytotoxic T cells", "CELL", 174, 191], ["CTL", "CELL", 193, 196], ["cells", "CELL", 262, 267], ["Ad5", "ORGANISM", 273, 276], ["adenovirus type-5", "ORGANISM", 385, 402], ["Ad5", "ORGANISM", 411, 414], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 460, 470], ["cytotoxic T cells", "CELL_TYPE", 174, 191], ["CTL", "CELL_TYPE", 193, 196], ["virus infected cells", "CELL_TYPE", 247, 267], ["recombinant spike protein", "PROTEIN", 431, 456], ["Ad5", "SPECIES", 273, 276], ["Ad5", "SPECIES", 411, 414], ["SARS-CoV", "SPECIES", 460, 468], ["antigenic protein expression", "TREATMENT", 41, 69], ["prophylactic use", "TREATMENT", 117, 133], ["these vaccines trigger", "TREATMENT", 137, 159], ["the cytotoxic T cells", "PROBLEM", 170, 191], ["the virus infected cells", "PROBLEM", 243, 267], ["replication defective adenovirus type-5 vector (Ad5", "TREATMENT", 363, 414], ["SARS", "TEST", 460, 464], ["CoV", "TEST", 465, 468]]], ["It was prepared by cloning an optimized full-length gene of the S Protein along with the plasminogen activator signal peptide gene in the Ad5 vector devoid of E1 and E3 genes.", [["plasminogen activator signal peptide", "GENE_OR_GENE_PRODUCT", 89, 125], ["Ad5", "ORGANISM", 138, 141], ["E1", "GENE_OR_GENE_PRODUCT", 159, 161], ["E3", "GENE_OR_GENE_PRODUCT", 166, 168], ["full-length gene", "DNA", 40, 56], ["S Protein", "PROTEIN", 64, 73], ["plasminogen activator signal peptide gene", "DNA", 89, 130], ["E1 and E3 genes", "DNA", 159, 174], ["Ad5", "SPECIES", 138, 141], ["the S Protein", "TREATMENT", 60, 73], ["the plasminogen activator signal peptide", "TREATMENT", 85, 125]]], ["The vaccine was constructed using the Admax system from the Microbix Biosystem (44) .", [["The vaccine", "TREATMENT", 0, 11]]], ["The phase I clinical trials have established a positive antibody response or seroconversion.", [["a positive antibody response", "PROBLEM", 45, 73], ["seroconversion", "PROBLEM", 77, 91], ["antibody response", "OBSERVATION", 56, 73]]], ["A four-fold increase in the RBD and S protein-specific neutralizing antibodies was noted within 14 days of immunization and peaked at day 28, post-vaccination.", [["RBD", "PROTEIN", 28, 31], ["S protein", "PROTEIN", 36, 45], ["neutralizing antibodies", "PROTEIN", 55, 78], ["A four-fold increase", "PROBLEM", 0, 20], ["the RBD", "TEST", 24, 31], ["S protein", "TEST", 36, 45], ["specific neutralizing antibodies", "PROBLEM", 46, 78], ["immunization", "TREATMENT", 107, 119], ["four-fold", "OBSERVATION_MODIFIER", 2, 11], ["increase", "OBSERVATION_MODIFIER", 12, 20], ["RBD", "OBSERVATION", 28, 31], ["neutralizing antibodies", "OBSERVATION", 55, 78]]], ["Furthermore, the CD4+ T cells and CD8+ T cells response peaked at day 14 post-vaccination.", [["CD4+ T cells", "ANATOMY", 17, 29], ["CD8+ T cells", "ANATOMY", 34, 46], ["CD4", "GENE_OR_GENE_PRODUCT", 17, 20], ["CD8", "GENE_OR_GENE_PRODUCT", 34, 37], ["CD4", "PROTEIN", 17, 20], ["T cells", "CELL_TYPE", 22, 29], ["CD8+ T cells", "CELL_TYPE", 34, 46], ["the CD4", "TEST", 13, 20], ["CD8", "TEST", 34, 37], ["T cells response", "PROBLEM", 39, 55]]], ["However, the preexisting anti-Ad5 immunity partly limited both the antibody and the T cell responses (44) .", [["T cell", "ANATOMY", 84, 90], ["anti-Ad5", "GENE_OR_GENE_PRODUCT", 25, 33], ["T cell", "CELL", 84, 90], ["the antibody", "TEST", 63, 75], ["the T cell responses", "TEST", 80, 100]]], ["The study will further evaluate antibody response in the recipients who are between the ages of 18 and 60, who received one of three study doses, with follow-up taking place at 3-and 6-months postvaccination (45).Coroflu (University of Wisconsin-Madison | FluGen | Bharat Biotech)M2SR, a self-limiting version of the influenza virus, which is modified by insertion of the SARS-CoV-2 gene sequence of the spike protein.", [["influenza virus", "DISEASE", 317, 332], ["recipients", "ORGANISM", 57, 67], ["influenza virus", "ORGANISM", 317, 332], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 372, 382], ["SARS-CoV-2 gene sequence", "DNA", 372, 396], ["spike protein", "PROTEIN", 404, 417], ["influenza virus", "SPECIES", 317, 332], ["influenza virus", "SPECIES", 317, 332], ["The study", "TEST", 0, 9], ["the influenza virus", "PROBLEM", 313, 332], ["the SARS", "TEST", 368, 376], ["CoV", "TEST", 377, 380], ["the spike protein", "PROBLEM", 400, 417], ["influenza virus", "OBSERVATION", 317, 332]]], ["Furthermore, the vaccine expresses the hemagglutinin protein of the influenza virus, thereby inducing immune response against both the viruses.", [["influenza", "DISEASE", 68, 77], ["influenza virus", "ORGANISM", 68, 83], ["hemagglutinin protein", "PROTEIN", 39, 60], ["influenza virus", "SPECIES", 68, 83], ["influenza virus", "SPECIES", 68, 83], ["the vaccine", "TREATMENT", 13, 24], ["the hemagglutinin protein", "PROBLEM", 35, 60], ["the influenza virus", "PROBLEM", 64, 83], ["influenza virus", "OBSERVATION", 68, 83], ["viruses", "OBSERVATION", 135, 142]]], ["The M2SR is self-limiting and does not undergo replication as it lacks the M2 gene.", [["M2SR", "GENE_OR_GENE_PRODUCT", 4, 8], ["M2", "GENE_OR_GENE_PRODUCT", 75, 77], ["M2SR", "PROTEIN", 4, 8], ["M2 gene", "DNA", 75, 82], ["replication", "TREATMENT", 47, 58], ["self-limiting", "OBSERVATION_MODIFIER", 12, 25], ["M2", "ANATOMY", 75, 77]]], ["It is able to enter into the cell, thereby inducing the immunity against the virus.", [["cell", "ANATOMY", 29, 33], ["cell", "CELL", 29, 33], ["the virus", "PROBLEM", 73, 82]]], ["It shall be administered intranasally, mimicking the natural route of viral infection.", [["intranasally", "ANATOMY", 25, 37], ["viral infection", "DISEASE", 70, 85], ["viral infection", "PROBLEM", 70, 85], ["viral", "OBSERVATION_MODIFIER", 70, 75], ["infection", "OBSERVATION", 76, 85]]], ["This route activates several modes of the immune system and has higher immunogenicity as compared to the intramuscular injections (46).LV-SMENP-DC (Shenzhen Geno-Immune Medical Institute)The LV-SMENP-DC vaccine is prepared by engineering the dendritic cells (DC) with the lentiviral vector expressing the conserved domains of the SARS-CoV-2 structural proteins and the protease using the SMENP minigenes.", [["intramuscular", "ANATOMY", 105, 118], ["DC", "ANATOMY", 144, 146], ["LV", "ANATOMY", 191, 193], ["DC", "ANATOMY", 200, 202], ["dendritic cells", "ANATOMY", 242, 257], ["DC", "ANATOMY", 259, 261], ["intramuscular", "IMMATERIAL_ANATOMICAL_ENTITY", 105, 118], ["dendritic cells", "CELL", 242, 257], ["DC", "CELL", 259, 261], ["lentiviral", "ORGANISM", 272, 282], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 330, 340], ["DC", "CELL_TYPE", 144, 146], ["dendritic cells", "CELL_TYPE", 242, 257], ["DC", "CELL_TYPE", 259, 261], ["SARS-CoV-2 structural proteins", "PROTEIN", 330, 360], ["protease", "PROTEIN", 369, 377], ["SMENP minigenes", "DNA", 388, 403], ["higher immunogenicity", "PROBLEM", 64, 85], ["the intramuscular injections", "TREATMENT", 101, 129], ["LV", "TEST", 135, 137], ["The LV", "TEST", 187, 193], ["SMENP-DC vaccine", "TREATMENT", 194, 210], ["the lentiviral vector", "TREATMENT", 268, 289], ["the SARS", "TEST", 326, 334], ["CoV", "TEST", 335, 338], ["the protease", "TREATMENT", 365, 377], ["the SMENP minigenes", "TREATMENT", 384, 403], ["higher", "OBSERVATION_MODIFIER", 64, 70], ["immunogenicity", "OBSERVATION", 71, 85], ["LV", "ANATOMY", 191, 193], ["dendritic cells", "OBSERVATION", 242, 257]]], ["The subcutaneous inoculation of the vaccine presents the antigens on antigen presenting cells (APCs), that ultimately activate the Cytotoxic T cells and generate the immune response (32).ChAdOx1 (University of Oxford)ChAdOx1 recombinant adenovirus vaccine was developed by codon optimization of the S glycoprotein for its expression in the human cell lines & synthesized with the tissue plasminogen activator (tPA) leader sequence at 5' end.", [["subcutaneous", "ANATOMY", 4, 16], ["antigen presenting cells", "ANATOMY", 69, 93], ["APCs", "ANATOMY", 95, 99], ["Cytotoxic T cells", "ANATOMY", 131, 148], ["cell lines", "ANATOMY", 346, 356], ["antigen presenting cells", "CELL", 69, 93], ["APCs", "CELL", 95, 99], ["Cytotoxic T cells", "CELL", 131, 148], ["ChAdOx1", "GENE_OR_GENE_PRODUCT", 217, 224], ["adenovirus", "ORGANISM", 237, 247], ["S glycoprotein", "GENE_OR_GENE_PRODUCT", 299, 313], ["human", "ORGANISM", 340, 345], ["cell lines", "CELL", 346, 356], ["tissue plasminogen activator", "GENE_OR_GENE_PRODUCT", 380, 408], ["PA", "GENE_OR_GENE_PRODUCT", 411, 413], ["antigen presenting cells", "CELL_TYPE", 69, 93], ["APCs", "CELL_TYPE", 95, 99], ["Cytotoxic T cells", "CELL_TYPE", 131, 148], ["S glycoprotein", "PROTEIN", 299, 313], ["human cell lines", "CELL_LINE", 340, 356], ["tissue plasminogen activator (tPA) leader sequence", "DNA", 380, 430], ["5' end", "DNA", 434, 440], ["human", "SPECIES", 340, 345], ["adenovirus", "SPECIES", 237, 247], ["human", "SPECIES", 340, 345], ["The subcutaneous inoculation of the vaccine", "TREATMENT", 0, 43], ["APCs", "TEST", 95, 99], ["the Cytotoxic T cells", "PROBLEM", 127, 148], ["ChAdOx1 (University of Oxford)", "TREATMENT", 187, 217], ["ChAdOx1 recombinant adenovirus vaccine", "TREATMENT", 217, 255], ["the S glycoprotein", "TREATMENT", 295, 313], ["the human cell lines", "TREATMENT", 336, 356], ["the tissue plasminogen activator (tPA) leader sequence", "TREATMENT", 376, 430], ["subcutaneous", "OBSERVATION_MODIFIER", 4, 16], ["inoculation", "OBSERVATION", 17, 28], ["Cytotoxic T cells", "OBSERVATION", 131, 148], ["human cell lines", "OBSERVATION", 340, 356]]], ["The sequence of SARS-CoV-2 coding for amino acids (2 to 1273) and the tPA leader was propagated into the shuttle plasmid.", [["plasmid", "ANATOMY", 113, 120], ["amino acids", "CHEMICAL", 38, 49], ["amino acids", "CHEMICAL", 38, 49], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 16, 26], ["amino acids", "AMINO_ACID", 38, 49], ["tPA", "GENE_OR_GENE_PRODUCT", 70, 73], ["SARS-CoV-2", "DNA", 16, 26], ["tPA leader", "DNA", 70, 80], ["shuttle plasmid", "DNA", 105, 120], ["SARS-CoV", "SPECIES", 16, 24], ["SARS", "TEST", 16, 20], ["amino acids", "TEST", 38, 49], ["the tPA leader", "TREATMENT", 66, 80], ["the shuttle plasmid", "TREATMENT", 101, 120]]], ["This shuttle plasmid is responsible for encoding for the major immediate early genes of the human cytomegalovirus (IE CMV) along with tetracycline operator (TetO) sites and polyadenylation signal from bovine growth hormone (BGH) between the Gateway\u00ae recombination cloning site.", [["plasmid", "ANATOMY", 13, 20], ["tetracycline", "CHEMICAL", 134, 146], ["tetracycline", "CHEMICAL", 134, 146], ["human", "ORGANISM", 92, 97], ["cytomegalovirus", "ORGANISM", 98, 113], ["IE CMV", "ORGANISM", 115, 121], ["tetracycline", "SIMPLE_CHEMICAL", 134, 146], ["bovine growth hormone", "GENE_OR_GENE_PRODUCT", 201, 222], ["BGH", "GENE_OR_GENE_PRODUCT", 224, 227], ["shuttle plasmid", "DNA", 5, 20], ["major immediate early genes", "DNA", 57, 84], ["tetracycline operator (TetO) sites", "DNA", 134, 168], ["Gateway\u00ae recombination cloning site", "DNA", 241, 276], ["human", "SPECIES", 92, 97], ["bovine", "SPECIES", 201, 207], ["human cytomegalovirus (IE CMV", "SPECIES", 92, 121], ["This shuttle plasmid", "TREATMENT", 0, 20], ["the human cytomegalovirus", "PROBLEM", 88, 113], ["tetracycline operator (TetO) sites", "TREATMENT", 134, 168], ["polyadenylation signal", "PROBLEM", 173, 195], ["bovine growth hormone", "PROBLEM", 201, 222], ["polyadenylation signal", "OBSERVATION", 173, 195]]], ["The Adenovirus vector genome is constructed in the Bacterial Artificial Chromosome by inserting the SARS-CoV-2 S gene into the E1 locus of ChAdOx1 adenovirus genome.", [["Adenovirus", "ORGANISM", 4, 14], ["SARS-CoV-2 S", "GENE_OR_GENE_PRODUCT", 100, 112], ["E1", "GENE_OR_GENE_PRODUCT", 127, 129], ["ChAdOx1 adenovirus", "ORGANISM", 139, 157], ["Adenovirus vector genome", "DNA", 4, 28], ["Bacterial Artificial Chromosome", "DNA", 51, 82], ["SARS-CoV-2 S gene", "DNA", 100, 117], ["E1 locus", "DNA", 127, 135], ["ChAdOx1 adenovirus genome", "DNA", 139, 164], ["Adenovirus", "SPECIES", 4, 14], ["The Adenovirus vector genome", "TREATMENT", 0, 28], ["the Bacterial Artificial Chromosome", "TREATMENT", 47, 82], ["the SARS", "TEST", 96, 104], ["CoV", "TEST", 105, 108], ["ChAdOx1 adenovirus genome", "PROBLEM", 139, 164], ["Adenovirus", "OBSERVATION", 4, 14], ["vector genome", "OBSERVATION", 15, 28], ["Bacterial Artificial Chromosome", "OBSERVATION", 51, 82], ["ChAdOx1 adenovirus genome", "OBSERVATION", 139, 164]]], ["The virus was then allowed to reproduce in the T-Rex 293 HEK (Human Embryonic Kidney 293) cell lines and purified by the CsCl gradient ultracentrifugation.", [["HEK", "ANATOMY", 57, 60], ["Embryonic Kidney 293) cell lines", "ANATOMY", 68, 100], ["T-Rex 293 HEK", "CELL", 47, 60], ["Human", "ORGANISM", 62, 67], ["Embryonic Kidney 293) cell lines", "CELL", 68, 100], ["T-Rex 293 HEK", "CELL_LINE", 47, 60], ["Human Embryonic Kidney 293) cell lines", "CELL_LINE", 62, 100], ["Human", "SPECIES", 62, 67], ["T-Rex 293", "SPECIES", 47, 56], ["Human Embryonic Kidney 293", "SPECIES", 62, 88], ["The virus", "PROBLEM", 0, 9], ["cell lines", "TREATMENT", 90, 100], ["the CsCl gradient ultracentrifugation", "TREATMENT", 117, 154], ["virus", "OBSERVATION", 4, 9], ["Kidney", "ANATOMY", 78, 84], ["cell lines", "OBSERVATION", 90, 100], ["CsCl gradient", "OBSERVATION", 121, 134]]], ["The absence of any sub-genomic RNA (sgRNA) in the intramuscularly vaccinated animals from the pre-clinical trials is indicative of the escalated immunity against the virus (47) .", [["sub-genomic RNA", "RNA", 19, 34], ["any sub-genomic RNA (sgRNA)", "PROBLEM", 15, 42], ["sub-", "OBSERVATION_MODIFIER", 19, 23], ["genomic RNA", "OBSERVATION", 23, 34]]], ["The previous studies have suggested that a single shot should marshal the immune response (1) .", [["The previous studies", "TEST", 0, 20]]], ["The vaccine has entered phase II clinical trials, where the vaccine shall be administered in a large sample of the population (48).mRNA VaccinemRNA is an emerging, non-infectious, and a non-integrating platform with almost no potential risk of insertional mutagenesis.", [["VaccinemRNA", "GENE_OR_GENE_PRODUCT", 136, 147], ["The vaccine", "TREATMENT", 0, 11], ["the vaccine", "TREATMENT", 56, 67], ["mRNA VaccinemRNA", "TEST", 131, 147], ["non-infectious", "PROBLEM", 164, 178], ["a non-integrating platform", "TEST", 184, 210], ["insertional mutagenesis", "PROBLEM", 244, 267], ["non-infectious", "OBSERVATION", 164, 178], ["no potential", "UNCERTAINTY", 223, 235], ["insertional mutagenesis", "OBSERVATION", 244, 267]]], ["Currently, the non-replicating RNA and the virus derived selfreplicating RNAs are being studied.", [["non-replicating RNA", "RNA", 15, 34], ["virus derived selfreplicating RNAs", "RNA", 43, 77], ["the non-replicating RNA", "PROBLEM", 11, 34], ["the virus derived selfreplicating RNAs", "TREATMENT", 39, 77]]], ["The immunogenicity of the mRNA can be minimized, and alterations can be made to increase the stability of these vaccines.", [["mRNA", "RNA", 26, 30], ["these vaccines", "TREATMENT", 106, 120]]], ["Furthermore, the anti-vector immunity is also avoided as the mRNA is the minimally immunogenic genetic vector, allowing repeated administration of the vaccine (49) .", [["mRNA", "RNA", 61, 65], ["the anti-vector immunity", "TREATMENT", 13, 37], ["the vaccine", "TREATMENT", 147, 158]]], ["This platform has empowered the rapid vaccine development program due to its flexibility and ability to mimic the antigen structure and expression as seen in the course of a natural infection (50).mRNA-1273 (Moderna TX, Inc)It is a vaccine composed of synthetic mRNA encapsulated in Lipid nanoparticle (LNP) which codes for the full-length, pre-fusion stabilized spike protein (S) of SARS-CoV-2.", [["infection", "DISEASE", 182, 191], ["RNA-1273", "CHEMICAL", 198, 206], ["Lipid nanoparticle", "SIMPLE_CHEMICAL", 283, 301], ["LNP", "SIMPLE_CHEMICAL", 303, 306], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 384, 394], ["synthetic mRNA", "RNA", 252, 266], ["pre-fusion stabilized spike protein", "PROTEIN", 341, 376], ["S", "PROTEIN", 378, 379], ["the rapid vaccine development program", "TREATMENT", 28, 65], ["a natural infection", "PROBLEM", 172, 191], ["RNA", "TEST", 198, 201], ["Moderna TX", "TREATMENT", 208, 218], ["a vaccine", "TREATMENT", 230, 239], ["synthetic mRNA", "TREATMENT", 252, 266], ["Lipid nanoparticle (LNP", "TREATMENT", 283, 306], ["SARS", "PROBLEM", 384, 388], ["CoV", "TEST", 389, 392], ["infection", "OBSERVATION", 182, 191]]], ["It has the potential to elicit a highly S-protein specific antiviral response.", [["a highly S-protein specific antiviral response", "PROBLEM", 31, 77], ["antiviral response", "OBSERVATION", 59, 77]]], ["Furthermore, it is considered to be relatively safe as it is neither made up of the inactivated pathogen nor the sub-units of the live pathogen (38) .", [["the inactivated pathogen", "PROBLEM", 80, 104]]], ["The vaccine has got a fast-track approval by the FDA, to conduct the Phase II trials (51).The company has released the interim phase I antibody data of eight participants who received various dose levels.", [["I antibody", "PROTEIN", 133, 143], ["participants", "SPECIES", 158, 170], ["The vaccine", "TREATMENT", 0, 11], ["various dose levels", "TREATMENT", 184, 203]]], ["The participants of the 25 \u00b5g arm gave results comparable to the convalescent sera.", [["sera", "ANATOMY", 78, 82], ["participants", "ORGANISM", 4, 16], ["sera", "ORGANISM_SUBSTANCE", 78, 82], ["participants", "SPECIES", 4, 16], ["the convalescent sera", "TEST", 61, 82]]], ["Whereas, in participants who received the 100 \u00b5g dose, the levels of nAb essentially surpassed the levels found in convalescent sera.", [["sera", "ANATOMY", 128, 132], ["nAb", "CHEMICAL", 69, 72], ["nAb", "GENE_OR_GENE_PRODUCT", 69, 72], ["sera", "ORGANISM_SUBSTANCE", 128, 132], ["nAb", "PROTEIN", 69, 72], ["participants", "SPECIES", 12, 24], ["the levels of nAb", "TEST", 55, 72], ["the levels", "TEST", 95, 105], ["convalescent sera", "TEST", 115, 132]]], ["The vaccine was found to be predominantly safe and well tolerated in the 25 \u00b5g and 100 \u00b5g dose cohorts, while three participants experienced grade 3 systemic symptoms after the administration of the second dose of 250 \u00b5g dose levels (52).BNT162b1 (BioNTech| FosunPharma| Pfizer)BNT162b1 is a codon-optimized mRNA vaccine that encodes for the trimerized SARS-CoV-2 RBD, a critical target of the virus nAb.", [["BNT162b1", "CHEMICAL", 238, 246], ["BNT162b1", "CHEMICAL", 238, 246], ["BNT162b1", "SIMPLE_CHEMICAL", 238, 246], ["BNT162b1", "GENE_OR_GENE_PRODUCT", 278, 286], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 353, 363], ["BNT162b1", "PROTEIN", 238, 246], ["BNT162b1", "DNA", 278, 286], ["trimerized SARS-CoV-2 RBD", "PROTEIN", 342, 367], ["participants", "SPECIES", 116, 128], ["The vaccine", "TREATMENT", 0, 11], ["grade 3 systemic symptoms", "PROBLEM", 141, 166], ["BNT162b1", "TEST", 238, 246], ["BioNTech", "TEST", 248, 256], ["a codon-optimized mRNA vaccine", "TREATMENT", 290, 320], ["the trimerized SARS", "TEST", 338, 357], ["CoV", "TEST", 358, 361], ["RBD", "PROBLEM", 364, 367]]], ["The vaccine portrays an increased immunogenicity due to the addition of T4 fibritin-derived foldon trimerization domain to the RBD antigen.", [["T4 fibritin", "SIMPLE_CHEMICAL", 72, 83], ["RBD antigen", "GENE_OR_GENE_PRODUCT", 127, 138], ["T4 fibritin", "PROTEIN", 72, 83], ["foldon trimerization domain", "PROTEIN", 92, 119], ["RBD antigen", "PROTEIN", 127, 138], ["The vaccine", "TREATMENT", 0, 11], ["an increased immunogenicity", "PROBLEM", 21, 48], ["T4 fibritin", "TREATMENT", 72, 83], ["increased", "OBSERVATION_MODIFIER", 24, 33], ["RBD", "ANATOMY", 127, 130]]], ["The mRNA is encapsulated in 80 nm ionizable cationic lipid nanoparticles, which ensures its efficient delivery.", [["mRNA", "RNA", 4, 8], ["80 nm ionizable cationic lipid nanoparticles", "TREATMENT", 28, 72], ["encapsulated", "OBSERVATION_MODIFIER", 12, 24]]], ["The Phase 1/2 clinical trials have revealed elevated RBD-specific IgG antibodies levels with a geometric mean concentration to be as high as 8 to 46.3 times sera of convalescent serum.", [["sera", "ANATOMY", 157, 161], ["serum", "ANATOMY", 178, 183], ["sera", "ORGANISM_SUBSTANCE", 157, 161], ["serum", "ORGANISM_SUBSTANCE", 178, 183], ["RBD", "PROTEIN", 53, 56], ["IgG antibodies", "PROTEIN", 66, 80], ["The Phase", "TEST", 0, 9], ["clinical trials", "TEST", 14, 29], ["elevated RBD-specific IgG antibodies levels", "PROBLEM", 44, 87], ["a geometric mean concentration", "TEST", 93, 123], ["convalescent serum", "TEST", 165, 183], ["elevated", "OBSERVATION_MODIFIER", 44, 52], ["RBD", "OBSERVATION", 53, 56]]], ["Whereas, the geometric mean titers of the SARS-CoV-2 neutralizing antibodies were found to be 1.8 to 2.8 times the convalescent serum panel.", [["serum", "ANATOMY", 128, 133], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 42, 52], ["serum", "ORGANISM_SUBSTANCE", 128, 133], ["SARS-CoV-2 neutralizing antibodies", "PROTEIN", 42, 76], ["SARS-CoV", "SPECIES", 42, 50], ["the geometric mean titers", "TEST", 9, 34], ["the SARS", "TEST", 38, 46], ["CoV", "TEST", 47, 50], ["neutralizing antibodies", "TEST", 53, 76], ["the convalescent serum panel", "TEST", 111, 139]]], ["Moderate and transient local reactions and systemic events were observed with no adverse effect.", [["Moderate and transient local reactions", "PROBLEM", 0, 38], ["systemic events", "PROBLEM", 43, 58], ["adverse effect", "PROBLEM", 81, 95], ["transient", "OBSERVATION_MODIFIER", 13, 22], ["local reactions", "OBSERVATION", 23, 38]]], ["However, the data analysis did not evaluate the safety and immune responses beyond 2 weeks following the administration of the second dose (50).DNA VaccinesThe most revolutionary approach to vaccination is the introduction of the DNA vaccine which encodes for the antigen and an adjuvant which induces the adaptive immune response.", [["DNA", "CELLULAR_COMPONENT", 144, 147], ["DNA", "CELLULAR_COMPONENT", 230, 233], ["the data analysis", "TEST", 9, 26], ["DNA Vaccines", "TREATMENT", 144, 156], ["vaccination", "TREATMENT", 191, 202], ["the DNA vaccine", "TREATMENT", 226, 241], ["the antigen", "PROBLEM", 260, 271], ["an adjuvant", "TREATMENT", 276, 287]]], ["The transfected cells express the transgene which provides a steady supply of the transgene specific proteins which is quite similar to the live virus.", [["cells", "ANATOMY", 16, 21], ["cells", "CELL", 16, 21], ["live virus", "ORGANISM", 140, 150], ["transfected cells", "CELL_LINE", 4, 21], ["transgene specific proteins", "PROTEIN", 82, 109], ["the transgene specific proteins", "PROBLEM", 78, 109], ["the live virus", "PROBLEM", 136, 150], ["transfected cells", "OBSERVATION", 4, 21]]], ["Furthermore, the antigenic material is endocytosed by the immature Dendritic Cells which ultimately present the antigen to the CD4+ and CD8+ T cells in association with MHC 2 and MHC 1 antigens on the cell surface hence stimulating effective humoral as well as cell-mediated immune responses (53).INO-4800 (Inovio Pharmaceuticals)It is a prophylactic DNA vaccine against SARS-CoV-2 (54).", [["Cells", "ANATOMY", 77, 82], ["CD4+ and CD8+", "ANATOMY", 127, 140], ["T cells", "ANATOMY", 141, 148], ["cell surface", "ANATOMY", 201, 213], ["cell", "ANATOMY", 261, 265], ["INO-4800", "CHEMICAL", 297, 305], ["INO-4800", "CHEMICAL", 297, 305], ["Dendritic Cells", "CELL", 67, 82], ["CD4", "GENE_OR_GENE_PRODUCT", 127, 130], ["CD8", "GENE_OR_GENE_PRODUCT", 136, 139], ["T cells", "CELL", 141, 148], ["MHC 2", "GENE_OR_GENE_PRODUCT", 169, 174], ["MHC 1 antigens", "GENE_OR_GENE_PRODUCT", 179, 193], ["cell surface", "CELLULAR_COMPONENT", 201, 213], ["cell", "CELL", 261, 265], ["INO-4800", "SIMPLE_CHEMICAL", 297, 305], ["DNA", "CELLULAR_COMPONENT", 351, 354], ["SARS-CoV-2", "ORGANISM", 371, 381], ["immature Dendritic Cells", "CELL_TYPE", 58, 82], ["CD4", "PROTEIN", 127, 130], ["CD8", "PROTEIN", 136, 139], ["T cells", "CELL_TYPE", 141, 148], ["MHC 2", "PROTEIN", 169, 174], ["MHC 1 antigens", "PROTEIN", 179, 193], ["SARS-CoV-2", "SPECIES", 371, 381], ["the antigenic material", "PROBLEM", 13, 35], ["the immature Dendritic Cells", "PROBLEM", 54, 82], ["the CD4", "TEST", 123, 130], ["CD8", "TEST", 136, 139], ["the cell surface", "TREATMENT", 197, 213], ["INO", "TEST", 297, 300], ["Inovio Pharmaceuticals", "TREATMENT", 307, 329], ["a prophylactic DNA vaccine", "TREATMENT", 336, 362], ["SARS", "PROBLEM", 371, 375], ["CoV", "TEST", 376, 379], ["immature", "OBSERVATION_MODIFIER", 58, 66], ["Dendritic Cells", "OBSERVATION", 67, 82]]], ["It uses codon optimized S protein sequence of SARS-CoV-2 to which an IgE leader sequence is affixed.", [["IgE", "GENE_OR_GENE_PRODUCT", 69, 72], ["S protein sequence", "DNA", 24, 42], ["IgE leader sequence", "DNA", 69, 88], ["codon optimized S protein sequence", "TEST", 8, 42], ["SARS", "PROBLEM", 46, 50], ["CoV", "TEST", 51, 54], ["an IgE leader sequence", "TEST", 66, 88]]], ["The SARS-CoV-2 IgEspike sequence was synthesized and digested using BamHI and XhoI.", [["BamHI", "GENE_OR_GENE_PRODUCT", 68, 73], ["XhoI", "GENE_OR_GENE_PRODUCT", 78, 82], ["SARS-CoV-2 IgEspike sequence", "DNA", 4, 32], ["BamHI", "DNA", 68, 73], ["XhoI", "DNA", 78, 82], ["The SARS", "TEST", 0, 8], ["BamHI and XhoI", "TREATMENT", 68, 82]]], ["The digested DNA was incorporated into the expression plasmid pGX0001 under the governance of IE CMV, and BGH polyadenylation signal.", [["plasmid", "ANATOMY", 54, 61], ["DNA", "CELLULAR_COMPONENT", 13, 16], ["pGX0001", "GENE_OR_GENE_PRODUCT", 62, 69], ["CMV", "ORGANISM", 97, 100], ["BGH", "GENE_OR_GENE_PRODUCT", 106, 109], ["digested DNA", "DNA", 4, 16], ["expression plasmid", "DNA", 43, 61], ["pGX0001", "DNA", 62, 69], ["The digested DNA", "PROBLEM", 0, 16], ["the expression plasmid", "TREATMENT", 39, 61], ["IE CMV", "TREATMENT", 94, 100], ["BGH polyadenylation signal", "PROBLEM", 106, 132], ["CMV", "OBSERVATION", 97, 100], ["polyadenylation signal", "OBSERVATION", 110, 132]]], ["The presence of functional antibodies and T cell response in the preclinical trials suggest that the vaccine can produce an effective immune response within 7 days postvaccination (55).", [["T cell", "ANATOMY", 42, 48], ["T cell", "CELL", 42, 48], ["functional antibodies", "PROTEIN", 16, 37], ["functional antibodies", "PROBLEM", 16, 37], ["T cell response", "PROBLEM", 42, 57], ["the vaccine", "TREATMENT", 97, 108], ["functional antibodies", "OBSERVATION", 16, 37]]], ["The vaccine has entered the Phase I clinical trials (Phase I: NCT04336410) and it is estimated to complete this phase of clinical trials by July, wherein the participants received 1.0 mg of INO-4800 by electroporation using CELLECTRA\u00ae 2000 device per dosing visit.", [["INO-4800", "CHEMICAL", 190, 198], ["INO", "CHEMICAL", 190, 193], ["participants", "SPECIES", 158, 170], ["The vaccine", "TREATMENT", 0, 11], ["INO", "TREATMENT", 190, 193], ["CELLECTRA\u00ae 2000 device", "TREATMENT", 224, 246]]], ["The trial will evaluate the immunological profile, safety, and tolerability of the vaccine candidate upon intradermal injection and the electroporation in healthy human adults (54).DelNS1-SARS-CoV2-RBD (University of Hong Kong)This LAV is influenza-based vaccine strain with a deletion in the NS1 gene.", [["intradermal", "ANATOMY", 106, 117], ["intradermal", "IMMATERIAL_ANATOMICAL_ENTITY", 106, 117], ["human", "ORGANISM", 163, 168], ["LAV", "ORGANISM", 232, 235], ["NS1", "GENE_OR_GENE_PRODUCT", 293, 296], ["NS1 gene", "DNA", 293, 301], ["human", "SPECIES", 163, 168], ["human", "SPECIES", 163, 168], ["the immunological profile", "TEST", 24, 49], ["the vaccine", "TREATMENT", 79, 90], ["intradermal injection", "TREATMENT", 106, 127], ["RBD", "PROBLEM", 198, 201], ["influenza", "PROBLEM", 239, 248], ["based vaccine strain", "PROBLEM", 249, 269], ["a deletion in the NS1 gene", "PROBLEM", 275, 301], ["LAV", "ANATOMY", 232, 235], ["influenza", "OBSERVATION", 239, 248], ["NS1 gene", "OBSERVATION", 293, 301]]], ["It is re-organized to express the RBD domain of SARS-CoV-2 spike protein on its surface and, is cultivated in the chick embryo and/or Madin Darby Canine Kidney Cells (MDCK) cells.", [["surface", "ANATOMY", 80, 87], ["embryo", "ANATOMY", 120, 126], ["Kidney Cells (MDCK) cells", "ANATOMY", 153, 178], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 48, 58], ["surface", "CELLULAR_COMPONENT", 80, 87], ["chick", "ORGANISM", 114, 119], ["embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 120, 126], ["Madin Darby Canine Kidney Cells", "CELL", 134, 165], ["MDCK) cells", "CELL", 167, 178], ["RBD domain", "PROTEIN", 34, 44], ["SARS-CoV-2 spike protein", "PROTEIN", 48, 72], ["Madin Darby Canine Kidney Cells (MDCK) cells", "CELL_LINE", 134, 178], ["SARS", "PROBLEM", 48, 52], ["CoV", "TEST", 53, 56], ["the chick embryo", "TREATMENT", 110, 126], ["Madin Darby Canine Kidney Cells", "TREATMENT", 134, 165], ["Kidney", "ANATOMY", 153, 159]]], ["It is potentially more immunogenic than the wild type influenza virus and can be administered as a nasal spray (56).OthersThe revelation of the structure and genome of the SARS-CoV-2 has led to the rapid development of various vaccine candidates with potential reactogenicity and immunogenicity.", [["nasal", "ANATOMY", 99, 104], ["influenza", "DISEASE", 54, 63], ["SARS", "DISEASE", 172, 176], ["wild type influenza virus", "ORGANISM", 44, 69], ["SARS-CoV-2", "ORGANISM", 172, 182], ["influenza virus", "SPECIES", 54, 69], ["wild type influenza virus", "SPECIES", 44, 69], ["the wild type influenza virus", "PROBLEM", 40, 69], ["a nasal spray", "TREATMENT", 97, 110], ["various vaccine candidates", "TREATMENT", 219, 245], ["potential reactogenicity and immunogenicity", "PROBLEM", 251, 294], ["potentially more", "UNCERTAINTY", 6, 22], ["genome", "OBSERVATION_MODIFIER", 158, 164], ["rapid", "OBSERVATION_MODIFIER", 198, 203]]], ["The task of vaccine development is long and cumbersome which requires evaluation in some long-lasting clinical trials.", [["vaccine development", "TREATMENT", 12, 31], ["evaluation", "TEST", 70, 80]]], ["Various Biotech ventures are using different technologies for the development of their vaccine candidates; British and American Tobacco Company (BAT) recently unfolded the COVID-19 vaccine using their new, and fast-growing tobacco plant technology (57), while Tianjin University has developed an oral vaccine which has successfully employed Saccharomyces cerevisiae to carry the S protein.", [["oral", "ANATOMY", 296, 300], ["Tobacco", "ORGANISM", 128, 135], ["tobacco", "ORGANISM", 223, 230], ["oral", "ORGANISM_SUBDIVISION", 296, 300], ["Saccharomyces cerevisiae", "ORGANISM", 341, 365], ["S protein", "PROTEIN", 379, 388], ["Saccharomyces cerevisiae", "SPECIES", 341, 365], ["tobacco", "SPECIES", 223, 230], ["Saccharomyces cerevisiae", "SPECIES", 341, 365], ["Various Biotech ventures", "TREATMENT", 0, 24], ["different technologies", "TREATMENT", 35, 57], ["an oral vaccine", "TREATMENT", 293, 308], ["Saccharomyces cerevisiae", "TREATMENT", 341, 365]]], ["The GRAS (Generally Regarded As Safe) status of the yeast provides high scalability, robustness, and cost-effective production of cosmic dosages required to fight off this pandemic (58) .", [["yeast", "SPECIES", 52, 57], ["yeast", "SPECIES", 52, 57], ["the yeast", "PROBLEM", 48, 57], ["high scalability", "PROBLEM", 67, 83], ["cosmic dosages", "TREATMENT", 130, 144]]], ["Furthermore, in silico studies, using various databases like VaxiJen, have revealed that the epitope sequences WTAGAAAYY and YDPLQPEL can be employed for the formulation of epitope-based peptide vaccines (59).Self Assembling Vaccine (HaloVax)The vaccine uses a heat shock protein (hsp) to activate the immune system.", [["immune system", "ANATOMY", 302, 315], ["YDPLQPEL", "CHEMICAL", 125, 133], ["VaxiJen", "GENE_OR_GENE_PRODUCT", 61, 68], ["YDPLQPEL", "SIMPLE_CHEMICAL", 125, 133], ["heat shock protein", "GENE_OR_GENE_PRODUCT", 261, 279], ["hsp", "GENE_OR_GENE_PRODUCT", 281, 284], ["VaxiJen", "PROTEIN", 61, 68], ["YDPLQPEL", "PROTEIN", 125, 133], ["heat shock protein", "PROTEIN", 261, 279], ["hsp", "PROTEIN", 281, 284], ["silico studies", "TEST", 16, 30], ["VaxiJen", "TREATMENT", 61, 68], ["the epitope sequences WTAGAAAYY", "TEST", 89, 120], ["epitope-based peptide vaccines", "TREATMENT", 173, 203], ["Self Assembling Vaccine (HaloVax)", "TREATMENT", 209, 242], ["The vaccine", "TREATMENT", 242, 253], ["a heat shock protein", "TREATMENT", 259, 279]]], ["It is composed of a fusion protein sandwiched between an hsp and Avidin.", [["hsp", "GENE_OR_GENE_PRODUCT", 57, 60], ["Avidin", "GENE_OR_GENE_PRODUCT", 65, 71], ["fusion protein", "PROTEIN", 20, 34], ["hsp", "PROTEIN", 57, 60], ["Avidin", "PROTEIN", 65, 71], ["a fusion protein sandwiched", "TREATMENT", 18, 45], ["an hsp and Avidin", "TREATMENT", 54, 71], ["fusion", "OBSERVATION", 20, 26]]], ["Biotinylated immunogenic peptides are also incorporated to customize the vaccine (60).", [["Biotinylated immunogenic peptides", "PROBLEM", 0, 33], ["the vaccine", "TREATMENT", 69, 80]]], ["The biotinylated immunogenic fusion protein is sandwiched between heat shock protein and avidin.University of Oxford/Ast raZenecaThe preliminary reports of phase 1/2 , single-blind, randomized controlled trials of the ChAdOx1 nCoV-19 vaccine have showcased the spike-specific T-cell responses along with the Anti-spike IgG response in 91% participants as per the micro-neutralization assay (MNA80) while a plaque reduction neutralization assay (PRNT50) depicted a 100% response after a single dose.", [["T-cell", "ANATOMY", 276, 282], ["plaque", "ANATOMY", 406, 412], ["heat shock protein", "GENE_OR_GENE_PRODUCT", 66, 84], ["avidin", "GENE_OR_GENE_PRODUCT", 89, 95], ["T-cell", "CELL", 276, 282], ["IgG", "GENE_OR_GENE_PRODUCT", 319, 322], ["plaque", "PATHOLOGICAL_FORMATION", 406, 412], ["biotinylated immunogenic fusion protein", "PROTEIN", 4, 43], ["heat shock protein", "PROTEIN", 66, 84], ["avidin", "PROTEIN", 89, 95], ["Anti-spike IgG", "PROTEIN", 308, 322], ["participants", "SPECIES", 339, 351], ["The biotinylated immunogenic fusion protein", "TREATMENT", 0, 43], ["heat shock protein", "TREATMENT", 66, 84], ["avidin", "TREATMENT", 89, 95], ["Ast raZeneca", "TREATMENT", 117, 129], ["the ChAdOx1 nCoV", "TREATMENT", 214, 230], ["the spike", "PROBLEM", 257, 266], ["the Anti-spike IgG response", "TEST", 304, 331], ["the micro-neutralization assay", "TEST", 359, 389], ["a plaque reduction neutralization assay", "TREATMENT", 404, 443], ["immunogenic fusion", "OBSERVATION", 17, 35], ["shock protein", "OBSERVATION", 71, 84], ["plaque", "OBSERVATION", 406, 412]]], ["Nevertheless, the administration of the booster dose displayed the neutralizing response in all the participants which had a substantial correlation with the neutralizing antibody titers as measured by ELISA.", [["participants", "SPECIES", 100, 112], ["the booster dose", "TREATMENT", 36, 52], ["the neutralizing antibody titers", "TEST", 154, 186]]], ["The volunteers depicted local and systemic reactions which were minimized by the administration of paracetamol.", [["paracetamol", "CHEMICAL", 99, 110], ["paracetamol", "CHEMICAL", 99, 110], ["volunteers", "ORGANISM", 4, 14], ["paracetamol", "SIMPLE_CHEMICAL", 99, 110], ["local and systemic reactions", "PROBLEM", 24, 52], ["paracetamol", "TREATMENT", 99, 110], ["local", "OBSERVATION_MODIFIER", 24, 29], ["systemic reactions", "OBSERVATION", 34, 52]]], ["Thus, the vaccine candidate has portrayed adequate safety and immunogenicity profile in the phase 1/2 clinical trials.Moderna/N IAIDThe geometric mean of RBD specific antibody titers showed a rapid increase in all the participants.", [["RBD", "PROTEIN", 154, 157], ["participants", "SPECIES", 218, 230], ["the vaccine", "TREATMENT", 6, 17], ["RBD specific antibody titers", "TEST", 154, 182], ["a rapid increase", "PROBLEM", 190, 206], ["rapid", "OBSERVATION_MODIFIER", 192, 197], ["increase", "OBSERVATION_MODIFIER", 198, 206]]], ["Seroconversion was observed after 15 days and the median magnitude of antibody responses was similar to the magnitude in convalescent sera.", [["sera", "ANATOMY", 134, 138], ["sera", "ORGANISM_SUBSTANCE", 134, 138], ["Seroconversion", "TREATMENT", 0, 14]]], ["However, the pseudovirus neutralizing activity was not high before the administration of the second dose, which indicates the requirement of a two-dose vaccination schedule.", [["pseudovirus", "ORGANISM", 13, 24], ["the pseudovirus neutralizing activity", "TEST", 9, 46], ["a two-dose vaccination schedule", "TREATMENT", 141, 172]]], ["Furthermore, the serum neutralizing activity, a generally accepted functional biomarker of the in vivo humoral response against the respiratory viruses, has not been determined as of now.BNT162 | (75)BioNTech| FosunPhar ma| Pfizer BNT162b1, the mRNA based vaccine induced a high, dose-dependent nAb titers along with the RBD-binding IgG concentrations after the second dose.", [["serum", "ANATOMY", 17, 22], ["respiratory viruses", "DISEASE", 132, 151], ["BNT162", "CHEMICAL", 187, 193], ["serum", "ORGANISM_SUBSTANCE", 17, 22], ["nAb", "SIMPLE_CHEMICAL", 295, 298], ["IgG", "GENE_OR_GENE_PRODUCT", 333, 336], ["nAb", "PROTEIN", 295, 298], ["RBD", "PROTEIN", 321, 324], ["IgG", "PROTEIN", 333, 336], ["the serum neutralizing activity", "PROBLEM", 13, 44], ["the respiratory viruses", "PROBLEM", 128, 151], ["BioNTech", "TEST", 200, 208], ["BNT162b1", "TEST", 231, 239], ["the mRNA based vaccine", "TREATMENT", 241, 263], ["dependent nAb titers", "PROBLEM", 285, 305], ["the RBD", "PROBLEM", 317, 324], ["binding IgG concentrations", "PROBLEM", 325, 351], ["respiratory viruses", "OBSERVATION", 132, 151]]], ["This was accompanied by the CD4+ and CD8+ T cell responses.", [["T cell", "ANATOMY", 42, 48], ["CD4", "GENE_OR_GENE_PRODUCT", 28, 31], ["CD8", "GENE_OR_GENE_PRODUCT", 37, 40], ["T cell", "CELL", 42, 48], ["CD4", "PROTEIN", 28, 31], ["CD8", "PROTEIN", 37, 40], ["the CD4", "TEST", 24, 31], ["CD4", "OBSERVATION", 28, 31]]], ["The administration of the vaccine was accompanied by certain adverse symptoms like fatigue, fever, chills, muscle pains etc. However, the recipients did not showcase any severe symptoms.Phase 3: NCT043 68728ZyCoV-D | (87; 85)Zydus CadilaZyCoV-D is a genetically engineered DNA plasmid based vaccine encoding for the membrane proteins of the virus.", [["muscle", "ANATOMY", 107, 113], ["membrane", "ANATOMY", 316, 324], ["fatigue", "DISEASE", 83, 90], ["fever", "DISEASE", 92, 97], ["chills", "DISEASE", 99, 105], ["muscle pains", "DISEASE", 107, 119], ["muscle", "ORGAN", 107, 113], ["recipients", "ORGANISM", 138, 148], ["NCT043 68728ZyCoV-D | (87; 85)Zydus CadilaZyCoV-D", "SIMPLE_CHEMICAL", 195, 244], ["DNA", "CELLULAR_COMPONENT", 273, 276], ["membrane", "CELLULAR_COMPONENT", 316, 324], ["genetically engineered DNA plasmid", "DNA", 250, 284], ["membrane proteins", "PROTEIN", 316, 333], ["the vaccine", "TREATMENT", 22, 33], ["certain adverse symptoms", "PROBLEM", 53, 77], ["fatigue", "PROBLEM", 83, 90], ["fever", "PROBLEM", 92, 97], ["chills", "PROBLEM", 99, 105], ["muscle pains", "PROBLEM", 107, 119], ["any severe symptoms", "PROBLEM", 166, 185], ["Phase", "TEST", 186, 191], ["NCT043", "TEST", 195, 201], ["Zydus", "TEST", 225, 230], ["a genetically engineered DNA plasmid based vaccine", "TREATMENT", 248, 298], ["the virus", "PROBLEM", 337, 346], ["muscle", "ANATOMY", 107, 113], ["pains", "OBSERVATION", 114, 119]]], ["The clinical trials to study the immunogenicity, and safety of the vaccine will administer three doses at an interval of 28 days in 1048 individuals.", [["study the immunogenicity", "TEST", 23, 47], ["the vaccine", "TREATMENT", 63, 74]]], ["Phase 1/2: CTRI/20 20/07/02 6352Passive Immunization/adoptive immunityIt is the use of preformed antibodies in therapeutics of various diseases.", [["preformed antibodies", "PROTEIN", 87, 107], ["Passive Immunization", "TREATMENT", 32, 52], ["preformed antibodies", "TREATMENT", 87, 107], ["various diseases", "PROBLEM", 127, 143], ["various", "OBSERVATION_MODIFIER", 127, 134], ["diseases", "OBSERVATION", 135, 143]]], ["It can be achieved by use of sera from convalescent patients, polyclonal serum raised in other animals such as horse, neutralizing monoclonal antibodies produced by hybridoma technology or humanized antibodies.Convalescent Plasma therapyTo date, no distinct treatment has been proven to be efficacious against the COVID-19.", [["sera", "ANATOMY", 29, 33], ["serum", "ANATOMY", 73, 78], ["sera", "ORGANISM_SUBSTANCE", 29, 33], ["patients", "ORGANISM", 52, 60], ["serum", "ORGANISM_SUBSTANCE", 73, 78], ["horse", "ORGANISM", 111, 116], ["Plasma", "ORGANISM_SUBSTANCE", 223, 229], ["neutralizing monoclonal antibodies", "PROTEIN", 118, 152], ["humanized antibodies", "PROTEIN", 189, 209], ["COVID-19", "DNA", 314, 322], ["patients", "SPECIES", 52, 60], ["horse", "SPECIES", 111, 116], ["horse", "SPECIES", 111, 116], ["sera", "TREATMENT", 29, 33], ["polyclonal serum", "TEST", 62, 78], ["neutralizing monoclonal antibodies", "TEST", 118, 152], ["hybridoma technology", "TREATMENT", 165, 185], ["humanized antibodies", "PROBLEM", 189, 209], ["Convalescent Plasma therapy", "TREATMENT", 210, 237], ["the COVID", "TEST", 310, 319], ["Plasma therapy", "OBSERVATION", 223, 237]]], ["Convalescent plasma (CP) therapy has been approved as an empirical treatment during the outbreaks (88) .", [["plasma", "ANATOMY", 13, 19], ["CP", "CHEMICAL", 21, 23], ["plasma", "ORGANISM_SUBSTANCE", 13, 19], ["CP", "MULTI-TISSUE_STRUCTURE", 21, 23], ["Convalescent plasma (CP) therapy", "TREATMENT", 0, 32], ["an empirical treatment", "TREATMENT", 54, 76]]], ["It is considered as the archetypal immunotherapy which has been used for the treatment and prevention of various viral diseases in the past such as SARS, MERS, H1N1 pandemic, measles, mumps, etc. (89) .", [["viral diseases", "DISEASE", 113, 127], ["SARS", "DISEASE", 148, 152], ["H1N1 pandemic", "DISEASE", 160, 173], ["measles", "DISEASE", 175, 182], ["mumps", "DISEASE", 184, 189], ["the archetypal immunotherapy", "TREATMENT", 20, 48], ["the treatment", "TREATMENT", 73, 86], ["various viral diseases", "PROBLEM", 105, 127], ["SARS", "PROBLEM", 148, 152], ["H1N1", "PROBLEM", 160, 164], ["measles", "PROBLEM", 175, 182], ["various", "OBSERVATION_MODIFIER", 105, 112], ["viral diseases", "OBSERVATION", 113, 127]]], ["A possible explanation for the efficacy of this classic adoptive immunotherapy is that the neutralizing immune-globulins from CP may conquer viremia, block new infection, and accelerate clearance of the infected cells.Convalescent Plasma therapyVarious studies conducted therapeutic potential of CP have convincingly shown that administration of the neutralizing antibodies in the critically ill patients led to the amelioration of the clinical status in all patients without any deaths (89; 90; 91; 92) .", [["cells", "ANATOMY", 212, 217], ["CP", "CHEMICAL", 126, 128], ["viremia", "DISEASE", 141, 148], ["infection", "DISEASE", 160, 169], ["critically ill", "DISEASE", 381, 395], ["deaths", "DISEASE", 480, 486], ["immune-globulins", "GENE_OR_GENE_PRODUCT", 104, 120], ["CP", "SIMPLE_CHEMICAL", 126, 128], ["cells", "CELL", 212, 217], ["patients", "ORGANISM", 396, 404], ["patients", "ORGANISM", 459, 467], ["neutralizing immune-globulins", "PROTEIN", 91, 120], ["infected cells", "CELL_TYPE", 203, 217], ["neutralizing antibodies", "PROTEIN", 350, 373], ["patients", "SPECIES", 396, 404], ["patients", "SPECIES", 459, 467], ["this classic adoptive immunotherapy", "TREATMENT", 43, 78], ["the neutralizing immune-globulins", "PROBLEM", 87, 120], ["CP", "PROBLEM", 126, 128], ["viremia", "PROBLEM", 141, 148], ["block new infection", "PROBLEM", 150, 169], ["the infected cells", "PROBLEM", 199, 217], ["Convalescent Plasma therapyVarious studies", "TEST", 218, 260], ["CP", "PROBLEM", 296, 298], ["the neutralizing antibodies", "TREATMENT", 346, 373], ["possible explanation for", "UNCERTAINTY", 2, 26], ["new", "OBSERVATION_MODIFIER", 156, 159], ["infection", "OBSERVATION", 160, 169], ["infected cells", "OBSERVATION", 203, 217]]], ["The dosage prescribed for the CP therapy has not been standardized as certain groups have administered 200 mL of CP with an antibody titer greater than 1:640 while another patient was administered with 2400 mL of CP (93) .", [["CP", "CHEMICAL", 30, 32], ["CP", "CHEMICAL", 213, 215], ["patient", "ORGANISM", 172, 179], ["patient", "SPECIES", 172, 179], ["The dosage", "TREATMENT", 0, 10], ["the CP therapy", "TREATMENT", 26, 40], ["CP", "PROBLEM", 113, 115], ["an antibody titer", "TEST", 121, 138], ["CP", "PROBLEM", 213, 215]]], ["The patients who were considered critically ill with some of them having co-morbid conditions like hypertension, cardiovascular diseases, cerebrovascular diseases, chronic renal failure, etc. were included in the study.", [["cardiovascular", "ANATOMY", 113, 127], ["cerebrovascular", "ANATOMY", 138, 153], ["renal", "ANATOMY", 172, 177], ["critically ill", "DISEASE", 33, 47], ["hypertension", "DISEASE", 99, 111], ["cardiovascular diseases", "DISEASE", 113, 136], ["cerebrovascular diseases", "DISEASE", 138, 162], ["chronic renal failure", "DISEASE", 164, 185], ["patients", "ORGANISM", 4, 12], ["cerebrovascular", "MULTI-TISSUE_STRUCTURE", 138, 153], ["renal", "ORGAN", 172, 177], ["patients", "SPECIES", 4, 12], ["critically ill", "PROBLEM", 33, 47], ["co-morbid conditions", "PROBLEM", 73, 93], ["hypertension", "PROBLEM", 99, 111], ["cardiovascular diseases", "PROBLEM", 113, 136], ["cerebrovascular diseases", "PROBLEM", 138, 162], ["chronic renal failure", "PROBLEM", 164, 185], ["the study", "TEST", 209, 218], ["hypertension", "OBSERVATION", 99, 111], ["cardiovascular", "ANATOMY", 113, 127], ["diseases", "OBSERVATION", 128, 136], ["cerebrovascular diseases", "OBSERVATION", 138, 162], ["chronic", "OBSERVATION_MODIFIER", 164, 171], ["renal", "ANATOMY", 172, 177], ["failure", "OBSERVATION", 178, 185]]], ["They were all admitted to the ICUs and were receiving either mechanical ventilation, high-flow nasal cannula oxygenation, or the low-flow nasal cannula oxygenation.", [["nasal", "ANATOMY", 95, 100], ["nasal", "ANATOMY", 138, 143], ["nasal cannula", "MULTI-TISSUE_STRUCTURE", 95, 108], ["nasal cannula", "MULTI-TISSUE_STRUCTURE", 138, 151], ["mechanical ventilation", "TREATMENT", 61, 83], ["high-flow nasal cannula oxygenation", "TREATMENT", 85, 120], ["the low-flow nasal cannula oxygenation", "TREATMENT", 125, 163], ["nasal cannula", "OBSERVATION", 95, 108], ["nasal cannula", "OBSERVATION", 138, 151]]], ["All the patients in these studies were receiving antiviral or antibacterial or antifungal drugs for the treatment of co-infection (89) .", [["co-infection", "DISEASE", 117, 129], ["patients", "ORGANISM", 8, 16], ["patients", "SPECIES", 8, 16], ["these studies", "TEST", 20, 33], ["antiviral", "TREATMENT", 49, 58], ["antibacterial", "TREATMENT", 62, 75], ["antifungal drugs", "TREATMENT", 79, 95], ["co-infection", "PROBLEM", 117, 129], ["co-infection", "OBSERVATION", 117, 129]]], ["Compared to the control group, the CP treatment group showed no notable differences in the baseline characteristics but exhibited a sizable difference in the clinical outcomes (i.e. normalization of the body temperature, absorption of pulmonary lesions, resolution of ARDS, weaning off the mechanical ventilators, etc.), and the death rates.", [["body", "ANATOMY", 203, 207], ["pulmonary lesions", "ANATOMY", 235, 252], ["pulmonary lesions", "DISEASE", 235, 252], ["ARDS", "DISEASE", 268, 272], ["death", "DISEASE", 329, 334], ["body", "ORGANISM_SUBDIVISION", 203, 207], ["pulmonary lesions", "PATHOLOGICAL_FORMATION", 235, 252], ["the CP treatment", "TREATMENT", 31, 47], ["the body temperature", "PROBLEM", 199, 219], ["pulmonary lesions", "PROBLEM", 235, 252], ["ARDS", "PROBLEM", 268, 272], ["the mechanical ventilators", "TREATMENT", 286, 312], ["the death rates", "TEST", 325, 340], ["no", "UNCERTAINTY", 61, 63], ["notable", "OBSERVATION_MODIFIER", 64, 71], ["sizable", "OBSERVATION_MODIFIER", 132, 139], ["difference", "OBSERVATION_MODIFIER", 140, 150], ["pulmonary", "ANATOMY", 235, 244], ["lesions", "OBSERVATION", 245, 252], ["ARDS", "OBSERVATION", 268, 272]]], ["The patients were tested negative for the viral loads after 7-37 days of CP infusion (94) .", [["CP", "CHEMICAL", 73, 75], ["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["the viral loads", "PROBLEM", 38, 53], ["CP infusion", "TREATMENT", 73, 84]]], ["A reduction in the net quantity of inflammatory biomarkers CRP, procalcitonin, and Interleukin 6 (IL-6) in the trial group was observed along with a significant increase in the antibody titers (RBD specific IgM and IgG) post-convalescent plasma therapy (95) .", [["plasma", "ANATOMY", 238, 244], ["CRP", "GENE_OR_GENE_PRODUCT", 59, 62], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 64, 77], ["Interleukin 6", "GENE_OR_GENE_PRODUCT", 83, 96], ["IL-6", "GENE_OR_GENE_PRODUCT", 98, 102], ["IgM", "GENE_OR_GENE_PRODUCT", 207, 210], ["plasma", "ORGANISM_SUBSTANCE", 238, 244], ["inflammatory biomarkers", "PROTEIN", 35, 58], ["CRP", "PROTEIN", 59, 62], ["procalcitonin", "PROTEIN", 64, 77], ["Interleukin 6", "PROTEIN", 83, 96], ["IL-6", "PROTEIN", 98, 102], ["RBD", "PROTEIN", 194, 197], ["IgM", "PROTEIN", 207, 210], ["IgG", "PROTEIN", 215, 218], ["A reduction", "PROBLEM", 0, 11], ["inflammatory biomarkers CRP", "TEST", 35, 62], ["procalcitonin", "TEST", 64, 77], ["Interleukin 6 (IL", "TREATMENT", 83, 100], ["a significant increase", "PROBLEM", 147, 169], ["the antibody titers", "TEST", 173, 192], ["RBD specific IgM", "TEST", 194, 210], ["IgG", "TEST", 215, 218], ["convalescent plasma therapy", "TREATMENT", 225, 252], ["reduction", "OBSERVATION_MODIFIER", 2, 11], ["net", "OBSERVATION_MODIFIER", 19, 22], ["quantity", "OBSERVATION_MODIFIER", 23, 31], ["inflammatory", "OBSERVATION_MODIFIER", 35, 47], ["significant", "OBSERVATION_MODIFIER", 149, 160], ["increase", "OBSERVATION_MODIFIER", 161, 169]]], ["However, these uncontrolled and non-randomized trials for the CP therapy impede the researchers to come to a conclusive statement about the prospective potency of this treatment, and these observations require further evaluation which is ongoing in the clinical trials (96).Monoclonal AntibodyThe monoclonal antibodies (mAb) or therapeutic antibodies, created in the laboratory are the clones of a unique parent which can bind to a single epitope, that is, they have a monovalent affinity (97) .", [["monoclonal antibodies", "PROTEIN", 297, 318], ["mAb", "PROTEIN", 320, 323], ["therapeutic antibodies", "PROTEIN", 328, 350], ["non-randomized trials", "TREATMENT", 32, 53], ["the CP therapy", "TREATMENT", 58, 72], ["this treatment", "TREATMENT", 163, 177], ["further evaluation", "TEST", 210, 228], ["Monoclonal Antibody", "TEST", 274, 293], ["The monoclonal antibodies", "TEST", 293, 318], ["therapeutic antibodies", "PROBLEM", 328, 350], ["uncontrolled", "OBSERVATION_MODIFIER", 15, 27]]], ["The use of mAb in the prevention and treatment of infectious diseases can overwhelm various drawbacks which are cognate with the convalescent plasma therapy in terms of specificity, safety, low risk of blood-borne infection, purity, and other factors.", [["plasma", "ANATOMY", 142, 148], ["blood", "ANATOMY", 202, 207], ["infectious diseases", "DISEASE", 50, 69], ["blood-borne infection", "DISEASE", 202, 223], ["convalescent", "ORGANISM", 129, 141], ["plasma", "ORGANISM_SUBSTANCE", 142, 148], ["blood", "ORGANISM_SUBSTANCE", 202, 207], ["mAb", "PROTEIN", 11, 14], ["mAb", "TREATMENT", 11, 14], ["infectious diseases", "PROBLEM", 50, 69], ["various drawbacks", "TREATMENT", 84, 101], ["the convalescent plasma therapy", "TREATMENT", 125, 156], ["blood-borne infection", "PROBLEM", 202, 223], ["infectious", "OBSERVATION", 50, 60], ["infection", "OBSERVATION", 214, 223]]], ["A wide array of monoclonal antibodies have already been developed which are implemented in the anti-tumor, anti-platelet, or antiviral therapy (98) .Monoclonal AntibodyA SARS-CoV specific human mAb CR3022 has been found to bind with the RBD of the S protein of SARS-CoV-2, stipulating it as a prospective therapeutic agent, which can either be used alone or in combination therapy for the management of COVID-19 (99) .", [["anti-tumor", "ANATOMY", 95, 105], ["CR3022", "CHEMICAL", 198, 204], ["COVID-19", "CHEMICAL", 403, 411], ["anti-tumor", "CANCER", 95, 105], ["anti-platelet", "CELL", 107, 120], ["human", "ORGANISM", 188, 193], ["SARS-CoV-2", "ORGANISM", 261, 271], ["monoclonal antibodies", "PROTEIN", 16, 37], ["Monoclonal AntibodyA SARS-CoV specific human mAb CR3022", "PROTEIN", 149, 204], ["RBD", "PROTEIN", 237, 240], ["S protein", "PROTEIN", 248, 257], ["human", "SPECIES", 188, 193], ["SARS-CoV", "SPECIES", 170, 178], ["human", "SPECIES", 188, 193], ["SARS-CoV", "SPECIES", 261, 269], ["A wide array of monoclonal antibodies", "PROBLEM", 0, 37], ["anti-platelet", "TREATMENT", 107, 120], ["antiviral therapy", "TREATMENT", 125, 142], ["Monoclonal AntibodyA SARS", "TEST", 149, 174], ["CoV specific human mAb", "TEST", 175, 197], ["SARS", "TEST", 261, 265], ["CoV", "TEST", 266, 269], ["stipulating", "TREATMENT", 273, 284], ["a prospective therapeutic agent", "TREATMENT", 291, 322], ["COVID", "TEST", 403, 408], ["wide", "OBSERVATION_MODIFIER", 2, 6], ["monoclonal antibodies", "OBSERVATION", 16, 37]]], ["To achieve higher efficiency of disease prevention and treatment, a combinatorial effect of monoclonal antibodies recognizing different epitopes of the viral surface can be considered for the neutralization of the virus as it may prove to be more effective and prevent the viral escape (99) .Monoclonal AntibodyThere are over 61 patents which claim to have prepared the SARS-specific, MERS-specific, and the diagnostic antibodies.", [["surface", "ANATOMY", 158, 165], ["SARS", "DISEASE", 370, 374], ["monoclonal antibodies", "PROTEIN", 92, 113], ["epitopes", "PROTEIN", 136, 144], ["MERS", "PROTEIN", 385, 389], ["diagnostic antibodies", "PROTEIN", 408, 429], ["disease prevention", "TREATMENT", 32, 50], ["treatment", "TREATMENT", 55, 64], ["monoclonal antibodies", "TREATMENT", 92, 113], ["the viral surface", "TREATMENT", 148, 165], ["the virus", "PROBLEM", 210, 219], ["the viral escape", "PROBLEM", 269, 285], ["Monoclonal Antibody", "TEST", 292, 311], ["the SARS", "PROBLEM", 366, 374], ["higher efficiency", "OBSERVATION_MODIFIER", 11, 28], ["disease", "OBSERVATION", 32, 39], ["viral surface", "OBSERVATION", 152, 165], ["viral escape", "OBSERVATION", 273, 285]]], ["Another group of 38 patents claims to have developed the antibodies that target the host proteins like IL-6/IL-6R, TLR3, CD16, ITAM (immune-receptor tyrosinebased activation motif), DC-SIGN (dendritic cell-specific intercellular adhesion moleculegrabbing non-integrin), ICAM-3 (intercellular adhesion molecule 3), or IP-10/CXCL10 (interferon \u03b3-inducible protein 10).", [["DC", "ANATOMY", 182, 184], ["dendritic cell", "ANATOMY", 191, 205], ["IL-6", "GENE_OR_GENE_PRODUCT", 103, 107], ["IL-6R", "GENE_OR_GENE_PRODUCT", 108, 113], ["TLR3", "GENE_OR_GENE_PRODUCT", 115, 119], ["CD16", "GENE_OR_GENE_PRODUCT", 121, 125], ["ITAM", "GENE_OR_GENE_PRODUCT", 127, 131], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 182, 189], ["dendritic cell", "CELL", 191, 205], ["intercellular adhesion moleculegrabbing non-integrin", "GENE_OR_GENE_PRODUCT", 215, 267], ["ICAM-3", "GENE_OR_GENE_PRODUCT", 270, 276], ["intercellular adhesion molecule 3", "GENE_OR_GENE_PRODUCT", 278, 311], ["IP-10", "GENE_OR_GENE_PRODUCT", 317, 322], ["CXCL10", "GENE_OR_GENE_PRODUCT", 323, 329], ["interferon \u03b3-inducible protein 10", "GENE_OR_GENE_PRODUCT", 331, 364], ["antibodies", "PROTEIN", 57, 67], ["IL-6", "PROTEIN", 103, 107], ["IL", "PROTEIN", 108, 110], ["6R", "PROTEIN", 111, 113], ["TLR3", "PROTEIN", 115, 119], ["CD16", "PROTEIN", 121, 125], ["ITAM", "PROTEIN", 127, 131], ["immune-receptor tyrosinebased activation motif", "PROTEIN", 133, 179], ["DC", "CELL_TYPE", 182, 184], ["SIGN", "PROTEIN", 185, 189], ["dendritic cell-specific intercellular adhesion moleculegrabbing non-integrin", "PROTEIN", 191, 267], ["ICAM-3", "PROTEIN", 270, 276], ["intercellular adhesion molecule 3", "PROTEIN", 278, 311], ["IP-10", "PROTEIN", 317, 322], ["CXCL10", "PROTEIN", 323, 329], ["interferon \u03b3-inducible protein 10", "PROTEIN", 331, 364], ["the antibodies", "PROBLEM", 53, 67], ["the host proteins", "TEST", 80, 97], ["IL", "TEST", 103, 105], ["IL", "TEST", 108, 110], ["TLR3", "TREATMENT", 115, 119], ["CD16", "TEST", 121, 125], ["ITAM", "TEST", 127, 131], ["immune-receptor tyrosinebased activation motif", "TREATMENT", 133, 179], ["specific intercellular adhesion moleculegrabbing non-integrin", "TREATMENT", 206, 267], ["ICAM", "TEST", 270, 274], ["intercellular adhesion molecule", "TEST", 278, 309], ["IP", "TEST", 317, 319], ["CXCL10 (interferon \u03b3-inducible protein", "TREATMENT", 323, 361], ["dendritic cell", "OBSERVATION", 191, 205]]], ["These antibodies can be used to counteract against the cytokine storm that has been reported to harmonize with the SARS-CoV-2 infection (100).", [["SARS-CoV-2 infection", "DISEASE", 115, 135], ["SARS-CoV-2", "ORGANISM", 115, 125], ["antibodies", "PROTEIN", 6, 16], ["cytokine", "PROTEIN", 55, 63], ["SARS-CoV-2", "SPECIES", 115, 125], ["These antibodies", "TREATMENT", 0, 16], ["the cytokine storm", "PROBLEM", 51, 69], ["the SARS", "PROBLEM", 111, 119], ["CoV-2 infection", "PROBLEM", 120, 135]]], ["Tocilizumab, an anti-IL 6 receptor antibody is likely to control the hyper-inflammatory pulmonary symptoms which are coupled with the cytokine storm involving the chemokine dysregulation and various interleukins.", [["pulmonary", "ANATOMY", 88, 97], ["Tocilizumab", "CHEMICAL", 0, 11], ["Tocilizumab", "CHEMICAL", 0, 11], ["Tocilizumab", "SIMPLE_CHEMICAL", 0, 11], ["anti-IL 6 receptor", "GENE_OR_GENE_PRODUCT", 16, 34], ["pulmonary", "ORGAN", 88, 97], ["interleukins", "GENE_OR_GENE_PRODUCT", 199, 211], ["anti-IL 6 receptor antibody", "PROTEIN", 16, 43], ["cytokine", "PROTEIN", 134, 142], ["chemokine", "PROTEIN", 163, 172], ["interleukins", "PROTEIN", 199, 211], ["Tocilizumab", "TREATMENT", 0, 11], ["an anti-IL 6 receptor antibody", "TREATMENT", 13, 43], ["the hyper-inflammatory pulmonary symptoms", "PROBLEM", 65, 106], ["the cytokine storm", "PROBLEM", 130, 148], ["the chemokine dysregulation", "TREATMENT", 159, 186], ["inflammatory", "OBSERVATION_MODIFIER", 75, 87], ["pulmonary", "ANATOMY", 88, 97], ["symptoms", "OBSERVATION", 98, 106], ["chemokine dysregulation", "OBSERVATION", 163, 186]]], ["Tocilizumab has been reported to block the cytokine axis IL6 hence inhibiting the inflammatory cascade.", [["Tocilizumab", "CHEMICAL", 0, 11], ["Tocilizumab", "CHEMICAL", 0, 11], ["Tocilizumab", "SIMPLE_CHEMICAL", 0, 11], ["IL6", "GENE_OR_GENE_PRODUCT", 57, 60], ["cytokine", "PROTEIN", 43, 51], ["IL6", "PROTEIN", 57, 60], ["Tocilizumab", "TREATMENT", 0, 11], ["the cytokine axis IL6", "TREATMENT", 39, 60], ["the inflammatory cascade", "PROBLEM", 78, 102], ["inflammatory cascade", "OBSERVATION", 82, 102]]], ["However, further clinical trials are essential to establish the effectiveness of the mAb (101).", [["mAb", "PROTEIN", 85, 88], ["the mAb", "TREATMENT", 81, 88]]], ["Israel Institute for Biological Research (IIBR) claims to have successfully developed the mAb against SARS-CoV-2.", [["SARS", "DISEASE", 102, 106], ["SARS-CoV-2", "ORGANISM", 102, 112], ["mAb", "PROTEIN", 90, 93], ["SARS-CoV", "SPECIES", 102, 110], ["the mAb", "TREATMENT", 86, 93], ["SARS", "PROBLEM", 102, 106], ["CoV", "TEST", 107, 110]]], ["A group led by Professor Vijay Chaudhary at the University of Delhi, Centre for Innovation in Infectious Disease Research, Education and Training (UDSC-CIIDRET), is isolating the genes encoding the antibodies responsible for the neutralization of the SARS-CoV-2.", [["Infectious Disease", "DISEASE", 94, 112], ["SARS", "DISEASE", 251, 255], ["SARS-CoV-2", "ORGANISM", 251, 261], ["antibodies", "PROTEIN", 198, 208], ["SARS-CoV", "SPECIES", 251, 259], ["the SARS", "TEST", 247, 255]]], ["These genes will be employed to foster the recombinant Ab by exploiting the pre-existing inhouse antibody library and a library fabricated from the cells of convalescent COVID-19 patients (103).LimitationsThe duration of clinical trials poses a sizable amount of hindrance to swift vaccine development.", [["cells", "ANATOMY", 148, 153], ["Ab", "GENE_OR_GENE_PRODUCT", 55, 57], ["cells", "CELL", 148, 153], ["patients", "ORGANISM", 179, 187], ["Ab", "PROTEIN", 55, 57], ["inhouse antibody library", "DNA", 89, 113], ["patients", "SPECIES", 179, 187], ["the pre-existing inhouse antibody library", "PROBLEM", 72, 113], ["convalescent COVID", "TEST", 157, 175], ["clinical trials", "TREATMENT", 221, 236], ["swift vaccine development", "TREATMENT", 276, 301], ["antibody library", "OBSERVATION", 97, 113], ["sizable", "OBSERVATION_MODIFIER", 245, 252], ["amount", "OBSERVATION_MODIFIER", 253, 259], ["hindrance", "OBSERVATION", 263, 272]]], ["According to the norms laid down by the US Food and Drug Administration (FDA), and WHO, a vaccine candidate has to pass through at least three phases of placebo-controlled clinical trials for the validation of its safety and efficacy, which can take years to complete.", [["a vaccine", "TREATMENT", 88, 97], ["placebo", "TREATMENT", 153, 160], ["clinical trials", "TREATMENT", 172, 187]]], ["Considering the severity of the pandemic, which has forced a complete shut-down of the global economy, rapid vaccine development is necessary.", [["the pandemic", "PROBLEM", 28, 40], ["rapid vaccine development", "TREATMENT", 103, 128], ["pandemic", "OBSERVATION", 32, 40]]], ["Some authors suggest that the controlled human challenge studies may be conducted to suitably divert the Phase 3 testing, and allow the rapid licensure of the immunogenic vaccines.", [["human", "ORGANISM", 41, 46], ["human", "SPECIES", 41, 46], ["human", "SPECIES", 41, 46], ["the controlled human challenge studies", "TEST", 26, 64], ["the Phase 3 testing", "TEST", 101, 120], ["the immunogenic vaccines", "TREATMENT", 155, 179]]], ["However, in the expanded field study participants will be monitored constantly to look for any long-term implications posed by the vaccine.", [["participants", "SPECIES", 37, 49]]], ["Furthermore, the safety trials for the special groups including, children and pregnant women, and immuno-compromised patients can be conducted before the extension of the vaccination for these groups (104) .LimitationsThe testing and development of safe and effective vaccines rely upon laboratory animal models.", [["children", "ORGANISM", 65, 73], ["women", "ORGANISM", 87, 92], ["patients", "ORGANISM", 117, 125], ["children", "SPECIES", 65, 73], ["women", "SPECIES", 87, 92], ["patients", "SPECIES", 117, 125], ["the vaccination", "TREATMENT", 167, 182], ["The testing", "TEST", 218, 229], ["safe and effective vaccines", "TREATMENT", 249, 276]]], ["These animal models must show a similar course of the disease as in human beings.", [["human", "ORGANISM", 68, 73], ["human", "SPECIES", 68, 73], ["human", "SPECIES", 68, 73], ["the disease", "PROBLEM", 50, 61], ["disease", "OBSERVATION", 54, 61]]], ["However, the standard inbred strains of mice are not susceptible to the COVID-19 infection, due to the difference between the humans and mice ACE2 receptors (105).", [["infection", "DISEASE", 81, 90], ["inbred strains", "ORGANISM", 22, 36], ["mice", "ORGANISM", 40, 44], ["COVID-19", "ORGANISM", 72, 80], ["humans", "ORGANISM", 126, 132], ["mice", "ORGANISM", 137, 141], ["ACE2", "GENE_OR_GENE_PRODUCT", 142, 146], ["ACE2 receptors", "PROTEIN", 142, 156], ["mice", "SPECIES", 40, 44], ["humans", "SPECIES", 126, 132], ["mice", "SPECIES", 137, 141], ["mice", "SPECIES", 40, 44], ["COVID-19", "SPECIES", 72, 80], ["humans", "SPECIES", 126, 132], ["mice", "SPECIES", 137, 141], ["the COVID-19 infection", "PROBLEM", 68, 90], ["mice ACE2 receptors", "TREATMENT", 137, 156], ["infection", "OBSERVATION", 81, 90]]], ["This calls for the development of transgenic mice, expressing the hACE2 receptor.", [["mice", "ORGANISM", 45, 49], ["hACE2 receptor", "GENE_OR_GENE_PRODUCT", 66, 80], ["hACE2 receptor", "PROTEIN", 66, 80], ["mice", "SPECIES", 45, 49], ["mice", "SPECIES", 45, 49]]], ["Two animal models (hACE2 transgenic mice model and another, primate Macaques model) were previously developed for the SARS-CoV but the current situation requires steady breeding and distribution of these animal models to meet demands of the researchers around the globe (106) .", [["SARS", "DISEASE", 118, 122], ["hACE2", "ORGANISM", 19, 24], ["mice", "ORGANISM", 36, 40], ["primate", "ORGANISM", 60, 67], ["Macaques", "ORGANISM", 68, 76], ["SARS-CoV", "ORGANISM", 118, 126], ["mice", "SPECIES", 36, 40], ["mice", "SPECIES", 36, 40], ["SARS-CoV", "SPECIES", 118, 126], ["Two animal models", "TEST", 0, 17], ["hACE2 transgenic mice model", "TREATMENT", 19, 46], ["the SARS-CoV", "PROBLEM", 114, 126], ["these animal models", "PROBLEM", 198, 217], ["globe", "ANATOMY", 264, 269]]], ["The SARS-CoV-2 virus isolates can efficiently replicate in the lungs of the Syrian hamsters.", [["lungs", "ANATOMY", 63, 68], ["SARS-CoV-2 virus", "ORGANISM", 4, 20], ["lungs", "ORGAN", 63, 68], ["Syrian hamsters", "ORGANISM", 76, 91], ["CoV-2 virus", "SPECIES", 9, 20], ["Syrian hamsters", "SPECIES", 76, 91], ["SARS-CoV-2 virus", "SPECIES", 4, 20], ["Syrian hamsters", "SPECIES", 76, 91], ["The SARS", "TEST", 0, 8], ["CoV-2 virus isolates", "TREATMENT", 9, 29], ["lungs", "ANATOMY", 63, 68]]], ["The lungs of infected hamsters exhibit the pathological lesions analogous to the COVID-19 patients with pneumonia.", [["lungs", "ANATOMY", 4, 9], ["lesions", "ANATOMY", 56, 63], ["pneumonia", "DISEASE", 104, 113], ["lungs", "ORGAN", 4, 9], ["hamsters", "ORGANISM", 22, 30], ["lesions", "PATHOLOGICAL_FORMATION", 56, 63], ["patients", "ORGANISM", 90, 98], ["patients", "SPECIES", 90, 98], ["hamsters", "SPECIES", 22, 30], ["the pathological lesions", "PROBLEM", 39, 63], ["pneumonia", "PROBLEM", 104, 113], ["lungs", "ANATOMY", 4, 9], ["infected", "OBSERVATION", 13, 21], ["pathological", "OBSERVATION_MODIFIER", 43, 55], ["lesions", "OBSERVATION", 56, 63], ["pneumonia", "OBSERVATION", 104, 113]]], ["Moreover, the nAb response exhibited by the infected hamster demonstrated immunity against the succeeding re-challenge studies.", [["hamster", "ANATOMY", 53, 60], ["nAb", "GENE_OR_GENE_PRODUCT", 14, 17], ["hamster", "ORGANISM", 53, 60], ["nAb", "PROTEIN", 14, 17], ["hamster", "SPECIES", 53, 60], ["hamster", "SPECIES", 53, 60]]], ["Furthermore, the transfusion of convalescent sera into the na\u00efve hamsters mounted the antibody response and hence hindered the viral replication in the lungs.", [["sera", "ANATOMY", 45, 49], ["lungs", "ANATOMY", 152, 157], ["convalescent", "ORGANISM", 32, 44], ["sera", "ORGANISM_SUBSTANCE", 45, 49], ["hamsters", "ORGANISM", 65, 73], ["lungs", "ORGAN", 152, 157], ["hamsters", "SPECIES", 65, 73], ["the transfusion of convalescent sera", "TREATMENT", 13, 49], ["the antibody response", "TEST", 82, 103], ["the viral replication in the lungs", "PROBLEM", 123, 157], ["viral replication", "OBSERVATION", 127, 144], ["lungs", "ANATOMY", 152, 157]]], ["The assemblage of these experiments have illustrated the Syrian hamster may be a perfect model for comprehending SARS-CoV-2 pathogenesis, and evaluating the vaccines, antiviral drugs, and the immunotherapies (107) .", [["hamster", "ANATOMY", 64, 71], ["Syrian hamster", "ORGANISM", 57, 71], ["CoV-2", "ORGANISM", 118, 123], ["Syrian hamster", "SPECIES", 57, 71], ["Syrian hamster", "SPECIES", 57, 71], ["SARS-CoV", "SPECIES", 113, 121], ["comprehending SARS", "PROBLEM", 99, 117], ["the vaccines", "TREATMENT", 153, 165], ["antiviral drugs", "TREATMENT", 167, 182], ["the immunotherapies", "TREATMENT", 188, 207], ["assemblage", "OBSERVATION_MODIFIER", 4, 14]]], ["Nevertheless, the assessment of the vaccine dependent immune enhancement cannot be extrapolated from the animal models and requires a legitimate survey from stage III human trials or the human challenge studies.LimitationsThe Antibody dependent enhancement (ADE) is exploited by various viruses like Dengue, HIV, animal coronaviruses, etc. as an alternative method of infecting a variety of host cells.", [["cells", "ANATOMY", 396, 401], ["Dengue, HIV, animal coronaviruses", "DISEASE", 300, 333], ["human", "ORGANISM", 167, 172], ["human", "ORGANISM", 187, 192], ["Dengue", "ORGANISM", 300, 306], ["HIV", "ORGANISM", 308, 311], ["animal coronaviruses", "ORGANISM", 313, 333], ["host cells", "CELL", 391, 401], ["host cells", "CELL_TYPE", 391, 401], ["human", "SPECIES", 167, 172], ["human", "SPECIES", 187, 192], ["HIV", "SPECIES", 308, 311], ["human", "SPECIES", 167, 172], ["human", "SPECIES", 187, 192], ["HIV", "SPECIES", 308, 311], ["the assessment", "TEST", 14, 28], ["the vaccine dependent immune enhancement", "PROBLEM", 32, 72], ["stage III human trials", "TREATMENT", 157, 179], ["the human challenge studies", "TEST", 183, 210], ["The Antibody dependent enhancement", "PROBLEM", 222, 256], ["various viruses", "PROBLEM", 279, 294], ["Dengue", "PROBLEM", 300, 306], ["HIV", "PROBLEM", 308, 311], ["animal coronaviruses", "PROBLEM", 313, 333], ["host cells", "PROBLEM", 391, 401], ["Antibody dependent", "OBSERVATION_MODIFIER", 226, 244], ["enhancement", "OBSERVATION_MODIFIER", 245, 256], ["viruses", "OBSERVATION", 287, 294], ["host cells", "OBSERVATION", 391, 401]]], ["The virusantibody complex can bind to the Fc receptors, activate the complement system, or induce a conformational change in the glycoprotein of the viral envelope (108).", [["virusantibody complex", "PROTEIN", 4, 25], ["Fc receptors", "PROTEIN", 42, 54], ["glycoprotein", "PROTEIN", 129, 141], ["The virusantibody complex", "PROBLEM", 0, 25], ["a conformational change", "PROBLEM", 98, 121]]], ["This mechanism is observed when the vaccine-induced antibodies are either non-neutralizing or they are present in inadequate concentrations.", [["vaccine-induced antibodies", "PROTEIN", 36, 62], ["the vaccine-induced antibodies", "TREATMENT", 32, 62], ["non-neutralizing", "PROBLEM", 74, 90]]], ["This process triggers the viral entry into the cell due to the intensified binding efficiency of the virus-antibody complexes to FcR bearing cells.", [["cell", "ANATOMY", 47, 51], ["cells", "ANATOMY", 141, 146], ["cell", "CELL", 47, 51], ["FcR", "GENE_OR_GENE_PRODUCT", 129, 132], ["cells", "CELL", 141, 146], ["virus-antibody complexes", "PROTEIN", 101, 125], ["FcR", "PROTEIN", 129, 132], ["the intensified binding efficiency", "PROBLEM", 59, 93], ["the virus", "PROBLEM", 97, 106]]], ["The clinical and preclinical trials of SARS-CoV vaccine candidates have demonstrated the aggravation of the disease due to ADE.", [["SARS", "DISEASE", 39, 43], ["ADE", "DISEASE", 123, 126], ["SARS-CoV", "ORGANISM", 39, 47], ["SARS-CoV", "SPECIES", 39, 47], ["SARS-CoV vaccine", "TREATMENT", 39, 55], ["the aggravation of the disease", "PROBLEM", 85, 115], ["disease", "OBSERVATION", 108, 115]]], ["Vaccine Associated Enhanced Respiratory Disease (VAERD) can also be induced by virusantibody immune complex and TH2-biased responses (36) .LimitationsThe viral genome is vulnerable to mutations and can undergo the antigenic shift and the antigenic drift, as it continues to spread from one population to the next.", [["Enhanced Respiratory Disease", "DISEASE", 19, 47], ["virusantibody immune complex", "GENE_OR_GENE_PRODUCT", 79, 107], ["TH2", "GENE_OR_GENE_PRODUCT", 112, 115], ["virusantibody immune complex", "PROTEIN", 79, 107], ["TH2", "PROTEIN", 112, 115], ["viral genome", "DNA", 154, 166], ["Vaccine", "TREATMENT", 0, 7], ["Enhanced Respiratory Disease (VAERD)", "PROBLEM", 19, 55], ["mutations", "PROBLEM", 184, 193], ["the antigenic shift", "PROBLEM", 210, 229], ["the antigenic drift", "PROBLEM", 234, 253], ["Enhanced", "OBSERVATION_MODIFIER", 19, 27], ["Respiratory Disease", "OBSERVATION", 28, 47], ["viral genome", "OBSERVATION", 154, 166], ["antigenic drift", "OBSERVATION", 238, 253]]], ["The mutations may vary according to the environmental conditions of a geographical area, and the population density.", [["The mutations", "PROBLEM", 0, 13], ["population", "OBSERVATION_MODIFIER", 97, 107], ["density", "OBSERVATION", 108, 115]]], ["By screening the 7500 samples of the infected patients, the scientists were able to figure out 198 mutations that may have materialized independently which may indicate the evolution of the virus inside the human host.", [["patients", "ORGANISM", 46, 54], ["human", "ORGANISM", 207, 212], ["patients", "SPECIES", 46, 54], ["human", "SPECIES", 207, 212], ["human", "SPECIES", 207, 212], ["the virus inside the human host", "PROBLEM", 186, 217], ["infected", "OBSERVATION_MODIFIER", 37, 45], ["virus", "OBSERVATION", 190, 195]]], ["These mutations may lead to different subtypes which may allow the virus to escape the immune system even after the administration of the vaccine (109).ConclusionSARS-CoV-2 has been the matter of the moment from the date it was declared as a pandemic, it has led to the termination of economic activities universally.", [["immune system", "ANATOMY", 87, 100], ["These mutations", "PROBLEM", 0, 15], ["different subtypes", "PROBLEM", 28, 46], ["the virus", "PROBLEM", 63, 72], ["the vaccine", "TREATMENT", 134, 145], ["ConclusionSARS", "TEST", 152, 166]]], ["Scientists across the continents are joining hands for the innovative tie-ups with both the pharmaceutical giants and the medical startups to repurpose drugs, develop vaccines, and devices to impede the progress of this overwhelming pandemic.", [["drugs", "TREATMENT", 152, 157], ["vaccines", "TREATMENT", 167, 175], ["devices", "TREATMENT", 181, 188], ["pandemic", "PROBLEM", 233, 241]]], ["A large number of COVID-19 vaccine candidates based upon various platforms have already been identified.", [["COVID-19 vaccine candidates", "TREATMENT", 18, 45], ["various platforms", "TEST", 57, 74], ["large", "OBSERVATION_MODIFIER", 2, 7], ["number", "OBSERVATION_MODIFIER", 8, 14]]], ["The process of vaccine development is quite laborious with various stages, including the pre-clinical stage, and clinical development which is a three-phase process.", [["vaccine development", "TREATMENT", 15, 34]]], ["However, if sufficient data is already available, it has been recommended to skip a few stages, to accelerate the attainment of a vaccine faster with a quick regulatory review, approval, manufacturing, and quality control.", [["a vaccine", "TREATMENT", 128, 137]]], ["This novel Coronavirus has therefore forced the scientific community to use unconventional approaches to accelerate the process of vaccine development.", [["Coronavirus", "CHEMICAL", 11, 22], ["This novel Coronavirus", "PROBLEM", 0, 22], ["unconventional approaches", "TREATMENT", 76, 101], ["vaccine development", "TREATMENT", 131, 150], ["Coronavirus", "OBSERVATION", 11, 22]]], ["According to WHO: \"vaccine must provide a highly favorable benefit-risk contour; with high efficacy, only mild or transient adverse effects and no serious ailments.\"", [["vaccine", "TREATMENT", 19, 26], ["mild or transient adverse effects", "PROBLEM", 106, 139], ["serious ailments", "PROBLEM", 147, 163], ["mild", "OBSERVATION_MODIFIER", 106, 110]]], ["The vaccine must be suitable for all ages, pregnant, and lactating women and should provide a rapid onset of protection with a single dose and confer safety for at least up to one year of administration.ConclusionThe use of novel technologies for vaccine development requires extensive testing for the safety and efficacy of a vaccine.", [["women", "ORGANISM", 67, 72], ["women", "SPECIES", 67, 72], ["The vaccine", "TREATMENT", 0, 11], ["novel technologies", "TREATMENT", 224, 242], ["vaccine development", "TREATMENT", 247, 266], ["extensive testing", "TEST", 276, 293], ["a vaccine", "TREATMENT", 325, 334]]], ["The scientific community needs to construct various processes and capacities for the largescale production of the manufacturing and administration of the coronavirus vaccines.", [["coronavirus", "DISEASE", 154, 165], ["coronavirus", "ORGANISM", 154, 165], ["the manufacturing", "TREATMENT", 110, 127], ["the coronavirus vaccines", "TREATMENT", 150, 174]]], ["The Coalition for Epidemic Preparedness Innovation (CEPI), an international nongovernmental organization, which is funded by the Wellcome Trust, the European Commission, the Bill and Melinda Gates Foundation, and eight countries, is subsidizing the development of a large number of pandemic vaccine candidates around the globe.", [["pandemic vaccine", "TREATMENT", 282, 298], ["large", "OBSERVATION_MODIFIER", 266, 271], ["globe", "ANATOMY", 321, 326]]], ["Moderna and the Vaccine Research Centre are co-developing an mRNA based vaccine candidate, wherein the mRNA is encapsulated in the lipid nanoparticles while Codagenix in collaboration with the Serum Institute of India is currently focused on developing the live attenuated viral vaccine.", [["Codagenix", "CHEMICAL", 157, 166], ["lipid nanoparticles", "SIMPLE_CHEMICAL", 131, 150], ["Codagenix", "SIMPLE_CHEMICAL", 157, 166], ["mRNA", "RNA", 103, 107], ["Moderna", "TREATMENT", 0, 7], ["an mRNA based vaccine", "TREATMENT", 58, 79], ["the lipid nanoparticles", "TREATMENT", 127, 150], ["Codagenix", "TREATMENT", 157, 166], ["viral vaccine", "TREATMENT", 273, 286]]], ["The pharmaceutical giants like Novavax, Sichuan Clover Biopharmaceuticals, iBio, and the University of Queensland are in the preclinical stage of the recombinant S glycoprotein vaccines.", [["Novavax", "CHEMICAL", 31, 38], ["Novavax", "TREATMENT", 31, 38], ["Sichuan Clover Biopharmaceuticals", "TREATMENT", 40, 73], ["the recombinant S glycoprotein vaccines", "TREATMENT", 146, 185]]], ["Additional strategies like the viral vector-based vaccines, targeting the S glycoprotein are being developed by the University of Oxford and CanSino Biologics, and other companies, Inovio and the Applied DNA Sciences are currently developing the DNA based vaccine candidates against the SARS-CoV-2 S Protein.", [["SARS", "DISEASE", 287, 291], ["S glycoprotein", "GENE_OR_GENE_PRODUCT", 74, 88], ["DNA", "CELLULAR_COMPONENT", 204, 207], ["DNA", "CELLULAR_COMPONENT", 246, 249], ["S glycoprotein", "PROTEIN", 74, 88], ["SARS-CoV-2 S Protein", "PROTEIN", 287, 307], ["SARS-CoV", "SPECIES", 287, 295], ["Additional strategies", "TREATMENT", 0, 21], ["the viral vector-based vaccines", "TREATMENT", 27, 58], ["the S glycoprotein", "TREATMENT", 70, 88], ["CanSino Biologics", "TREATMENT", 141, 158], ["Inovio", "TREATMENT", 181, 187], ["the DNA based vaccine", "TREATMENT", 242, 263], ["the SARS", "TEST", 283, 291], ["CoV", "TEST", 292, 295]]], ["Some of these vaccine candidates are at least months, away from being ready for human use, while others may take longer if at all approved for final use.ConclusionIn India alone, six biotech ventures i.e. Serum Institute of India, ZydusCadila, Biological E, Indian Immunologicals, Bharat Biotech, and Mynvax are working in collaboration with various international vaccine developers.", [["human", "ORGANISM", 80, 85], ["human", "SPECIES", 80, 85], ["human", "SPECIES", 80, 85], ["these vaccine candidates", "TREATMENT", 8, 32], ["Mynvax", "TREATMENT", 301, 307]]], ["They are working on DNA vaccines, live attenuated recombinant measles vaccines, inactivated viral vaccines, subunit vaccines, and the vaccines developed by codon-optimization (110) .", [["DNA", "CELLULAR_COMPONENT", 20, 23], ["DNA vaccines", "TREATMENT", 20, 32], ["live attenuated recombinant measles vaccines", "TREATMENT", 34, 78], ["inactivated viral vaccines", "TREATMENT", 80, 106], ["subunit vaccines", "TREATMENT", 108, 124], ["the vaccines", "TREATMENT", 130, 142]]], ["Furthermore, the academic institutes like National Institute of Immunology (NII), Indian Institute of Science (IISc), International Center for Genetic Engineering and Biotechnology (ICGEB) New Delhi, Translational Health Service, and Technology Institute (THSTI), etc. are attempting to develop the vaccines, and therapies, and the SARS-CoV-2 animal models to restrain the pandemic shortly (111) .ConclusionThe need of the hour is to develop a safe and effective COVID-19 vaccine which can induce an appropriate immune response to terminate this pandemic.", [["SARS-CoV", "SPECIES", 332, 340], ["the vaccines", "TREATMENT", 295, 307], ["therapies", "TREATMENT", 313, 322], ["the SARS", "TEST", 328, 336], ["CoV", "TEST", 337, 340], ["a safe and effective COVID-19 vaccine", "TREATMENT", 442, 479]]], ["It is the universal priority to spot the international funding mechanisms to support the development, manufacturing, and stockpiling of the coronavirus vaccines.", [["coronavirus", "DISEASE", 140, 151], ["coronavirus", "ORGANISM", 140, 151], ["the coronavirus vaccines", "TREATMENT", 136, 160]]], ["A pan-coronavirus vaccine is urgently needed as the delay of vaccine rollout even by one week will accompany millions of deaths.", [["deaths", "DISEASE", 121, 127], ["A pan-coronavirus vaccine", "TREATMENT", 0, 25], ["the delay of vaccine rollout", "TREATMENT", 48, 76]]]], "aee3a47fa1a1968a63cc9631b387db7656876f65": [["IntroductionCOVID-19 (Coronavirus Disease 2019) is an infectious virus outbreak which emerged as an epidemic in one city in December 2019 and within 3 months swept across 213 countries and territories into a pandemic global health crisis with more than 3 million confirmed infected cases and 217,000 deaths as of April 30, 2020 (WHO).", [["Coronavirus Disease", "DISEASE", 22, 41], ["deaths", "DISEASE", 300, 306], ["IntroductionCOVID", "TEST", 0, 17], ["Coronavirus Disease", "PROBLEM", 22, 41], ["an infectious virus outbreak", "PROBLEM", 51, 79], ["a pandemic global health crisis", "PROBLEM", 206, 237], ["infectious", "OBSERVATION_MODIFIER", 54, 64]]], ["The novel coronavirus (SARS-CoV-2/nCoV -19) has been identified as the causative agent of this coronavirus disease named COVID-19 (19 refers to the year 2019 when it started).", [["coronavirus disease", "DISEASE", 95, 114], ["coronavirus", "ORGANISM", 10, 21], ["SARS-CoV-2", "ORGANISM", 23, 33], ["nCoV -19", "ORGANISM", 34, 42], ["coronavirus", "ORGANISM", 95, 106], ["coronavirus", "SPECIES", 10, 21], ["coronavirus", "SPECIES", 95, 106], ["SARS-CoV-2/nCoV -19", "SPECIES", 23, 42], ["The novel coronavirus", "TEST", 0, 21], ["SARS", "TEST", 23, 27], ["CoV", "TEST", 28, 31], ["nCoV", "TEST", 34, 38], ["this coronavirus disease", "PROBLEM", 90, 114], ["COVID", "TEST", 121, 126], ["coronavirus", "OBSERVATION", 10, 21]]], ["1 nCoV19 belongs to the large family of coronaviruses (coronaviridae) known to be pathogenic in mammals and birds.", [["nCoV19", "GENE_OR_GENE_PRODUCT", 2, 8], ["coronaviruses", "ORGANISM", 40, 53], ["coronaviridae", "CANCER", 55, 68], ["birds", "ORGANISM", 108, 113], ["nCoV19", "PROTEIN", 2, 8], ["coronaviruses (coronaviridae", "TREATMENT", 40, 68], ["pathogenic", "OBSERVATION", 82, 92]]], ["They are enveloped viruses with a positive-sense single-stranded RNA genome of 26.2-31.7 kilobases.", [["positive-sense single-stranded RNA genome", "DNA", 34, 75], ["stranded RNA genome", "TEST", 56, 75], ["viruses", "OBSERVATION", 19, 26]]], ["2 In humans, they cause respiratory infections ranging from the common cold to possibly-fatal acute respiratory distress syndrome (ARDS) and acute lung injury (ALI), which are noted in COVID-19 as well as in its predecessors, namely, SARS (severe acute respiratory syndrome, [2002] [2003] and MERS (middle east respiratory syndrome, 2012).", [["respiratory", "ANATOMY", 24, 35], ["respiratory", "ANATOMY", 100, 111], ["lung", "ANATOMY", 147, 151], ["respiratory infections", "DISEASE", 24, 46], ["acute respiratory distress syndrome", "DISEASE", 94, 129], ["ARDS", "DISEASE", 131, 135], ["acute lung injury", "DISEASE", 141, 158], ["ALI", "DISEASE", 160, 163], ["SARS", "DISEASE", 234, 238], ["acute respiratory syndrome", "DISEASE", 247, 273], ["middle east respiratory syndrome", "DISEASE", 299, 331], ["humans", "ORGANISM", 5, 11], ["lung", "ORGAN", 147, 151], ["humans", "SPECIES", 5, 11], ["humans", "SPECIES", 5, 11], ["respiratory infections", "PROBLEM", 24, 46], ["fatal acute respiratory distress syndrome", "PROBLEM", 88, 129], ["ARDS)", "PROBLEM", 131, 136], ["acute lung injury", "PROBLEM", 141, 158], ["ALI", "PROBLEM", 160, 163], ["COVID", "TEST", 185, 190], ["SARS (severe acute respiratory syndrome", "PROBLEM", 234, 273], ["MERS (middle east respiratory syndrome", "PROBLEM", 293, 331], ["respiratory", "ANATOMY", 24, 35], ["infections", "OBSERVATION", 36, 46], ["fatal", "OBSERVATION_MODIFIER", 88, 93], ["acute", "OBSERVATION_MODIFIER", 94, 99], ["respiratory distress syndrome", "OBSERVATION", 100, 129], ["ARDS", "OBSERVATION", 131, 135], ["acute", "OBSERVATION_MODIFIER", 141, 146], ["lung", "ANATOMY", 147, 151], ["injury", "OBSERVATION", 152, 158], ["ALI", "OBSERVATION", 160, 163], ["severe", "OBSERVATION_MODIFIER", 240, 246], ["acute", "OBSERVATION_MODIFIER", 247, 252], ["respiratory syndrome", "OBSERVATION", 253, 273]]], ["3 nCoV19 is airborne, and causes no symptoms in several infected people who may become silent carriers of the disease to more vulnerable population; COVID-19 is spreading at an exponential rate globally, prompting efforts to develop technologies, therapeutics and vaccines to prevent it from reaching its projected peak.", [["people", "ORGANISM", 65, 71], ["COVID-19", "CELL", 149, 157], ["people", "SPECIES", 65, 71], ["symptoms", "PROBLEM", 36, 44], ["the disease", "PROBLEM", 106, 117], ["COVID", "TEST", 149, 154], ["therapeutics", "TREATMENT", 247, 259], ["vaccines", "TREATMENT", 264, 272], ["no", "UNCERTAINTY", 33, 35]]], ["Scientists across the globe are studying the genetic features of nCoV19 and investigating the mechanisms of its host invasion and hostresponse to viral infection, in hopes of discovering treatment strategies to combat the outbreak.IntroductionThe viral infection sets off a cascade of interactions among multiple genes and proteins in the host cell.", [["cell", "ANATOMY", 344, 348], ["viral infection", "DISEASE", 146, 161], ["viral infection", "DISEASE", 247, 262], ["nCoV19", "GENE_OR_GENE_PRODUCT", 65, 71], ["host cell", "CELL", 339, 348], ["host cell", "CELL_TYPE", 339, 348], ["nCoV19", "TREATMENT", 65, 71], ["its host invasion", "PROBLEM", 108, 125], ["viral infection", "PROBLEM", 146, 161], ["treatment strategies", "TREATMENT", 187, 207], ["the outbreak", "PROBLEM", 218, 230], ["The viral infection", "PROBLEM", 243, 262], ["globe", "ANATOMY", 22, 27], ["host invasion", "OBSERVATION", 112, 125], ["viral", "OBSERVATION_MODIFIER", 146, 151], ["infection", "OBSERVATION", 152, 161], ["viral", "OBSERVATION_MODIFIER", 247, 252], ["infection", "OBSERVATION", 253, 262], ["host cell", "OBSERVATION", 339, 348]]], ["This complex network has the potential to restrict viral replication in host cells, or conversely to be taken over by the virus for its replication.", [["cells", "ANATOMY", 77, 82], ["host cells", "CELL", 72, 82], ["host cells", "CELL_TYPE", 72, 82], ["viral replication in host cells", "TREATMENT", 51, 82], ["host cells", "OBSERVATION", 72, 82]]], ["Several research groups have studied the effects of nCoV19 on the host from a systems-level perspective.", [["nCoV19", "CHEMICAL", 52, 58], ["nCoV19", "GENE_OR_GENE_PRODUCT", 52, 58], ["nCoV19", "PROTEIN", 52, 58]]], ["[4] [5] [6] 332 human proteins that bind to nCoV19 proteins were identified through affinity purificationmass spectrometry (AP-MS) by Gordon et al. 6 Melo et al. identified 120 genes differentially expressed in the A549 human cell line on nCoV19 infection.", [["A549", "ANATOMY", 215, 219], ["cell line", "ANATOMY", 226, 235], ["nCoV19", "ANATOMY", 239, 245], ["[4] [5", "CHEMICAL", 0, 6], ["infection", "DISEASE", 246, 255], ["[4] [5] [6", "SIMPLE_CHEMICAL", 0, 10], ["human", "ORGANISM", 16, 21], ["nCoV19", "GENE_OR_GENE_PRODUCT", 44, 50], ["A549", "CELL", 215, 219], ["human", "ORGANISM", 220, 225], ["cell line", "CELL", 226, 235], ["nCoV19", "CELL", 239, 245], ["human proteins", "PROTEIN", 16, 30], ["nCoV19 proteins", "PROTEIN", 44, 59], ["A549 human cell line", "CELL_LINE", 215, 235], ["human", "SPECIES", 16, 21], ["human", "SPECIES", 220, 225], ["human", "SPECIES", 16, 21], ["human", "SPECIES", 220, 225], ["human proteins", "TEST", 16, 30], ["nCoV19 proteins", "TEST", 44, 59], ["affinity purificationmass spectrometry", "TEST", 84, 122], ["the A549 human cell line", "TREATMENT", 211, 235], ["nCoV19 infection", "PROBLEM", 239, 255], ["A549 human cell line", "OBSERVATION", 215, 235], ["infection", "OBSERVATION", 246, 255]]], ["5 Bojkova et al. monitored nCoV19 infection in Caco2 cell line and generated temporal infection profiles of 2,687 genes in the host translatome and 6,258 gene in the proteome.", [["Caco2 cell line", "ANATOMY", 47, 62], ["infection", "DISEASE", 34, 43], ["Caco2 cell line", "CELL", 47, 62], ["translatome", "CANCER", 132, 143], ["Caco2 cell line", "CELL_LINE", 47, 62], ["2,687 genes", "DNA", 108, 119], ["6,258 gene", "DNA", 148, 158], ["nCoV19 infection", "PROBLEM", 27, 43], ["Caco2 cell line", "TREATMENT", 47, 62], ["temporal infection profiles", "TEST", 77, 104], ["infection", "OBSERVATION", 34, 43], ["Caco2 cell line", "OBSERVATION", 47, 62], ["temporal", "OBSERVATION_MODIFIER", 77, 85], ["infection", "OBSERVATION", 86, 95]]], ["7 Data generated by these studies can be employed to conduct a systematic, unbiased and data-driven investigation into COVD-19 from the perspective of the host, by constructing the relevant protein interactome (i.e. protein-protein interaction network).IntroductionProtein-protein interactions (PPIs) drive the cellular machinery and facilitate biological processes including signal transduction, formation of cellular structures and enzymatic complexes.", [["cellular", "ANATOMY", 311, 319], ["cellular structures", "ANATOMY", 410, 429], ["cellular", "CELL", 311, 319], ["cellular structures", "CELLULAR_COMPONENT", 410, 429], ["COVD-19", "DNA", 119, 126], ["protein-protein interaction network", "PROTEIN", 216, 251], ["enzymatic complexes", "PROTEIN", 434, 453], ["these studies", "TEST", 20, 33], ["protein-protein interaction network", "TREATMENT", 216, 251], ["IntroductionProtein-protein interactions (PPIs)", "TREATMENT", 253, 300], ["the cellular machinery", "TREATMENT", 307, 329], ["signal transduction", "TREATMENT", 376, 395], ["cellular structures", "OBSERVATION", 410, 429], ["enzymatic complexes", "OBSERVATION", 434, 453]]], ["When viral proteins bind to some proteins in the host cell, this effect spreads through regulatory and biophysical interactions along the interactome affecting other proteins in the PPI network, posing deeper implications for the infection, host immunity, and the effect of therapeutics.", [["cell", "ANATOMY", 54, 58], ["infection", "DISEASE", 230, 239], ["host cell", "CELL", 49, 58], ["viral proteins", "PROTEIN", 5, 19], ["viral proteins bind", "PROBLEM", 5, 24], ["some proteins in the host cell", "PROBLEM", 28, 58], ["the PPI network", "TREATMENT", 178, 193], ["the infection", "PROBLEM", 226, 239], ["therapeutics", "TREATMENT", 274, 286], ["host cell", "OBSERVATION", 49, 58], ["infection", "OBSERVATION", 230, 239]]], ["8 Despite being critical to unravelling novel disease mechanisms and drugs, ~85% of estimated PPIs are currently unknown and several disease-associated genes have no known PPIs.", [["disease-associated genes", "DNA", 133, 157], ["unravelling novel disease mechanisms", "PROBLEM", 28, 64], ["drugs", "TREATMENT", 69, 74], ["estimated PPIs", "PROBLEM", 84, 98], ["several disease", "PROBLEM", 125, 140], ["known PPIs", "PROBLEM", 166, 176], ["several", "OBSERVATION_MODIFIER", 125, 132], ["disease", "OBSERVATION", 133, 140], ["PPIs", "OBSERVATION", 172, 176]]], ["More than ~600,000 PPIs are said to exist in the human interactome 9 and only ~90,000 PPIs are known from PPI repositories such as HPRD 10 and BioGRID 11 .", [["human", "ORGANISM", 49, 54], ["human", "SPECIES", 49, 54], ["human", "SPECIES", 49, 54], ["PPIs", "TREATMENT", 19, 23], ["the human interactome", "TEST", 45, 66], ["PPIs", "TREATMENT", 86, 90], ["PPI repositories", "TREATMENT", 106, 122], ["HPRD", "TEST", 131, 135], ["BioGRID", "TREATMENT", 143, 150]]], ["Detecting the PPIs using experimental techniques such as co-immunoprecipitation (Co-IP) 12, 13 are prohibitively laborious and timeconsuming at large scale.", [["the PPIs", "TREATMENT", 10, 18], ["experimental techniques", "TREATMENT", 25, 48], ["co-immunoprecipitation (Co-IP)", "TREATMENT", 57, 87], ["PPIs", "OBSERVATION", 14, 18]]], ["Tens of thousands of PPIs are being added into the interactome through systematic high throughput studies with yeast two hybrid system 14 and AP-MS 15 .", [["yeast", "SPECIES", 111, 116], ["yeast", "SPECIES", 111, 116], ["PPIs", "TREATMENT", 21, 25], ["yeast two hybrid system", "PROBLEM", 111, 134], ["AP-MS", "TEST", 142, 147], ["thousands", "OBSERVATION_MODIFIER", 8, 17], ["PPIs", "OBSERVATION", 21, 25]]], ["A large part of the interactome (>70-80%) remains unknown yet.", [["the interactome", "TEST", 16, 31], ["large", "OBSERVATION_MODIFIER", 2, 7]]], ["Hence, computational algorithms have been developed to predict PPIs in human as well as model organisms.", [["human", "ORGANISM", 71, 76], ["human", "SPECIES", 71, 76], ["human", "SPECIES", 71, 76], ["computational algorithms", "TEST", 7, 31], ["PPIs in human", "PROBLEM", 63, 76], ["model organisms", "PROBLEM", 88, 103]]], ["[16] [17] [18] [19] [20] [21] [22] [23] [24] We developed a computational model called HiPPIP (high-precision protein-protein interaction prediction) that was deemed highly accurate by computational evaluations, and experimental validations of some pairs (sixteen PPIs were tested by experiments and all sixteen were shown to be true PPIs (Supplementary Table S1 )).", [["[16] [17] [18] [19] [20] [21] [22] [23] [24]", "SIMPLE_CHEMICAL", 0, 44], ["HiPPIP", "SIMPLE_CHEMICAL", 87, 93], ["HiPPIP", "PROTEIN", 87, 93], ["HiPPIP", "TEST", 87, 93], ["computational evaluations", "TEST", 185, 210], ["some pairs", "PROBLEM", 244, 254], ["sixteen PPIs", "TREATMENT", 256, 268]]], ["25, 26 HiPPIP computes features of protein pairs such as cellular localization, molecular function, biological process membership, genomic location of the gene, and gene expression in microarray experiments, and classifies the pairwise features as interacting or non-interacting based on a random forest model.", [["cellular", "ANATOMY", 57, 65], ["cellular", "CELL", 57, 65], ["HiPPIP", "PROTEIN", 7, 13], ["protein pairs", "PROBLEM", 35, 48], ["cellular localization", "TEST", 57, 78], ["a random forest model", "TREATMENT", 288, 309], ["protein pairs", "OBSERVATION", 35, 48]]], ["25 The threshold of HiPPIP to classify a proteinpair as \"a PPI\" was set high in such a way that it yields very high-precision even if low recall.", [["HiPPIP", "PROTEIN", 20, 26], ["HiPPIP", "TREATMENT", 20, 26], ["a proteinpair", "TREATMENT", 39, 52], ["a PPI\"", "TREATMENT", 57, 63]]], ["Some of the PPIs predicted by HiPPIP proved to be of high translational impact.", [["HiPPIP", "CHEMICAL", 30, 36], ["HiPPIP", "SIMPLE_CHEMICAL", 30, 36], ["HiPPIP", "PROTEIN", 30, 36], ["the PPIs", "TREATMENT", 8, 16], ["high translational impact", "PROBLEM", 53, 78], ["high", "OBSERVATION", 53, 57]]], ["For example, we predicted that the human OASL protein (IFNinducible oligoadenylate synthetases-like) interacts with RIG-I (retinoic acid-inducible gene I); it was validated to be a true PPI.", [["human", "ORGANISM", 35, 40], ["OASL", "GENE_OR_GENE_PRODUCT", 41, 45], ["IFNinducible oligoadenylate synthetases", "GENE_OR_GENE_PRODUCT", 55, 94], ["RIG-I", "GENE_OR_GENE_PRODUCT", 116, 121], ["retinoic acid-inducible gene I", "GENE_OR_GENE_PRODUCT", 123, 153], ["human OASL protein", "PROTEIN", 35, 53], ["IFNinducible oligoadenylate synthetases", "PROTEIN", 55, 94], ["RIG-I", "PROTEIN", 116, 121], ["retinoic acid-inducible gene I", "DNA", 123, 153], ["human", "SPECIES", 35, 40], ["human", "SPECIES", 35, 40], ["the human OASL protein", "TEST", 31, 53], ["IFNinducible oligoadenylate synthetases", "PROBLEM", 55, 94], ["RIG-I (retinoic acid-inducible", "TREATMENT", 116, 146], ["a true PPI", "TREATMENT", 179, 189]]], ["Further investigations conclusively showed that this interaction is responsible for activating cellular innate immunity to virus infections: 26 OASL enhances antiviral signalling mediated by the viral RNA sensor RIG-I by binding through its C-terminal ubiquitin-like domain.", [["cellular", "ANATOMY", 95, 103], ["infections", "DISEASE", 129, 139], ["C", "CHEMICAL", 241, 242], ["cellular", "CELL", 95, 103], ["OASL", "GENE_OR_GENE_PRODUCT", 144, 148], ["RIG-I", "GENE_OR_GENE_PRODUCT", 212, 217], ["viral RNA sensor RIG-I", "PROTEIN", 195, 217], ["C-terminal ubiquitin-like domain", "PROTEIN", 241, 273], ["Further investigations", "TEST", 0, 22], ["virus infections", "PROBLEM", 123, 139], ["terminal ubiquitin", "ANATOMY_MODIFIER", 243, 261]]], ["26 Other high-impact results from interactome analysis include shared PPIs explaining inverse epidemiological relationship between schizophrenia and rheumatoid arthritis 27 and cilia-transduced cell signaling in congenital heart disease, 28,29 and more.", [["cilia", "ANATOMY", 177, 182], ["cell", "ANATOMY", 194, 198], ["heart", "ANATOMY", 223, 228], ["schizophrenia", "DISEASE", 131, 144], ["rheumatoid arthritis", "DISEASE", 149, 169], ["congenital heart disease", "DISEASE", 212, 236], ["cell", "CELL", 194, 198], ["heart", "ORGAN", 223, 228], ["interactome analysis", "TEST", 34, 54], ["shared PPIs", "TREATMENT", 63, 74], ["schizophrenia", "PROBLEM", 131, 144], ["rheumatoid arthritis", "PROBLEM", 149, 169], ["cilia", "TEST", 177, 182], ["congenital heart disease", "PROBLEM", 212, 236], ["rheumatoid arthritis", "OBSERVATION", 149, 169], ["transduced cell", "OBSERVATION", 183, 198], ["congenital", "OBSERVATION_MODIFIER", 212, 222], ["heart", "ANATOMY", 223, 228], ["disease", "OBSERVATION", 229, 236]]], ["30 In this work, we present the host protein interactome (HoP Interactome) of nCoV19, namely PPIs of the 332 human proteins that the virus proteins bind to (Gordon et al. 6 ).", [["nCoV19", "GENE_OR_GENE_PRODUCT", 78, 84], ["human", "ORGANISM", 109, 114], ["nCoV19", "PROTEIN", 78, 84], ["332 human proteins", "PROTEIN", 105, 123], ["virus proteins", "PROTEIN", 133, 147], ["human", "SPECIES", 109, 114], ["human", "SPECIES", 109, 114], ["nCoV19", "TREATMENT", 78, 84], ["PPIs", "TREATMENT", 93, 97], ["the virus proteins", "TREATMENT", 129, 147]]], ["Key contributions of this work are a set of novel PPIs that are computationally predicted with high-precision, combined with known PPIs from public databases, and the results of analyzing the network of interactions with functional annotations and with nCoV19-relevant transcriptomic and proteomic data.", [["nCoV19", "GENE_OR_GENE_PRODUCT", 253, 259], ["nCoV19", "PROTEIN", 253, 259], ["novel PPIs", "TREATMENT", 44, 54], ["known PPIs", "PROBLEM", 125, 135], ["public databases", "TEST", 141, 157], ["nCoV19", "TREATMENT", 253, 259], ["proteomic data", "TEST", 288, 302], ["PPIs", "OBSERVATION", 131, 135]]], ["Importantly, we are making this interactome, including about two thousand hitherto unknown PPIs with rich annotations on a webserver with search capabilities to the scientific community and in graph formats amenable for computational analyses.", [["graph formats", "TEST", 193, 206], ["computational analyses", "TEST", 220, 242]]], ["A concept diagram of analysis carried out here is shown in Figure 1 .IntroductionAt a time when biomedical science researchers have closed their labs to practice social distancing, 31 this digital resource presents new computationally derived information at their fingertips, presenting an avenue for continued scientific enquiry.", [["fingertips", "ORGANISM_SUBDIVISION", 264, 274], ["A concept diagram of analysis", "TEST", 0, 29]]], ["A biomedical scientist typically has undeterred focus, say on a specific protein or a pathway even when broadly interested in the study of a specific disease.", [["the study", "TEST", 126, 135], ["a specific disease", "PROBLEM", 139, 157]]], ["We believe that it would be very timely and of immense value to present these computational results to the biomedical community, when the scientists are currently having to work in a digital mode away from their wet labs.", [["their wet labs", "TEST", 206, 220]]], ["Many of these two thousand novel PPIs may serve as seeds for new directions to science, similar to how OASL-DDX58 interaction has advanced the study of the role of OASL proteins in viral immunity.", [["OASL", "GENE_OR_GENE_PRODUCT", 103, 107], ["DDX58", "GENE_OR_GENE_PRODUCT", 108, 113], ["OASL", "GENE_OR_GENE_PRODUCT", 164, 168], ["OASL", "PROTEIN", 103, 107], ["DDX58", "PROTEIN", 108, 113], ["OASL proteins", "PROTEIN", 164, 177], ["these two thousand novel PPIs", "TREATMENT", 8, 37], ["the study", "TEST", 139, 148], ["OASL proteins", "TREATMENT", 164, 177], ["viral immunity", "OBSERVATION", 181, 195]]], ["26ResultsWe collected 332 host proteins that were identified to interact with 27 nCoV19 viral proteins by Gordon et al. 6 To assemble the interactome of these host proteins, we compiled known PPIs from HPRD 10 (Human Protein Reference Database) and BioGRID 11 (Biological General Repository for Interaction Datasets) and predicted novel PPIs by applying the HiPPIP algorithm described earlier.", [["Human", "ORGANISM", 211, 216], ["27 nCoV19 viral proteins", "PROTEIN", 78, 102], ["host proteins", "PROTEIN", 159, 172], ["HPRD 10", "PROTEIN", 202, 209], ["Human", "SPECIES", 211, 216], ["HPRD", "TREATMENT", 202, 206], ["BioGRID", "TEST", 249, 256], ["novel PPIs", "TREATMENT", 331, 341], ["the HiPPIP algorithm", "TREATMENT", 354, 374]]], ["32 Note that the interactome is human protein interactome, and not a host-virus interactome; the relevance to COVID19 is that the core proteins for which the interactome is assembled are those that viral proteins bind to.", [["human", "ORGANISM", 32, 37], ["COVID19", "GENE_OR_GENE_PRODUCT", 110, 117], ["COVID19", "PROTEIN", 110, 117], ["core proteins", "PROTEIN", 130, 143], ["viral proteins", "PROTEIN", 198, 212], ["human", "SPECIES", 32, 37], ["human", "SPECIES", 32, 37], ["the core proteins", "PROBLEM", 126, 143], ["viral proteins bind", "PROBLEM", 198, 217]]], ["HiPPIP predicted ~2,600 PPIs of which ~600 PPIs are previously cataloged in HPRD and BioGRID, leaving ~2,000 PPIs to be considered as novel PPIs of the host proteins.", [["HPRD", "PROTEIN", 76, 80], ["host proteins", "PROTEIN", 152, 165], ["PPIs", "TREATMENT", 24, 28], ["PPIs", "TREATMENT", 43, 47], ["BioGRID", "TREATMENT", 85, 92], ["PPIs", "TREATMENT", 109, 113], ["the host proteins", "TREATMENT", 148, 165]]], ["There are an additional 3,500 PPIs that are known and not predicted by HiPPIP (this is as it should be: HiPPIP prediction threshold has already been fixed 32 to achieve high precision by compromising recall, which is required for adoption into biology; in other words, it is set to predict only a few PPIs out of the hundreds of thousands of unknown PPIs, but those will be highly accurate).", [["HiPPIP", "PROTEIN", 104, 110], ["an additional 3,500 PPIs", "TREATMENT", 10, 34], ["a few PPIs", "TREATMENT", 295, 305], ["unknown PPIs", "TREATMENT", 342, 354], ["PPIs", "OBSERVATION", 30, 34]]], ["As reported in Supplementary File 1, prior validations of 16 PPIs predicted by HiPPIP in our other studies validated all 16 to be true; the experiments were carried out by diverse research labs.", [["HiPPIP", "CHEMICAL", 79, 85], ["prior validations", "TEST", 37, 54], ["16 PPIs", "TREATMENT", 58, 65], ["our other studies", "TEST", 89, 106]]], ["Overall, the host protein (HoP) interactome consists of 4,408 proteins and 6,076 interactions (Supplementary Data File 1).", [["HoP", "GENE_OR_GENE_PRODUCT", 27, 30], ["host protein", "PROTEIN", 13, 25], ["HoP", "PROTEIN", 27, 30], ["4,408 proteins", "PROTEIN", 56, 70]]], ["A partial network of host proteins and their novel interactors is shown in Figure 2A (see Supplementary Figure S1 for the full network of novel interactors).", [["host proteins", "PROTEIN", 21, 34], ["S1", "PROTEIN", 111, 113], ["novel interactors", "PROTEIN", 138, 155], ["host proteins", "TREATMENT", 21, 34], ["partial", "OBSERVATION_MODIFIER", 2, 9]]], ["Within each module, colored nodes depict genes with at least one evidence of transcriptomic/proteomic relevance to nCoV19.ResultsWe verified whether any of the 2,000 novel PPIs came up in recent interactome maps HuRI (HI-Union) 14 and BioPlex 15 .", [["nodes", "ANATOMY", 28, 33], ["colored nodes", "MULTI-TISSUE_STRUCTURE", 20, 33], ["nCoV19", "GENE_OR_GENE_PRODUCT", 115, 121], ["nCoV19", "DNA", 115, 121], ["BioPlex 15", "DNA", 235, 245], ["colored nodes depict genes", "PROBLEM", 20, 46], ["nCoV19", "TREATMENT", 115, 121], ["novel PPIs", "TREATMENT", 166, 176], ["recent interactome maps HuRI (HI-Union)", "TREATMENT", 188, 227], ["BioPlex", "TREATMENT", 235, 242], ["colored", "OBSERVATION_MODIFIER", 20, 27], ["nodes", "OBSERVATION", 28, 33]]], ["While there was no overlap with HuRI union dataset, there were 8 PPIs in the BioPlex map (ADAM9-ADAM32, P3H3-OS9, PVR-NECTIN2, SRRM2-SNIP1, PABPC4-LUC7L2, PRKACA-AKAP1, NDUFA13-ECSIT, and NPTX1-NPTX2).", [["P3H3-OS9", "GENE_OR_GENE_PRODUCT", 104, 112], ["PVR-NECTIN2", "GENE_OR_GENE_PRODUCT", 114, 125], ["SRRM2-SNIP1", "GENE_OR_GENE_PRODUCT", 127, 138], ["PABPC4-LUC7L2", "GENE_OR_GENE_PRODUCT", 140, 153], ["PRKACA-AKAP1", "GENE_OR_GENE_PRODUCT", 155, 167], ["NDUFA13-ECSIT", "GENE_OR_GENE_PRODUCT", 169, 182], ["NPTX1-NPTX2", "GENE_OR_GENE_PRODUCT", 188, 199], ["BioPlex map", "DNA", 77, 88], ["ADAM9", "DNA", 90, 95], ["ADAM32", "DNA", 96, 102], ["P3H3", "DNA", 104, 108], ["OS9", "DNA", 109, 112], ["PVR", "DNA", 114, 117], ["NECTIN2", "DNA", 118, 125], ["SRRM2", "DNA", 127, 132], ["SNIP1", "DNA", 133, 138], ["PABPC4", "DNA", 140, 146], ["LUC7L2", "DNA", 147, 153], ["PRKACA", "DNA", 155, 161], ["AKAP1", "DNA", 162, 167], ["NDUFA13", "DNA", 169, 176], ["ECSIT", "DNA", 177, 182], ["NPTX1", "DNA", 188, 193], ["NPTX2", "DNA", 194, 199], ["8 PPIs", "TREATMENT", 63, 69], ["the BioPlex map", "TEST", 73, 88], ["ADAM9", "TEST", 90, 95], ["ADAM32", "TEST", 96, 102], ["P3H3", "TEST", 104, 108], ["OS9", "TEST", 109, 112], ["PVR", "TEST", 114, 117], ["NECTIN2", "TEST", 118, 125], ["SRRM2", "TEST", 127, 132], ["SNIP1", "TEST", 133, 138], ["PABPC4", "TEST", 140, 146], ["LUC7L2", "TEST", 147, 153], ["PRKACA", "TEST", 155, 161], ["AKAP1", "TEST", 162, 167], ["NDUFA13", "TEST", 169, 176], ["NPTX1", "TEST", 188, 193], ["no overlap", "UNCERTAINTY", 16, 26], ["PVR", "OBSERVATION", 114, 117]]], ["The small overlap is not surprising because even high-throughput biotechnological methods discover different parts of the interactome with only small overlaps with each other6, this demonstrating complementary strengths.", [["The small overlap", "PROBLEM", 0, 17], ["small", "OBSERVATION_MODIFIER", 4, 9], ["overlap", "OBSERVATION", 10, 17], ["not surprising", "UNCERTAINTY", 21, 35], ["small", "OBSERVATION_MODIFIER", 144, 149], ["overlaps", "OBSERVATION", 150, 158]]], ["30, [33] [34] [35] To facilitate '(1)', we are making these results available over an interactive webserver, and to facilitate '(2)', we are releasing the data as downloadable files in various formats.ResultsWe employed 'Netbox' 36 to identify modules based on network topology.", [["network topology", "MULTI-TISSUE_STRUCTURE", 261, 277], ["Netbox' 36", "DNA", 221, 231]]], ["It expands the core proteins by adding nodes from the interactome whose number of links to core proteins are statistically significant compared to its degree in the human interactome.", [["human", "ORGANISM", 165, 170], ["core proteins", "PROTEIN", 15, 28], ["core proteins", "PROTEIN", 91, 104], ["human", "SPECIES", 165, 170], ["human", "SPECIES", 165, 170], ["nodes", "OBSERVATION", 39, 44], ["statistically", "OBSERVATION_MODIFIER", 109, 122], ["significant", "OBSERVATION_MODIFIER", 123, 134], ["human interactome", "OBSERVATION", 165, 182]]], ["From this network, it identifies highly interconnected modules.", [["highly", "OBSERVATION_MODIFIER", 33, 39], ["interconnected modules", "OBSERVATION", 40, 62]]], ["It was able to connect 323 proteins (220 host proteins and 103 linker proteins) into 21 modules, of which 14 modules had 4 or more nodes each (Supplementary Figure S2) .", [["nodes", "ANATOMY", 131, 136], ["323 proteins", "PROTEIN", 23, 35], ["220 host proteins", "PROTEIN", 37, 54], ["103 linker proteins", "PROTEIN", 59, 78], ["host proteins", "TEST", 41, 54], ["linker proteins", "TEST", 63, 78], ["nodes", "OBSERVATION", 131, 136]]], ["For comparison, when novel PPIs are not included, it connects 199 proteins (138 host proteins and 61 linker proteins) into 18 modules of which 10 had 4 or more proteins each.", [["199 proteins", "PROTEIN", 62, 74], ["138 host proteins", "PROTEIN", 76, 93], ["61 linker proteins", "PROTEIN", 98, 116], ["novel PPIs", "TREATMENT", 21, 31], ["host proteins", "TEST", 80, 93], ["linker proteins", "TEST", 101, 116]]], ["Scaled modularity score (zscore compared to random networks) was 17.0 with novel PPIs, and it was 14.5 without novel PPIs (z-score compared to corresponding random networks).", [["Scaled modularity score", "PROBLEM", 0, 23], ["novel PPIs", "TEST", 75, 85], ["novel PPIs", "TREATMENT", 111, 121], ["z-score", "TEST", 123, 130]]], ["Bioinformatic analysis of the computed modules showed that five modules formed with novel interactors had statistically significant enrichment of Gene Ontology biological process terms: epigenetic regulation of gene expression (p-value=3.3E-04, odds ratio=10.4), nuclear transport (p-value=2.4E-12, odds ratio=21.6), cilium organization (p-value=1.28E-03, odds ratio= 7.8) ribonucleoprotein complex biogenesis (p-value=0, odds ratio=22.4), and vesicle-mediated transport between endosomal compartments (p-value=9.4E-06, odds ratio=123.4) ( Figure 2C i-vi).", [["nuclear", "ANATOMY", 263, 270], ["cilium", "ANATOMY", 317, 323], ["vesicle", "ANATOMY", 444, 451], ["endosomal compartments", "ANATOMY", 479, 501], ["nuclear", "CELLULAR_COMPONENT", 263, 270], ["cilium", "CELLULAR_COMPONENT", 317, 323], ["vesicle", "CELLULAR_COMPONENT", 444, 451], ["endosomal", "CELLULAR_COMPONENT", 479, 488], ["ribonucleoprotein complex", "PROTEIN", 373, 398], ["Bioinformatic analysis", "TEST", 0, 22], ["the computed modules", "TEST", 26, 46], ["novel interactors", "PROBLEM", 84, 101], ["gene expression", "TEST", 211, 226], ["p-value", "TEST", 228, 235], ["odds ratio", "TEST", 245, 255], ["nuclear transport", "TEST", 263, 280], ["p-value", "TEST", 282, 289], ["odds ratio", "TEST", 299, 309], ["cilium organization", "TEST", 317, 336], ["p-value", "TEST", 338, 345], ["odds ratio", "TEST", 356, 366], ["ribonucleoprotein complex biogenesis", "TEST", 373, 409], ["p-value", "TEST", 411, 418], ["odds ratio", "TEST", 422, 432], ["p-value", "TEST", 503, 510], ["odds ratio", "TEST", 520, 530], ["vesicle", "ANATOMY", 444, 451]]], ["When novel PPIs are excluded, some of these associations were missed and the modules were smaller, but three additional functional modules were found: cell cycle G2/M phase transition (p-value=0.0019, odds ratio=21.7, 20 proteins), DNA replication (p-value=0.0049, odds ratio=55.25, 3 proteins) and cell-cell signaling by Wnt (p-value=0.0049, odds ratio=9.3, 24 proteins) (Supplementary Table S2 ).ACE2 InteractomeSARS-CoV-2 engages the host receptor ACE2 (angiotensin-converting enzyme 2) for cell entry.", [["cell", "ANATOMY", 151, 155], ["cell", "ANATOMY", 299, 303], ["cell", "ANATOMY", 304, 308], ["cell", "ANATOMY", 494, 498], ["angiotensin", "CHEMICAL", 457, 468], ["cell", "CELL", 151, 155], ["DNA", "CELLULAR_COMPONENT", 232, 235], ["cell", "CELL", 299, 303], ["cell", "CELL", 304, 308], ["Wnt", "GENE_OR_GENE_PRODUCT", 322, 325], ["ACE2", "GENE_OR_GENE_PRODUCT", 398, 402], ["InteractomeSARS-CoV-2", "GENE_OR_GENE_PRODUCT", 403, 424], ["ACE2", "GENE_OR_GENE_PRODUCT", 451, 455], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 457, 488], ["cell", "CELL", 494, 498], ["Wnt", "PROTEIN", 322, 325], ["ACE2", "PROTEIN", 398, 402], ["CoV-2", "PROTEIN", 419, 424], ["ACE2", "PROTEIN", 451, 455], ["angiotensin-converting enzyme 2", "PROTEIN", 457, 488], ["novel PPIs", "TREATMENT", 5, 15], ["cell cycle G2/M phase transition", "TEST", 151, 183], ["p-value", "TEST", 185, 192], ["odds ratio", "TEST", 201, 211], ["proteins", "TEST", 221, 229], ["DNA replication", "TEST", 232, 247], ["p-value", "TEST", 249, 256], ["odds ratio", "TEST", 265, 275], ["proteins", "TEST", 285, 293], ["cell", "TEST", 299, 303], ["Wnt", "TEST", 322, 325], ["p-value", "TEST", 327, 334], ["odds ratio", "TEST", 343, 353], ["ACE2", "TEST", 398, 402], ["InteractomeSARS", "TEST", 403, 418], ["CoV", "TEST", 419, 422], ["the host receptor ACE2 (angiotensin-converting enzyme", "TREATMENT", 433, 486], ["cell entry", "PROBLEM", 494, 504], ["PPIs", "OBSERVATION", 11, 15], ["smaller", "OBSERVATION_MODIFIER", 90, 97]]], ["37 Viral entry happens prior to the interaction of the viral proteins with host cellular proteins; it was the latter that was studied by Gordon et al. 6 Therefore, it was not part of the 332 core genes considered in constructing the interactome.", [["cellular", "ANATOMY", 80, 88], ["cellular", "CELL", 80, 88], ["viral proteins", "PROTEIN", 55, 69], ["host cellular proteins", "PROTEIN", 75, 97], ["332 core genes", "DNA", 187, 201], ["the viral proteins", "PROBLEM", 51, 69], ["host cellular proteins", "PROBLEM", 75, 97]]], ["Owing to its crucial role in nCov19 infection, we assembled its known and novel PPIs separately and found that it was connected to four host proteins (SIL1, LOX, MDN1 and NINL) through an intermediate interactor, i.e. separated by two edges, where one or both intermediary PPIs are novel predicted ones (see red edges in Figure 2B ).ACE2 InteractomeThese connections reveal interesting insights: ACE2 is a key player of the renin-angiotensin hormone system that regulates blood pressure and electrolyte balance.", [["blood", "ANATOMY", 472, 477], ["infection", "DISEASE", 36, 45], ["angiotensin", "CHEMICAL", 430, 441], ["nCov19", "GENE_OR_GENE_PRODUCT", 29, 35], ["SIL1", "GENE_OR_GENE_PRODUCT", 151, 155], ["LOX", "GENE_OR_GENE_PRODUCT", 157, 160], ["MDN1", "GENE_OR_GENE_PRODUCT", 162, 166], ["NINL", "GENE_OR_GENE_PRODUCT", 171, 175], ["ACE2", "GENE_OR_GENE_PRODUCT", 333, 337], ["ACE2", "GENE_OR_GENE_PRODUCT", 396, 400], ["renin-angiotensin hormone", "GENE_OR_GENE_PRODUCT", 424, 449], ["blood", "ORGANISM_SUBSTANCE", 472, 477], ["electrolyte", "SIMPLE_CHEMICAL", 491, 502], ["host proteins", "PROTEIN", 136, 149], ["SIL1", "PROTEIN", 151, 155], ["LOX", "PROTEIN", 157, 160], ["MDN1", "PROTEIN", 162, 166], ["NINL", "PROTEIN", 171, 175], ["intermediate interactor", "PROTEIN", 188, 211], ["ACE2", "PROTEIN", 333, 337], ["ACE2", "PROTEIN", 396, 400], ["renin", "PROTEIN", 424, 429], ["nCov19 infection", "PROBLEM", 29, 45], ["novel PPIs", "TREATMENT", 74, 84], ["MDN1", "TREATMENT", 162, 166], ["NINL", "TREATMENT", 171, 175], ["an intermediate interactor", "TREATMENT", 185, 211], ["both intermediary PPIs", "TREATMENT", 255, 277], ["the renin-angiotensin hormone system", "TREATMENT", 420, 456], ["blood pressure", "TEST", 472, 486], ["infection", "OBSERVATION", 36, 45], ["intermediate interactor", "OBSERVATION", 188, 211], ["edges", "OBSERVATION_MODIFIER", 235, 240], ["intermediary PPIs", "OBSERVATION", 260, 277], ["electrolyte balance", "OBSERVATION", 491, 510]]], ["38 In line with this, we found that its interactors AGT (angiotensin), GHRL, CLTRN and POMC are associated with the Reactome Pathway peptide hormone metabolism (p-value=2.9E-05).", [["angiotensin", "CHEMICAL", 57, 68], ["AGT", "GENE_OR_GENE_PRODUCT", 52, 55], ["angiotensin", "GENE_OR_GENE_PRODUCT", 57, 68], ["GHRL", "GENE_OR_GENE_PRODUCT", 71, 75], ["CLTRN", "GENE_OR_GENE_PRODUCT", 77, 82], ["POMC", "GENE_OR_GENE_PRODUCT", 87, 91], ["AGT", "PROTEIN", 52, 55], ["angiotensin", "PROTEIN", 57, 68], ["GHRL", "PROTEIN", 71, 75], ["CLTRN", "PROTEIN", 77, 82], ["POMC", "PROTEIN", 87, 91], ["its interactors AGT (angiotensin), GHRL, CLTRN and POMC", "PROBLEM", 36, 91], ["p-value", "TEST", 161, 168]]], ["ACE2 and its interactors were also enriched in the Gene Ontology Biological Process circulatory system process (ACE2, AGT, NTS, POMC, GHRL and the host protein MYL4; p-value=0.001).", [["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["ACE2", "GENE_OR_GENE_PRODUCT", 112, 116], ["AGT", "GENE_OR_GENE_PRODUCT", 118, 121], ["NTS", "GENE_OR_GENE_PRODUCT", 123, 126], ["POMC", "GENE_OR_GENE_PRODUCT", 128, 132], ["GHRL", "GENE_OR_GENE_PRODUCT", 134, 138], ["MYL4", "GENE_OR_GENE_PRODUCT", 160, 164], ["ACE2", "PROTEIN", 0, 4], ["ACE2", "PROTEIN", 112, 116], ["AGT", "PROTEIN", 118, 121], ["NTS", "PROTEIN", 123, 126], ["POMC", "PROTEIN", 128, 132], ["GHRL", "PROTEIN", 134, 138], ["host protein MYL4", "PROTEIN", 147, 164], ["ACE2", "TREATMENT", 0, 4], ["ACE2", "TEST", 112, 116], ["AGT", "TEST", 118, 121], ["POMC", "TEST", 128, 132], ["p-value", "TEST", 166, 173]]], ["Three host proteins are associated with numerous vascular and cardiac phenotypes: LOX with abnormality of blood volume homeostasis, aortic root aneurysm, ascending aortic dissection, carotid artery dilatation, coronary artery atherosclerosis, cystic medial necrosis of the aorta, descending thoracic aorta aneurysm, dilatation of the cerebral artery, left ventricular failure, peripheral arterial stenosis, MYL4 with paroxysmal atrial fibrillation and bradycardia, and SIL1 with abnormal aldolase level.ACE2 InteractomeThe co-morbidity of hypertension, diabetes and cardiovascular among the group of COVID19 patients with high fatality rate warrants a closer look at ACE2 and other host proteins linked to cardiac and vascular phenotypes.Wiki-CORONA: A web server of novel host PPIsThe HoP interactome is available on a website called Wiki-CORONA (http://hagrid.dbmi.pitt.edu/corona/).", [["vascular", "ANATOMY", 49, 57], ["cardiac", "ANATOMY", 62, 69], ["blood", "ANATOMY", 106, 111], ["aortic root aneurysm", "ANATOMY", 132, 152], ["ascending aortic", "ANATOMY", 154, 170], ["carotid artery", "ANATOMY", 183, 197], ["coronary artery", "ANATOMY", 210, 225], ["cystic", "ANATOMY", 243, 249], ["aorta", "ANATOMY", 273, 278], ["descending thoracic aorta", "ANATOMY", 280, 305], ["cerebral artery", "ANATOMY", 334, 349], ["left ventricular", "ANATOMY", 351, 367], ["peripheral arterial", "ANATOMY", 377, 396], ["atrial", "ANATOMY", 428, 434], ["cardiovascular", "ANATOMY", 566, 580], ["cardiac", "ANATOMY", 706, 713], ["vascular", "ANATOMY", 718, 726], ["abnormality of blood volume", "DISEASE", 91, 118], ["aortic root aneurysm", "DISEASE", 132, 152], ["carotid artery dilatation", "DISEASE", 183, 208], ["coronary artery atherosclerosis", "DISEASE", 210, 241], ["cystic medial necrosis", "DISEASE", 243, 265], ["aorta aneurysm", "DISEASE", 300, 314], ["left ventricular failure", "DISEASE", 351, 375], ["peripheral arterial stenosis", "DISEASE", 377, 405], ["atrial fibrillation", "DISEASE", 428, 447], ["bradycardia", "DISEASE", 452, 463], ["hypertension", "DISEASE", 539, 551], ["diabetes", "DISEASE", 553, 561], ["cardiac and vascular phenotypes", "DISEASE", 706, 737], ["vascular", "MULTI-TISSUE_STRUCTURE", 49, 57], ["cardiac", "ORGAN", 62, 69], ["LOX", "GENE_OR_GENE_PRODUCT", 82, 85], ["blood", "ORGANISM_SUBSTANCE", 106, 111], ["aortic root", "MULTI-TISSUE_STRUCTURE", 132, 143], ["aortic", "MULTI-TISSUE_STRUCTURE", 164, 170], ["carotid artery", "MULTI-TISSUE_STRUCTURE", 183, 197], ["coronary artery", "MULTI-TISSUE_STRUCTURE", 210, 225], ["aorta", "MULTI-TISSUE_STRUCTURE", 273, 278], ["thoracic aorta", "MULTI-TISSUE_STRUCTURE", 291, 305], ["cerebral artery", "MULTI-TISSUE_STRUCTURE", 334, 349], ["ventricular", "MULTI-TISSUE_STRUCTURE", 356, 367], ["peripheral arterial", "MULTI-TISSUE_STRUCTURE", 377, 396], ["atrial", "MULTI-TISSUE_STRUCTURE", 428, 434], ["SIL1", "GENE_OR_GENE_PRODUCT", 469, 473], ["aldolase", "GENE_OR_GENE_PRODUCT", 488, 496], ["ACE2", "GENE_OR_GENE_PRODUCT", 503, 507], ["patients", "ORGANISM", 608, 616], ["ACE2", "GENE_OR_GENE_PRODUCT", 667, 671], ["cardiac", "MULTI-TISSUE_STRUCTURE", 706, 713], ["vascular", "MULTI-TISSUE_STRUCTURE", 718, 726], ["LOX", "PROTEIN", 82, 85], ["ACE2", "PROTEIN", 503, 507], ["ACE2", "PROTEIN", 667, 671], ["host proteins", "PROTEIN", 682, 695], ["patients", "SPECIES", 608, 616], ["numerous vascular and cardiac phenotypes", "PROBLEM", 40, 80], ["abnormality of blood volume homeostasis", "PROBLEM", 91, 130], ["aortic root aneurysm", "PROBLEM", 132, 152], ["ascending aortic dissection", "PROBLEM", 154, 181], ["carotid artery dilatation", "PROBLEM", 183, 208], ["coronary artery atherosclerosis", "PROBLEM", 210, 241], ["cystic medial necrosis of the aorta", "PROBLEM", 243, 278], ["descending thoracic aorta aneurysm", "PROBLEM", 280, 314], ["dilatation of the cerebral artery", "PROBLEM", 316, 349], ["left ventricular failure", "PROBLEM", 351, 375], ["peripheral arterial stenosis", "PROBLEM", 377, 405], ["MYL4", "PROBLEM", 407, 411], ["paroxysmal atrial fibrillation", "PROBLEM", 417, 447], ["bradycardia", "PROBLEM", 452, 463], ["abnormal aldolase level", "PROBLEM", 479, 502], ["hypertension", "PROBLEM", 539, 551], ["diabetes", "PROBLEM", 553, 561], ["high fatality rate", "PROBLEM", 622, 640], ["cardiac and vascular phenotypes", "PROBLEM", 706, 737], ["host proteins", "OBSERVATION", 6, 19], ["numerous", "OBSERVATION_MODIFIER", 40, 48], ["vascular", "ANATOMY", 49, 57], ["cardiac", "ANATOMY", 62, 69], ["phenotypes", "OBSERVATION", 70, 80], ["blood volume homeostasis", "OBSERVATION", 106, 130], ["aortic", "ANATOMY", 132, 138], ["root", "ANATOMY_MODIFIER", 139, 143], ["aneurysm", "OBSERVATION", 144, 152], ["ascending", "ANATOMY_MODIFIER", 154, 163], ["aortic", "ANATOMY", 164, 170], ["dissection", "OBSERVATION", 171, 181], ["carotid artery", "ANATOMY", 183, 197], ["dilatation", "OBSERVATION", 198, 208], ["coronary artery", "ANATOMY", 210, 225], ["atherosclerosis", "OBSERVATION", 226, 241], ["cystic", "OBSERVATION_MODIFIER", 243, 249], ["medial", "OBSERVATION_MODIFIER", 250, 256], ["necrosis", "OBSERVATION", 257, 265], ["aorta", "ANATOMY", 273, 278], ["descending", "ANATOMY_MODIFIER", 280, 290], ["thoracic aorta", "ANATOMY", 291, 305], ["aneurysm", "OBSERVATION", 306, 314], ["dilatation", "OBSERVATION", 316, 326], ["cerebral artery", "ANATOMY", 334, 349], ["left ventricular", "ANATOMY", 351, 367], ["failure", "OBSERVATION", 368, 375], ["peripheral", "ANATOMY_MODIFIER", 377, 387], ["arterial", "ANATOMY", 388, 396], ["stenosis", "OBSERVATION", 397, 405], ["paroxysmal atrial fibrillation", "OBSERVATION", 417, 447], ["bradycardia", "OBSERVATION", 452, 463], ["abnormal", "OBSERVATION_MODIFIER", 479, 487], ["aldolase level", "OBSERVATION", 488, 502], ["hypertension", "OBSERVATION", 539, 551], ["diabetes", "OBSERVATION", 553, 561], ["cardiac", "ANATOMY", 706, 713], ["vascular", "ANATOMY", 718, 726]]], ["It has advanced-search capabilities, and presents comprehensive annotations, namely Gene Ontology, diseases, drugs and pathways, of the two proteins of each PPI side-by-side.", [["drugs", "TREATMENT", 109, 114], ["advanced", "OBSERVATION_MODIFIER", 7, 15]]], ["Here, a user can query for results such as \"PPIs where one protein is anti-viral and the other is involved in immunity\", and then see the results with the functional details of the two proteins side-by-side.", [["PPIs", "TREATMENT", 44, 48], ["anti-viral", "TREATMENT", 70, 80]]], ["The PPIs and their annotations also get indexed in major search engines like Google and Bing.", [["The PPIs", "TREATMENT", 0, 8]]], ["Querying by biomedical associations is a unique feature which we developed in Wiki-Pi that presents known interactions of all human proteins.", [["Pi", "CHEMICAL", 83, 85], ["human", "ORGANISM", 126, 131], ["human proteins", "PROTEIN", 126, 140], ["human", "SPECIES", 126, 131], ["human", "SPECIES", 126, 131], ["all human proteins", "TREATMENT", 122, 140]]], ["39Transcriptome AnalysisSignificantly large number of proteins in the interactome were differentially expressed in epithelial cells infected with SARS coronavirus (GSE17400, Calu-3 cell, 48 hours post-infection; p-value=4.76E-12).", [["epithelial cells", "ANATOMY", 115, 131], ["Calu-3 cell", "ANATOMY", 174, 185], ["SARS coronavirus", "DISEASE", 146, 162], ["epithelial cells", "CELL", 115, 131], ["SARS coronavirus", "ORGANISM", 146, 162], ["GSE17400", "CELL", 164, 172], ["Calu-3 cell", "CELL", 174, 185], ["epithelial cells", "CELL_TYPE", 115, 131], ["SARS coronavirus", "SPECIES", 146, 162], ["epithelial cells", "PROBLEM", 115, 131], ["SARS coronavirus", "PROBLEM", 146, 162], ["GSE", "TEST", 164, 167], ["Calu", "TEST", 174, 178], ["p-value", "TEST", 212, 219], ["large", "OBSERVATION_MODIFIER", 38, 43], ["number", "OBSERVATION_MODIFIER", 44, 50], ["epithelial cells", "OBSERVATION", 115, 131]]], ["Several proteins also showed differential expression in the transcriptome level after infection by Urbani strain of SARS coronavirus (GSE37827, Calu-3 cells, 72 hours post-infection) and in peripheral blood mononuclear cells of SARS patients (GSE1739 40 ).", [["Calu-3 cells", "ANATOMY", 144, 156], ["peripheral blood mononuclear cells", "ANATOMY", 190, 224], ["infection", "DISEASE", 86, 95], ["SARS coronavirus", "DISEASE", 116, 132], ["infection", "DISEASE", 172, 181], ["SARS", "DISEASE", 228, 232], ["Urbani strain", "ORGANISM", 99, 112], ["SARS coronavirus", "ORGANISM", 116, 132], ["GSE37827", "CELL", 134, 142], ["Calu-3 cells", "CELL", 144, 156], ["peripheral blood mononuclear cells", "CELL", 190, 224], ["patients", "ORGANISM", 233, 241], ["peripheral blood mononuclear cells", "CELL_TYPE", 190, 224], ["coronavirus", "SPECIES", 121, 132], ["patients", "SPECIES", 233, 241], ["SARS coronavirus", "SPECIES", 116, 132], ["Several proteins", "TEST", 0, 16], ["differential expression in the transcriptome level", "PROBLEM", 29, 79], ["infection", "PROBLEM", 86, 95], ["Urbani strain", "PROBLEM", 99, 112], ["SARS coronavirus", "PROBLEM", 116, 132], ["GSE", "TEST", 134, 137], ["Calu", "TEST", 144, 148], ["infection", "PROBLEM", 172, 181], ["peripheral blood mononuclear cells", "TEST", 190, 224], ["differential expression", "OBSERVATION", 29, 52], ["peripheral", "ANATOMY_MODIFIER", 190, 200], ["blood", "ANATOMY", 201, 206], ["mononuclear cells", "OBSERVATION", 207, 224]]], ["These latter two datasets of differential expression did not show statistically significant overlaps; yet, the transcriptomic evidence highlights key protein-encoding genes associated with viral infection that interact with the core proteins considered in this study.", [["viral infection", "DISEASE", 189, 204], ["core proteins", "PROTEIN", 228, 241], ["statistically significant overlaps", "PROBLEM", 66, 100], ["key protein", "PROBLEM", 146, 157], ["viral infection", "PROBLEM", 189, 204], ["the core proteins", "PROBLEM", 224, 241], ["this study", "TEST", 256, 266], ["viral", "OBSERVATION_MODIFIER", 189, 194], ["infection", "OBSERVATION", 195, 204]]], ["As several of the interactors here are revealed through computational prediction, the information that they are differentially expressed in SARS/SARS-Cov-2 infections presents opportunity to prioritize consideration of novel PPIs for further study.Transcriptome AnalysisMelo et al. had identified 120 differentially expressed genes (DEGs) associated with nCoV19 infection in the A549 cell line.", [["A549 cell line", "ANATOMY", 379, 393], ["SARS", "DISEASE", 140, 144], ["infections", "DISEASE", 156, 166], ["infection", "DISEASE", 362, 371], ["Cov-2", "ORGANISM", 150, 155], ["nCoV19", "GENE_OR_GENE_PRODUCT", 355, 361], ["A549 cell line", "CELL", 379, 393], ["120 differentially expressed genes", "DNA", 297, 331], ["DEGs", "DNA", 333, 337], ["A549 cell line", "CELL_LINE", 379, 393], ["SARS/SARS", "PROBLEM", 140, 149], ["Cov-2 infections", "PROBLEM", 150, 166], ["novel PPIs", "TREATMENT", 219, 229], ["further study", "TEST", 234, 247], ["120 differentially expressed genes (DEGs)", "PROBLEM", 297, 338], ["nCoV19 infection", "PROBLEM", 355, 371], ["the A549 cell line", "TREATMENT", 375, 393], ["infection", "OBSERVATION", 362, 371], ["A549 cell line", "OBSERVATION", 379, 393]]], ["5 Of these, only 2 were common with the 332 host proteins identified through AP-MS study 6 ('host proteins').", [["332 host proteins", "PROTEIN", 40, 57], ["AP", "PROTEIN", 77, 79], ["AP-MS study", "TEST", 77, 88]]], ["However, our study revealed several interesting links between the two sets: We studied tissue specific expression of the proteins in the interactome using GTEx data.", [["tissue", "ANATOMY", 87, 93], ["tissue", "TISSUE", 87, 93], ["GTEx", "PROTEIN", 155, 159], ["our study", "TEST", 9, 18]]], ["41 Genes with an expression level greater than 1 TPM (transcripts per million) and relative expression at least 5-fold higher in a particular tissue (tissueenriched) or a group of 2-7 tissues (group-enriched) were considered.", [["tissue", "ANATOMY", 142, 148], ["tissues", "ANATOMY", 184, 191], ["tissue", "TISSUE", 142, 148], ["tissues", "TISSUE", 184, 191], ["an expression level", "TEST", 14, 33]]], ["As expected, many genes showed specific expression in lung which is the target tissue of the virus, and in spleen which regulates the immune response of the host (Figure 3) .", [["lung", "ANATOMY", 54, 58], ["tissue", "ANATOMY", 79, 85], ["spleen", "ANATOMY", 107, 113], ["lung", "ORGAN", 54, 58], ["tissue", "TISSUE", 79, 85], ["spleen", "ORGAN", 107, 113], ["specific expression in lung", "PROBLEM", 31, 58], ["the virus", "PROBLEM", 89, 98], ["specific", "OBSERVATION_MODIFIER", 31, 39], ["expression", "OBSERVATION", 40, 50], ["lung", "ANATOMY", 54, 58], ["virus", "OBSERVATION", 93, 98], ["spleen", "ANATOMY", 107, 113], ["immune response", "OBSERVATION", 134, 149]]], ["New PPIs were found of host proteins with 37 lung-specific proteins and 49 spleen-specific proteins.", [["lung", "ANATOMY", 45, 49], ["spleen", "ANATOMY", 75, 81], ["lung", "ORGAN", 45, 49], ["spleen", "ORGAN", 75, 81], ["host proteins", "PROTEIN", 23, 36], ["37 lung-specific proteins", "PROTEIN", 42, 67], ["49 spleen-specific proteins", "PROTEIN", 72, 99], ["New PPIs", "TREATMENT", 0, 8], ["host proteins", "TEST", 23, 36], ["specific proteins", "TEST", 50, 67], ["spleen", "TEST", 75, 81], ["PPIs", "OBSERVATION", 4, 8], ["lung", "ANATOMY", 45, 49], ["spleen", "ANATOMY", 75, 81]]], ["Host proteins also interacted with several brain and heart tissue specific proteins, which is of importance as cerebrovascular diseases and coronary heart diseases are co-morbidities among COVID-19 non-survivors.", [["brain", "ANATOMY", 43, 48], ["heart tissue", "ANATOMY", 53, 65], ["cerebrovascular", "ANATOMY", 111, 126], ["coronary", "ANATOMY", 140, 148], ["heart", "ANATOMY", 149, 154], ["cerebrovascular diseases", "DISEASE", 111, 135], ["coronary heart diseases", "DISEASE", 140, 163], ["brain", "ORGAN", 43, 48], ["heart tissue", "TISSUE", 53, 65], ["cerebrovascular", "MULTI-TISSUE_STRUCTURE", 111, 126], ["heart", "ORGAN", 149, 154], ["Host proteins", "PROTEIN", 0, 13], ["several brain and heart tissue specific proteins", "PROBLEM", 35, 83], ["cerebrovascular diseases", "PROBLEM", 111, 135], ["coronary heart diseases", "PROBLEM", 140, 163], ["COVID", "TEST", 189, 194], ["heart tissue", "ANATOMY", 53, 65], ["coronary heart", "ANATOMY", 140, 154], ["diseases", "OBSERVATION", 155, 163]]], ["42 (Figure 3) .PML bodies and the midbody may function as subcellular targets of nCoV19Gene Ontology enrichment analysis of the interactome identified several subcellular locations that may be targeted by nCoV19.", [["PML bodies", "ANATOMY", 15, 25], ["midbody", "ANATOMY", 34, 41], ["subcellular", "ANATOMY", 58, 69], ["subcellular", "ANATOMY", 159, 170], ["PML", "GENE_OR_GENE_PRODUCT", 15, 18], ["midbody", "CELLULAR_COMPONENT", 34, 41], ["nCoV19Gene", "GENE_OR_GENE_PRODUCT", 81, 91], ["nCoV19", "GENE_OR_GENE_PRODUCT", 205, 211], ["nCoV19", "PROTEIN", 205, 211], ["PML bodies", "PROBLEM", 15, 25], ["midbody", "ANATOMY_MODIFIER", 34, 41]]], ["Cellular locations included points of virus entry such as the cell-substrate junction, nuclear periphery and specific sites from where viral proteins may potentiate viral replication, gene expression and modulate the immune response of the host such as the midbody, nuclear chromatin and PML body (each term with p-value<0.0001).", [["cell", "ANATOMY", 62, 66], ["junction", "ANATOMY", 77, 85], ["nuclear periphery", "ANATOMY", 87, 104], ["sites", "ANATOMY", 118, 123], ["midbody", "ANATOMY", 257, 264], ["nuclear chromatin", "ANATOMY", 266, 283], ["PML body", "ANATOMY", 288, 296], ["cell-", "CELLULAR_COMPONENT", 62, 67], ["substrate junction", "CELLULAR_COMPONENT", 67, 85], ["nuclear periphery", "CELLULAR_COMPONENT", 87, 104], ["midbody", "CELLULAR_COMPONENT", 257, 264], ["nuclear", "CELLULAR_COMPONENT", 266, 273], ["chromatin", "CELLULAR_COMPONENT", 274, 283], ["PML body", "CELLULAR_COMPONENT", 288, 296], ["viral proteins", "PROTEIN", 135, 149], ["Cellular locations", "PROBLEM", 0, 18], ["virus entry", "PROBLEM", 38, 49], ["viral proteins", "PROBLEM", 135, 149], ["viral replication", "PROBLEM", 165, 182], ["gene expression", "PROBLEM", 184, 199], ["p-value", "TEST", 313, 320], ["virus", "OBSERVATION", 38, 43], ["substrate junction", "OBSERVATION", 67, 85], ["periphery", "OBSERVATION_MODIFIER", 95, 104], ["viral replication", "OBSERVATION", 165, 182], ["midbody", "ANATOMY_MODIFIER", 257, 264], ["nuclear chromatin", "OBSERVATION", 266, 283], ["PML body", "OBSERVATION", 288, 296]]], ["PML (promyelocytic leukaemia bodies are nuclear sub-compartments that repress viral replication through entrapment or epigenetic silencing of the viral genomes.", [["PML", "ANATOMY", 0, 3], ["promyelocytic leukaemia bodies", "ANATOMY", 5, 35], ["nuclear sub-compartments", "ANATOMY", 40, 64], ["PML", "DISEASE", 0, 3], ["promyelocytic leukaemia", "DISEASE", 5, 28], ["PML", "GENE_OR_GENE_PRODUCT", 0, 3], ["promyelocytic leukaemia", "CANCER", 5, 28], ["PML", "CELL_TYPE", 0, 3], ["viral genomes", "DNA", 146, 159], ["PML (promyelocytic leukaemia bodies", "PROBLEM", 0, 35], ["viral replication through entrapment", "PROBLEM", 78, 114], ["the viral genomes", "PROBLEM", 142, 159], ["promyelocytic leukaemia", "OBSERVATION", 5, 28], ["sub", "OBSERVATION_MODIFIER", 48, 51], ["viral replication", "OBSERVATION", 78, 95], ["entrapment", "OBSERVATION", 104, 114], ["epigenetic silencing", "OBSERVATION", 118, 138], ["viral genomes", "OBSERVATION", 146, 159]]], ["43 Components of PML bodies activate interferon-stimulated genes and cytokines, and may also be upregulated on induction of interferons.", [["PML bodies", "ANATOMY", 17, 27], ["PML", "GENE_OR_GENE_PRODUCT", 17, 20], ["interferon-stimulated genes", "GENE_OR_GENE_PRODUCT", 37, 64], ["interferons", "GENE_OR_GENE_PRODUCT", 124, 135], ["interferon-stimulated genes", "DNA", 37, 64], ["cytokines", "PROTEIN", 69, 78], ["interferons", "PROTEIN", 124, 135], ["PML bodies", "TREATMENT", 17, 27], ["interferon", "TREATMENT", 37, 47], ["cytokines", "TREATMENT", 69, 78], ["induction of interferons", "TREATMENT", 111, 135], ["PML bodies", "OBSERVATION", 17, 27], ["interferon", "OBSERVATION_MODIFIER", 37, 47]]], ["43 Therefore, it is conceivable that viruses target PPIs in these structures to circumvent anti-viral defences of the host cell.", [["cell", "ANATOMY", 123, 127], ["host cell", "CELL", 118, 127], ["host cell", "CELL_TYPE", 118, 127], ["viruses target PPIs", "TREATMENT", 37, 56], ["viruses", "OBSERVATION", 37, 44], ["host cell", "OBSERVATION", 118, 127]]], ["Sixty-one proteins in the HoP interactome are PML components.", [["HoP", "GENE_OR_GENE_PRODUCT", 26, 29], ["PML", "GENE_OR_GENE_PRODUCT", 46, 49], ["PML components", "PROTEIN", 46, 60], ["PML components", "PROBLEM", 46, 60], ["HoP interactome", "OBSERVATION", 26, 41], ["PML", "OBSERVATION", 46, 49]]], ["These include the host protein AKAP8L, which has been known to promote retroviral gene expression, and 55 known interactors and 5 novel interactors (RNF111, SP140, ELF4, NFE2, CIART) of other host proteins.", [["AKAP8L", "GENE_OR_GENE_PRODUCT", 31, 37], ["retroviral", "ORGANISM", 71, 81], ["RNF111", "GENE_OR_GENE_PRODUCT", 149, 155], ["SP140", "GENE_OR_GENE_PRODUCT", 157, 162], ["ELF4", "GENE_OR_GENE_PRODUCT", 164, 168], ["NFE2", "GENE_OR_GENE_PRODUCT", 170, 174], ["CIART", "GENE_OR_GENE_PRODUCT", 176, 181], ["AKAP8L", "PROTEIN", 31, 37], ["5 novel interactors", "PROTEIN", 128, 147], ["RNF111", "PROTEIN", 149, 155], ["SP140", "PROTEIN", 157, 162], ["ELF4", "PROTEIN", 164, 168], ["NFE2", "PROTEIN", 170, 174], ["CIART", "PROTEIN", 176, 181], ["host proteins", "PROTEIN", 192, 205], ["the host protein AKAP8L", "TEST", 14, 37], ["RNF111", "TEST", 149, 155], ["SP140", "TEST", 157, 162], ["retroviral gene expression", "OBSERVATION", 71, 97]]], ["Our model predicted an interaction of EIF4E2 with SP140, an interferon-inducible PML component; nCoV19 may perturb this PPI.", [["EIF4E2", "GENE_OR_GENE_PRODUCT", 38, 44], ["SP140", "GENE_OR_GENE_PRODUCT", 50, 55], ["PML", "GENE_OR_GENE_PRODUCT", 81, 84], ["nCoV19", "SIMPLE_CHEMICAL", 96, 102], ["EIF4E2", "PROTEIN", 38, 44], ["SP140", "PROTEIN", 50, 55], ["interferon", "PROTEIN", 60, 70], ["PML component", "PROTEIN", 81, 94], ["nCoV19", "PROTEIN", 96, 102], ["an interferon-inducible PML component", "PROBLEM", 57, 94], ["nCoV19", "TREATMENT", 96, 102], ["this PPI", "TREATMENT", 115, 123], ["inducible PML", "OBSERVATION", 71, 84]]], ["The midbody is a microtubule-rich stricture that connects the daughter cells and marks the site of abscission during cytokinesis.", [["midbody", "ANATOMY", 4, 11], ["microtubule", "ANATOMY", 17, 28], ["daughter cells", "ANATOMY", 62, 76], ["site", "ANATOMY", 91, 95], ["midbody", "CELLULAR_COMPONENT", 4, 11], ["microtubule", "CELLULAR_COMPONENT", 17, 28], ["stricture", "PATHOLOGICAL_FORMATION", 34, 43], ["daughter cells", "CELL", 62, 76], ["microtubule", "PROTEIN", 17, 28], ["daughter cells", "CELL_TYPE", 62, 76], ["a microtubule-rich stricture", "PROBLEM", 15, 43], ["abscission during cytokinesis", "PROBLEM", 99, 128], ["midbody", "OBSERVATION_MODIFIER", 4, 11], ["microtubule", "OBSERVATION_MODIFIER", 17, 28], ["rich", "OBSERVATION_MODIFIER", 29, 33], ["stricture", "OBSERVATION", 34, 43], ["daughter cells", "OBSERVATION", 62, 76], ["site", "OBSERVATION_MODIFIER", 91, 95], ["abscission", "OBSERVATION", 99, 109]]], ["Viruses have been known to recruit certain protein complexes that also localize to the midbody during cytokinesis, to the host cell membrane to promote its scission and thereby the release of viruses.", [["midbody", "ANATOMY", 87, 94], ["cell membrane", "ANATOMY", 127, 140], ["midbody", "CELLULAR_COMPONENT", 87, 94], ["cell membrane", "CELLULAR_COMPONENT", 127, 140], ["protein complexes", "PROTEIN", 43, 60], ["Viruses", "PROBLEM", 0, 7], ["viruses", "PROBLEM", 192, 199], ["midbody", "ANATOMY_MODIFIER", 87, 94], ["cytokinesis", "OBSERVATION", 102, 113], ["host cell membrane", "OBSERVATION", 122, 140], ["viruses", "OBSERVATION", 192, 199]]], ["44 Enriched biological processes in the interactome included (G1/S and G2/M) mitotic cell cycle phase transitions, regulation of vesicle-mediated transport, covalent chromatin modification and nuclear transport (p-value<0.0001).", [["cell", "ANATOMY", 85, 89], ["vesicle", "ANATOMY", 129, 136], ["chromatin", "ANATOMY", 166, 175], ["nuclear", "ANATOMY", 193, 200], ["vesicle", "CELLULAR_COMPONENT", 129, 136], ["chromatin", "CELLULAR_COMPONENT", 166, 175], ["nuclear", "CELLULAR_COMPONENT", 193, 200], ["G1/S", "TEST", 62, 66], ["mitotic cell cycle phase transitions", "PROBLEM", 77, 113], ["vesicle-mediated transport", "TREATMENT", 129, 155], ["covalent chromatin modification", "TREATMENT", 157, 188], ["nuclear transport (p-value", "TEST", 193, 219], ["mitotic cell cycle phase", "OBSERVATION", 77, 101], ["covalent chromatin", "OBSERVATION", 157, 175]]], ["The response of the host cell to nCoV19 infection has been shown to be significantly delayed and devoid of several anti-viral mechanisms.", [["cell", "ANATOMY", 25, 29], ["nCoV19", "CHEMICAL", 33, 39], ["infection", "DISEASE", 40, 49], ["host cell", "CELL", 20, 29], ["nCoV19", "GENE_OR_GENE_PRODUCT", 33, 39], ["the host cell", "PROBLEM", 16, 29], ["nCoV19 infection", "PROBLEM", 33, 49], ["several anti-viral mechanisms", "TREATMENT", 107, 136], ["host cell", "OBSERVATION", 20, 29], ["infection", "OBSERVATION", 40, 49], ["anti-viral mechanisms", "OBSERVATION", 115, 136]]], ["5 During early stages of the infection, it is possible that the virus induces a G1/S phase transition to surreptitiously synergize the replication of the viral genome with that of the host genome.", [["infection", "DISEASE", 29, 38], ["viral genome", "DNA", 154, 166], ["host genome", "DNA", 184, 195], ["the infection", "PROBLEM", 25, 38], ["the virus", "PROBLEM", 60, 69], ["a G1/S phase transition", "TREATMENT", 78, 101], ["the viral genome", "PROBLEM", 150, 166], ["infection", "OBSERVATION", 29, 38], ["virus", "OBSERVATION", 64, 69], ["viral genome", "OBSERVATION", 154, 166], ["host genome", "OBSERVATION", 184, 195]]], ["45 In the later stages, it may block the G2/M phase transition to maximise the levels of viral genome.", [["viral genome", "DNA", 89, 101], ["the G2/M phase transition", "TREATMENT", 37, 62], ["viral genome", "PROBLEM", 89, 101], ["viral genome", "OBSERVATION", 89, 101]]], ["45 We found novel (predicted) interactions of host proteins with 34 proteins involved in cell cycle phase transition: ANAPC4, ANAPC7, ARPP19, CCNB3, CDC14B, CDC16, CDC7, CEP164, CETN2, CLSPN, CRLF3, DCTN1, DNM2, DYNC1H1, E2F6, ENSA, FBXL7, GFI1, GML, HYAL1, INHBA, JADE1, NEUROG1, NPAT, ORC2, PPM1D, RAD17, SPDYA, TAOK2, TICRR, TRIAP1, XPC, ZFP36L1, ZNF655.Resveratrol-modulated sub-network of genes involved in the tristetraproline pathwayUsing WebGestalt, 46 we compiled the list of the Reactome pathways (Figure 4) , which showed a statistically significant enrichment of several pathways related to viral entry and infection such as infectious disease, HIV life cycle, vesiclemediated transport and membrane trafficking.", [["cell", "ANATOMY", 89, 93], ["membrane", "ANATOMY", 703, 711], ["Resveratrol", "CHEMICAL", 357, 368], ["tristetraproline", "CHEMICAL", 416, 432], ["infection", "DISEASE", 619, 628], ["infectious disease", "DISEASE", 637, 655], ["Resveratrol", "CHEMICAL", 357, 368], ["tristetraproline", "CHEMICAL", 416, 432], ["cell", "CELL", 89, 93], ["ANAPC4", "GENE_OR_GENE_PRODUCT", 118, 124], ["ANAPC7", "GENE_OR_GENE_PRODUCT", 126, 132], ["ARPP19", "GENE_OR_GENE_PRODUCT", 134, 140], ["CCNB3", "GENE_OR_GENE_PRODUCT", 142, 147], ["CDC14B", "GENE_OR_GENE_PRODUCT", 149, 155], ["CDC16", "GENE_OR_GENE_PRODUCT", 157, 162], ["CDC7", "GENE_OR_GENE_PRODUCT", 164, 168], ["CEP164", "GENE_OR_GENE_PRODUCT", 170, 176], ["CETN2", "GENE_OR_GENE_PRODUCT", 178, 183], ["CLSPN", "GENE_OR_GENE_PRODUCT", 185, 190], ["CRLF3", "GENE_OR_GENE_PRODUCT", 192, 197], ["DCTN1", "GENE_OR_GENE_PRODUCT", 199, 204], ["DNM2", "GENE_OR_GENE_PRODUCT", 206, 210], ["DYNC1H1", "GENE_OR_GENE_PRODUCT", 212, 219], ["E2F6", "GENE_OR_GENE_PRODUCT", 221, 225], ["ENSA", "GENE_OR_GENE_PRODUCT", 227, 231], ["FBXL7", "GENE_OR_GENE_PRODUCT", 233, 238], ["GFI1", "GENE_OR_GENE_PRODUCT", 240, 244], ["GML", "GENE_OR_GENE_PRODUCT", 246, 249], ["HYAL1", "GENE_OR_GENE_PRODUCT", 251, 256], ["INHBA", "GENE_OR_GENE_PRODUCT", 258, 263], ["JADE1", "GENE_OR_GENE_PRODUCT", 265, 270], ["NEUROG1", "GENE_OR_GENE_PRODUCT", 272, 279], ["NPAT", "GENE_OR_GENE_PRODUCT", 281, 285], ["ORC2", "GENE_OR_GENE_PRODUCT", 287, 291], ["PPM1D", "GENE_OR_GENE_PRODUCT", 293, 298], ["RAD17", "GENE_OR_GENE_PRODUCT", 300, 305], ["SPDYA", "GENE_OR_GENE_PRODUCT", 307, 312], ["TAOK2", "GENE_OR_GENE_PRODUCT", 314, 319], ["TICRR", "GENE_OR_GENE_PRODUCT", 321, 326], ["TRIAP1", "GENE_OR_GENE_PRODUCT", 328, 334], ["XPC", "GENE_OR_GENE_PRODUCT", 336, 339], ["ZFP36L1", "GENE_OR_GENE_PRODUCT", 341, 348], ["ZNF655", "GENE_OR_GENE_PRODUCT", 350, 356], ["Resveratrol", "SIMPLE_CHEMICAL", 357, 368], ["membrane", "CELLULAR_COMPONENT", 703, 711], ["host proteins", "PROTEIN", 46, 59], ["34 proteins", "PROTEIN", 65, 76], ["ANAPC4", "PROTEIN", 118, 124], ["ANAPC7", "PROTEIN", 126, 132], ["ARPP19", "PROTEIN", 134, 140], ["CCNB3", "PROTEIN", 142, 147], ["CDC14B", "PROTEIN", 149, 155], ["CDC16", "PROTEIN", 157, 162], ["CDC7", "PROTEIN", 164, 168], ["CEP164", "PROTEIN", 170, 176], ["CETN2", "PROTEIN", 178, 183], ["CLSPN", "PROTEIN", 185, 190], ["CRLF3", "PROTEIN", 192, 197], ["DCTN1", "PROTEIN", 199, 204], ["DNM2", "PROTEIN", 206, 210], ["DYNC1H1", "PROTEIN", 212, 219], ["E2F6", "PROTEIN", 221, 225], ["ENSA", "PROTEIN", 227, 231], ["FBXL7", "PROTEIN", 233, 238], ["GFI1", "PROTEIN", 240, 244], ["GML", "PROTEIN", 246, 249], ["HYAL1", "PROTEIN", 251, 256], ["INHBA", "PROTEIN", 258, 263], ["JADE1", "PROTEIN", 265, 270], ["NEUROG1", "PROTEIN", 272, 279], ["NPAT", "PROTEIN", 281, 285], ["ORC2", "PROTEIN", 287, 291], ["PPM1D", "PROTEIN", 293, 298], ["RAD17", "PROTEIN", 300, 305], ["SPDYA", "PROTEIN", 307, 312], ["TAOK2", "PROTEIN", 314, 319], ["TICRR", "PROTEIN", 321, 326], ["TRIAP1", "PROTEIN", 328, 334], ["XPC", "PROTEIN", 336, 339], ["ZFP36L1", "PROTEIN", 341, 348], ["ZNF655", "PROTEIN", 350, 356], ["HIV", "SPECIES", 657, 660], ["HIV", "SPECIES", 657, 660], ["host proteins", "TEST", 46, 59], ["ANAPC4", "TEST", 118, 124], ["ANAPC7", "TEST", 126, 132], ["CDC14B", "TEST", 149, 155], ["CDC16", "TEST", 157, 162], ["CDC7", "TEST", 164, 168], ["CEP164", "TEST", 170, 176], ["CETN2", "TEST", 178, 183], ["CLSPN", "TEST", 185, 190], ["CRLF3", "TEST", 192, 197], ["ZNF655", "TREATMENT", 350, 356], ["Resveratrol", "TREATMENT", 357, 368], ["viral entry", "PROBLEM", 603, 614], ["infection", "PROBLEM", 619, 628], ["infectious disease", "PROBLEM", 637, 655], ["HIV life cycle", "TREATMENT", 657, 671], ["significant", "OBSERVATION_MODIFIER", 549, 560], ["enrichment", "OBSERVATION", 561, 571], ["viral entry", "OBSERVATION", 603, 614], ["infection", "OBSERVATION", 619, 628]]], ["Several immunity-related pathways which mediate the host response such as MyD88 dependent TLR4 signalling and ISG15 anti-viral mechanism were also identified.", [["MyD88", "GENE_OR_GENE_PRODUCT", 74, 79], ["TLR4", "GENE_OR_GENE_PRODUCT", 90, 94], ["ISG15", "GENE_OR_GENE_PRODUCT", 110, 115], ["MyD88", "PROTEIN", 74, 79], ["TLR4", "PROTEIN", 90, 94], ["ISG15", "PROTEIN", 110, 115], ["MyD88 dependent TLR4 signalling", "TREATMENT", 74, 105], ["ISG15 anti-viral mechanism", "TREATMENT", 110, 136], ["ISG15 anti-viral", "OBSERVATION", 110, 126]]], ["The transcriptional profile of the host cell after nCoV19 infection had revealed a remarkably limited anti-viral response compared to that elicited by seasonal influenza-A and respiratory syncytial viruses.", [["cell", "ANATOMY", 40, 44], ["infection", "DISEASE", 58, 67], ["respiratory syncytial viruses", "DISEASE", 176, 205], ["host cell", "CELL", 35, 44], ["nCoV19", "CELL", 51, 57], ["seasonal influenza-A", "ORGANISM", 151, 171], ["respiratory syncytial viruses", "ORGANISM", 176, 205], ["seasonal influenza-A", "SPECIES", 151, 171], ["nCoV19 infection", "PROBLEM", 51, 67], ["seasonal influenza", "PROBLEM", 151, 169], ["respiratory syncytial viruses", "PROBLEM", 176, 205], ["host cell", "OBSERVATION", 35, 44], ["respiratory syncytial viruses", "OBSERVATION", 176, 205]]], ["5 This prompted us to inspect a posttranscriptional regulatory pathway that was enriched in the HoP interactome, namely, tristetraproline (ZFP36) binds and destabilizes mRNA (p-value<0.0001).", [["tristetraproline", "CHEMICAL", 121, 137], ["ZFP36", "CHEMICAL", 139, 144], ["tristetraproline", "CHEMICAL", 121, 137], ["ZFP36", "CHEMICAL", 139, 144], ["HoP", "GENE_OR_GENE_PRODUCT", 96, 99], ["tristetraproline", "SIMPLE_CHEMICAL", 121, 137], ["ZFP36", "GENE_OR_GENE_PRODUCT", 139, 144], ["ZFP36", "PROTEIN", 139, 144], ["mRNA", "RNA", 169, 173], ["tristetraproline (ZFP36)", "TREATMENT", 121, 145], ["p-value", "TEST", 175, 182]]], ["ZFP36 is an RNA-binding protein that targets AU-rich sites in the mRNA transcripts coding for immune proteins and destabilizes them by promoting the deadenylation of their poly(A) tails.", [["ZFP36", "GENE_OR_GENE_PRODUCT", 0, 5], ["poly(A) tails", "GENE_OR_GENE_PRODUCT", 172, 185], ["ZFP36", "PROTEIN", 0, 5], ["RNA-binding protein", "PROTEIN", 12, 31], ["AU-rich sites", "DNA", 45, 58], ["mRNA transcripts", "RNA", 66, 82], ["immune proteins", "PROTEIN", 94, 109], ["poly(A) tails", "PROTEIN", 172, 185], ["an RNA-binding protein", "TREATMENT", 9, 31], ["AU-rich sites", "TREATMENT", 45, 58], ["the mRNA transcripts", "TREATMENT", 62, 82], ["immune proteins", "PROBLEM", 94, 109]]], ["47, 48 YWHAB increases cytoplasmic localization of ZFP36, possibly preventing destabilization of these genes and attenuation of immune response.", [["cytoplasmic", "ANATOMY", 23, 34], ["cytoplasmic", "ORGANISM_SUBSTANCE", 23, 34], ["ZFP36", "GENE_OR_GENE_PRODUCT", 51, 56], ["ZFP36", "PROTEIN", 51, 56], ["cytoplasmic localization", "TEST", 23, 47], ["ZFP36", "TREATMENT", 51, 56], ["destabilization of these genes", "PROBLEM", 78, 108], ["immune response", "PROBLEM", 128, 143], ["possibly preventing", "UNCERTAINTY", 58, 77], ["destabilization", "OBSERVATION", 78, 93], ["attenuation", "OBSERVATION_MODIFIER", 113, 124], ["immune response", "OBSERVATION", 128, 143]]], ["49 We extracted the direct PPIs of the 17 genes belonging to this pathway from the HoP interactome and isolated this sub-network for further inspection ( Figure 5 ).", [["HoP", "GENE_OR_GENE_PRODUCT", 83, 86], ["17 genes", "DNA", 39, 47], ["HoP interactome", "DNA", 83, 98], ["the direct PPIs", "TREATMENT", 16, 31], ["further inspection", "TEST", 133, 151]]], ["Our predictions show that the host protein DCAF7, which is known to function as a scaffold protein and a facilitator of PPIs, interacts with YWHAB and ACE1, belonging to the class of receptors targeted by nCoV19 ( Figure 5) .", [["DCAF7", "GENE_OR_GENE_PRODUCT", 43, 48], ["PPIs", "GENE_OR_GENE_PRODUCT", 120, 124], ["YWHAB", "GENE_OR_GENE_PRODUCT", 141, 146], ["ACE1", "GENE_OR_GENE_PRODUCT", 151, 155], ["nCoV19", "GENE_OR_GENE_PRODUCT", 205, 211], ["Figure 5", "ORGANISM", 214, 222], ["DCAF7", "PROTEIN", 43, 48], ["scaffold protein", "PROTEIN", 82, 98], ["PPIs", "PROTEIN", 120, 124], ["YWHAB", "PROTEIN", 141, 146], ["ACE1", "PROTEIN", 151, 155], ["nCoV19", "PROTEIN", 205, 211], ["the host protein DCAF7", "TEST", 26, 48], ["a scaffold protein", "TREATMENT", 80, 98], ["PPIs", "TREATMENT", 120, 124], ["ACE1", "TREATMENT", 151, 155]]], ["This raises the possibility that the virus protein Nsp9 (which interacts with DCAF7) may somehow perturb YWHAB-induced cytoplasmic localization of ZFP36 through its action on DCAF7.", [["cytoplasmic", "ANATOMY", 119, 130], ["YWHAB", "CHEMICAL", 105, 110], ["Nsp9", "GENE_OR_GENE_PRODUCT", 51, 55], ["DCAF7", "GENE_OR_GENE_PRODUCT", 78, 83], ["YWHAB", "GENE_OR_GENE_PRODUCT", 105, 110], ["cytoplasmic", "ORGANISM_SUBSTANCE", 119, 130], ["ZFP36", "GENE_OR_GENE_PRODUCT", 147, 152], ["DCAF7", "GENE_OR_GENE_PRODUCT", 175, 180], ["virus protein", "PROTEIN", 37, 50], ["Nsp9", "PROTEIN", 51, 55], ["DCAF7", "PROTEIN", 78, 83], ["YWHAB", "PROTEIN", 105, 110], ["ZFP36", "PROTEIN", 147, 152], ["DCAF7", "PROTEIN", 175, 180], ["the virus protein Nsp9", "PROBLEM", 33, 55], ["ZFP36", "TREATMENT", 147, 152], ["DCAF7", "TREATMENT", 175, 180], ["raises the possibility", "UNCERTAINTY", 5, 27]]], ["Nsp9 may activate or promote the sequestration of YWHAB with DCAF7, thereby reducing its capacity to form a complex with YWHAB.", [["Nsp9", "CHEMICAL", 0, 4], ["Nsp9", "GENE_OR_GENE_PRODUCT", 0, 4], ["YWHAB", "GENE_OR_GENE_PRODUCT", 50, 55], ["DCAF7", "GENE_OR_GENE_PRODUCT", 61, 66], ["YWHAB", "GENE_OR_GENE_PRODUCT", 121, 126], ["Nsp9", "PROTEIN", 0, 4], ["YWHAB", "PROTEIN", 50, 55], ["DCAF7", "PROTEIN", 61, 66], ["YWHAB", "PROTEIN", 121, 126], ["DCAF7", "TREATMENT", 61, 66]]], ["YWHAB-mediated destabilization of immune genes may then lead to a weakened immune response, creating a conducive environment for nCoV19 infection.", [["YWHAB", "CHEMICAL", 0, 5], ["infection", "DISEASE", 136, 145], ["YWHAB", "SIMPLE_CHEMICAL", 0, 5], ["nCoV19", "GENE_OR_GENE_PRODUCT", 129, 135], ["YWHAB", "PROTEIN", 0, 5], ["immune genes", "DNA", 34, 46], ["immune genes", "PROBLEM", 34, 46], ["a weakened immune response", "PROBLEM", 64, 90], ["nCoV19 infection", "PROBLEM", 129, 145], ["immune genes", "OBSERVATION", 34, 46], ["infection", "OBSERVATION", 136, 145]]], ["We also identified 3 drugs targeting the proteins in this sub-network using Drug Bank: 50 resveratrol targeting KHSRP and APP, known interactors of the host protein EXOSC2, which is involved in the tristetraprolin (TTP) pathway, staurosporine targeting TTP-associated MAPKAPK2 which has been predicted to interact with PABPC1 and dacarbazine targeting the host protein POLA2 ( Figure 5 ).", [["resveratrol", "CHEMICAL", 90, 101], ["staurosporine", "CHEMICAL", 229, 242], ["PABPC1", "CHEMICAL", 319, 325], ["dacarbazine", "CHEMICAL", 330, 341], ["resveratrol", "CHEMICAL", 90, 101], ["tristetraprolin", "CHEMICAL", 198, 213], ["staurosporine", "CHEMICAL", 229, 242], ["PABPC1", "CHEMICAL", 319, 325], ["dacarbazine", "CHEMICAL", 330, 341], ["resveratrol", "SIMPLE_CHEMICAL", 90, 101], ["KHSRP", "GENE_OR_GENE_PRODUCT", 112, 117], ["APP", "GENE_OR_GENE_PRODUCT", 122, 125], ["EXOSC2", "GENE_OR_GENE_PRODUCT", 165, 171], ["tristetraprolin", "GENE_OR_GENE_PRODUCT", 198, 213], ["TTP", "GENE_OR_GENE_PRODUCT", 215, 218], ["staurosporine", "SIMPLE_CHEMICAL", 229, 242], ["TTP", "GENE_OR_GENE_PRODUCT", 253, 256], ["MAPKAPK2", "GENE_OR_GENE_PRODUCT", 268, 276], ["PABPC1", "GENE_OR_GENE_PRODUCT", 319, 325], ["dacarbazine", "SIMPLE_CHEMICAL", 330, 341], ["POLA2", "GENE_OR_GENE_PRODUCT", 369, 374], ["KHSRP", "PROTEIN", 112, 117], ["APP", "PROTEIN", 122, 125], ["EXOSC2", "PROTEIN", 165, 171], ["TTP", "PROTEIN", 215, 218], ["TTP", "PROTEIN", 253, 256], ["MAPKAPK2", "PROTEIN", 268, 276], ["PABPC1", "PROTEIN", 319, 325], ["POLA2", "PROTEIN", 369, 374], ["Figure 5", "PROTEIN", 377, 385], ["3 drugs", "TREATMENT", 19, 26], ["the proteins", "TREATMENT", 37, 49], ["the tristetraprolin (TTP) pathway", "TREATMENT", 194, 227], ["staurosporine targeting TTP", "PROBLEM", 229, 256], ["PABPC1", "TREATMENT", 319, 325], ["dacarbazine", "TREATMENT", 330, 341]]], ["Gene expression profiles induced by these drugs in various cell lines were found to have a negative correlation with SARS-associated gene expression profiles, namely, that of lung fibroblast MRC5 cells infected with SARS-CoV and in peripheral blood mononuclear cells of SARS patients (analysis using NextBio; https://www.nextbio.com).", [["cell lines", "ANATOMY", 59, 69], ["lung fibroblast MRC5 cells", "ANATOMY", 175, 201], ["peripheral blood mononuclear cells", "ANATOMY", 232, 266], ["SARS", "DISEASE", 270, 274], ["cell lines", "CELL", 59, 69], ["lung fibroblast MRC5 cells", "CELL", 175, 201], ["SARS-CoV", "ORGANISM", 216, 224], ["peripheral blood mononuclear cells", "CELL", 232, 266], ["patients", "ORGANISM", 275, 283], ["various cell lines", "CELL_LINE", 51, 69], ["lung fibroblast MRC5 cells", "CELL_LINE", 175, 201], ["peripheral blood mononuclear cells", "CELL_TYPE", 232, 266], ["patients", "SPECIES", 275, 283], ["SARS-CoV", "SPECIES", 216, 224], ["Gene expression profiles", "PROBLEM", 0, 24], ["these drugs", "TREATMENT", 36, 47], ["various cell lines", "TREATMENT", 51, 69], ["SARS", "PROBLEM", 117, 121], ["gene expression profiles", "PROBLEM", 133, 157], ["lung fibroblast MRC5 cells", "PROBLEM", 175, 201], ["SARS", "PROBLEM", 216, 220], ["CoV", "PROBLEM", 221, 224], ["peripheral blood mononuclear cells", "TEST", 232, 266], ["cell lines", "OBSERVATION", 59, 69], ["lung", "ANATOMY", 175, 179], ["fibroblast MRC5 cells", "OBSERVATION", 180, 201], ["peripheral", "ANATOMY_MODIFIER", 232, 242], ["blood", "ANATOMY", 243, 248], ["mononuclear cells", "OBSERVATION", 249, 266]]], ["Resveratrol has been proposed as a therapeutic option for nCoV19 based on its antagonistic properties against MERS-CoV.", [["Resveratrol", "CHEMICAL", 0, 11], ["nCoV19", "CHEMICAL", 58, 64], ["Resveratrol", "CHEMICAL", 0, 11], ["Resveratrol", "SIMPLE_CHEMICAL", 0, 11], ["nCoV19", "SIMPLE_CHEMICAL", 58, 64], ["MERS-CoV", "ORGANISM", 110, 118], ["MERS-CoV", "SPECIES", 110, 118], ["Resveratrol", "TREATMENT", 0, 11], ["a therapeutic option", "TREATMENT", 33, 53], ["nCoV19", "TREATMENT", 58, 64]]], ["53Network proximity of genes associated with diabetes and hypertension to the host proteinsWe studied the association of interactome genes with any genetic disorders/traits in the OMIM database.", [["diabetes", "DISEASE", 45, 53], ["hypertension", "DISEASE", 58, 70], ["host proteins", "PROTEIN", 78, 91], ["interactome genes", "DNA", 121, 138], ["diabetes", "PROBLEM", 45, 53], ["hypertension to the host proteins", "PROBLEM", 58, 91], ["any genetic disorders", "PROBLEM", 144, 165], ["diabetes", "OBSERVATION", 45, 53], ["hypertension", "OBSERVATION", 58, 70]]], ["155 genes in the interactome, including 9 host protein-encoding genes, and 121 known interactors and 25 novel interactors of host proteins, were found to be associated with 35 disorders (overlap of each disease had p-value<0.05).", [["9 host protein-encoding genes", "DNA", 40, 69], ["host proteins", "PROTEIN", 125, 138], ["35 disorders", "PROBLEM", 173, 185], ["each disease", "PROBLEM", 198, 210], ["p-value", "TEST", 215, 222]]], ["This included 13 types of cancers, 7 metabolic disorders, 4 neurological disorders, 3 developmental disorders, 2 eye-related disorders, 2 vascular diseases, 1 infectious disease, 1 inflammatory disorder, 1 respiratory disorder and 1 skin disease ( Figure 6 and Table 1 ).", [["cancers", "ANATOMY", 26, 33], ["neurological", "ANATOMY", 60, 72], ["vascular", "ANATOMY", 138, 146], ["respiratory", "ANATOMY", 206, 217], ["skin", "ANATOMY", 233, 237], ["cancers", "DISEASE", 26, 33], ["metabolic disorders", "DISEASE", 37, 56], ["neurological disorders", "DISEASE", 60, 82], ["developmental disorders", "DISEASE", 86, 109], ["eye-related disorders", "DISEASE", 113, 134], ["vascular diseases", "DISEASE", 138, 155], ["infectious disease", "DISEASE", 159, 177], ["inflammatory disorder", "DISEASE", 181, 202], ["respiratory disorder", "DISEASE", 206, 226], ["skin disease", "DISEASE", 233, 245], ["cancers", "CANCER", 26, 33], ["vascular", "MULTI-TISSUE_STRUCTURE", 138, 146], ["skin", "ORGAN", 233, 237], ["cancers", "PROBLEM", 26, 33], ["7 metabolic disorders", "PROBLEM", 35, 56], ["4 neurological disorders", "PROBLEM", 58, 82], ["3 developmental disorders", "PROBLEM", 84, 109], ["2 eye-related disorders", "PROBLEM", 111, 134], ["2 vascular diseases", "PROBLEM", 136, 155], ["1 infectious disease", "PROBLEM", 157, 177], ["1 inflammatory disorder", "PROBLEM", 179, 202], ["1 respiratory disorder", "PROBLEM", 204, 226], ["1 skin disease", "PROBLEM", 231, 245], ["cancers", "OBSERVATION", 26, 33], ["vascular", "ANATOMY", 138, 146], ["diseases", "OBSERVATION", 147, 155], ["inflammatory", "OBSERVATION_MODIFIER", 181, 193], ["respiratory disorder", "OBSERVATION", 206, 226], ["skin", "ANATOMY", 233, 237], ["disease", "OBSERVATION", 238, 245]]], ["Some of these diseases enriched in the interactome are co-morbidities among non-survivors and critically ill COVID patients (e.g. diabetes, hypertension, cerebrovascular events and cancer).", [["cerebrovascular", "ANATOMY", 154, 169], ["cancer", "ANATOMY", 181, 187], ["critically ill", "DISEASE", 94, 108], ["COVID", "DISEASE", 109, 114], ["diabetes", "DISEASE", 130, 138], ["hypertension", "DISEASE", 140, 152], ["cerebrovascular events", "DISEASE", 154, 176], ["cancer", "DISEASE", 181, 187], ["patients", "ORGANISM", 115, 123], ["cerebrovascular", "ANATOMICAL_SYSTEM", 154, 169], ["cancer", "CANCER", 181, 187], ["patients", "SPECIES", 115, 123], ["these diseases", "PROBLEM", 8, 22], ["diabetes", "PROBLEM", 130, 138], ["hypertension", "PROBLEM", 140, 152], ["cerebrovascular events", "PROBLEM", 154, 176], ["cancer", "PROBLEM", 181, 187], ["diseases", "OBSERVATION", 14, 22], ["hypertension", "OBSERVATION", 140, 152], ["cerebrovascular", "ANATOMY", 154, 169], ["cancer", "OBSERVATION", 181, 187]]], ["42, 54 Thirteen genes in the interactome were associated with non-insulin dependent diabetes mellitus (odds ratio=10.8, p-value=4.38E-10), 6 genes with essential hypertension (odds ratio=12, p-value=2.34E-05), 3 genes with ischemic stroke (odds ratio=14.4, p-value=0.0017) and 10 genes with lung cancer (odds ratio=14.1, p-value=2.36E-09).", [["lung cancer", "ANATOMY", 291, 302], ["non-insulin", "DISEASE", 62, 73], ["diabetes mellitus", "DISEASE", 84, 101], ["hypertension", "DISEASE", 162, 174], ["ischemic stroke", "DISEASE", 223, 238], ["lung cancer", "DISEASE", 291, 302], ["lung cancer", "CANCER", 291, 302], ["non-insulin dependent diabetes mellitus", "PROBLEM", 62, 101], ["ratio", "TEST", 108, 113], ["p-value", "TEST", 120, 127], ["essential hypertension", "PROBLEM", 152, 174], ["odds ratio", "TEST", 176, 186], ["p-value", "TEST", 191, 198], ["ischemic stroke", "PROBLEM", 223, 238], ["odds ratio", "TEST", 240, 250], ["p-value", "TEST", 257, 264], ["lung cancer", "PROBLEM", 291, 302], ["odds ratio", "TEST", 304, 314], ["p-value", "TEST", 321, 328], ["hypertension", "OBSERVATION", 162, 174], ["ischemic", "OBSERVATION_MODIFIER", 223, 231], ["stroke", "OBSERVATION", 232, 238], ["lung", "ANATOMY", 291, 295], ["cancer", "OBSERVATION", 296, 302]]], ["Network proximity of the proteins associated with these comorbid conditions to the nCoV19 host proteins may explain why patients with these conditions are increasingly affected by the viral infection.", [["viral infection", "DISEASE", 184, 199], ["nCoV19", "GENE_OR_GENE_PRODUCT", 83, 89], ["patients", "ORGANISM", 120, 128], ["nCoV19 host proteins", "PROTEIN", 83, 103], ["patients", "SPECIES", 120, 128], ["these comorbid conditions", "PROBLEM", 50, 75], ["these conditions", "PROBLEM", 134, 150], ["the viral infection", "PROBLEM", 180, 199], ["viral", "OBSERVATION_MODIFIER", 184, 189], ["infection", "OBSERVATION", 190, 199]]], ["Further investigations are necessary to dissect these co-morbidities.", [["Further investigations", "TEST", 0, 22], ["these co-morbidities", "PROBLEM", 48, 68]]], ["Treatment strategies that prevent the deterioration of the underlying genetic conditions must be devised to combat COVID-19 in susceptible individuals.", [["COVID-19", "CHEMICAL", 115, 123], ["COVID-19", "CHEMICAL", 115, 123], ["Treatment strategies", "TREATMENT", 0, 20], ["the deterioration", "PROBLEM", 34, 51], ["the underlying genetic conditions", "PROBLEM", 55, 88], ["COVID", "TEST", 115, 120]]], ["Additionally, neurological disorders such as Alzheimer's disease (odds ratio=15.3, p-value=5.13E-07) and schizophrenia (odds ratio=12, p-value=4.19E-06) were also found to be enriched in the interactome, warranting further investigations into these potential co-morbidities.Interconnections to Ciliary ProteinsSARS coronavirus which emerged in 2002 has been known to induce necrosis in ciliated airway epithelium of humans in a species-specific manner.", [["neurological", "ANATOMY", 14, 26], ["airway epithelium", "ANATOMY", 395, 412], ["neurological disorders", "DISEASE", 14, 36], ["Alzheimer's disease", "DISEASE", 45, 64], ["schizophrenia", "DISEASE", 105, 118], ["necrosis", "DISEASE", 374, 382], ["Ciliary ProteinsSARS coronavirus", "ORGANISM", 294, 326], ["ciliated airway epithelium", "TISSUE", 386, 412], ["humans", "ORGANISM", 416, 422], ["humans", "SPECIES", 416, 422], ["Ciliary ProteinsSARS coronavirus", "SPECIES", 294, 326], ["humans", "SPECIES", 416, 422], ["neurological disorders", "PROBLEM", 14, 36], ["Alzheimer's disease", "PROBLEM", 45, 64], ["odds ratio", "TEST", 66, 76], ["p-value", "TEST", 83, 90], ["schizophrenia", "PROBLEM", 105, 118], ["odds ratio", "TEST", 120, 130], ["p-value", "TEST", 135, 142], ["further investigations", "TEST", 215, 237], ["Ciliary ProteinsSARS coronavirus", "PROBLEM", 294, 326], ["necrosis in ciliated airway epithelium of humans", "PROBLEM", 374, 422], ["Ciliary", "ANATOMY_MODIFIER", 294, 301], ["necrosis", "OBSERVATION", 374, 382], ["ciliated", "ANATOMY_MODIFIER", 386, 394], ["airway", "ANATOMY", 395, 401], ["epithelium", "ANATOMY_MODIFIER", 402, 412]]], ["55 nCoV19's host receptor ACE2 is highly expressed in ciliated respiratory cells.", [["ciliated respiratory cells", "ANATOMY", 54, 80], ["ACE2", "GENE_OR_GENE_PRODUCT", 26, 30], ["ciliated respiratory cells", "CELL", 54, 80], ["55 nCoV19's host receptor", "PROTEIN", 0, 25], ["ACE2", "PROTEIN", 26, 30], ["ciliated respiratory cells", "CELL_TYPE", 54, 80], ["ACE2", "TEST", 26, 30], ["ciliated respiratory cells", "PROBLEM", 54, 80], ["respiratory cells", "OBSERVATION", 63, 80]]], ["56 Cilia may serve as virus entry points and potential modulators of viral pathogenesis.", [["Cilia", "ANATOMY", 3, 8], ["viral pathogenesis", "PROBLEM", 69, 87], ["viral pathogenesis", "OBSERVATION", 69, 87]]], ["This conjecture prompted us to investigate the ciliary association of the host proteins and their interactors in the HoP interactome.", [["ciliary", "ANATOMY", 47, 54], ["HoP", "GENE_OR_GENE_PRODUCT", 117, 120], ["host proteins", "PROTEIN", 74, 87]]], ["Network proximity of diabetes and hypertension to host proteins: Dark blue nodes are host proteins, light blue nodes are known interactors and red nodes are novel interactors.", [["red nodes", "ANATOMY", 143, 152], ["diabetes", "DISEASE", 21, 29], ["hypertension", "DISEASE", 34, 46], ["blue nodes", "MULTI-TISSUE_STRUCTURE", 70, 80], ["red nodes", "MULTI-TISSUE_STRUCTURE", 143, 152], ["diabetes", "PROBLEM", 21, 29], ["hypertension", "PROBLEM", 34, 46], ["Dark blue nodes", "PROBLEM", 65, 80], ["host proteins", "TEST", 85, 98], ["light blue nodes", "PROBLEM", 100, 116], ["red nodes", "PROBLEM", 143, 152], ["diabetes", "OBSERVATION", 21, 29], ["hypertension", "OBSERVATION", 34, 46], ["blue nodes", "OBSERVATION", 70, 80], ["host proteins", "OBSERVATION_MODIFIER", 85, 98], ["light", "OBSERVATION_MODIFIER", 100, 105], ["blue nodes", "OBSERVATION", 106, 116], ["red nodes", "OBSERVATION", 143, 152]]], ["Nodes with orange labels are diabetes-associated genes, whereas nodes with dark green labels are hypertension-associated genes.Interconnections to Ciliary Proteinsinteractome of 165 ciliary proteins that we constructed in a similar manner.", [["nodes", "ANATOMY", 64, 69], ["ciliary", "ANATOMY", 182, 189], ["diabetes", "DISEASE", 29, 37], ["hypertension", "DISEASE", 97, 109], ["diabetes-associated genes", "DNA", 29, 54], ["hypertension-associated genes", "DNA", 97, 126], ["Ciliary Proteinsinteractome", "PROTEIN", 147, 174], ["165 ciliary proteins", "PROTEIN", 178, 198], ["diabetes", "PROBLEM", 29, 37], ["dark green labels", "PROBLEM", 75, 92], ["hypertension", "PROBLEM", 97, 109], ["ciliary proteins", "TREATMENT", 182, 198], ["nodes", "OBSERVATION", 64, 69], ["hypertension", "OBSERVATION", 97, 109]]], ["The ciliary protein interactome contained 1,665 proteins.", [["ciliary", "ANATOMY", 4, 11], ["1,665 proteins", "PROTEIN", 42, 56], ["The ciliary protein interactome", "TEST", 0, 31], ["ciliary", "OBSERVATION", 4, 11], ["protein interactome", "OBSERVATION", 12, 31]]], ["617 of these proteins, and specifically 30 core ciliary proteins, are also found in nCoV19's host protein interactome, and the overlap was found to be statistically significant (p-value=2.24E-10, odds ratio=1.22).", [["ciliary", "ANATOMY", 48, 55], ["nCoV19", "GENE_OR_GENE_PRODUCT", 84, 90], ["ciliary proteins", "PROTEIN", 48, 64], ["nCoV19", "PROTEIN", 84, 90], ["these proteins", "TEST", 7, 21], ["p-value", "TEST", 178, 185], ["odds ratio", "TEST", 196, 206]]], ["Thirteen novel predicted interactions connected host proteins to ciliary proteins: NUP98-CHMP5, GG3BP1-DNAH1, SEPSECS-DNAH1, NEK9-IFT43, TLE1-DNAH5, ATP6AP1-CETN2, C1orf50-ZMYND12, RAB10-IFT172, TOR1AIP1-GPR161, DNAJC19-CETN3, NLRX1-IFT46, FKBP7-TTC30B, POLA2-TMEM216 and NDUFB9-DRC7.", [["ciliary", "ANATOMY", 65, 72], ["NUP98", "GENE_OR_GENE_PRODUCT", 83, 88], ["CHMP5", "GENE_OR_GENE_PRODUCT", 89, 94], ["GG3BP1-DNAH1", "GENE_OR_GENE_PRODUCT", 96, 108], ["SEPSECS-DNAH1", "GENE_OR_GENE_PRODUCT", 110, 123], ["NEK9-IFT43", "GENE_OR_GENE_PRODUCT", 125, 135], ["TLE1-DNAH5", "GENE_OR_GENE_PRODUCT", 137, 147], ["ATP6AP1-CETN2", "GENE_OR_GENE_PRODUCT", 149, 162], ["C1orf50-ZMYND12", "GENE_OR_GENE_PRODUCT", 164, 179], ["RAB10-IFT172", "GENE_OR_GENE_PRODUCT", 181, 193], ["TOR1AIP1-GPR161", "GENE_OR_GENE_PRODUCT", 195, 210], ["DNAJC19-CETN3", "GENE_OR_GENE_PRODUCT", 212, 225], ["NLRX1-IFT46", "GENE_OR_GENE_PRODUCT", 227, 238], ["FKBP7-TTC30B", "GENE_OR_GENE_PRODUCT", 240, 252], ["POLA2-TMEM216", "GENE_OR_GENE_PRODUCT", 254, 267], ["NDUFB9-DRC7", "GENE_OR_GENE_PRODUCT", 272, 283], ["host proteins", "PROTEIN", 48, 61], ["ciliary proteins", "PROTEIN", 65, 81], ["NUP98", "PROTEIN", 83, 88], ["CHMP5", "PROTEIN", 89, 94], ["GG3BP1", "PROTEIN", 96, 102], ["DNAH1", "PROTEIN", 103, 108], ["SEPSECS", "PROTEIN", 110, 117], ["DNAH1", "PROTEIN", 118, 123], ["NEK9", "PROTEIN", 125, 129], ["IFT43", "PROTEIN", 130, 135], ["TLE1", "PROTEIN", 137, 141], ["DNAH5", "PROTEIN", 142, 147], ["ATP6AP1", "PROTEIN", 149, 156], ["CETN2", "PROTEIN", 157, 162], ["C1orf50", "PROTEIN", 164, 171], ["ZMYND12", "PROTEIN", 172, 179], ["RAB10", "PROTEIN", 181, 186], ["IFT172", "PROTEIN", 187, 193], ["TOR1AIP1", "PROTEIN", 195, 203], ["GPR161", "PROTEIN", 204, 210], ["DNAJC19", "PROTEIN", 212, 219], ["CETN3", "PROTEIN", 220, 225], ["NLRX1", "PROTEIN", 227, 232], ["IFT46", "PROTEIN", 233, 238], ["FKBP7", "PROTEIN", 240, 245], ["TTC30B", "PROTEIN", 246, 252], ["POLA2", "PROTEIN", 254, 259], ["TMEM216", "PROTEIN", 260, 267], ["NDUFB9", "PROTEIN", 272, 278], ["DRC7", "PROTEIN", 279, 283], ["ciliary proteins", "TEST", 65, 81], ["NUP98", "TEST", 83, 88], ["CHMP5", "TEST", 89, 94], ["GG3BP1", "TEST", 96, 102], ["DNAH1", "TEST", 103, 108], ["SEPSECS", "TEST", 110, 117], ["DNAH1", "TEST", 118, 123], ["NEK9", "TEST", 125, 129], ["TLE1", "TEST", 137, 141], ["DNAH5", "TEST", 142, 147], ["ATP6AP1", "TEST", 149, 156], ["CETN2", "TEST", 157, 162], ["C1orf50", "TEST", 164, 171], ["ZMYND12", "TEST", 172, 179], ["RAB10", "TEST", 181, 186], ["TOR1AIP1", "TEST", 195, 203], ["DNAJC19", "TEST", 212, 219], ["CETN3", "TEST", 220, 225], ["NLRX1", "TEST", 227, 232], ["FKBP7", "TEST", 240, 245], ["POLA2", "TEST", 254, 259]]], ["Pathway analysis of the 617 common proteins (i.e., common to HoP and cilia interactomes) revealed two interesting pathways: budding and maturation of HIV virion (p-value=1.29E-06; odds ratio=8.8) and anti-viral mechanism by IFNstimulated genes (p-value=0.013; odds ratio=2.98).", [["cilia", "ANATOMY", 69, 74], ["HoP", "GENE_OR_GENE_PRODUCT", 61, 64], ["cilia", "CELLULAR_COMPONENT", 69, 74], ["HIV", "ORGANISM", 150, 153], ["617 common proteins", "PROTEIN", 24, 43], ["HoP", "PROTEIN", 61, 64], ["cilia interactomes", "PROTEIN", 69, 87], ["IFNstimulated genes", "DNA", 224, 243], ["HIV", "SPECIES", 150, 153], ["Pathway analysis", "TEST", 0, 16], ["cilia interactomes", "TEST", 69, 87], ["budding", "PROBLEM", 124, 131], ["HIV virion", "TEST", 150, 160], ["p-value", "TEST", 162, 169], ["odds ratio", "TEST", 180, 190], ["anti-viral mechanism", "PROBLEM", 200, 220], ["p-value", "TEST", 245, 252], ["odds ratio", "TEST", 260, 270]]], ["We predicted that ciliary protein CHMP5 involved in the former pathway interacts with host protein NUP98 which is involved in the latter pathway.", [["ciliary", "ANATOMY", 18, 25], ["CHMP5", "GENE_OR_GENE_PRODUCT", 34, 39], ["NUP98", "GENE_OR_GENE_PRODUCT", 99, 104], ["ciliary protein", "PROTEIN", 18, 33], ["CHMP5", "PROTEIN", 34, 39], ["NUP98", "PROTEIN", 99, 104], ["ciliary protein CHMP5", "TREATMENT", 18, 39], ["host protein NUP98", "TREATMENT", 86, 104]]], ["This prompted us to ask whether the predicted interaction connected the functional modules of viral budding to interferon (IFN) signaling.Novel interaction of NUP98 with CHMP5 may activate an IFN-stimulated pathway that interferes with viral buddingWe extracted the PPIs of the 20 proteins belonging to viral budding and IFN pathways and isolated this sub-network, containing 171 proteins and 176 PPIs, for further analysis.", [["NUP98", "CHEMICAL", 159, 164], ["CHMP5", "CHEMICAL", 170, 175], ["interferon", "GENE_OR_GENE_PRODUCT", 111, 121], ["IFN", "GENE_OR_GENE_PRODUCT", 123, 126], ["NUP98", "GENE_OR_GENE_PRODUCT", 159, 164], ["CHMP5", "GENE_OR_GENE_PRODUCT", 170, 175], ["IFN", "GENE_OR_GENE_PRODUCT", 192, 195], ["IFN", "GENE_OR_GENE_PRODUCT", 321, 324], ["interferon", "PROTEIN", 111, 121], ["IFN", "PROTEIN", 123, 126], ["NUP98", "PROTEIN", 159, 164], ["CHMP5", "PROTEIN", 170, 175], ["IFN", "PROTEIN", 192, 195], ["IFN", "PROTEIN", 321, 324], ["171 proteins", "PROTEIN", 376, 388], ["viral budding", "PROBLEM", 94, 107], ["CHMP5", "TREATMENT", 170, 175], ["an IFN-stimulated pathway", "TREATMENT", 189, 214], ["viral budding", "PROBLEM", 236, 249], ["the PPIs", "TREATMENT", 262, 270], ["the 20 proteins", "TREATMENT", 274, 289], ["viral budding", "PROBLEM", 303, 316], ["IFN pathways", "TREATMENT", 321, 333], ["PPIs", "TEST", 397, 401], ["further analysis", "TEST", 407, 423]]], ["Firstly, we identified 343 functional interactions (i.e. activation, inhibition etc.) among 98 proteins in the network.", [["98 proteins", "PROTEIN", 92, 103]]], ["Strikingly, distinct functional modules were identified for both the pathways; CHMP5 seemed to serve as a connector from the viral budding pathway to the IFN pathway through NUP98 (Figure 7) .", [["CHMP5", "GENE_OR_GENE_PRODUCT", 79, 84], ["IFN", "GENE_OR_GENE_PRODUCT", 154, 157], ["NUP98", "GENE_OR_GENE_PRODUCT", 174, 179], ["CHMP5", "PROTEIN", 79, 84], ["IFN", "PROTEIN", 154, 157], ["NUP98", "PROTEIN", 174, 179], ["distinct functional modules", "PROBLEM", 12, 39], ["CHMP5", "TREATMENT", 79, 84], ["distinct", "OBSERVATION_MODIFIER", 12, 20], ["functional modules", "OBSERVATION", 21, 39]]], ["The gene UBC was shared between the clusters.Novel interaction of NUP98 with CHMP5 may activate an IFN-stimulated pathway that interferes with viral buddingWe then checked whether the genes in these modules were differentially expressed in Calu-3 lung cells infected with SARS CoV Urbani (for 72 hours) versus mock infected cells.", [["Calu-3 lung cells", "ANATOMY", 240, 257], ["cells", "ANATOMY", 324, 329], ["NUP98", "CHEMICAL", 66, 71], ["CHMP5", "CHEMICAL", 77, 82], ["UBC", "GENE_OR_GENE_PRODUCT", 9, 12], ["NUP98", "GENE_OR_GENE_PRODUCT", 66, 71], ["CHMP5", "GENE_OR_GENE_PRODUCT", 77, 82], ["IFN", "GENE_OR_GENE_PRODUCT", 99, 102], ["Calu-3 lung cells", "CELL", 240, 257], ["SARS CoV Urbani", "ORGANISM", 272, 287], ["cells", "CELL", 324, 329], ["UBC", "DNA", 9, 12], ["NUP98", "PROTEIN", 66, 71], ["CHMP5", "PROTEIN", 77, 82], ["IFN", "PROTEIN", 99, 102], ["Calu-3 lung cells", "CELL_LINE", 240, 257], ["mock infected cells", "CELL_TYPE", 310, 329], ["SARS CoV Urbani", "SPECIES", 272, 287], ["The gene UBC", "TEST", 0, 12], ["CHMP5", "TREATMENT", 77, 82], ["an IFN-stimulated pathway", "TREATMENT", 96, 121], ["viral budding", "PROBLEM", 143, 156], ["the genes in these modules", "PROBLEM", 180, 206], ["Calu", "TEST", 240, 244], ["SARS CoV Urbani", "TREATMENT", 272, 287], ["mock infected cells", "PROBLEM", 310, 329], ["UBC", "OBSERVATION", 9, 12], ["lung", "ANATOMY", 247, 251], ["infected cells", "OBSERVATION", 315, 329]]], ["This was done to identify the functional interactions that remain active during viral infection.", [["viral infection", "DISEASE", 80, 95], ["viral infection", "PROBLEM", 80, 95], ["active", "OBSERVATION_MODIFIER", 66, 72], ["viral", "OBSERVATION_MODIFIER", 80, 85], ["infection", "OBSERVATION", 86, 95]]], ["20 genes including NUP98 and CHMP5 were found to be differentially expressed (Figure 7) .", [["NUP98", "GENE_OR_GENE_PRODUCT", 19, 24], ["CHMP5", "GENE_OR_GENE_PRODUCT", 29, 34], ["NUP98", "DNA", 19, 24], ["CHMP5", "DNA", 29, 34], ["NUP98 and CHMP5", "TEST", 19, 34]]], ["Viruses hijack the ESCRT/VPS4 (endosomal sorting complex required for transport) machinery of the host cell to release viral particles through membrane scission.", [["endosomal", "ANATOMY", 31, 40], ["cell", "ANATOMY", 103, 107], ["membrane", "ANATOMY", 143, 151], ["ESCRT", "GENE_OR_GENE_PRODUCT", 19, 24], ["VPS4", "GENE_OR_GENE_PRODUCT", 25, 29], ["endosomal", "CELLULAR_COMPONENT", 31, 40], ["host cell", "CELL", 98, 107], ["membrane", "CELLULAR_COMPONENT", 143, 151], ["ESCRT", "PROTEIN", 19, 24], ["VPS4", "PROTEIN", 25, 29], ["endosomal sorting complex", "PROTEIN", 31, 56], ["VPS4", "PROBLEM", 25, 29], ["the host cell", "TREATMENT", 94, 107], ["viral particles through membrane scission", "PROBLEM", 119, 160], ["host cell", "OBSERVATION", 98, 107], ["viral particles", "OBSERVATION", 119, 134], ["membrane scission", "OBSERVATION", 143, 160]]], ["57 This machinery is normally recruited during endocytic and membrane repair processes in the host cell.", [["endocytic", "ANATOMY", 47, 56], ["membrane", "ANATOMY", 61, 69], ["cell", "ANATOMY", 99, 103], ["endocytic", "CELLULAR_COMPONENT", 47, 56], ["membrane", "CELLULAR_COMPONENT", 61, 69], ["host cell", "CELL", 94, 103], ["host cell", "CELL_TYPE", 94, 103], ["endocytic and membrane repair processes", "TREATMENT", 47, 86], ["membrane repair", "OBSERVATION", 61, 76], ["host cell", "OBSERVATION", 94, 103]]], ["The process of membrane scission is catalyzed by various ESCRT-III proteins including CHMP5.", [["membrane", "ANATOMY", 15, 23], ["membrane", "CELLULAR_COMPONENT", 15, 23], ["ESCRT-III", "GENE_OR_GENE_PRODUCT", 57, 66], ["CHMP5", "GENE_OR_GENE_PRODUCT", 86, 91], ["ESCRT-III proteins", "PROTEIN", 57, 75], ["CHMP5", "PROTEIN", 86, 91], ["membrane scission", "PROBLEM", 15, 32], ["membrane scission", "OBSERVATION", 15, 32]]], ["57 VPS4 is an ATPase that is found in the cytoplasm in its inactive form.", [["cytoplasm", "ANATOMY", 42, 51], ["VPS4", "GENE_OR_GENE_PRODUCT", 3, 7], ["ATPase", "GENE_OR_GENE_PRODUCT", 14, 20], ["cytoplasm", "ORGANISM_SUBSTANCE", 42, 51], ["VPS4", "PROTEIN", 3, 7], ["ATPase", "PROTEIN", 14, 20], ["an ATPase", "PROBLEM", 11, 20], ["cytoplasm", "OBSERVATION", 42, 51], ["inactive", "OBSERVATION_MODIFIER", 59, 67]]], ["Activation of the VPS4 and its ATPase activity is essential for membrane budding and the release of viral particles.", [["membrane", "ANATOMY", 64, 72], ["VPS4", "GENE_OR_GENE_PRODUCT", 18, 22], ["ATPase", "GENE_OR_GENE_PRODUCT", 31, 37], ["membrane", "CELLULAR_COMPONENT", 64, 72], ["VPS4", "PROTEIN", 18, 22], ["ATPase", "PROTEIN", 31, 37], ["the VPS4", "TEST", 14, 22], ["membrane budding", "PROBLEM", 64, 80], ["viral particles", "PROBLEM", 100, 115], ["viral particles", "OBSERVATION", 100, 115]]], ["57 VPS4 is activated on membranes in the presence of its co-activator VTA (also known as LIP5).", [["membranes", "ANATOMY", 24, 33], ["VPS4", "GENE_OR_GENE_PRODUCT", 3, 7], ["membranes", "CELLULAR_COMPONENT", 24, 33], ["VTA", "SIMPLE_CHEMICAL", 70, 73], ["LIP5", "GENE_OR_GENE_PRODUCT", 89, 93], ["VPS4", "PROTEIN", 3, 7], ["LIP5", "PROTEIN", 89, 93], ["membranes", "TREATMENT", 24, 33]]], ["VTA is delivered to the membranes by ESCRT-III proteins such as CHMP5.", [["membranes", "ANATOMY", 24, 33], ["VTA", "CHEMICAL", 0, 3], ["VTA", "SIMPLE_CHEMICAL", 0, 3], ["membranes", "CELLULAR_COMPONENT", 24, 33], ["ESCRT-III", "GENE_OR_GENE_PRODUCT", 37, 46], ["CHMP5", "GENE_OR_GENE_PRODUCT", 64, 69], ["ESCRT-III proteins", "PROTEIN", 37, 55], ["CHMP5", "PROTEIN", 64, 69]]], ["57 Hence, the interaction of VPS4 and VTA is facilitated by CHMP5.", [["VPS4", "GENE_OR_GENE_PRODUCT", 29, 33], ["VTA", "SIMPLE_CHEMICAL", 38, 41], ["CHMP5", "GENE_OR_GENE_PRODUCT", 60, 65], ["VPS4", "PROTEIN", 29, 33], ["VTA", "PROTEIN", 38, 41], ["CHMP5", "PROTEIN", 60, 65], ["VPS4 and VTA", "TREATMENT", 29, 41]]], ["However, when interferons are induced in the host cell following viral infection, ISGs (interferon stimulated genes) such as ISG15, a dimer homologue of ubiquitin, may be activated.", [["cell", "ANATOMY", 50, 54], ["viral infection", "DISEASE", 65, 80], ["host cell", "CELL", 45, 54], ["ISGs", "GENE_OR_GENE_PRODUCT", 82, 86], ["interferon stimulated genes", "GENE_OR_GENE_PRODUCT", 88, 115], ["ISG15", "GENE_OR_GENE_PRODUCT", 125, 130], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 153, 162], ["interferons", "PROTEIN", 14, 25], ["ISGs", "DNA", 82, 86], ["interferon stimulated genes", "DNA", 88, 115], ["ISG15", "PROTEIN", 125, 130], ["dimer homologue", "PROTEIN", 134, 149], ["ubiquitin", "PROTEIN", 153, 162], ["interferons", "TREATMENT", 14, 25], ["viral infection", "PROBLEM", 65, 80], ["ISGs (interferon stimulated genes", "TREATMENT", 82, 115], ["ISG15", "TREATMENT", 125, 130], ["a dimer homologue of ubiquitin", "TREATMENT", 132, 162], ["host cell", "OBSERVATION", 45, 54], ["viral infection", "OBSERVATION", 65, 80]]], ["57 ISG15 may then conjugate to CHMP5 and promote its accumulation in the membrane, effectively blocking the interaction of VTA with VPS4 and preventing viral budding.", [["membrane", "ANATOMY", 73, 81], ["ISG15", "GENE_OR_GENE_PRODUCT", 3, 8], ["CHMP5", "GENE_OR_GENE_PRODUCT", 31, 36], ["membrane", "CELLULAR_COMPONENT", 73, 81], ["VTA", "SIMPLE_CHEMICAL", 123, 126], ["VPS4", "GENE_OR_GENE_PRODUCT", 132, 136], ["ISG15", "PROTEIN", 3, 8], ["CHMP5", "PROTEIN", 31, 36], ["VPS4", "PROTEIN", 132, 136], ["CHMP5", "TREATMENT", 31, 36], ["its accumulation in the membrane", "PROBLEM", 49, 81], ["VPS4", "TREATMENT", 132, 136], ["viral budding", "PROBLEM", 152, 165], ["viral budding", "OBSERVATION", 152, 165]]], ["57 The novel interaction of CHMP5 with NUP98 may serve as the critical juncture at which the IFN-stimulated anti-viral mechanism interferes with viral budding.", [["NUP98", "CHEMICAL", 39, 44], ["CHMP5", "GENE_OR_GENE_PRODUCT", 28, 33], ["NUP98", "GENE_OR_GENE_PRODUCT", 39, 44], ["IFN", "GENE_OR_GENE_PRODUCT", 93, 96], ["CHMP5", "PROTEIN", 28, 33], ["NUP98", "PROTEIN", 39, 44], ["IFN", "PROTEIN", 93, 96], ["CHMP5 with NUP98", "TREATMENT", 28, 44], ["the IFN", "TREATMENT", 89, 96], ["stimulated anti-viral mechanism", "TREATMENT", 97, 128], ["viral budding", "PROBLEM", 145, 158]]], ["NUP98, a protein induced on viral expression, has been shown to promote anti-viral gene expression in drosophila.", [["NUP98", "CHEMICAL", 0, 5], ["NUP98", "GENE_OR_GENE_PRODUCT", 0, 5], ["drosophila", "ORGANISM", 102, 112], ["NUP98", "PROTEIN", 0, 5], ["viral expression", "OBSERVATION", 28, 44], ["anti-viral gene expression", "OBSERVATION", 72, 98]]], ["58 Both CHMP5 and NUP98 are overexpressed following SARS CoV Urbani infection.", [["SARS CoV Urbani infection", "DISEASE", 52, 77], ["CHMP5", "GENE_OR_GENE_PRODUCT", 8, 13], ["NUP98", "GENE_OR_GENE_PRODUCT", 18, 23], ["SARS CoV Urbani", "ORGANISM", 52, 67], ["CHMP5", "PROTEIN", 8, 13], ["NUP98", "PROTEIN", 18, 23], ["SARS CoV Urbani", "SPECIES", 52, 67], ["SARS CoV Urbani infection", "PROBLEM", 52, 77], ["infection", "OBSERVATION", 68, 77]]], ["This interaction may serve as a signal for the initiation of ISG15-mediated interference of viral budding.", [["ISG15", "GENE_OR_GENE_PRODUCT", 61, 66], ["ISG15", "PROTEIN", 61, 66], ["ISG15", "TREATMENT", 61, 66], ["viral budding", "PROBLEM", 92, 105], ["viral budding", "OBSERVATION", 92, 105]]], ["ISG15 may further regulate this mechanism through feedback inhibition of NUP98.", [["ISG15", "GENE_OR_GENE_PRODUCT", 0, 5], ["NUP98", "GENE_OR_GENE_PRODUCT", 73, 78], ["ISG15", "PROTEIN", 0, 5], ["NUP98", "PROTEIN", 73, 78], ["ISG15", "TREATMENT", 0, 5]]], ["Hence, potentiation of this anti-viral mechanism through administration of recombinant interferon alfa-2b and interferon alfacon-1 may be a feasible therapeutic option for nCoV19.", [["interferon alfa-2b", "CHEMICAL", 87, 105], ["interferon alfacon-1", "CHEMICAL", 110, 130], ["alfa-2b", "GENE_OR_GENE_PRODUCT", 98, 105], ["interferon alfacon-1", "GENE_OR_GENE_PRODUCT", 110, 130], ["nCoV19", "SIMPLE_CHEMICAL", 172, 178], ["recombinant interferon alfa-2b", "PROTEIN", 75, 105], ["interferon", "PROTEIN", 110, 120], ["this anti-viral mechanism", "TREATMENT", 23, 48], ["recombinant interferon alfa", "TREATMENT", 75, 102], ["interferon alfacon", "TREATMENT", 110, 128], ["nCoV19", "TREATMENT", 172, 178]]], ["Both these interferons induce gene expression profiles negatively correlated with SARS-associated profiles.", [["SARS", "DISEASE", 82, 86], ["interferons", "PROTEIN", 11, 22], ["gene expression profiles", "TEST", 30, 54], ["SARS", "PROBLEM", 82, 86]]], ["The machinery of ESCRT-III and VPS4 is co-opted into two subcellular structures that are intricately linked to cilia function, namely, the centrosomes and the midbody.", [["subcellular structures", "ANATOMY", 57, 79], ["cilia", "ANATOMY", 111, 116], ["centrosomes", "ANATOMY", 139, 150], ["midbody", "ANATOMY", 159, 166], ["ESCRT-III", "GENE_OR_GENE_PRODUCT", 17, 26], ["VPS4", "GENE_OR_GENE_PRODUCT", 31, 35], ["cilia", "CELLULAR_COMPONENT", 111, 116], ["centrosomes", "CELLULAR_COMPONENT", 139, 150], ["midbody", "CELLULAR_COMPONENT", 159, 166], ["ESCRT-III", "PROTEIN", 17, 26], ["VPS4", "PROTEIN", 31, 35], ["ESCRT", "OBSERVATION", 17, 22], ["cilia function", "OBSERVATION", 111, 125], ["centrosomes", "ANATOMY_MODIFIER", 139, 150], ["midbody", "ANATOMY_MODIFIER", 159, 166]]], ["44 It is important to study these structures as potential modulators of viral infections.DiscussionIn this study, to gain insight into the biological processes and pathways that may be involved in host upon nCoV19 infection, we assembled the interactome of the host proteins targeted by the virus.", [["viral infections", "DISEASE", 72, 88], ["infection", "DISEASE", 214, 223], ["nCoV19", "GENE_OR_GENE_PRODUCT", 207, 213], ["host proteins", "PROTEIN", 261, 274], ["viral infections", "PROBLEM", 72, 88], ["this study", "TEST", 102, 112], ["nCoV19 infection", "PROBLEM", 207, 223], ["viral", "OBSERVATION_MODIFIER", 72, 77], ["infections", "OBSERVATION", 78, 88]]], ["The host protein (HoP) interactome has ~4,000 previously known PPIs in addition to ~2,000 PPIs we computationally predicted.", [["HoP", "GENE_OR_GENE_PRODUCT", 18, 21], ["HoP", "PROTEIN", 18, 21]]], ["The HoP interactome was found to share a large and statistically significant overlap with a SARS-specific gene expression profile.", [["SARS", "DISEASE", 92, 96], ["HoP", "GENE_OR_GENE_PRODUCT", 4, 7], ["a SARS", "TEST", 90, 96], ["large", "OBSERVATION_MODIFIER", 41, 46]]], ["Proteins with tissuespecific gene expression in lungs, spleen, brain and heart were also found in the interactome.", [["lungs", "ANATOMY", 48, 53], ["spleen", "ANATOMY", 55, 61], ["brain", "ANATOMY", 63, 68], ["heart", "ANATOMY", 73, 78], ["lungs", "ORGAN", 48, 53], ["spleen", "ORGAN", 55, 61], ["brain", "ORGAN", 63, 68], ["heart", "ORGAN", 73, 78], ["Proteins", "TEST", 0, 8], ["tissuespecific gene expression in lungs, spleen, brain and heart", "PROBLEM", 14, 78], ["gene expression", "OBSERVATION", 29, 44], ["lungs", "ANATOMY", 48, 53], ["spleen", "ANATOMY", 55, 61], ["brain", "ANATOMY", 63, 68], ["heart", "ANATOMY", 73, 78]]], ["Topologically connected modules in the network showed functional association to cilium organization, nuclear transport, ribonucleoprotein complex biogenesis, endosomal transport and epigenetic regulation of gene expression.", [["cilium", "ANATOMY", 80, 86], ["nuclear", "ANATOMY", 101, 108], ["endosomal", "ANATOMY", 158, 167], ["cilium", "CELLULAR_COMPONENT", 80, 86], ["nuclear", "CELLULAR_COMPONENT", 101, 108], ["endosomal", "CELLULAR_COMPONENT", 158, 167], ["ribonucleoprotein complex", "PROTEIN", 120, 145], ["ribonucleoprotein complex biogenesis", "TREATMENT", 120, 156], ["endosomal transport", "TREATMENT", 158, 177], ["cilium organization", "OBSERVATION", 80, 99], ["gene expression", "OBSERVATION", 207, 222]]], ["The interactome is enriched for subcellular locations and host cellular processes that may be targeted by nCoV19.", [["subcellular", "ANATOMY", 32, 43], ["cellular", "ANATOMY", 63, 71], ["cellular", "CELL", 63, 71], ["nCoV19", "GENE_OR_GENE_PRODUCT", 106, 112], ["nCoV19", "PROTEIN", 106, 112], ["interactome", "OBSERVATION", 4, 15], ["enriched", "OBSERVATION_MODIFIER", 19, 27], ["host cellular processes", "OBSERVATION", 58, 81], ["may be", "UNCERTAINTY", 87, 93]]], ["Host proteins were found to directly interact with proteins associated with two co-morbidities, hypertension and diabetes, that are commonly found among COVID-19 non-survivors.", [["hypertension", "DISEASE", 96, 108], ["diabetes", "DISEASE", 113, 121], ["Host proteins", "PROTEIN", 0, 13], ["Host proteins", "PROBLEM", 0, 13], ["two co-morbidities", "PROBLEM", 76, 94], ["hypertension", "PROBLEM", 96, 108], ["diabetes", "PROBLEM", 113, 121], ["COVID", "TEST", 153, 158], ["hypertension", "OBSERVATION", 96, 108], ["diabetes", "OBSERVATION", 113, 121]]], ["The nCoV19 host proteins and ciliary proteins shared several common interactors.", [["ciliary", "ANATOMY", 29, 36], ["nCoV19", "GENE_OR_GENE_PRODUCT", 4, 10], ["ciliary proteins", "GENE_OR_GENE_PRODUCT", 29, 45], ["nCoV19 host proteins", "PROTEIN", 4, 24], ["ciliary proteins", "PROTEIN", 29, 45], ["The nCoV19 host proteins", "TREATMENT", 0, 24], ["ciliary proteins", "TEST", 29, 45], ["ciliary proteins", "OBSERVATION", 29, 45], ["several", "OBSERVATION_MODIFIER", 53, 60], ["common interactors", "OBSERVATION", 61, 79]]], ["The role of cilia as viral entry points and modulators of viral infections should be investigated further on this premise.", [["cilia", "ANATOMY", 12, 17], ["viral infections", "DISEASE", 58, 74], ["cilia", "CELLULAR_COMPONENT", 12, 17], ["viral infections", "PROBLEM", 58, 74], ["cilia", "ANATOMY_MODIFIER", 12, 17], ["viral infections", "OBSERVATION", 58, 74]]], ["With further analysis of the shared interactome, we hypothesize that the novel interaction of NUP98 with CHMP5, a ciliary (and centrosome and midbody-localizing) protein, may activate an IFN-stimulated pathway with the potential to interfere with viral budding.DiscussionThe HoP interactome with nCoV19 associated host proteins and their interacting partners will help biologists, bioinformaticians and clinicians to piece together an integrated view on how host genes in various high throughput studies are functionally linked.", [["ciliary", "ANATOMY", 114, 121], ["centrosome", "ANATOMY", 127, 137], ["midbody", "ANATOMY", 142, 149], ["NUP98", "GENE_OR_GENE_PRODUCT", 94, 99], ["CHMP5", "GENE_OR_GENE_PRODUCT", 105, 110], ["centrosome", "CELLULAR_COMPONENT", 127, 137], ["midbody", "CELLULAR_COMPONENT", 142, 149], ["IFN", "GENE_OR_GENE_PRODUCT", 187, 190], ["HoP", "GENE_OR_GENE_PRODUCT", 275, 278], ["nCoV19", "GENE_OR_GENE_PRODUCT", 296, 302], ["NUP98", "PROTEIN", 94, 99], ["CHMP5", "PROTEIN", 105, 110], ["ciliary (and centrosome and midbody-localizing) protein", "PROTEIN", 114, 169], ["IFN", "PROTEIN", 187, 190], ["nCoV19 associated host proteins", "PROTEIN", 296, 327], ["host genes", "DNA", 458, 468], ["further analysis", "TEST", 5, 21], ["CHMP5", "TREATMENT", 105, 110], ["an IFN-stimulated pathway", "TREATMENT", 184, 209], ["viral budding", "PROBLEM", 247, 260]]], ["While we carried out several analyses and presented the results here, the network of HoP interactome will facilitate several future systems biology studies derived from overlaying the interactome with data generated for research on coronaviruses in general and COVID-19 in particular.", [["HoP", "GENE_OR_GENE_PRODUCT", 85, 88], ["coronaviruses", "ORGANISM", 232, 245], ["coronaviruses", "TREATMENT", 232, 245], ["COVID", "TEST", 261, 266]]], ["For example, consider comparing the 332 SARS-CoV-2 host proteins 6 considered in this work, with the 65 host proteins of SARS coronavirus 59 ('SARS-2' and 'SARS-1' respectively, for clarity).", [["SARS", "DISEASE", 40, 44], ["SARS coronavirus", "DISEASE", 121, 137], ["SARS coronavirus 59", "ORGANISM", 121, 140], ["332 SARS-CoV-2 host proteins 6", "PROTEIN", 36, 66], ["65 host proteins", "PROTEIN", 101, 117], ["coronavirus", "SPECIES", 126, 137], ["SARS-CoV", "SPECIES", 40, 48], ["SARS coronavirus", "SPECIES", 121, 137], ["CoV", "TEST", 45, 48], ["SARS coronavirus", "TEST", 121, 137], ["SARS", "TEST", 143, 147], ["'SARS", "TEST", 155, 160]]], ["There are only 4 proteins common to them (BZW2, MARK2, MARK3 and SMOC1).", [["BZW2", "GENE_OR_GENE_PRODUCT", 42, 46], ["MARK2", "GENE_OR_GENE_PRODUCT", 48, 53], ["MARK3", "GENE_OR_GENE_PRODUCT", 55, 60], ["SMOC1", "GENE_OR_GENE_PRODUCT", 65, 70], ["BZW2", "PROTEIN", 42, 46], ["MARK2", "PROTEIN", 48, 53], ["MARK3", "PROTEIN", 55, 60], ["SMOC1", "PROTEIN", 65, 70], ["BZW2", "TEST", 42, 46], ["MARK2", "TEST", 48, 53], ["4 proteins", "OBSERVATION_MODIFIER", 15, 25]]], ["However, the interactome reveals that 41 SARS-2 host proteins interact with 29 SARS-1 host proteins and that eight of these PPIs are novel PPIs (N4BP2L2-EXOSC8, NMB-MRPS5, MKRN2-MRPS25, HOXC6-BRD2, XPA-AP2M1, VKORC1-DCTPP1, RSRP1-CEP350 and TPSAB1-ADAMTS1).", [["SARS-2", "GENE_OR_GENE_PRODUCT", 41, 47], ["SARS-1", "GENE_OR_GENE_PRODUCT", 79, 85], ["N4BP2L2-EXOSC8", "GENE_OR_GENE_PRODUCT", 145, 159], ["NMB-MRPS5", "GENE_OR_GENE_PRODUCT", 161, 170], ["MKRN2-MRPS25", "GENE_OR_GENE_PRODUCT", 172, 184], ["HOXC6-BRD2", "GENE_OR_GENE_PRODUCT", 186, 196], ["XPA-AP2M1", "GENE_OR_GENE_PRODUCT", 198, 207], ["VKORC1-DCTPP1", "GENE_OR_GENE_PRODUCT", 209, 222], ["RSRP1-CEP350", "GENE_OR_GENE_PRODUCT", 224, 236], ["TPSAB1-ADAMTS1", "GENE_OR_GENE_PRODUCT", 241, 255], ["41 SARS-2 host proteins", "PROTEIN", 38, 61], ["29 SARS-1 host proteins", "PROTEIN", 76, 99], ["N4BP2L2", "PROTEIN", 145, 152], ["EXOSC8", "PROTEIN", 153, 159], ["NMB", "PROTEIN", 161, 164], ["MRPS5", "PROTEIN", 165, 170], ["MKRN2", "PROTEIN", 172, 177], ["MRPS25", "PROTEIN", 178, 184], ["HOXC6", "PROTEIN", 186, 191], ["BRD2", "PROTEIN", 192, 196], ["XPA", "PROTEIN", 198, 201], ["AP2M1", "PROTEIN", 202, 207], ["VKORC1", "DNA", 209, 215], ["DCTPP1", "DNA", 216, 222], ["RSRP1", "DNA", 224, 229], ["CEP350", "DNA", 230, 236], ["TPSAB1", "DNA", 241, 247], ["ADAMTS1", "DNA", 248, 255], ["SARS", "TEST", 41, 45], ["29 SARS", "TEST", 76, 83], ["host proteins", "TEST", 86, 99], ["these PPIs", "TEST", 118, 128], ["PPIs", "TEST", 139, 143], ["N4BP2L2", "TEST", 145, 152], ["EXOSC8", "TEST", 153, 159], ["NMB", "TEST", 161, 164], ["MRPS5", "TEST", 165, 170], ["MKRN2", "TEST", 172, 177], ["MRPS25", "TEST", 178, 184], ["HOXC6", "TEST", 186, 191], ["XPA", "TEST", 198, 201], ["VKORC1", "TEST", 209, 215], ["DCTPP1", "TEST", 216, 222], ["RSRP1", "TEST", 224, 229]]], ["Gene Ontology Biological Processes such as autophagic mechanism (odds ratio=4.5, p-value=2.21E-05) regulation of mitochondrion organization (odds ratio=7.5, p-value=5.49E-05) and protein localization to mitochondrion (odds ratio=7.8, p-value=3.74E-04) may be commonly targeted by both these viruses as they were enriched among the proteins that are targeted by SARS-CoV-1 that also interact with host proteins of SARS-CoV-2.", [["mitochondrion", "ANATOMY", 113, 126], ["mitochondrion", "ANATOMY", 203, 216], ["mitochondrion", "CELLULAR_COMPONENT", 113, 126], ["mitochondrion", "CELLULAR_COMPONENT", 203, 216], ["SARS-CoV-1", "ORGANISM", 361, 371], ["SARS-CoV-2", "ORGANISM", 413, 423], ["host proteins", "PROTEIN", 396, 409], ["SARS-CoV", "SPECIES", 361, 369], ["SARS-CoV", "SPECIES", 413, 421], ["autophagic mechanism", "TEST", 43, 63], ["ratio", "TEST", 70, 75], ["p-value", "TEST", 81, 88], ["mitochondrion organization", "TEST", 113, 139], ["ratio", "TEST", 146, 151], ["p-value", "TEST", 157, 164], ["protein localization", "TEST", 179, 199], ["odds ratio", "TEST", 218, 228], ["p-value", "TEST", 234, 241], ["CoV", "TEST", 418, 421], ["viruses", "OBSERVATION", 291, 298]]], ["Mitochondria may be directly targeted by viral proteins, influenced by the cellular changes arising from viral infection or may even play a crucial role in viral pathogenesis due to their function as immune signalling hubs.", [["Mitochondria", "ANATOMY", 0, 12], ["cellular", "ANATOMY", 75, 83], ["viral infection", "DISEASE", 105, 120], ["Mitochondria", "CELLULAR_COMPONENT", 0, 12], ["cellular", "CELL", 75, 83], ["viral proteins", "PROTEIN", 41, 55], ["Mitochondria", "PROBLEM", 0, 12], ["viral proteins", "PROBLEM", 41, 55], ["the cellular changes", "PROBLEM", 71, 91], ["viral infection", "PROBLEM", 105, 120], ["viral pathogenesis", "PROBLEM", 156, 174], ["viral infection", "OBSERVATION", 105, 120]]], ["60 These organelles are constantly eliminated and recycled through a process called mitophagy.", [["organelles", "ANATOMY", 9, 19], ["organelles", "CELLULAR_COMPONENT", 9, 19]]], ["Viruses may modulate mitochondrial function and mitophagy to exacerbate infection.", [["mitochondrial", "ANATOMY", 21, 34], ["infection", "DISEASE", 72, 81], ["mitochondrial", "CELLULAR_COMPONENT", 21, 34], ["Viruses", "PROBLEM", 0, 7], ["mitophagy", "PROBLEM", 48, 57], ["infection", "PROBLEM", 72, 81], ["mitochondrial function", "OBSERVATION", 21, 43], ["infection", "OBSERVATION", 72, 81]]], ["60 Thus, in addition to the results presented here, several future studies may be carried out with the interactome to generate biologically insightful results that may be translated to biomedically actionable results.Compilation of host proteins and prediction of novel interactionsLists of 332 host proteins identified to interact with 27 nCoV19 proteins were compiled from data files in Gordon et al. 6 Novel PPIs of these proteins were predicted using the HiPPIP model that we developed.", [["nCoV19", "GENE_OR_GENE_PRODUCT", 340, 346], ["332 host proteins", "PROTEIN", 291, 308], ["27 nCoV19 proteins", "PROTEIN", 337, 355], ["several future studies", "TEST", 52, 74], ["host proteins", "TREATMENT", 232, 245], ["host proteins", "TEST", 295, 308], ["these proteins", "TREATMENT", 419, 433], ["the HiPPIP model", "TREATMENT", 455, 471], ["host proteins", "OBSERVATION", 232, 245], ["PPIs", "OBSERVATION", 411, 415]]], ["32 Each host protein (say N1) was paired with each of the other human protein say, (M1, M2,\u2026Mn), and each pair was evaluated with the HiPPIP model.", [["Mn", "CHEMICAL", 92, 94], ["human", "ORGANISM", 64, 69], ["N1", "PROTEIN", 26, 28], ["M1", "PROTEIN", 84, 86], ["M2", "PROTEIN", 88, 90], ["Mn", "PROTEIN", 92, 94], ["human", "SPECIES", 64, 69], ["human", "SPECIES", 64, 69], ["Each host protein", "TEST", 3, 20], ["the HiPPIP model", "TREATMENT", 130, 146]]], ["32 The predicted interactions of each of the host proteins were extracted (namely, the pairs whose score is >0.5, a threshold which through computational evaluations and experimental validations was revealed to indicate interacting partners with high confidence).", [["host proteins", "PROTEIN", 45, 58], ["computational evaluations", "TEST", 140, 165], ["experimental validations", "TEST", 170, 194]]], ["This resulted in 1941 newly discovered PPIs of the host proteins.Compilation of host proteins and prediction of novel interactionsThe significance of the overlap of this interactome with two datasets, namely, with the ciliary protein interactome and the interactome of 120 genes differentially expressed in nCoV19-infected A549 cell line, 5 was computed based on hypergeometric distribution.Network functional module analysisNetwork modules among host proteins and their interactors were identified using Netbox.", [["A549 cell line", "ANATOMY", 323, 337], ["nCoV19", "CELL", 307, 313], ["A549 cell line", "CELL", 323, 337], ["host proteins", "PROTEIN", 51, 64], ["host proteins", "PROTEIN", 80, 93], ["120 genes", "DNA", 269, 278], ["nCoV19", "CELL_LINE", 307, 313], ["A549 cell line", "CELL_LINE", 323, 337], ["host proteins", "PROTEIN", 447, 460], ["Netbox", "PROTEIN", 505, 511], ["the host proteins", "PROBLEM", 47, 64], ["host proteins", "TREATMENT", 80, 93], ["novel interactions", "PROBLEM", 112, 130], ["the ciliary protein interactome", "TEST", 214, 245], ["infected A549 cell line", "TREATMENT", 314, 337], ["host proteins", "OBSERVATION", 80, 93], ["infected", "OBSERVATION_MODIFIER", 314, 322], ["A549 cell line", "OBSERVATION", 323, 337], ["hypergeometric distribution", "OBSERVATION", 363, 390]]], ["36 Netbox reports modularity and a scaled modularity score, as compared with the modularity observed in 1000 random permutations of the subnetwork.", [["a scaled modularity score", "PROBLEM", 33, 58], ["modularity", "OBSERVATION", 18, 28], ["scaled", "OBSERVATION_MODIFIER", 35, 41], ["modularity", "OBSERVATION", 42, 52], ["modularity", "OBSERVATION", 81, 91]]], ["Scaled modularity refers to the standard deviation difference between the observed subnetwork and the mean modularity of the random networks.", [["Scaled modularity", "PROBLEM", 0, 17], ["modularity", "OBSERVATION", 7, 17], ["mean modularity", "OBSERVATION", 102, 117]]], ["61Gene expression analysisThe severe acute respiratory syndrome (SARS) dataset used was obtained from GSE17400 (Calu-3 epithelial cells infected with SARS coronavirus for 48 hours versus mock infected cells).", [["Calu-3 epithelial cells", "ANATOMY", 112, 135], ["cells", "ANATOMY", 201, 206], ["acute respiratory syndrome", "DISEASE", 37, 63], ["SARS", "DISEASE", 65, 69], ["SARS coronavirus", "DISEASE", 150, 166], ["Calu-3 epithelial cells", "CELL", 112, 135], ["SARS coronavirus", "ORGANISM", 150, 166], ["cells", "CELL", 201, 206], ["61Gene", "DNA", 0, 6], ["Calu-3 epithelial cells", "CELL_LINE", 112, 135], ["SARS coronavirus", "SPECIES", 150, 166], ["expression analysis", "TEST", 7, 26], ["The severe acute respiratory syndrome", "PROBLEM", 26, 63], ["Calu", "TEST", 112, 116], ["epithelial cells", "PROBLEM", 119, 135], ["SARS coronavirus", "PROBLEM", 150, 166], ["mock infected cells", "TREATMENT", 187, 206], ["severe", "OBSERVATION_MODIFIER", 30, 36], ["acute", "OBSERVATION_MODIFIER", 37, 42], ["respiratory syndrome", "OBSERVATION", 43, 63]]], ["Statistical significance of the overlap between genes in the HoP interactome and those differentially expressed in SARS was computed based on hypergeometric distribution.", [["SARS", "DISEASE", 115, 119], ["HoP", "GENE_OR_GENE_PRODUCT", 61, 64], ["HoP interactome", "DNA", 61, 76], ["SARS", "PROBLEM", 115, 119]]], ["In this method, P-value is computed from the probability of k successes in n draws (without replacement) from a finite population of size N containing exactly k objects with an interesting feature.", [["P", "DNA", 16, 17], ["P-value", "TEST", 16, 23], ["replacement", "TREATMENT", 92, 103], ["size", "OBSERVATION_MODIFIER", 133, 137]]], ["N= Total number of genes whose expression was assayed K= Number of genes differentially expressed in SARS n= Number of genes in the HoP interactome k= K \u2229 n Differential gene expression in Calu-3 lung cells infected with SARS CoV Urbani (GSE37827) and in peripheral blood mononuclear cells of SARS patients (GSE1739 40 ) was checked using the Base Space Correlation Engine, a software suite for analysis of publicly available gene expression datasets.", [["Calu-3 lung cells", "ANATOMY", 189, 206], ["peripheral blood mononuclear cells", "ANATOMY", 255, 289], ["SARS", "DISEASE", 101, 105], ["K", "CHEMICAL", 151, 152], ["SARS", "DISEASE", 293, 297], ["Calu-3 lung cells", "CELL", 189, 206], ["SARS CoV Urbani", "ORGANISM", 221, 236], ["GSE37827", "CELL", 238, 246], ["peripheral blood mononuclear cells", "CELL", 255, 289], ["patients", "ORGANISM", 298, 306], ["Calu-3 lung cells", "CELL_LINE", 189, 206], ["peripheral blood mononuclear cells", "CELL_TYPE", 255, 289], ["CoV Urbani", "SPECIES", 226, 236], ["patients", "SPECIES", 298, 306], ["SARS CoV Urbani", "SPECIES", 221, 236], ["K", "TEST", 151, 152], ["\u2229", "TEST", 153, 154], ["Differential gene expression", "TEST", 157, 185], ["Calu", "TEST", 189, 193], ["lung cells", "PROBLEM", 196, 206], ["SARS CoV Urbani", "TEST", 221, 236], ["peripheral blood mononuclear cells", "TEST", 255, 289], ["lung", "ANATOMY", 196, 200], ["peripheral", "ANATOMY_MODIFIER", 255, 265], ["blood", "ANATOMY", 266, 271], ["mononuclear cells", "OBSERVATION", 272, 289]]], ["62 Genes with fold change >2 or <\u00bd were considered as significantly overexpressed and underexpressed respectively at p-value<0.05.Tissue-specificity analysisTissue-specificity of the genes in the HoP interactome were checked using TissueEnrich.", [["Tissue", "ANATOMY", 130, 136], ["Tissue", "TISSUE", 130, 136], ["HoP", "GENE_OR_GENE_PRODUCT", 196, 199], ["fold change", "PROBLEM", 14, 25], ["p-value", "TEST", 117, 124], ["the HoP interactome", "TEST", 192, 211]]], ["63 The analysis was based on genes from the GTEx database.", [["GTEx", "DNA", 44, 48], ["The analysis", "TEST", 3, 15]]], ["41 This included 'tissue-enriched genes' with at least 5-fold higher mRNA levels in a particular tissue compared to all the other tissues, 'group-enriched genes' with at least 5-fold higher mRNA levels in a group of 2-7 tissues and 'tissue-enhanced genes' with at least 5-fold higher mRNA levels in a particular tissue compared to average levels in all tissues.Functional enrichment analysisGene Ontology (GO), Pathway and genetic disorder enrichments were computed using WebGestalt.", [["tissue", "ANATOMY", 18, 24], ["tissue", "ANATOMY", 97, 103], ["tissues", "ANATOMY", 130, 137], ["tissues", "ANATOMY", 220, 227], ["tissue", "ANATOMY", 233, 239], ["tissue", "ANATOMY", 312, 318], ["tissues", "ANATOMY", 353, 360], ["disorder", "DISEASE", 431, 439], ["tissue", "TISSUE", 18, 24], ["tissue", "TISSUE", 97, 103], ["tissues", "TISSUE", 130, 137], ["tissues", "TISSUE", 220, 227], ["tissue", "TISSUE", 233, 239], ["tissue", "TISSUE", 312, 318], ["tissues", "TISSUE", 353, 360], ["enhanced genes'", "PROBLEM", 240, 255], ["genetic disorder enrichments", "PROBLEM", 423, 451], ["all tissues", "ANATOMY", 349, 360]]], ["46 P-values indicating significance of enrichment of the Reactome pathways, GO Biological Process and Cellular Component and OMIM diseases were corrected using the Benjamini-Hochberg test for multiple test adjustment.", [["OMIM diseases", "DISEASE", 125, 138], ["enrichment of the Reactome pathways", "PROBLEM", 39, 74], ["OMIM diseases", "PROBLEM", 125, 138], ["the Benjamini-Hochberg test", "TREATMENT", 160, 187], ["multiple test adjustment", "TREATMENT", 192, 216], ["enrichment", "OBSERVATION", 39, 49]]], ["Annotations with FDR-corrected p-value<0.05 were considered significant.", [["Annotations", "TEST", 0, 11], ["FDR", "TEST", 17, 20], ["corrected p-value", "TEST", 21, 38]]], ["ReactomeFIViz, a Cytoscape plugin, was used to extract known functional interactions among genes in the HoP interactome.", [["ReactomeFIViz", "SIMPLE_CHEMICAL", 0, 13], ["HoP", "GENE_OR_GENE_PRODUCT", 104, 107], ["a Cytoscape plugin", "PROBLEM", 15, 33], ["Cytoscape plugin", "OBSERVATION", 17, 33]]], ["64 It was also used to analyse the connections between the functional modules of viral budding and interferon signalling pathways.Data Availability 1The interactome, consists of 332 host proteins, their known interactions and computationally predicted interactions.", [["interferon", "GENE_OR_GENE_PRODUCT", 99, 109], ["interferon", "PROTEIN", 99, 109], ["332 host proteins", "PROTEIN", 178, 195], ["viral budding", "TREATMENT", 81, 94], ["viral budding", "OBSERVATION", 81, 94]]], ["It is being released via a webserver (http://hagrid.dbmi.pitt.edu/corona) as well as in the following electronic data formats.Data Availability 1The list of Proteins and Protein-Protein Interactions is available in Supplementary Data File S1.", [["a webserver (http://hagrid.dbmi.pitt.edu/corona)", "TREATMENT", 25, 73]]], ["The nodes and edges are labeled to indicate their type (host protein, or known or novel interactor, and known or novel PPI).", [["nodes", "ANATOMY", 4, 9], ["host protein", "PROTEIN", 56, 68], ["novel interactor", "PROTEIN", 82, 98], ["their type (host protein", "PROBLEM", 44, 68], ["novel PPI", "TREATMENT", 113, 122], ["nodes", "OBSERVATION", 4, 9], ["edges", "OBSERVATION_MODIFIER", 14, 19]]]], "c27f5379b25327aacb035420d439753e4c040772": [["Othocoronavirinae, family Coronaviridae, order Nidovirales, four genera, as alphacoronavirus (alpha-CoV), betacoronavirus (beta-CoV), gammacoronavirus (gamma-CoV), and deltacoronavirus (delta-CoV) 5 .", [["Othocoronavirinae", "GENE_OR_GENE_PRODUCT", 0, 17], ["alphacoronavirus", "GENE_OR_GENE_PRODUCT", 76, 92], ["alpha-CoV", "GENE_OR_GENE_PRODUCT", 94, 103], ["betacoronavirus", "GENE_OR_GENE_PRODUCT", 106, 121], ["beta-CoV", "GENE_OR_GENE_PRODUCT", 123, 131], ["gammacoronavirus", "GENE_OR_GENE_PRODUCT", 134, 150], ["gamma-CoV", "GENE_OR_GENE_PRODUCT", 152, 161], ["delta-CoV) 5", "ORGANISM", 186, 198], ["alphacoronavirus", "PROTEIN", 76, 92], ["alpha", "PROTEIN", 94, 99], ["CoV", "PROTEIN", 100, 103], ["betacoronavirus", "PROTEIN", 106, 121], ["beta", "PROTEIN", 123, 127], ["CoV", "PROTEIN", 128, 131], ["gammacoronavirus", "PROTEIN", 134, 150], ["gamma", "PROTEIN", 152, 157], ["CoV", "PROTEIN", 158, 161], ["deltacoronavirus", "PROTEIN", 168, 184], ["beta-CoV", "SPECIES", 123, 131], ["gamma-CoV", "SPECIES", 152, 161], ["deltacoronavirus (delta-CoV", "SPECIES", 168, 195], ["Nidovirales", "TREATMENT", 47, 58], ["four genera", "TREATMENT", 60, 71], ["alphacoronavirus (alpha-CoV)", "TREATMENT", 76, 104], ["betacoronavirus (beta-CoV)", "TREATMENT", 106, 132], ["gammacoronavirus (gamma-CoV)", "TREATMENT", 134, 162], ["deltacoronavirus (delta-CoV)", "TREATMENT", 168, 196]]], ["Alpha-and beta-CoVs have the ability to infect mammals as bats, pigs, cats, mice, and humans 6-11 .", [["Alpha", "GENE_OR_GENE_PRODUCT", 0, 5], ["beta-CoVs", "GENE_OR_GENE_PRODUCT", 10, 19], ["bats", "ORGANISM", 58, 62], ["pigs", "ORGANISM", 64, 68], ["cats", "ORGANISM", 70, 74], ["mice", "ORGANISM", 76, 80], ["humans", "ORGANISM", 86, 92], ["Alpha-and beta-CoVs", "PROTEIN", 0, 19], ["pigs", "SPECIES", 64, 68], ["cats", "SPECIES", 70, 74], ["mice", "SPECIES", 76, 80], ["humans", "SPECIES", 86, 92], ["mice", "SPECIES", 76, 80], ["humans", "SPECIES", 86, 92], ["Alpha", "TEST", 0, 5], ["beta-CoVs", "TREATMENT", 10, 19]]], ["Gamma-and delta-CoVs normally infect birds, while some have the ability to infect mammals [12] [13] [14] [15] .", [["Gamma", "GENE_OR_GENE_PRODUCT", 0, 5], ["delta-CoVs", "GENE_OR_GENE_PRODUCT", 10, 20], ["birds", "ORGANISM", 37, 42], ["[12] [13] [14] [15]", "SIMPLE_CHEMICAL", 90, 109], ["Gamma-and delta-CoVs", "PROTEIN", 0, 20], ["Gamma", "TEST", 0, 5], ["delta-CoVs normally infect birds", "PROBLEM", 10, 42]]], ["Considering the importance of the coronavirus spike (S) glycoprotein which facilitates infection through fusion of the viral and cellular membranes with conformational changes 16 and through ACE2 receptors, and consequently, the emerging importance of spike surface protein for the development of drugs and vaccination, we aim to study the phylogeny and genetic variabilities for spike proteins at genomic, amino acid and structural levels.Methodology:Gene sequences from gene bank:Methodology:Total 562 complete genome sequences of the SARS-CoV-2 strains from the infected individuals are retrieved from the GISAID and NCBI database.", [["cellular membranes", "ANATOMY", 129, 147], ["spike surface", "ANATOMY", 252, 265], ["infection", "DISEASE", 87, 96], ["amino acid", "CHEMICAL", 407, 417], ["amino acid", "CHEMICAL", 407, 417], ["coronavirus spike (S) glycoprotein", "GENE_OR_GENE_PRODUCT", 34, 68], ["cellular membranes", "CELLULAR_COMPONENT", 129, 147], ["ACE2", "GENE_OR_GENE_PRODUCT", 191, 195], ["amino acid", "AMINO_ACID", 407, 417], ["SARS-CoV-2 strains", "ORGANISM", 537, 555], ["individuals", "ORGANISM", 574, 585], ["coronavirus spike (S) glycoprotein", "PROTEIN", 34, 68], ["ACE2 receptors", "PROTEIN", 191, 205], ["spike surface protein", "PROTEIN", 252, 273], ["spike proteins", "PROTEIN", 380, 394], ["Gene sequences", "DNA", 452, 466], ["GISAID and NCBI database", "DNA", 609, 633], ["SARS-CoV-2", "SPECIES", 537, 547], ["the coronavirus spike (S) glycoprotein", "PROBLEM", 30, 68], ["infection", "PROBLEM", 87, 96], ["fusion", "TREATMENT", 105, 111], ["the viral and cellular membranes", "PROBLEM", 115, 147], ["spike surface protein", "PROBLEM", 252, 273], ["drugs", "TREATMENT", 297, 302], ["vaccination", "TREATMENT", 307, 318], ["spike proteins", "PROBLEM", 380, 394], ["amino acid", "TEST", 407, 417], ["the SARS", "PROBLEM", 533, 541], ["CoV", "TEST", 542, 545], ["2 strains", "PROBLEM", 546, 555], ["the infected individuals", "PROBLEM", 561, 585], ["infection", "OBSERVATION", 87, 96], ["viral", "OBSERVATION", 119, 124], ["cellular membranes", "OBSERVATION", 129, 147]]], ["We have retrieved some of the nucleotide sequence and amino acid sequence from gene bank, NCBI.", [["nucleotide", "CHEMICAL", 30, 40], ["amino acid", "CHEMICAL", 54, 64], ["nucleotide", "CHEMICAL", 30, 40], ["amino acid", "CHEMICAL", 54, 64], ["amino acid", "AMINO_ACID", 54, 64], ["the nucleotide sequence", "TEST", 26, 49], ["amino acid sequence", "TEST", 54, 73]]], ["For phylogenetic analysis, we retrieved complete genome sequences of SARS Cov2 sequences (multiple sequences from each country) across the globe, pertinent to different continents as Asia, Europe, North America, Africa, South America, Australia.", [["Cov2", "GENE_OR_GENE_PRODUCT", 74, 78], ["SARS Cov2 sequences", "DNA", 69, 88], ["phylogenetic analysis", "TEST", 4, 25], ["SARS Cov2 sequences", "TEST", 69, 88], ["multiple sequences", "TEST", 90, 108], ["globe", "ANATOMY", 139, 144]]], ["The countries and territories, which are Gene sequences are shown as in Supplementary file1.", [["Gene sequences", "DNA", 41, 55], ["Gene sequences", "TEST", 41, 55]]], ["We get the spike sequences from the same sequences, retrieved from NCBI gene bank.", [["spike sequences", "DNA", 11, 26], ["NCBI gene bank", "DNA", 67, 81], ["the spike sequences", "TEST", 7, 26]]], ["We retrieved the ACE2 receptor from NCBI protein sequence id NM_021804.3 and also the PDB id 1R42.Three-dimensional structure prediction and Model quality assessmentPSI-BLAST (http://blast.ncbi.nlm.nih.gov/Blast) was employed for identification of the templates that possessed the highest sequence identity with our target template.", [["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 17, 30], ["ACE2 receptor", "PROTEIN", 17, 30], ["NCBI protein sequence", "DNA", 36, 57], ["PDB id 1R42", "PROTEIN", 86, 97], ["Model quality assessmentPSI", "TEST", 141, 168], ["the templates", "TREATMENT", 248, 261], ["our target template", "TREATMENT", 312, 331]]], ["PDB structure (3D structure) was developed based on homology modelling of the homologous template structures using PHYRE2 server 17 .", [["PHYRE2 server 17", "DNA", 115, 131]]], ["The Swiss PDB Viewer was used for controlling energy minimization.", [["controlling energy minimization", "TREATMENT", 34, 65]]], ["SAVES (Structural Analysis and Verification Server, http://nihserver.mbi.ucla.edu/SAVES/) was employed for structural evaluation and stereochemical quality assessment of predicted model.", [["Structural Analysis", "TEST", 7, 26], ["structural evaluation", "TEST", 107, 128], ["stereochemical quality assessment", "TEST", 133, 166]]], ["The ProSA (Protein Structure Analysis) webserver (https://prosa.services.came.sbg.ac.at/prosa) was employed for refining and validating protein structure 18 .", [["ProSA", "PROTEIN", 4, 9], ["protein structure 18", "PROTEIN", 136, 156]]], ["TM align software was utilized for the alignment of spike proteins for SARS Cov2 and RMSD estimation to assess the structural differentiation 19 .Phylogenetic analysis of SARS Cov 2 world wide:We had studied phylogenetic analysis and detected mutations among the SARS Cov2 sequences spread globally through NJ method using JTT substitution model of MAAFT( https://mafft.cbrc.jp/alignment/server/spool/_phyloio.html) software 20 .", [["SARS", "DISEASE", 263, 267], ["TM", "PROTEIN", 0, 2], ["spike proteins", "PROTEIN", 52, 66], ["SARS Cov2", "PROTEIN", 71, 80], ["SARS Cov2 sequences", "DNA", 263, 282], ["spike proteins", "PROBLEM", 52, 66], ["SARS Cov2", "TEST", 71, 80], ["RMSD estimation", "TEST", 85, 100], ["Phylogenetic analysis", "TEST", 146, 167], ["phylogenetic analysis", "TEST", 208, 229], ["mutations", "PROBLEM", 243, 252], ["the SARS Cov2 sequences", "PROBLEM", 259, 282], ["NJ method", "TREATMENT", 307, 316], ["JTT substitution model of MAAFT", "TREATMENT", 323, 354]]], ["We attempted to collect complete genome sequences for SARS Cov2 from different countries belonging to different continents.Phylogenetic analysis of SARS Cov 2 world wide:Considering the wide variability, we had considered phylogenetic tree for different spike proteins for SARS Cov2 studied with MAFFT software.Assessment of structural differences between different spike proteins for SARS Cov2Based on the phylogenetic tree, we identified 20 variants of spike protein existing in the globe.", [["genome sequences", "DNA", 33, 49], ["SARS Cov2", "DNA", 54, 63], ["spike proteins", "PROTEIN", 254, 268], ["SARS Cov2", "PROTEIN", 273, 282], ["spike proteins", "PROTEIN", 366, 380], ["SARS Cov2Based", "PROTEIN", 385, 399], ["spike protein", "PROTEIN", 455, 468], ["SARS Cov2", "PROBLEM", 54, 63], ["Phylogenetic analysis", "TEST", 123, 144], ["SARS Cov", "PROBLEM", 148, 156], ["phylogenetic tree", "PROBLEM", 222, 239], ["different spike proteins", "PROBLEM", 244, 268], ["SARS Cov2", "TEST", 273, 282], ["structural differences", "PROBLEM", 325, 347], ["different spike proteins", "PROBLEM", 356, 380], ["SARS", "PROBLEM", 385, 389], ["spike protein existing in the globe", "PROBLEM", 455, 490], ["globe", "ANATOMY", 485, 490]]], ["In order to identify the differences, we employed TM align software 19 and assessed RMSD score 19 .Molecular DockingMolecular docking is a bioinformatics tool used for in silico analysis for the prediction of the binding mode of a ligand with a protein 3D structure.", [["protein 3D structure", "PROTEIN", 245, 265], ["RMSD score", "TEST", 84, 94], ["a bioinformatics tool", "TEST", 137, 158], ["silico analysis", "TEST", 171, 186], ["Molecular docking", "OBSERVATION", 116, 133]]], ["Patch dock is an algorithm for molecular docking based on shape complementarity principle 21 .", [["an algorithm", "TEST", 14, 26]]], ["We subject patchdock analysis of ACE2 receptor with spike protein of SARS Cov2 virus 21 .", [["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 33, 46], ["SARS Cov2 virus 21", "ORGANISM", 69, 87], ["ACE2 receptor", "PROTEIN", 33, 46], ["spike protein", "PROTEIN", 52, 65], ["SARS Cov2 virus", "SPECIES", 69, 84], ["ACE2 receptor", "TEST", 33, 46], ["spike protein of SARS Cov2 virus", "PROBLEM", 52, 84]]], ["We validated the results with Firedock 22 .We had also predicted the binding sites and visualized through Pymol (http://www.pymol.org/).Mutation and sequence variability studies among SARS Cov2 complete genome world wide.High degree of sequence variability has been observed among the SARS Cov2 variants distributed globally.", [["SARS", "DISEASE", 285, 289], ["Cov2", "GENE_OR_GENE_PRODUCT", 290, 294], ["binding sites", "DNA", 69, 82], ["Pymol", "DNA", 106, 111], ["SARS Cov2 complete genome", "DNA", 184, 209], ["SARS Cov2 variants", "DNA", 285, 303], ["sequence variability studies", "TEST", 149, 177], ["High degree of sequence variability", "PROBLEM", 221, 256], ["the SARS Cov2 variants", "PROBLEM", 281, 303]]], ["Phylogenetic tree (Fig2) depicts wide variability.", [["Fig2", "DNA", 19, 23], ["tree", "ANATOMY_MODIFIER", 13, 17], ["wide", "OBSERVATION_MODIFIER", 33, 37], ["variability", "OBSERVATION_MODIFIER", 38, 49]]], ["However, two distinct clades were observed, but not restricted to infection within a country.", [["infection", "DISEASE", 66, 75], ["two distinct clades", "PROBLEM", 9, 28], ["infection", "PROBLEM", 66, 75], ["distinct", "OBSERVATION_MODIFIER", 13, 21], ["clades", "OBSERVATION", 22, 28], ["infection", "OBSERVATION", 66, 75]]], ["An interesting observation was that there exists wide variability among virus strains within a country and even within the same geographical area.", [["wide variability among virus strains", "PROBLEM", 49, 85], ["wide", "OBSERVATION_MODIFIER", 49, 53], ["variability", "OBSERVATION_MODIFIER", 54, 65], ["virus strains", "OBSERVATION", 72, 85]]], ["We observed multiple strains existing within the same country and also within same geographical location, as in USA (MT88341& MT188340).", [["multiple strains", "PROBLEM", 12, 28], ["multiple", "OBSERVATION_MODIFIER", 12, 20], ["strains", "OBSERVATION", 21, 28]]], ["The other two sequences from USA analyzed even belong to a different clade (MT308704 and MT344956) with genetic variability.", [["genetic variability", "TEST", 104, 123]]], ["Two sequences identified from Kerala state of India and sequenced in the same laboratory depicted enormous genetic variability and they belong to two different clades (MT050493 & MT012098).", [["Two sequences", "TEST", 0, 13], ["enormous", "OBSERVATION_MODIFIER", 98, 106], ["genetic variability", "OBSERVATION", 107, 126]]], ["These conditions are very alarming for effective vaccination or treatment.", [["effective vaccination", "TREATMENT", 39, 60], ["treatment", "TREATMENT", 64, 73]]], ["The detail phylogenetic distribution of SARS COV2 across the globe is being presented in Fig 3, as revealed through GISAID data base (www.gisaid.org) as time progresses.Mutation and sequence variability studies among SARS Cov2 spike protein world wide.Molecular phylogeny for different variants for spike proteins were depicted through phylogenetic tree in Fig 4 .", [["SARS", "DISEASE", 40, 44], ["SARS Cov2 spike protein", "PROTEIN", 217, 240], ["spike proteins", "PROTEIN", 299, 313], ["SARS COV2 across the globe", "PROBLEM", 40, 66], ["Mutation and sequence variability studies", "TEST", 169, 210], ["SARS", "PROBLEM", 217, 221], ["different variants", "PROBLEM", 276, 294], ["spike proteins", "PROBLEM", 299, 313], ["phylogenetic", "OBSERVATION_MODIFIER", 11, 23], ["distribution", "OBSERVATION_MODIFIER", 24, 36], ["SARS", "OBSERVATION", 40, 44], ["globe", "ANATOMY", 61, 66]]], ["Out of 20 different spike proteins identified, 7 types were clustered together, indicating genetic closeness.", [["spike proteins", "PROTEIN", 20, 34], ["genetic closeness", "OBSERVATION", 91, 108]]], ["They may be regarded as the dominant type.", [["may be regarded", "UNCERTAINTY", 5, 20], ["dominant", "OBSERVATION_MODIFIER", 28, 36], ["type", "OBSERVATION_MODIFIER", 37, 41]]], ["Phylogenetic tree was constructed which reveal spike protein 1 (QIS60288.1), 2 (QIZ15537), 13 (QIV64989), 14(QIU78707), 16(QJA17668), 19(QJZ27839) and 20 (QJW69307) were clustered together, indicating genetic similarity and may be regarded as dominant type.Mutation and sequence variability studies among SARS Cov2 spike protein world wide.Alignment of different variants of 3D structure of spike protein for SARS Cov2 were compared and RMSD listed in Table 1 .", [["spike protein 1", "GENE_OR_GENE_PRODUCT", 47, 62], ["Cov2", "GENE_OR_GENE_PRODUCT", 414, 418], ["spike protein 1", "PROTEIN", 47, 62], ["SARS Cov2 spike protein", "PROTEIN", 305, 328], ["spike protein", "PROTEIN", 391, 404], ["SARS Cov2", "PROTEIN", 409, 418], ["Phylogenetic tree", "TEST", 0, 17], ["spike protein", "TEST", 47, 60], ["QIZ", "TEST", 80, 83], ["Mutation and sequence variability studies", "TEST", 257, 298], ["SARS", "PROBLEM", 305, 309], ["spike protein", "PROBLEM", 391, 404], ["SARS Cov2", "PROBLEM", 409, 418], ["different", "OBSERVATION_MODIFIER", 353, 362]]], ["We have visualized alignment report of genetically distant variants with Spike protein1, considering it as dominant type.", [["Spike protein1", "GENE_OR_GENE_PRODUCT", 73, 87], ["Spike protein1", "DNA", 73, 87], ["genetically distant variants", "PROBLEM", 39, 67], ["Spike protein1", "PROBLEM", 73, 87], ["distant variants", "OBSERVATION", 51, 67], ["dominant", "OBSERVATION_MODIFIER", 107, 115], ["type", "OBSERVATION_MODIFIER", 116, 120]]], ["Certain important novel non-synonymous mutations have been identified among the variants of spike protein leading to amino acid changes as S247R , R408I, G612D, A930V and deletion detected at amino acid position 144 (Fig 5) .", [["amino acid", "CHEMICAL", 117, 127], ["amino acid", "CHEMICAL", 192, 202], ["amino acid", "CHEMICAL", 117, 127], ["amino acid", "CHEMICAL", 192, 202], ["amino acid", "AMINO_ACID", 117, 127], ["S247R", "GENE_OR_GENE_PRODUCT", 139, 144], ["amino acid position 144", "AMINO_ACID", 192, 215], ["spike protein", "PROTEIN", 92, 105], ["Certain important novel non-synonymous mutations", "PROBLEM", 0, 48], ["spike protein", "PROBLEM", 92, 105], ["amino acid changes", "PROBLEM", 117, 135], ["deletion", "PROBLEM", 171, 179], ["amino acid position", "TEST", 192, 211]]], ["R408I lies within Peptidase S domain.", [["Peptidase S domain", "GENE_OR_GENE_PRODUCT", 18, 36], ["R408I", "DNA", 0, 5], ["Peptidase S domain", "PROTEIN", 18, 36]]], ["3D structural alignments are revealed with respect to dominant type spike 1 (Fig 6) However, the alignment studies reveal structural differences as revealed through RMSD.", [["3D structural alignments", "TEST", 0, 24], ["dominant type spike", "PROBLEM", 54, 73], ["the alignment studies", "TEST", 93, 114], ["structural alignments", "OBSERVATION", 3, 24]]], ["We had considered variant1 as representative for the dominant variant.", [["variant1", "TREATMENT", 18, 26], ["the dominant variant", "PROBLEM", 49, 69], ["dominant variant", "OBSERVATION", 53, 69]]], ["Maximum variability observed for variant 4 (from US) and variant 5 from Pakistan (patient had travel history to Iran, and returned to Pakistan 5 days before sample was collected).Molecular Docking of ACE2 receptor with spike proteinWe assessed the binding ability of ACE2 receptor with dominant spike protein1 with binding sites detected.", [["patient", "ORGANISM", 82, 89], ["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 200, 213], ["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 267, 280], ["dominant spike protein1", "GENE_OR_GENE_PRODUCT", 286, 309], ["ACE2 receptor", "PROTEIN", 200, 213], ["spike proteinWe", "PROTEIN", 219, 234], ["ACE2 receptor", "PROTEIN", 267, 280], ["dominant spike protein1", "PROTEIN", 286, 309], ["binding sites", "DNA", 315, 328], ["patient", "SPECIES", 82, 89], ["Maximum variability", "TEST", 0, 19], ["ACE2 receptor", "TREATMENT", 200, 213], ["spike proteinWe", "PROBLEM", 219, 234], ["ACE2 receptor", "TREATMENT", 267, 280], ["dominant spike protein1", "PROBLEM", 286, 309], ["binding sites", "PROBLEM", 315, 328]]], ["(Fig 7a &7b.) .We identified molecular docking of ACE2 receptor (blue) with spike protein(red) for SARS Cov2 virus.", [["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 50, 63], ["blue) with spike protein", "GENE_OR_GENE_PRODUCT", 65, 89], ["SARS Cov2 virus", "ORGANISM", 99, 114], ["ACE2 receptor", "PROTEIN", 50, 63], ["spike protein", "PROTEIN", 76, 89], ["red", "PROTEIN", 90, 93], ["SARS Cov2 virus", "SPECIES", 99, 114], ["spike protein", "PROBLEM", 76, 89], ["SARS Cov2 virus", "PROBLEM", 99, 114]]], ["We used spike protein1 for binding with ACE2 receptor as in Fig 7a, 7b .", [["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 40, 53], ["spike protein1", "PROTEIN", 8, 22], ["ACE2 receptor", "PROTEIN", 40, 53], ["spike protein1", "PROBLEM", 8, 22], ["ACE2 receptor", "TREATMENT", 40, 53]]], ["The binding domains for ACE2 with spike protein are being identified as Ile54, Gly337, Val 293, Gln305, Lys363, Asn394, Lys309, Asn149 as represented as yellow sphere (Fig 7a) .Molecular Docking of ACE2 receptor with spike proteinSimultaneously, we also predicted the receptor binding domains for spike protein1 with ACE2 receptor as Ser221, Phe220, Phe32, Asn 280, Lys206 (Fig 7b) .Discussion:We identified a wide genetic variabilities among the SARS Cov2 complete genome sequences distributed worldwide across different countries belonging to different continents.", [["SARS", "DISEASE", 447, 451], ["Ile54", "CHEMICAL", 72, 77], ["Gly", "CHEMICAL", 79, 82], ["Val", "CHEMICAL", 87, 90], ["Gln305", "CHEMICAL", 96, 102], ["Lys363", "CHEMICAL", 104, 110], ["Asn394", "CHEMICAL", 112, 118], ["Lys309", "CHEMICAL", 120, 126], ["Asn149", "CHEMICAL", 128, 134], ["Phe220", "CHEMICAL", 342, 348], ["Phe32", "CHEMICAL", 350, 355], ["Asn", "CHEMICAL", 357, 360], ["Lys206", "CHEMICAL", 366, 372], ["ACE2", "GENE_OR_GENE_PRODUCT", 24, 28], ["Ile54", "GENE_OR_GENE_PRODUCT", 72, 77], ["Gly337", "AMINO_ACID", 79, 85], ["Gln305", "GENE_OR_GENE_PRODUCT", 96, 102], ["Lys363", "GENE_OR_GENE_PRODUCT", 104, 110], ["Asn394", "GENE_OR_GENE_PRODUCT", 112, 118], ["Lys309", "GENE_OR_GENE_PRODUCT", 120, 126], ["Asn149", "GENE_OR_GENE_PRODUCT", 128, 134], ["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 198, 211], ["spike protein1", "GENE_OR_GENE_PRODUCT", 297, 311], ["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 317, 330], ["Ser221", "GENE_OR_GENE_PRODUCT", 334, 340], ["Phe220", "GENE_OR_GENE_PRODUCT", 342, 348], ["Phe32", "GENE_OR_GENE_PRODUCT", 350, 355], ["Asn 280", "AMINO_ACID", 357, 364], ["binding domains", "PROTEIN", 4, 19], ["ACE2", "PROTEIN", 24, 28], ["spike protein", "PROTEIN", 34, 47], ["Asn149", "PROTEIN", 128, 134], ["ACE2 receptor", "PROTEIN", 198, 211], ["receptor binding domains", "PROTEIN", 268, 292], ["spike protein1", "PROTEIN", 297, 311], ["ACE2 receptor", "PROTEIN", 317, 330], ["Ser221", "PROTEIN", 334, 340], ["Phe220", "PROTEIN", 342, 348], ["Phe32", "PROTEIN", 350, 355], ["SARS Cov2 complete genome sequences", "DNA", 447, 482], ["ACE2", "TEST", 24, 28], ["spike protein", "TEST", 34, 47], ["Gly", "TEST", 79, 82], ["Val", "TEST", 87, 90], ["ACE2 receptor", "TREATMENT", 198, 211], ["spike proteinSimultaneously", "PROBLEM", 217, 244], ["spike protein1", "PROBLEM", 297, 311], ["ACE2 receptor", "TEST", 317, 330], ["Phe220", "TEST", 342, 348], ["Asn", "TEST", 357, 360], ["a wide genetic variabilities", "PROBLEM", 408, 436], ["the SARS", "PROBLEM", 443, 451]]], ["In our study, we observed sufficient genetic variabilities among the SARS Cov2 virus within two different samples collected from Kerala, India.", [["samples", "ANATOMY", 106, 113], ["SARS Cov2 virus", "ORGANISM", 69, 84], ["SARS Cov2 virus", "SPECIES", 69, 84], ["our study", "TEST", 3, 12], ["sufficient genetic variabilities", "PROBLEM", 26, 58], ["the SARS Cov2 virus", "PROBLEM", 65, 84]]], ["In the same way, different strains were identified from the same state of USA.", [["different strains", "PROBLEM", 17, 34], ["strains", "OBSERVATION", 27, 34]]], ["Even within the same country USA, different strains belong to two different clades.", [["different strains", "PROBLEM", 34, 51]]], ["Evolutionary studies for SARS Cov2 have been conducted by a number of workers, but due to rapidly evolving virus, molecular phylogeny varies frequently.", [["Cov2", "GENE_OR_GENE_PRODUCT", 30, 34], ["SARS Cov2", "PROTEIN", 25, 34], ["Evolutionary studies", "TEST", 0, 20], ["SARS Cov2", "PROBLEM", 25, 34], ["rapidly evolving virus", "PROBLEM", 90, 112], ["virus", "OBSERVATION", 107, 112], ["phylogeny varies", "OBSERVATION", 124, 140]]], ["Initial report indicates two major types 23 , three types 24 followed by 11 subtypes 25 .It is suggested that O type as the ancestral type first evolved from China, Wuhan outbreak, while A2 type as the dominant one, characterized by a nonsynonymous D614G mutation at the junction of S1-RBD and S2 of the SARS-CoV-2 spike (S) protein 25 .", [["S1-RBD", "GENE_OR_GENE_PRODUCT", 283, 289], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 304, 314], ["S1", "PROTEIN", 283, 285], ["RBD", "PROTEIN", 286, 289], ["S2", "PROTEIN", 294, 296], ["SARS-CoV-2 spike (S) protein 25", "PROTEIN", 304, 335], ["a nonsynonymous D614G mutation", "PROBLEM", 233, 263], ["the SARS", "TEST", 300, 308], ["CoV", "TEST", 309, 312], ["protein", "TEST", 325, 332], ["S1", "ANATOMY", 283, 285], ["RBD", "ANATOMY", 286, 289], ["S2", "ANATOMY", 294, 296]]], ["This high genetic variability restricts the development of satisfactory vaccines.", [["This high genetic variability", "PROBLEM", 0, 29], ["satisfactory vaccines", "TREATMENT", 59, 80], ["satisfactory vaccines", "OBSERVATION", 59, 80]]], ["Lack of genetic uniformity within a particular region, makes the vaccination process more complicated.", [["the vaccination process", "PROBLEM", 61, 84], ["genetic uniformity", "OBSERVATION", 8, 26]]], ["The possibilities of transmission of SARS Cov2 through animals (bat, pangolin, reptiles, ferret, pet animals as dog, cat, clinical trial in monkey ) with zoonotic importance have been well discussed 26 .Discussion:Considering the importance of surface glycoprotein or spike protein in attachment to ACE receptor, during the entry in host, we identified 20 different spike variants numbered as (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) .", [["surface", "ANATOMY", 244, 251], ["SARS", "DISEASE", 37, 41], ["Cov2", "GENE_OR_GENE_PRODUCT", 42, 46], ["bat", "ORGANISM_SUBDIVISION", 64, 67], ["pangolin", "GENE_OR_GENE_PRODUCT", 69, 77], ["ferret", "ORGANISM", 89, 95], ["pet animals", "ORGANISM", 97, 108], ["dog", "ORGANISM", 112, 115], ["cat", "ORGANISM", 117, 120], ["monkey", "ORGANISM", 140, 146], ["surface glycoprotein", "GENE_OR_GENE_PRODUCT", 244, 264], ["ACE receptor", "GENE_OR_GENE_PRODUCT", 299, 311], ["surface glycoprotein", "PROTEIN", 244, 264], ["spike protein", "PROTEIN", 268, 281], ["ACE receptor", "PROTEIN", 299, 311], ["ferret", "SPECIES", 89, 95], ["dog", "SPECIES", 112, 115], ["SARS Cov2", "PROBLEM", 37, 46], ["surface glycoprotein", "TREATMENT", 244, 264], ["spike protein", "PROBLEM", 268, 281], ["ACE receptor", "TREATMENT", 299, 311], ["20 different spike variants", "PROBLEM", 353, 380]]], ["Phylogenetic tree revealed seven spike proteins (1,2,13,14, 16 19, 20) to be genetically similar and clustered together.", [["spike proteins", "PROTEIN", 33, 47], ["Phylogenetic tree", "TEST", 0, 17], ["seven spike proteins", "PROBLEM", 27, 47], ["tree", "ANATOMY_MODIFIER", 13, 17], ["seven spike", "OBSERVATION", 27, 38]]], ["However there still exists certain differences in 3D structures among these spike proteins.", [["spike proteins", "PROTEIN", 76, 90], ["these spike proteins", "PROBLEM", 70, 90]]], ["It is interesting to note that spike variant18 has a different structure compared to others.", [["spike variant", "PROBLEM", 31, 44], ["different structure", "OBSERVATION_MODIFIER", 53, 72]]], ["Reports are available that the coronavirus spike (S) glycoprotein fuses with host cellular membranes via ACE receptor by conformation changes of the spike 16 .", [["cellular membranes", "ANATOMY", 82, 100], ["coronavirus spike (S) glycoprotein", "GENE_OR_GENE_PRODUCT", 31, 65], ["cellular membranes", "CELLULAR_COMPONENT", 82, 100], ["ACE receptor", "GENE_OR_GENE_PRODUCT", 105, 117], ["coronavirus spike (S) glycoprotein", "PROTEIN", 31, 65], ["ACE receptor", "PROTEIN", 105, 117], ["spike 16", "PROTEIN", 149, 157], ["the coronavirus spike (S) glycoprotein fuses", "PROBLEM", 27, 71], ["host cellular membranes", "TREATMENT", 77, 100], ["ACE receptor", "TREATMENT", 105, 117], ["the spike", "PROBLEM", 145, 154]]], ["This has been illustrated through biochemical characterization, limited proteolysis, mass spectrometry, and single-particle EM 16 .", [["biochemical characterization", "TEST", 34, 62], ["limited proteolysis", "PROBLEM", 64, 83], ["mass spectrometry", "TEST", 85, 102]]], ["It has been reported that that the stability of SARS-CoV-2 Spike protein is less than SARS-CoV S 27 .", [["SARS", "DISEASE", 48, 52], ["SARS-CoV-2 Spike", "GENE_OR_GENE_PRODUCT", 48, 64], ["SARS-CoV-2 Spike protein", "PROTEIN", 48, 72], ["SARS-CoV", "SPECIES", 86, 94], ["SARS", "TEST", 48, 52], ["CoV", "TEST", 53, 56], ["Spike protein", "TEST", 59, 72], ["CoV S", "TEST", 91, 96], ["stability", "OBSERVATION_MODIFIER", 35, 44]]], ["We detected certain novel mutations at S247R, R408I, G612D, A930V and del 144, one involved with important domain of peptidase S. We presume that the variabilities in spike protein have arisen due to non-synonymous mutations in spike protein distributed world wide.", [["spike protein", "PROTEIN", 167, 180], ["spike protein", "PROTEIN", 228, 241], ["certain novel mutations", "PROBLEM", 12, 35], ["peptidase S.", "TREATMENT", 117, 129], ["the variabilities in spike protein", "PROBLEM", 146, 180], ["non-synonymous mutations", "PROBLEM", 200, 224], ["non-synonymous mutations", "OBSERVATION", 200, 224]]], ["Such wide variabilities in ssRNA virus is very common as we detected in avian influenza virus 28 .", [["avian influenza virus", "DISEASE", 72, 93], ["ssRNA virus", "ORGANISM", 27, 38], ["avian influenza virus 28", "ORGANISM", 72, 96], ["avian influenza virus", "SPECIES", 72, 93], ["avian influenza virus", "SPECIES", 72, 93], ["Such wide variabilities in ssRNA virus", "PROBLEM", 0, 38], ["avian influenza virus", "PROBLEM", 72, 93], ["ssRNA virus", "OBSERVATION", 27, 38]]], ["It has been reported that SARS-CoV-2 binds with human angiotensin converting enzyme 2 (ACE2) 1 as a receptor and enter the human lung.", [["lung", "ANATOMY", 129, 133], ["angiotensin", "CHEMICAL", 54, 65], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 26, 36], ["human", "ORGANISM", 48, 53], ["angiotensin converting enzyme 2 (ACE2) 1", "GENE_OR_GENE_PRODUCT", 54, 94], ["human", "ORGANISM", 123, 128], ["lung", "ORGAN", 129, 133], ["human angiotensin converting enzyme 2 (ACE2) 1", "PROTEIN", 48, 94], ["human", "SPECIES", 48, 53], ["human", "SPECIES", 123, 128], ["human", "SPECIES", 48, 53], ["human", "SPECIES", 123, 128], ["SARS", "PROBLEM", 26, 30], ["human angiotensin converting enzyme", "TREATMENT", 48, 83], ["human lung", "ANATOMY", 123, 133]]], ["The spike (S) protein acts through receptor binding and membrane fusion 29 .", [["membrane", "ANATOMY", 56, 64], ["membrane", "CELLULAR_COMPONENT", 56, 64], ["spike (S) protein", "PROTEIN", 4, 21], ["membrane fusion 29", "PROTEIN", 56, 74], ["The spike (S) protein acts", "TEST", 0, 26], ["receptor binding", "TEST", 35, 51], ["membrane fusion", "TEST", 56, 71]]], ["The spike protein of coronaviruses has two functional domains -S1, involved with receptor binding, and S2 domain, causes cell membrane fusion 30 .Discussion:We identified the receptor binding domain sites for ACE2 receptor as Ser221, Phe220, Phe32, Asn 280, Lys206.", [["cell membrane", "ANATOMY", 121, 134], ["Ser221", "CHEMICAL", 226, 232], ["Phe220", "CHEMICAL", 234, 240], ["Phe32", "CHEMICAL", 242, 247], ["Asn", "CHEMICAL", 249, 252], ["Lys206", "CHEMICAL", 258, 264], ["S1", "GENE_OR_GENE_PRODUCT", 63, 65], ["S2", "GENE_OR_GENE_PRODUCT", 103, 105], ["cell membrane", "CELLULAR_COMPONENT", 121, 134], ["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 209, 222], ["Ser221", "GENE_OR_GENE_PRODUCT", 226, 232], ["Phe220", "GENE_OR_GENE_PRODUCT", 234, 240], ["Phe32", "GENE_OR_GENE_PRODUCT", 242, 247], ["Asn 280", "AMINO_ACID", 249, 256], ["Lys206", "GENE_OR_GENE_PRODUCT", 258, 264], ["spike protein", "PROTEIN", 4, 17], ["S1", "PROTEIN", 63, 65], ["S2 domain", "PROTEIN", 103, 112], ["receptor binding domain sites", "PROTEIN", 175, 204], ["ACE2 receptor", "PROTEIN", 209, 222], ["Ser221", "PROTEIN", 226, 232], ["Phe220", "PROTEIN", 234, 240], ["Phe32", "PROTEIN", 242, 247], ["The spike protein of coronaviruses", "PROBLEM", 0, 34], ["receptor binding", "PROBLEM", 81, 97], ["S2 domain", "PROBLEM", 103, 112], ["cell membrane fusion", "TREATMENT", 121, 141], ["ACE2 receptor", "TEST", 209, 222], ["S2", "ANATOMY", 103, 105], ["cell membrane fusion", "OBSERVATION", 121, 141]]], ["However others have identified five key residues in the receptor binding domain enable efficient binding of SARS-CoV-2 to human ACE2; these are Asn439, Asn501, Gln493, Gly485 and Phe486 38 .", [["Asn439", "CHEMICAL", 144, 150], ["Asn501", "CHEMICAL", 152, 158], ["Gl", "CHEMICAL", 160, 162], ["n493", "CHEMICAL", 162, 166], ["Gly485", "CHEMICAL", 168, 174], ["Phe486", "CHEMICAL", 179, 185], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 108, 118], ["human", "ORGANISM", 122, 127], ["ACE2", "GENE_OR_GENE_PRODUCT", 128, 132], ["Asn439", "GENE_OR_GENE_PRODUCT", 144, 150], ["Asn501", "GENE_OR_GENE_PRODUCT", 152, 158], ["Gl", "GENE_OR_GENE_PRODUCT", 160, 162], ["Gly485", "GENE_OR_GENE_PRODUCT", 168, 174], ["receptor binding domain", "PROTEIN", 56, 79], ["human ACE2", "PROTEIN", 122, 132], ["human", "SPECIES", 122, 127], ["human", "SPECIES", 122, 127], ["five key residues", "PROBLEM", 31, 48], ["CoV", "TEST", 113, 116], ["human ACE2", "TEST", 122, 132], ["Asn501", "TEST", 152, 158], ["Gl", "TEST", 160, 162], ["Phe486", "TEST", 179, 185]]], ["The variation might occur due to wide variability in spike proteins identified.", [["spike proteins", "PROTEIN", 53, 67], ["wide variability in spike proteins", "PROBLEM", 33, 67]]], ["Another mutation, A23403G, located in the gene encoding the spike glycoprotein results in an amino acid change (D614G) from aspartic acid to glycine.", [["amino acid", "CHEMICAL", 93, 103], ["aspartic acid", "CHEMICAL", 124, 137], ["glycine", "CHEMICAL", 141, 148], ["amino acid", "CHEMICAL", 93, 103], ["aspartic acid", "CHEMICAL", 124, 137], ["glycine", "CHEMICAL", 141, 148], ["amino acid", "AMINO_ACID", 93, 103], ["aspartic acid", "AMINO_ACID", 124, 137], ["glycine", "AMINO_ACID", 141, 148], ["spike glycoprotein", "PROTEIN", 60, 78], ["Another mutation", "PROBLEM", 0, 16], ["an amino acid change", "TREATMENT", 90, 110], ["aspartic acid to glycine", "TREATMENT", 124, 148]]], ["Although the effect of the D614G mutation is not clear, the location of this mutation was reported in the S1-S2 junction near the furin recognition site (R667) for the cleavage of S protein.", [["D614G", "GENE_OR_GENE_PRODUCT", 27, 32], ["furin", "GENE_OR_GENE_PRODUCT", 130, 135], ["S protein", "GENE_OR_GENE_PRODUCT", 180, 189], ["D614G", "DNA", 27, 32], ["S1-S2 junction", "DNA", 106, 120], ["furin recognition site", "DNA", 130, 152], ["S protein", "PROTEIN", 180, 189], ["the D614G mutation", "PROBLEM", 23, 41], ["this mutation", "PROBLEM", 72, 85], ["S1", "ANATOMY", 106, 108], ["S2 junction", "ANATOMY", 109, 120]]], ["This site was observed to be essential for the entry of the virion into the host cell 30 .", [["cell", "ANATOMY", 81, 85], ["virion", "CELLULAR_COMPONENT", 60, 66], ["host cell", "CELL", 76, 85], ["host cell", "OBSERVATION", 76, 85]]], ["In this current study, we had also identified four nonsynonymous mutations and one site for deletion.", [["this current study", "TEST", 3, 21], ["four nonsynonymous mutations", "PROBLEM", 46, 74], ["deletion", "PROBLEM", 92, 100], ["nonsynonymous mutations", "OBSERVATION", 51, 74]]], ["It is important to note that R408I lies within Peptidase S domain, which might be responsible for variation in 3D structures of the spikes leading to greater RMSD.", [["Peptidase S", "GENE_OR_GENE_PRODUCT", 47, 58], ["R408I", "PROTEIN", 29, 34], ["Peptidase S domain", "PROTEIN", 47, 65], ["Peptidase S domain", "TEST", 47, 65], ["the spikes", "PROBLEM", 128, 138], ["might be responsible for", "UNCERTAINTY", 73, 97], ["greater RMSD", "OBSERVATION", 150, 162]]], ["This might aid in altered pathogenicity affecting recognition and binding of host receptor.", [["host receptor", "PROTEIN", 77, 90], ["altered pathogenicity", "PROBLEM", 18, 39], ["altered", "OBSERVATION_MODIFIER", 18, 25], ["pathogenicity", "OBSERVATION", 26, 39]]], ["With the help of SARS-CoV-2 S protein pseudovirus system, it was proved that human angiotensin converting enzyme 2 (hACE2) is the receptor for SARS-CoV-2.", [["angiotensin", "CHEMICAL", 83, 94], ["SARS-CoV-2 S", "GENE_OR_GENE_PRODUCT", 17, 29], ["human", "ORGANISM", 77, 82], ["angiotensin converting enzyme 2", "GENE_OR_GENE_PRODUCT", 83, 114], ["hACE2", "GENE_OR_GENE_PRODUCT", 116, 121], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 143, 153], ["human angiotensin converting enzyme 2", "PROTEIN", 77, 114], ["hACE2", "PROTEIN", 116, 121], ["human", "SPECIES", 77, 82], ["human", "SPECIES", 77, 82], ["SARS", "TEST", 17, 21], ["CoV", "TEST", 22, 25], ["human angiotensin converting enzyme", "TREATMENT", 77, 112], ["SARS", "TEST", 143, 147], ["CoV", "TEST", 148, 151]]], ["It has been reported that SARS-CoV-2 gets its entry through 293/hACE2 cells mainly through endocytosis.", [["293/hACE2 cells", "ANATOMY", 60, 75], ["SARS", "DISEASE", 26, 30], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 26, 36], ["hACE2 cells", "CELL", 64, 75], ["293/hACE2 cells", "CELL_LINE", 60, 75], ["SARS-CoV", "TEST", 26, 34]]], ["Factors such as PIKfyve, TPC2, and cathepsin L are reported to be critical for the entry 27 .", [["PIKfyve", "GENE_OR_GENE_PRODUCT", 16, 23], ["TPC2", "GENE_OR_GENE_PRODUCT", 25, 29], ["cathepsin L", "GENE_OR_GENE_PRODUCT", 35, 46], ["PIKfyve", "PROTEIN", 16, 23], ["TPC2", "PROTEIN", 25, 29], ["cathepsin L", "PROTEIN", 35, 46], ["PIKfyve", "TEST", 16, 23], ["TPC2", "TREATMENT", 25, 29], ["cathepsin L", "TREATMENT", 35, 46]]], ["The wide variabilities in spike protein leads to different domain binding site for ACE2 receptor.", [["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 83, 96], ["spike protein", "PROTEIN", 26, 39], ["domain binding site", "PROTEIN", 59, 78], ["ACE2 receptor", "PROTEIN", 83, 96], ["The wide variabilities", "PROBLEM", 0, 22], ["spike protein", "PROBLEM", 26, 39], ["different domain binding site", "PROBLEM", 49, 78], ["ACE2 receptor", "TREATMENT", 83, 96], ["wide", "OBSERVATION_MODIFIER", 4, 8], ["variabilities", "OBSERVATION_MODIFIER", 9, 22]]], ["This may also be one of the reason for difference in susceptibility to infection.", [["infection", "DISEASE", 71, 80], ["infection", "PROBLEM", 71, 80], ["may also be", "UNCERTAINTY", 5, 16], ["infection", "OBSERVATION", 71, 80]]], ["Other researchers identified polymorphism of ACE2 receptor and regard it to be responsible for varying susceptibility 31 .Discussion:An important subunit observed with greater affinity and binding ability was S (surface glycoprotein molecule) for most of the immune response molecule studied.", [["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 45, 58], ["ACE2 receptor", "PROTEIN", 45, 58], ["surface glycoprotein molecule", "PROTEIN", 212, 241], ["immune response molecule", "PROTEIN", 259, 283], ["ACE2 receptor", "TREATMENT", 45, 58], ["greater affinity", "PROBLEM", 168, 184], ["S (surface glycoprotein molecule", "TREATMENT", 209, 241]]], ["Considering its importance studied earlier, it has been considered as an effective antigen molecule for subunit vaccine production 32 .", [["an effective antigen molecule", "TREATMENT", 70, 99], ["subunit vaccine production", "TREATMENT", 104, 130]]], ["Spike protein of human CoVs help in viral entry into host cells leading to membrane fusion, causing viral infection 32, 33 .", [["cells", "ANATOMY", 58, 63], ["membrane", "ANATOMY", 75, 83], ["viral infection", "DISEASE", 100, 115], ["Spike", "GENE_OR_GENE_PRODUCT", 0, 5], ["human", "ORGANISM", 17, 22], ["CoVs", "GENE_OR_GENE_PRODUCT", 23, 27], ["host cells", "CELL", 53, 63], ["membrane", "CELLULAR_COMPONENT", 75, 83], ["Spike protein", "PROTEIN", 0, 13], ["human CoVs", "PROTEIN", 17, 27], ["host cells", "CELL_TYPE", 53, 63], ["human", "SPECIES", 17, 22], ["human", "SPECIES", 17, 22], ["Spike protein", "PROBLEM", 0, 13], ["human CoVs", "PROBLEM", 17, 27], ["viral entry into host cells", "PROBLEM", 36, 63], ["membrane fusion", "PROBLEM", 75, 90], ["viral infection", "PROBLEM", 100, 115], ["host cells", "OBSERVATION", 53, 63], ["membrane fusion", "OBSERVATION", 75, 90], ["viral", "OBSERVATION_MODIFIER", 100, 105], ["infection", "OBSERVATION", 106, 115]]], ["The S protein is a class I viral protein, that cleave into two functional subunits, designated as S1 and S2.", [["S2", "GENE_OR_GENE_PRODUCT", 105, 107], ["S protein", "PROTEIN", 4, 13], ["class I viral protein", "PROTEIN", 19, 40], ["S1", "PROTEIN", 98, 100], ["S2", "PROTEIN", 105, 107], ["S2", "ANATOMY", 105, 107]]], ["S1 is an aminoterminal subunit and S2 is a carboxyl-terminal subunit.", [["carboxyl", "CHEMICAL", 43, 51], ["S1", "GENE_OR_GENE_PRODUCT", 0, 2], ["S2", "GENE_OR_GENE_PRODUCT", 35, 37], ["S1", "PROTEIN", 0, 2], ["aminoterminal subunit", "PROTEIN", 9, 30], ["S2", "PROTEIN", 35, 37], ["carboxyl-terminal subunit", "PROTEIN", 43, 68], ["an aminoterminal subunit", "PROBLEM", 6, 30], ["a carboxyl-terminal subunit", "TREATMENT", 41, 68], ["aminoterminal subunit", "OBSERVATION", 9, 30], ["S2", "ANATOMY", 35, 37]]], ["The function of S1 subunit is virus-host cell receptor binding, whereas the S2 subunit is responsible for virus-host membrane fusion 32 .Discussion:Two major domains are present in S1, termed as an N-terminal domain (NTD) and a C-terminal domain (CTD).", [["cell", "ANATOMY", 41, 45], ["membrane", "ANATOMY", 117, 125], ["N", "CHEMICAL", 198, 199], ["C", "CHEMICAL", 228, 229], ["S1", "GENE_OR_GENE_PRODUCT", 16, 18], ["host cell", "CELL", 36, 45], ["S2", "GENE_OR_GENE_PRODUCT", 76, 78], ["S1", "GENE_OR_GENE_PRODUCT", 181, 183], ["S1 subunit", "PROTEIN", 16, 26], ["S2 subunit", "PROTEIN", 76, 86], ["S1", "PROTEIN", 181, 183], ["N-terminal domain", "PROTEIN", 198, 215], ["NTD", "PROTEIN", 217, 220], ["C-terminal domain", "PROTEIN", 228, 245], ["CTD", "PROTEIN", 247, 250], ["virus", "PROBLEM", 30, 35], ["host cell receptor binding", "PROBLEM", 36, 62], ["virus", "PROBLEM", 106, 111], ["host membrane fusion", "TREATMENT", 112, 132], ["an N-terminal domain (NTD)", "PROBLEM", 195, 221], ["a C-terminal domain (CTD)", "PROBLEM", 226, 251], ["S1", "ANATOMY", 16, 18], ["virus", "OBSERVATION", 30, 35], ["host cell receptor binding", "OBSERVATION", 36, 62], ["responsible for", "UNCERTAINTY", 90, 105]]], ["NTDs aid in sugar binding 32 , whereas CTDs act as protein receptor .", [["sugar", "CHEMICAL", 12, 17], ["sugar binding 32", "GENE_OR_GENE_PRODUCT", 12, 28], ["protein receptor", "PROTEIN", 51, 67], ["NTDs aid in sugar binding", "PROBLEM", 0, 25]]], ["S1 subunit is responsible for binding host receptors or function as receptor-binding domains (RBDs) 32 .", [["S1", "GENE_OR_GENE_PRODUCT", 0, 2], ["S1 subunit", "PROTEIN", 0, 10], ["receptor-binding domains (RBDs) 32", "PROTEIN", 68, 102], ["binding host receptors", "PROBLEM", 30, 52], ["RBDs", "TEST", 94, 98], ["responsible for", "UNCERTAINTY", 14, 29]]], ["The viral membrane protein interacts with host cellular membrane protein and ultimately enters the host.", [["membrane", "ANATOMY", 10, 18], ["cellular membrane", "ANATOMY", 47, 64], ["cellular membrane", "CELLULAR_COMPONENT", 47, 64], ["viral membrane protein", "PROTEIN", 4, 26], ["host cellular membrane protein", "PROTEIN", 42, 72], ["The viral membrane protein", "TREATMENT", 0, 26], ["host cellular membrane protein", "TREATMENT", 42, 72], ["viral membrane protein", "OBSERVATION", 4, 26], ["host cellular membrane protein", "OBSERVATION", 42, 72]]], ["The infection is initiated as S1 subunit recognize receptor or sugar moiety on the cell surface.", [["cell surface", "ANATOMY", 83, 95], ["infection", "DISEASE", 4, 13], ["sugar", "CHEMICAL", 63, 68], ["sugar moiety", "SIMPLE_CHEMICAL", 63, 75], ["cell surface", "CELLULAR_COMPONENT", 83, 95], ["S1 subunit", "PROTEIN", 30, 40], ["The infection", "PROBLEM", 0, 13], ["infection", "OBSERVATION", 4, 13], ["sugar moiety", "OBSERVATION", 63, 75]]], ["As the next step, the S protein undergoes conformational changes, leading to membrane fusion by the S2 region 32 .Finally, the viral genetic particles are inserted or delivered into the host cell by the fusion core 32, 34 .", [["membrane", "ANATOMY", 77, 85], ["cell", "ANATOMY", 191, 195], ["membrane", "CELLULAR_COMPONENT", 77, 85], ["host cell", "CELL", 186, 195], ["S protein", "PROTEIN", 22, 31], ["S2 region 32", "PROTEIN", 100, 112], ["conformational changes", "PROBLEM", 42, 64], ["membrane fusion", "TREATMENT", 77, 92], ["the viral genetic particles", "TREATMENT", 123, 150], ["the fusion core", "TEST", 199, 214], ["membrane fusion", "OBSERVATION", 77, 92], ["S2", "ANATOMY", 100, 102], ["viral", "OBSERVATION", 127, 132], ["genetic particles", "OBSERVATION", 133, 150], ["host cell", "OBSERVATION", 186, 195]]], ["Reports indicate the existence of spike glycoprotein as metastable prefusion trimer as characterized by its structure 32 .", [["spike glycoprotein", "PROTEIN", 34, 52], ["metastable prefusion trimer", "PROTEIN", 56, 83], ["spike glycoprotein", "PROBLEM", 34, 52], ["metastable prefusion trimer", "PROBLEM", 56, 83], ["prefusion trimer", "OBSERVATION", 67, 83]]], ["The structural and functional basis of receptor binding site for SARS Cov2 have been studied 35, 36 .", [["Cov2", "GENE_OR_GENE_PRODUCT", 70, 74], ["receptor binding site", "DNA", 39, 60], ["SARS Cov2", "PROTEIN", 65, 74], ["SARS Cov2", "TEST", 65, 74]]], ["We observed spike protein 18 as completely different from others, which may occur due to the conformational changes of spike.Discussion:The receptor binding domain (CTD) of the trimeric spike protein exists in two states -standing or lying.", [["spike protein 18", "PROTEIN", 12, 28], ["receptor binding domain", "PROTEIN", 140, 163], ["CTD", "PROTEIN", 165, 168], ["trimeric spike protein", "PROTEIN", 177, 199], ["spike protein", "TEST", 12, 25], ["the conformational changes of spike", "PROBLEM", 89, 124], ["The receptor binding domain (CTD)", "TREATMENT", 136, 169], ["the trimeric spike protein", "PROBLEM", 173, 199], ["spike", "OBSERVATION_MODIFIER", 119, 124]]], ["ACE2 receptor are able to bind to standing RBD, particularly in the receptor-binding motif (RBM), aiding the RBD to exist in the \"standing\" state 32 .", [["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 0, 13], ["RBD", "GENE_OR_GENE_PRODUCT", 43, 46], ["ACE2 receptor", "PROTEIN", 0, 13], ["RBD", "PROTEIN", 43, 46], ["receptor-binding motif", "PROTEIN", 68, 90], ["RBD", "PROTEIN", 109, 112], ["ACE2 receptor", "TREATMENT", 0, 13], ["standing RBD", "PROBLEM", 34, 46], ["the RBD", "PROBLEM", 105, 112]]], ["Along with human ACE2, SARS-CoV2 S protein have the ability to bind to palm civet and mouse ACE2s 35, 36 .", [["human", "ORGANISM", 11, 16], ["ACE2", "GENE_OR_GENE_PRODUCT", 17, 21], ["SARS-CoV2 S", "GENE_OR_GENE_PRODUCT", 23, 34], ["mouse", "ORGANISM", 86, 91], ["human ACE2", "PROTEIN", 11, 21], ["SARS-CoV2 S protein", "PROTEIN", 23, 42], ["human", "SPECIES", 11, 16], ["mouse", "SPECIES", 86, 91], ["human", "SPECIES", 11, 16], ["mouse", "SPECIES", 86, 91], ["human ACE2", "TREATMENT", 11, 21]]], ["It has been reported that mutations in the RBD of S1 subunit are essential for crossspecies transmission of SARS-CoV 32 .", [["SARS", "DISEASE", 108, 112], ["RBD", "GENE_OR_GENE_PRODUCT", 43, 46], ["S1", "GENE_OR_GENE_PRODUCT", 50, 52], ["SARS-CoV 32", "ORGANISM", 108, 119], ["RBD", "PROTEIN", 43, 46], ["S1 subunit", "PROTEIN", 50, 60], ["SARS-CoV", "SPECIES", 108, 116], ["mutations in the RBD of S1 subunit", "PROBLEM", 26, 60], ["CoV", "TEST", 113, 116]]], ["Like SARS-CoV, 2019-nCoV also employs ACE2 as its cellular receptor for its entry in host cells 32 .", [["cellular", "ANATOMY", 50, 58], ["cells", "ANATOMY", 90, 95], ["SARS", "DISEASE", 5, 9], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 5, 13], ["2019-nCoV", "GENE_OR_GENE_PRODUCT", 15, 24], ["ACE2", "GENE_OR_GENE_PRODUCT", 38, 42], ["cellular", "CELL", 50, 58], ["host cells", "CELL", 85, 95], ["ACE2", "PROTEIN", 38, 42], ["cellular receptor", "PROTEIN", 50, 67], ["SARS-CoV", "SPECIES", 5, 13]]], ["We observed ACE2 receptor was able to bind effectively with different identified variants with nonsynonymous mutations in silico, thus initiates infection.", [["infection", "DISEASE", 145, 154], ["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 12, 25], ["ACE2", "PROTEIN", 12, 16], ["ACE2 receptor", "TREATMENT", 12, 25], ["nonsynonymous mutations in silico", "PROBLEM", 95, 128], ["infection", "PROBLEM", 145, 154], ["nonsynonymous mutations", "OBSERVATION", 95, 118], ["infection", "OBSERVATION", 145, 154]]], ["This might be due to the fact that identified the samples were from virulent strains of SARS Cov2.", [["samples", "ANATOMY", 50, 57], ["SARS", "DISEASE", 88, 92], ["Cov2", "GENE_OR_GENE_PRODUCT", 93, 97], ["the samples", "TEST", 46, 57], ["virulent strains of SARS Cov2", "PROBLEM", 68, 97]]], ["However, polymorphism of ACE2 receptor had also been identified 31 , that might also explain the variabilities in pathogenicity in SARS Cov2.Conclusion:We identified wide variabilities in SARSCov2 virus distributed world wide and even within same geographical region as revealed through phylogenetic tree .", [["SARS", "DISEASE", 131, 135], ["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 25, 38], ["SARSCov2 virus", "ORGANISM", 188, 202], ["ACE2 receptor", "PROTEIN", 25, 38], ["SARSCov2 virus", "SPECIES", 188, 202], ["polymorphism of ACE2 receptor", "PROBLEM", 9, 38], ["the variabilities in pathogenicity in SARS Cov2", "PROBLEM", 93, 140], ["wide variabilities in SARSCov2 virus", "PROBLEM", 166, 202], ["might also explain", "UNCERTAINTY", 74, 92], ["wide", "OBSERVATION_MODIFIER", 166, 170], ["phylogenetic tree", "OBSERVATION", 287, 304]]], ["Out of 20 different variants of spike proteins identified, seven were observed to be genetically similar and may be regarded as dominant type, may be helpful for vaccination or drug development.", [["spike proteins", "PROTEIN", 32, 46], ["spike proteins", "PROBLEM", 32, 46], ["vaccination", "TREATMENT", 162, 173], ["drug development", "PROBLEM", 177, 193], ["20 different", "OBSERVATION_MODIFIER", 7, 19]]], ["Five novel mutations detected in spike proteins as S247R, R408I, G612D, A930V and del 144,when R408I involved with important domain of peptidase S. ACE2 receptor bind with the variants of spike proteins.", [["S247R", "GENE_OR_GENE_PRODUCT", 51, 56], ["S. ACE2 receptor", "GENE_OR_GENE_PRODUCT", 145, 161], ["spike proteins", "PROTEIN", 33, 47], ["S247R", "PROTEIN", 51, 56], ["R408I", "PROTEIN", 58, 63], ["R408I", "PROTEIN", 95, 100], ["peptidase S. ACE2 receptor", "PROTEIN", 135, 161], ["spike proteins", "PROTEIN", 188, 202], ["Five novel mutations", "PROBLEM", 0, 20], ["spike proteins", "TEST", 33, 47], ["peptidase S. ACE2 receptor bind", "TREATMENT", 135, 166], ["spike proteins", "PROBLEM", 188, 202]]]]}